96_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 1_CD Presentation_NN of_IN the_DT Financial_NNP statements_NNS Additional_JJ information_NN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS US_NNP GAAP_NNP is_VBZ included_VBN Description_NN of_IN business_NN in_IN the_DT Notes_NNS to_TO the_DT Financial_NNP statements_NNS ._.
In_IN Note_NN 37_CD a_DT statement_NN GlaxoSmithKline_NNP is_VBZ a_DT major_JJ global_JJ healthcare_NN group_NN which_WDT is_VBZ of_IN differences_NNS ,_, and_CC reconciliations_NNS of_IN net_JJ income_NN and_CC shareholders_NNS engaged_VBN in_IN the_DT creation_NN and_CC discovery_NN ,_, development_NN ,_, manufacture_NN equity_NN ,_, between_IN UK_NNP and_CC US_NNP GAAP_NNP are_VBP provided_VBN ._.
and_CC marketing_NN of_IN pharmaceutical_JJ products_NNS ,_, including_VBG vaccines_NNS ,_, over-the-counter_JJ OTC_NNP medicines_NNS and_CC health-related_JJ consumer_NN Presentation_NN of_IN statement_NN of_IN profit_NN and_CC loss_NN products_NNS ._.
GlaxoSmithKlines_NNS principal_JJ pharmaceutical_JJ products_NNS During_IN the_DT years_NNS 2000_CD to_TO 2003_CD ,_, a_DT columnar_NN presentation_NN was_VBD include_VBP medicines_NNS in_IN the_DT following_VBG therapeutic_JJ areas_NNS :_: adopted_VBN in_IN the_DT statement_NN of_IN profit_NN and_CC loss_NN in_IN order_NN to_TO illustrate_VB central_JJ nervous_JJ system_NN ,_, respiratory_JJ ,_, anti-virals_NNS ,_, anti-bacterials_NNS ,_, underlying_VBG business_NN performance_NN ,_, as_IN this_DT was_VBD the_DT primary_JJ measure_NN vaccines_NNS ,_, oncology_NN and_CC emesis_NN ,_, metabolic_JJ ,_, cardiovascular_JJ and_CC used_VBN by_IN management_NN ._.
For_IN this_DT purpose_NN certain_JJ items_NNS were_VBD urogenital_JJ ._.
identied_JJ separately_RB and_CC excluded_VBN from_IN business_NN performance_NN ._.
These_DT comprised_VBN :_: merger_NN and_CC integration_NN items_NNS ,_, including_VBG product_NN Financial_JJ period_NN divestments_NNS :_: costs_NNS relating_VBG to_TO previously_RB announced_VBN manufacturing_NN These_DT Financial_NNP statements_NNS cover_VBP the_DT financial_JJ year_NN from_IN and_CC other_JJ restructuring_NN ,_, and_CC the_DT effect_NN of_IN disposals_NNS of_IN subsidiaries_NNS ._.
1st_CD January_NNP to_TO 31st_VB December_NNP 2004_CD ,_, with_IN comparative_JJ gures_NNS for_IN Management_NNP believes_VBZ that_IN exclusion_NN of_IN these_DT items_NNS provided_VBD a_DT the_DT financial_JJ years_NNS from_IN 1st_CD January_NNP to_TO 31st_VB December_NNP 2003_CD and_CC better_JJR reection_NN for_IN those_DT years_NNS of_IN the_DT way_NN in_IN which_WDT the_DT business_NN from_IN 1st_CD January_NNP to_TO 31st_VB December_NNP 2002_CD ._.
was_VBD managed_VBN and_CC gives_VBZ an_DT indication_NN of_IN the_DT performance_NN of_IN the_DT Group_NNP in_IN terms_NNS of_IN those_DT elements_NNS of_IN revenue_NN and_CC expenditure_NN Composition_NN of_IN the_DT Group_NNP which_WDT local_JJ management_NN is_VBZ able_JJ to_TO inuence_NN ._.
A_DT list_NN of_IN the_DT subsidiary_NN and_CC associated_VBN undertakings_NNS which_WDT ,_, in_IN the_DT opinion_NN of_IN the_DT Directors_NNS ,_, principally_RB affected_VBD the_DT amount_NN of_IN profit_NN For_IN 2004_CD ,_, with_IN the_DT completion_NN of_IN these_DT programs_NNS ,_, the_DT Group_NNP or_CC the_DT net_JJ assets_NNS of_IN the_DT Group_NNP is_VBZ given_VBN in_IN Principal_NN Group_NNP is_VBZ reporting_VBG results_NNS on_IN a_DT statutory_JJ basis_NN only_RB ._.
Growth_NN rates_NNS are_VBP companies_NNS ,_, Note_VB 38_CD ._.
presented_VBN comparing_VBG 2004_CD results_NNS both_DT with_IN 2003_CD business_NN performance_NN results_NNS and_CC 2003_CD statutory_JJ results_NNS ._.
Management_NNP Composition_NNP of_IN financial_JJ statements_NNS considers_VBZ that_IN the_DT comparison_NN of_IN 2004_CD statutory_JJ results_NNS with_IN 2003_CD The_DT consolidated_JJ Financial_NNP statements_NNS are_VBP drawn_VBN up_RP in_IN accordance_NN business_NN performance_NN results_NNS gives_VBZ the_DT most_RBS appropriate_JJ indication_NN with_IN UK_NNP generally_RB accepted_VBD accounting_NN principles_NNS UK_NNP GAAP_NNP and_CC of_IN the_DT Groups_NNS performance_NN for_IN that_DT period_NN ._.
Trading_NN profit_NN reects_VBZ turnover_NN less_RBR :_: cost_NN of_IN sales_NNS ,_, comprising_VBG The_DT Financial_NNP statements_NNS comprise_VBP :_: costs_NNS of_IN manufacture_NN and_CC external_JJ royalties_NNS :_: selling_NN ,_, general_JJ and_CC administrative_JJ expenditure_NN ,_, comprising_VBG the_DT costs_NNS of_IN selling_NN ,_, Consolidated_NNP statement_NN of_IN profit_NN and_CC loss_NN distribution_NN and_CC medical_JJ support_NN of_IN currently_RB marketed_VBN products_NNS Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS and_CC the_DT costs_NNS of_IN administration_NN :_: and_CC the_DT costs_NNS of_IN research_NN and_CC Consolidated_NNP statement_NN of_IN cash_NN ow_NN development_NN to_TO create_VB future_JJ products_NNS for_IN sale_NN ._.
Consolidated_NNP balance_NN sheet_NN Reconciliation_NNP of_IN movements_NNS in_IN consolidated_JJ equity_NN Accounting_NN convention_NN shareholders_NNS funds_NNS The_DT Financial_NNP statements_NNS have_VBP been_VBN prepared_VBN using_VBG the_DT historical_JJ Company_NN balance_NN sheet_NN cost_NN convention_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS ._.
As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Accounting_NN standards_NNS profit_NN and_CC loss_NN account_NN of_IN the_DT company_NN is_VBZ not_RB presented_VBN ._.
The_DT Financial_NNP statements_NNS comply_VBP with_IN applicable_JJ UK_NNP accounting_NN standards_NNS ._.
The_DT consolidated_JJ statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS includes_VBZ :_: Accounting_NNP principles_NNS and_CC policies_NNS the_DT realized_VBN profit_NN attributable_JJ to_TO shareholders_NNS as_IN reected_VBN The_DT preparation_NN of_IN the_DT Financial_NNP statements_NNS in_IN conformity_NN with_IN in_IN the_DT consolidated_JJ statement_NN of_IN profit_NN and_CC loss_NN generally_RB accepted_VBD accounting_NN principles_NNS requires_VBZ management_NN the_DT unrealised_JJ gain_NN or_CC loss_NN in_IN the_DT value_NN of_IN the_DT Groups_NNS to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN overseas_JJ net_JJ assets_NNS ,_, less_JJR related_JJ foreign_JJ currency_NN borrowings_NNS ,_, amounts_NNS of_IN assets_NNS and_CC liabilities_NNS and_CC disclosure_NN of_IN contingent_JJ attributable_JJ to_TO currency_NN movements_NNS over_IN the_DT period_NN assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT Financial_NNP statements_NNS and_CC tax_NN on_IN the_DT above_JJ items_NNS ._.
the_DT reported_JJ amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
The_DT reconciliation_NN of_IN movements_NNS in_IN equity_NN shareholders_NNS funds_NNS comprises_VBZ the_DT items_NNS contributing_VBG to_TO the_DT increase_NN or_CC decrease_NN The_DT Financial_NNP statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN over_IN the_DT period_NN in_IN shareholders_NNS funds_NNS ._.
Such_JJ items_NNS include_VBP :_: the_DT companys_NNS accounting_VBG policies_NNS approved_VBN by_IN the_DT Board_NNP and_CC described_VBN in_IN Note_NN 2_CD ._.
the_DT total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT period_NN dividends_NNS paid_VBN and_CC proposed_VBN the_DT proceeds_NNS of_IN shares_NNS issued_VBN during_IN the_DT period_NN the_DT cost_NN of_IN shares_NNS purchased_VBN as_IN Treasury_NNP shares_NNS or_CC for_IN cancellation_NN under_IN the_DT share_NN buy-back_NN program_NN changes_NNS to_TO goodwill_NN ,_, arising_VBG on_IN acquisitions_NNS prior_RB to_TO 1st_CD January_NNP 1998_CD ,_, which_WDT has_VBZ been_VBN set_VBN directly_RB against_IN reserves_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 97_CD 2_CD Accounting_NN policies_NNS Foreign_JJ currency_NN transactions_NNS Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS are_VBP booked_VBN Consolidation_NN in_IN local_JJ currency_NN at_IN the_DT exchange_NN rate_NN ruling_NN on_IN the_DT date_NN of_IN The_DT consolidated_JJ Financial_NNP statements_NNS include_VBP :_: transaction_NN ,_, or_CC at_IN the_DT forward_JJ rate_NN if_IN hedged_VBN by_IN a_DT forward_RB the_DT assets_NNS and_CC liabilities_NNS ,_, and_CC the_DT results_NNS and_CC cash_NN ow_NN ,_, of_IN the_DT exchange_NN contract_NN ._.
Foreign_JJ currency_NN assets_NNS and_CC liabilities_NNS are_VBP company_NN and_CC its_PRP$ subsidiary_NN undertakings_NNS ,_, including_VBG Employee_NNP translated_VBN into_IN local_JJ currency_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT Share_NN Ownership_NN Plan_NN ESOP_NNP Trusts_NNPS balance_NN sheet_NN date_NN ,_, or_CC at_IN the_DT forward_JJ rate_NN ._.
Exchange_NNP differences_NNS the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS and_CC results_NNS of_IN joint_JJ ventures_NNS are_VBP included_VBN in_IN trading_NN profit_NN ._.
Revenue_NN The_DT Financial_NNP statements_NNS of_IN undertakings_NNS consolidated_VBN are_VBP made_VBN Revenue_NN is_VBZ recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN when_WRB goods_NNS up_IN to_TO 31st_CD December_NNP ._.
are_VBP supplied_VBN or_CC made_VBN available_JJ to_TO external_JJ customers_NNS against_IN orders_NNS Undertakings_NNS in_IN which_WDT the_DT Group_NNP has_VBZ a_DT material_NN interest_NN are_VBP received_VBN and_CC when_WRB title_NN and_CC risk_NN of_IN loss_NN passes_VBZ to_TO the_DT customer_NN ._.
accounted_VBD for_IN as_IN subsidiaries_NNS where_WRB the_DT Group_NNP exercises_VBZ dominant_JJ Turnover_NN represents_VBZ net_JJ invoice_NN value_NN after_IN the_DT deduction_NN of_IN inuence_NN ,_, as_IN joint_JJ ventures_NNS where_WRB the_DT Group_NNP exercises_VBZ joint_JJ control_NN discounts_NNS given_VBN at_IN the_DT point_NN of_IN sale_NN ,_, and_CC accruals_NNS for_IN estimated_VBN and_CC as_IN associates_NNS where_WRB the_DT Group_NNP can_MD exercise_VB significant_JJ future_JJ rebates_NNS and_CC returns_NNS ._.
The_DT methodology_NN and_CC assumptions_NNS inuence_NN ._.
used_VBN to_TO estimate_VB rebates_NNS and_CC returns_NNS are_VBP monitored_VBN and_CC adjusted_VBN regularly_RB in_IN the_DT light_NN of_IN contractual_JJ and_CC historical_JJ information_NN and_CC Interests_NNS acquired_VBN in_IN undertakings_NNS are_VBP consolidated_VBN from_IN the_DT past_JJ experience_NN ._.
Turnover_NN also_RB includes_VBZ co-promotion_JJ income_NN effective_JJ date_NN of_IN acquisition_NN and_CC interests_NNS sold_VBN are_VBP consolidated_JJ where_WRB the_DT Group_NNP records_NNS its_PRP$ share_NN of_IN the_DT revenue_NN but_CC with_IN no_DT up_RB to_TO the_DT date_NN of_IN disposal_NN ._.
Value_NNP added_VBD tax_NN and_CC other_JJ sales_NNS taxes_NNS are_VBP Transactions_NNS and_CC balances_NNS between_IN subsidiary_NN undertakings_NNS are_VBP excluded_VBN from_IN revenue_NN ._.
eliminated_VBN :_: no_DT profit_NN is_VBZ taken_VBN on_IN sales_NNS between_IN subsidiary_NN undertakings_NNS or_CC sales_NNS to_TO joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS Expenditure_NN until_IN the_DT products_NNS are_VBP sold_VBN to_TO customers_NNS outside_IN the_DT Group_NNP ._.
Expenditure_NN is_VBZ recognized_VBN in_IN respect_NN of_IN goods_NNS and_CC services_NNS received_VBN when_WRB supplied_VBN in_IN accordance_NN with_IN contractual_JJ terms_NNS ._.
Provision_NNP is_VBZ Goodwill_NNP arising_VBG on_IN the_DT acquisition_NN of_IN interests_NNS in_IN subsidiary_NN made_VBN when_WRB an_DT obligation_NN exists_VBZ for_IN a_DT future_JJ liability_NN in_IN respect_NN of_IN a_DT undertakings_NNS ,_, joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ,_, past_JJ event_NN and_CC where_WRB the_DT amount_NN of_IN the_DT obligation_NN can_MD be_VB reliably_RB representing_VBG the_DT excess_NN of_IN the_DT purchase_NN consideration_NN over_IN the_DT estimated_VBN ._.
Advertising_NN and_CC promotion_NN expenditure_NN is_VBZ charged_VBN to_TO Groups_NNS share_NN of_IN the_DT separable_JJ net_JJ assets_NNS acquired_VBN ,_, is_VBZ capitalized_VBN the_DT profit_NN and_CC loss_NN account_NN as_IN incurred_VBN ._.
Shipment_NN costs_NNS on_IN interas_NNS a_DT separate_JJ item_NN in_IN the_DT case_NN of_IN subsidiary_NN undertakings_NNS and_CC as_IN company_NN transfers_NNS are_VBP charged_VBN to_TO cost_NN of_IN sales_NNS :_: distribution_NN costs_NNS part_NN of_IN the_DT cost_NN of_IN investment_NN in_IN the_DT case_NN of_IN joint_JJ ventures_NNS and_CC on_IN sales_NNS to_TO customers_NNS are_VBP included_VBN in_IN selling_NN ,_, general_JJ and_CC associated_VBN undertakings_NNS ._.
Goodwill_NN is_VBZ denominated_VBN in_IN the_DT currency_NN administrative_JJ expenditure_NN ._.
Restructuring_NN costs_NNS are_VBP recognized_VBN in_IN in_IN which_WDT the_DT acquisition_NN is_VBZ made_VBN and_CC nanced_VBN ._.
In_IN the_DT case_NN of_IN respect_NN of_IN the_DT direct_JJ expenditures_NNS of_IN a_DT business_NN reorganisation_NN acquisitions_NNS prior_RB to_TO 1998_CD ,_, goodwill_NN was_VBD written_VBN off_RP against_IN where_WRB the_DT plans_NNS are_VBP sufciently_RB detailed_VBN and_CC well_RB advanced_VBD ,_, and_CC reserves_NNS :_: on_IN a_DT subsequent_JJ disposal_NN of_IN assets_NNS from_IN such_JJ acquisitions_NNS ,_, where_WRB appropriate_JJ communication_NN to_TO those_DT affected_VBN has_VBZ been_VBN any_DT related_JJ goodwill_NN is_VBZ removed_VBN from_IN consolidated_JJ reserves_NNS and_CC undertaken_VBN at_IN the_DT balance_NN sheet_NN date_NN ._.
charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
The_DT Groups_NNS interests_NNS in_IN its_PRP$ joint_JJ ventures_NNS are_VBP accounted_VBN for_IN using_VBG Research_NNP and_CC development_NN the_DT gross_JJ equity_NN method_NN ._.
The_DT Groups_NNS interests_NNS in_IN its_PRP$ associated_VBN Research_NNP and_CC development_NN expenditure_NN is_VBZ charged_VBN to_TO the_DT profit_NN undertakings_NNS are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
and_CC loss_NN account_NN in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Tangible_JJ xed_JJ assets_NNS used_VBN for_IN research_NN and_CC development_NN are_VBP depreciated_VBN Deferred_JJ taxation_NN relief_NN on_IN unrealised_JJ intra-Group_JJ profit_NN is_VBZ in_IN accordance_NN with_IN the_DT Groups_NNS policy_NN ._.
accounted_VBD for_IN only_RB to_TO the_DT extent_NN that_IN it_PRP is_VBZ considered_VBN recoverable_JJ ._.
Assets_NNS and_CC liabilities_NNS of_IN overseas_JJ subsidiary_NN and_CC associated_VBN Environmental_JJ expenditure_NN undertakings_NNS and_CC joint_JJ ventures_NNS including_VBG related_JJ goodwill_NN ,_, are_VBP Environmental_JJ expenditure_NN related_VBN to_TO existing_VBG conditions_NNS resulting_VBG translated_VBN into_IN sterling_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT balance_NN from_IN past_JJ or_CC current_JJ operations_NNS and_CC from_IN which_WDT no_DT current_JJ or_CC sheet_NN date_NN ._.
The_DT results_NNS and_CC cash_NN ows_NNS of_IN overseas_JJ subsidiary_NN and_CC future_JJ benefit_NN is_VBZ discernible_JJ is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN associated_VBN undertakings_NNS and_CC joint_JJ ventures_NNS are_VBP translated_VBN into_IN account_NN ._.
The_DT Group_NNP determines_VBZ its_PRP$ liability_NN on_IN a_DT site-by-site_JJ basis_NN sterling_NN using_VBG average_JJ rates_NNS of_IN exchange_NN ._.
Exchange_NNP adjustments_NNS and_CC records_NNS a_DT liability_NN at_IN the_DT time_NN when_WRB it_PRP is_VBZ probable_JJ and_CC can_MD be_VB arising_VBG when_WRB the_DT opening_NN net_JJ assets_NNS and_CC the_DT profits_NNS for_IN the_DT year_NN reasonably_RB estimated_VBN ._.
This_DT liability_NN includes_VBZ the_DT Groups_NNS own_VBP retained_VBN by_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS and_CC portion_NN of_IN the_DT costs_NNS and_CC also_RB a_DT portion_NN of_IN other_JJ potentially_RB joint_JJ ventures_NNS are_VBP translated_VBN into_IN sterling_NN ,_, less_JJR exchange_NN differences_NNS responsible_JJ parties_NNS costs_NNS when_WRB it_PRP is_VBZ probable_JJ that_IN they_PRP will_MD not_RB be_VB arising_VBG on_IN related_VBN foreign_JJ currency_NN borrowings_NNS ,_, are_VBP taken_VBN directly_RB able_JJ to_TO satisfy_VB their_PRP$ respective_JJ shares_NNS of_IN the_DT clean-up_JJ obligation_NN ._.
to_TO reserves_NNS and_CC reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN When_WRB recoveries_NNS of_IN reimbursements_NNS are_VBP virtually_RB certain_JJ they_PRP are_VBP gains_NNS and_CC losses_NNS ._.
In_IN translating_VBG into_IN sterling_JJ assets_NNS ,_, liabilities_NNS ,_, results_NNS and_CC cash_NN ows_VBZ Pensions_NNS and_CC post-retirement_JJ benets_NNS of_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS and_CC joint_JJ The_DT cost_NN of_IN providing_VBG pensions_NNS and_CC other_JJ employee_NN post-retirement_JJ ventures_NNS reported_VBN in_IN currencies_NNS of_IN hyper-inationary_JJ economies_NNS ,_, benets_NNS is_VBZ charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN on_IN a_DT adjustments_NNS are_VBP made_VBN to_TO reect_VB current_JJ price_NN levels_NNS ._.
Any_DT loss_NN on_IN systematic_JJ and_CC rational_JJ basis_NN ,_, based_VBN on_IN actuarial_JJ assumptions_NNS ,_, over_IN net_JJ monetary_JJ assets_NNS is_VBZ charged_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN the_DT period_NN during_IN which_WDT benefit_NN is_VBZ derived_VBN from_IN employees_NNS services_NNS ._.
Any_DT difference_NN between_IN this_DT charge_NN and_CC the_DT contributions_NNS paid_VBN is_VBZ included_VBN as_IN an_DT asset_NN or_CC liability_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN ._.
98_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 2_CD Accounting_NN policies_NNS continued_VBD Brands_NNS are_VBP valued_VBN independently_RB as_IN part_NN of_IN the_DT fair_JJ value_NN of_IN businesses_NNS acquired_VBN from_IN third_JJ parties_NNS where_WRB the_DT brand_NN has_VBZ a_DT Legal_JJ and_CC other_JJ disputes_NNS value_NN which_WDT is_VBZ substantial_JJ and_CC long-term_JJ and_CC where_WRB the_DT brands_NNS Provision_NNP is_VBZ made_VBN for_IN anticipated_JJ settlement_NN costs_NNS where_WRB a_DT can_MD be_VB sold_VBN separately_RB from_IN the_DT rest_NN of_IN the_DT businesses_NNS acquired_VBN ._.
reasonable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT likely_JJ outcome_NN of_IN legal_JJ or_CC Brands_NNS are_VBP amortised_VBN over_IN the_DT estimated_VBN useful_JJ lives_NNS but_CC no_DT longer_JJR other_JJ disputes_NNS against_IN the_DT Group_NNP ._.
In_IN addition_NN provision_NN is_VBZ made_VBN for_IN than_IN 20_CD years_NNS ,_, except_IN where_WRB the_DT end_NN of_IN the_DT useful_JJ economic_JJ life_NN legal_JJ and_CC other_JJ expenses_NNS arising_VBG from_IN claims_NNS received_VBN or_CC other_JJ of_IN the_DT brand_NN can_MD not_RB be_VB foreseen_VBN ._.
In_IN respect_NN of_IN product_NN liability_NN claims_NNS related_VBN to_TO products_NNS where_WRB there_EX is_VBZ sufficient_JJ history_NN of_IN claims_NNS made_VBN and_CC settlements_NNS ,_, an_DT Prior_RB to_TO 1998_CD ,_, acquired_VBN minor_JJ brands_NNS and_CC similar_JJ intangibles_NNS were_VBD incurred_VBN but_CC not_RB reported_VBD IBNR_NNP actuarial_JJ technique_NN is_VBZ used_VBN to_TO eliminated_VBN in_IN the_DT Group_NNP balance_NN sheet_NN against_IN reserves_NNS in_IN the_DT year_NN determine_VB a_DT reasonable_JJ estimate_NN of_IN the_DT Groups_NNS exposure_NN to_TO of_IN acquisition_NN ._.
unasserted_JJ claims_NNS for_IN those_DT products_NNS and_CC a_DT provision_NN is_VBZ made_VBN on_IN that_DT basis_NN ._.
No_DT provision_NN is_VBZ made_VBN for_IN other_JJ unasserted_JJ claims_NNS or_CC Tangible_JJ xed_JJ assets_NNS where_WRB an_DT obligation_NN exists_VBZ under_IN a_DT dispute_NN but_CC it_PRP is_VBZ not_RB possible_JJ to_TO Tangible_JJ xed_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provisions_NNS for_IN make_VBP a_DT reasonable_JJ estimate_NN ._.
Costs_NNS associated_VBN with_IN claims_NNS made_VBN by_IN depreciation_NN or_CC impairment_NN ._.
The_DT costs_NNS of_IN acquiring_VBG and_CC developing_VBG the_DT Group_NNP against_IN third_JJ parties_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN computer_NN software_NN for_IN internal_JJ use_NN and_CC internet_NN sites_NNS for_IN external_JJ account_NN as_IN they_PRP are_VBP incurred_VBN ._.
use_NN are_VBP capitalized_VBN as_IN a_DT tangible_JJ xed_JJ asset_NN where_WRB the_DT software_NN or_CC site_NN supports_VBZ a_DT significant_JJ business_NN system_NN and_CC the_DT expenditure_NN Employee_NN share_NN plans_VBZ leads_NNS to_TO the_DT creation_NN of_IN a_DT durable_JJ asset_NN ._.
Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO employees_NNS under_IN Depreciation_NN is_VBZ calculated_VBN to_TO write_VB off_RP the_DT cost_NN of_IN tangible_JJ xed_JJ share_NN option_NN and_CC share_NN award_NN schemes_NNS ._.
In_IN respect_NN of_IN certain_JJ award_NN assets_NNS ,_, excluding_VBG freehold_JJ land_NN ,_, in_IN equal_JJ annual_JJ instalments_NNS over_IN schemes_NNS and_CC share_NN option_NN grants_NNS ,_, the_DT company_NN provides_VBZ finance_NN to_TO their_PRP$ expected_VBN useful_JJ lives_NNS ._.
The_DT normal_JJ expected_VBN useful_JJ lives_NNS of_IN the_DT ESOP_NNP Trusts_NNPS to_TO purchase_VB company_NN shares_NNS on_IN the_DT open_JJ market_NN to_TO major_JJ categories_NNS of_IN tangible_JJ xed_JJ assets_NNS are_VBP reviewed_VBN annually_RB meet_VB the_DT companys_NNS obligation_NN to_TO provide_VB shares_NNS when_WRB employees_NNS and_CC are_VBP :_: exercise_VB their_PRP$ option_NN or_CC award_NN ._.
Any_DT excess_NN of_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN the_DT award_NN over_IN the_DT exercise_NN price_NN of_IN the_DT Freehold_NNP buildings_NNS 20_CD to_TO 50_CD years_NNS options_NNS or_CC awards_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN Leasehold_NNP land_NN and_CC The_DT shorter_JJR of_IN lease_NN term_NN and_CC 50_CD the_DT periods_NNS of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT options_NNS and_CC awards_NNS buildings_NNS years_NNS are_VBP granted_VBN ._.
In_IN respect_NN of_IN other_JJ share_NN option_NN grants_NNS ,_, share_NN options_NNS Plant_NN and_CC machinery_NN 10_CD to_TO 20_CD years_NNS when_WRB exercised_VBN are_VBP accounted_VBN for_IN as_IN share_NN issues_NNS at_IN exercise_NN price_NN ._.
Fixtures_NNS and_CC equipment_NN 3_CD to_TO 10_CD years_NNS Additional_JJ employer_NN costs_NNS in_IN respect_NN of_IN options_NNS and_CC awards_NNS are_VBP ERP_NNP systems_NNS software_NN 7_CD years_NNS charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT periods_NNS of_IN service_NN ._.
Other_JJ computer_NN software_NN 3_CD to_TO 5_CD years_NNS Assets_NNS and_CC liabilities_NNS of_IN the_DT ESOP_NNP Trusts_NNPS are_VBP included_VBN in_IN the_DT Group_NNP Enterprise_NNP Resource_NNP Planning_NNP ERP_NNP systems_NNS software_NN generally_RB balance_NN sheet_NN ._.
Costs_NNS of_IN running_VBG the_DT Trusts_NNPS are_VBP charged_VBN to_TO the_DT profit_NN involves_VBZ significant_JJ customisation_NN prior_RB to_TO implementation_NN and_CC is_VBZ and_CC loss_NN account_NN ._.
Company_NN shares_NNS held_VBN by_IN the_DT Trusts_NNPS are_VBP deducted_VBN expected_VBN to_TO have_VB a_DT useful_JJ economic_JJ life_NN of_IN seven_CD years_NNS ,_, rather_RB than_IN from_IN other_JJ reserves_NNS and_CC held_VBN at_IN a_DT value_NN which_WDT recognizes_VBZ any_DT the_DT maximum_NN five_CD years_NNS of_IN other_JJ computer_NN software_NN ._.
On_IN disposal_NN shortfall_NN in_IN the_DT proceeds_NNS receivable_NN from_IN employees_NNS on_IN exercise_NN ._.
of_IN a_DT tangible_JJ xed_JJ asset_NN ,_, the_DT cost_NN and_CC related_JJ accumulated_VBN If_IN there_EX is_VBZ deemed_VBN to_TO be_VB a_DT further_JJ permanent_JJ impairment_NN in_IN value_NN depreciation_NN are_VBP removed_VBN from_IN the_DT financial_JJ statements_NNS and_CC the_DT this_DT is_VBZ reected_VBN by_IN a_DT transfer_NN to_TO profit_NN and_CC loss_NN account_NN reserve_NN ._.
net_JJ amount_NN ,_, less_JJR any_DT proceeds_NNS ,_, is_VBZ taken_VBN to_TO the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
Goodwill_NNP Goodwill_NNP is_VBZ stated_VBN at_IN cost_NN less_JJR a_DT provision_NN for_IN amortisation_NN ._.
Leases_NNP Amortisation_NNP is_VBZ calculated_VBN to_TO write_VB off_RP the_DT cost_NN in_IN equal_JJ annual_JJ Leasing_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP substantially_RB all_DT instalments_NNS over_IN its_PRP$ expected_VBN useful_JJ life_NN ._.
The_DT useful_JJ life_NN is_VBZ not_RB the_DT benets_NNS and_CC risks_NNS of_IN ownership_NN of_IN an_DT asset_NN are_VBP treated_VBN as_IN normally_RB expected_VBN to_TO exceed_VB 20_CD years_NNS ._.
finance_NN leases_NNS ,_, as_IN if_IN the_DT asset_NN had_VBD been_VBN purchased_VBN outright_RB ._.
The_DT assets_NNS are_VBP included_VBN in_IN tangible_JJ xed_JJ assets_NNS and_CC the_DT capital_NN element_NN Intangible_NNP xed_VBD assets_NNS of_IN the_DT leasing_NN commitments_NNS is_VBZ shown_VBN as_IN obligations_NNS under_IN finance_NN Intangible_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR a_DT provision_NN for_IN amortisation_NN ._.
Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP depreciated_VBN over_IN the_DT Acquired_VBN licences_NNS ,_, patents_NNS ,_, know-how_NN and_CC marketing_NN rights_NNS are_VBP shorter_JJR of_IN the_DT lease_NN terms_NNS and_CC the_DT useful_JJ lives_NNS of_IN the_DT assets_NNS ._.
The_DT amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS in_IN equal_JJ instalments_NNS ,_, interest_NN element_NN of_IN the_DT lease_NN rental_NN is_VBZ charged_VBN against_IN profit_NN ._.
Items_NNS capitalized_VBN are_VBP restricted_VBN to_TO All_DT other_JJ leases_NNS are_VBP operating_VBG leases_NNS and_CC the_DT annual_JJ rentals_NNS are_VBP those_DT related_VBN to_TO specic_JJ compounds_NNS or_CC products_NNS which_WDT are_VBP being_VBG charged_VBN against_IN profit_NN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ._.
The_DT estimated_VBN useful_JJ lives_NNS for_IN determining_VBG the_DT amortisation_NN charge_NN are_VBP reviewed_VBN annually_RB ,_, Impairment_NN of_IN xed_JJ assets_NNS and_CC take_VB into_IN account_NN the_DT estimated_VBN time_NN it_PRP takes_VBZ to_TO bring_VB the_DT The_DT carrying_VBG values_NNS of_IN xed_JJ assets_NNS are_VBP reviewed_VBN for_IN impairment_NN compounds_NNS or_CC products_NNS to_TO market_NN as_IN marketable_JJ products_NNS ._.
when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT assets_NNS might_MD be_VB impaired_VBN ._.
Any_DT development_NN costs_NNS which_WDT are_VBP incurred_VBN by_IN the_DT Group_NNP and_CC Any_DT provision_NN for_IN impairment_NN is_VBZ charged_VBN against_IN profit_NN in_IN the_DT year_NN are_VBP associated_VBN with_IN an_DT acquired_VBN licence_NN ,_, patent_NN ,_, know-how_NN or_CC concerned_VBN ._.
First_JJ year_NN impairment_NN reviews_NNS are_VBP conducted_VBN for_IN marketing_NN rights_NNS are_VBP written_VBN off_RP to_TO the_DT profit_NN and_CC loss_NN account_NN acquired_VBD goodwill_NN and_CC intangible_JJ assets_NNS ._.
Certain_JJ intangibles_NNS are_VBP when_WRB incurred_VBN ._.
considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC are_VBP therefore_RB not_RB amortised_VBN ._.
Such_JJ intangibles_NNS are_VBP subject_JJ to_TO annual_JJ impairment_NN tests_NNS ._.
Impairment_NN is_VBZ determined_VBN by_IN reference_NN to_TO the_DT higher_JJR of_IN net_JJ realisable_JJ value_NN and_CC value_NN in_IN use_NN ,_, which_WDT is_VBZ measured_VBN by_IN reference_NN to_TO discounted_JJ future_JJ cash_NN ows_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 99_CD 2_CD Accounting_NN policies_NNS continued_VBD Gains_NNS and_CC losses_NNS on_IN foreign_JJ exchange_NN contracts_NNS designated_VBN as_IN hedges_NNS of_IN forecast_NN foreign_JJ exchange_NN transactions_NNS are_VBP deferred_VBN Investments_NNP in_IN joint_JJ ventures_NNS and_CC associates_NNS and_CC included_VBN in_IN the_DT measurement_NN of_IN the_DT related_VBN foreign_JJ currency_NN Investments_NNP in_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS are_VBP transactions_NNS in_IN the_DT period_NN they_PRP occur_VBP ._.
Gains_NNS and_CC losses_NNS on_IN balance_NN carried_VBD in_IN the_DT consolidated_JJ balance_NN sheet_NN at_IN the_DT Groups_NNS share_VBP sheet_NN hedges_NNS are_VBP accrued_VBN and_CC are_VBP taken_VBN directly_RB to_TO reserves_NNS ,_, except_IN of_IN their_PRP$ net_JJ assets_NNS at_IN date_NN of_IN acquisition_NN and_CC of_IN their_PRP$ postthat_NN forward_RB premiums_NNS discounts_NNS are_VBP recognized_VBN as_IN interest_NN over_IN acquisition_NN retained_VBD profits_NNS or_CC losses_NNS together_RB with_IN any_DT goodwill_NN the_DT life_NN of_IN the_DT contracts_NNS ._.
arising_VBG on_IN the_DT acquisition_NN ,_, net_NN of_IN amortisation_NN ._.
Interest_NN differentials_NNS under_IN interest_NN swap_NN agreements_NNS are_VBP recognized_VBN Stocks_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN by_IN adjustment_NN of_IN interest_NN expense_NN Stocks_NNS are_VBP included_VBN in_IN the_DT financial_JJ statements_NNS at_IN the_DT lower_JJR of_IN over_IN the_DT life_NN of_IN the_DT agreement_NN ._.
cost_NN including_VBG manufacturing_NN overheads_NNS ,_, where_WRB appropriate_JJ and_CC net_JJ realisable_JJ value_NN ._.
Cost_NN is_VBZ generally_RB determined_VBN on_IN a_DT first_JJ in_IN ,_, Debt_NN instruments_NNS first_RB out_IN basis_NN ._.
Debt_NN instruments_NNS are_VBP stated_VBN at_IN the_DT amount_NN of_IN net_JJ proceeds_NNS adjusted_VBN to_TO amortise_VB the_DT issue_NN cost_NN of_IN debt_NN evenly_RB over_IN the_DT Taxation_NNP term_NN of_IN the_DT debt_NN ._.
The_DT Group_NNP accounts_NNS for_IN taxation_NN which_WDT is_VBZ deferred_VBN or_CC accelerated_VBN by_IN reason_NN of_IN timing_NN differences_NNS which_WDT have_VBP originated_VBN but_CC not_RB 3_CD New_JJ accounting_NN policies_NNS and_CC future_JJ requirements_NNS reversed_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN assets_NNS are_VBP only_RB In_IN December_NNP 2003_CD ,_, the_DT Urgent_NNP Issues_NNP Task_NNP Force_NNP issued_VBD Abstract_NNP recognized_VBD to_TO the_DT extent_NN that_IN they_PRP are_VBP considered_VBN recoverable_JJ 38_CD and_CC amended_VBN Abstract_NNP 17_CD ,_, relating_VBG to_TO the_DT accounting_NN for_IN and_CC against_IN future_JJ taxable_JJ profits_NNS ._.
Deferred_JJ tax_NN on_IN the_DT retained_VBN presentation_NN of_IN ESOP_NNP Trusts_NNPS and_CC share_NN options_NNS and_CC awards_NNS granted_VBN earnings_NNS of_IN overseas_JJ subsidiaries_NNS is_VBZ only_RB provided_VBN when_WRB there_EX is_VBZ a_DT to_TO employees_NNS ._.
These_DT requirements_NNS became_VBD mandatory_JJ for_IN 2004_CD binding_JJ commitment_NN to_TO distribute_VB past_JJ earnings_NNS in_IN future_NN periods_NNS ._.
reporting_VBG and_CC require_VB the_DT shares_NNS held_VBN by_IN the_DT ESOP_NNP Trusts_NNPS to_TO be_VB Deferred_VBN tax_NN is_VBZ measured_VBN at_IN the_DT average_JJ tax_NN rates_NNS that_WDT are_VBP expected_VBN shown_VBN as_IN a_DT deduction_NN in_IN arriving_VBG at_IN shareholders_NNS funds_NNS ._.
The_DT to_TO apply_VB in_IN the_DT periods_NNS in_IN which_WDT the_DT timing_NN differences_NNS are_VBP charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN for_IN employee_NN share_NN options_NNS expected_VBN to_TO reverse_VB ._.
Deferred_JJ tax_NN liabilities_NNS and_CC assets_NNS are_VBP not_RB is_VBZ restricted_VBN to_TO the_DT intrinsic_JJ loss_NN ,_, the_DT difference_NN between_IN the_DT market_NN discounted_VBD ._.
price_NN and_CC exercise_NN price_NN ,_, at_IN the_DT date_NN of_IN grant_NN ._.
Comparative_JJ data_NNS for_IN prior_JJ periods_NNS has_VBZ been_VBN restated_VBN for_IN comparability_NN ._.
Trading_NN profit_NN Current_JJ asset_NN investments_NNS and_CC profit_NN before_IN tax_NN in_IN 2003_CD have_VBP been_VBN reduced_VBN by_IN 16_CD million_CD Current_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_NN and_CC net_JJ assets_NNS at_IN 31st_CD December_NNP 2003_CD by_IN 2,661_CD million_CD ._.
It_PRP is_VBZ not_RB realisable_JJ value_NN ._.
practicable_JJ to_TO quantify_VB the_DT effect_NN on_IN 2004_CD because_IN of_IN the_DT different_JJ measurement_NN basis_NN adopted_VBN ._.
In_IN the_DT case_NN of_IN securities_NNS acquired_VBN at_IN a_DT significant_JJ premium_NN or_CC discount_NN to_TO maturity_NN value_NN ,_, and_CC intended_VBN to_TO be_VB held_VBN to_TO redemption_NN ,_, In_IN June_NNP 2002_CD ,_, the_DT Council_NNP of_IN the_DT European_NNP Union_NNP adopted_VBD a_DT cost_NN is_VBZ adjusted_VBN to_TO amortise_VB the_DT premium_NN or_CC discount_NN over_IN the_DT life_NN Regulation_NN requiring_VBG listed_VBN companies_NNS in_IN its_PRP$ Member_NNP States_NNPS to_TO to_TO maturity_NN of_IN the_DT security_NN ._.
Floating_VBG rate_NN bonds_NNS are_VBP stated_VBN at_IN cost_NN ._.
prepare_VB their_PRP$ consolidated_JJ financial_JJ statements_NNS in_IN accordance_NN Interest_NN income_NN is_VBZ taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP from_IN 2005_CD ._.
receivable_JJ basis_NN ._.
GlaxoSmithKline_NNP has_VBZ completed_VBN its_PRP$ conversion_NN project_NN ,_, subject_JJ to_TO any_DT changes_NNS in_IN standards_NNS and_CC pronouncements_NNS ,_, and_CC unaudited_JJ Equity_NN investments_NNS are_VBP included_VBN as_IN current_JJ assets_NNS when_WRB regarded_VBN information_NN for_IN 2004_CD and_CC 2003_CD restated_VBN onto_IN an_DT IFRS_NNP basis_NN ,_, is_VBZ as_IN available_JJ for_IN sale_NN ._.
Derivative_JJ financial_JJ instruments_NNS 4_CD Exchange_NNP rates_NNS The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS for_IN trading_NN purposes_NNS ._.
The_DT Group_NNP uses_VBZ the_DT average_NN of_IN exchange_NN rates_NNS prevailing_VBG during_IN the_DT period_NN to_TO translate_VB the_DT results_NNS and_CC cash_NN ows_NNS of_IN overseas_JJ Derivative_JJ financial_JJ instruments_NNS are_VBP used_VBN to_TO manage_VB exposure_NN to_TO subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS into_IN market_NN risks_NNS from_IN treasury_NN operations_NNS ._.
The_DT principal_JJ derivative_JJ sterling_NN and_CC period_NN end_NN rates_NNS to_TO translate_VB the_DT net_JJ assets_NNS of_IN those_DT instruments_NNS are_VBP currency_NN swaps_NNS ,_, forward_RB exchange_NN contracts_NNS and_CC undertakings_NNS ._.
The_DT currencies_NNS which_WDT most_RBS inuence_JJ these_DT interest_NN rate_NN swaps_NNS ._.
The_DT derivative_JJ contracts_NNS are_VBP treated_VBN from_IN translations_NNS ,_, and_CC the_DT relevant_JJ exchange_NN rates_NNS ,_, were_VBD :_: inception_NN as_IN an_DT economic_JJ hedge_NN of_IN the_DT underlying_VBG financial_JJ 2004 2003 2002_CD instrument_NN ,_, with_IN matching_JJ accounting_NN treatment_NN and_CC cash_NN ows_NNS ._.
The_DT derivative_JJ contracts_NNS have_VBP high_JJ correlation_NN with_IN the_DT specic_JJ Average_JJ rates_NNS :_: financial_JJ instrument_NN being_VBG hedged_VBN both_DT at_IN inception_NN and_CC US$_$ 1.83_CD 1.64_CD 1.50_CD throughout_IN the_DT hedge_JJ period_NN ._.
Derivative_JJ instruments_NNS no_RB longer_RB Euro_NNP 1.47_CD 1.45_CD 1.59_CD designated_VBN as_IN hedges_NNS are_VBP restated_VBN at_IN market_NN value_NN and_CC any_DT future_JJ Yen_NNP 197.00_CD 191.00_CD 188.00_CD changes_NNS in_IN value_NN are_VBP taken_VBN directly_RB to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Period_NN end_NN rates_NNS :_: US$_$ 1.92_CD 1.79_CD 1.61_CD Currency_NN swaps_NNS and_CC forward_RB exchange_NN contracts_NNS used_VBN to_TO x_SYM the_DT Euro_NNP 1.41_CD 1.42_CD 1.54_CD value_NN of_IN the_DT related_JJ asset_NN or_CC liability_NN in_IN the_DT contract_NN currency_NN and_CC Yen_NNP 197.00_CD 192.00_CD 192.00_CD at_IN the_DT contract_NN rate_NN are_VBP accrued_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT life_NN of_IN the_DT contract_NN ._.
100_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 5_CD Merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP The_NNP combination_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc_NN was_VBD treated_VBN as_IN a_DT merger_NN at_IN 27th_JJ December_NNP 2000_CD under_IN UK_NNP GAAP_NNP ._.
Under_IN the_DT merger_NN relief_NN provisions_NNS of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT shares_NNS issued_VBN by_IN GlaxoSmithKline_NNP plc_NN to_TO acquire_VB Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP were_VBD accounted_VBN for_IN at_IN par_NN and_CC no_DT share_NN premium_NN arose_VBD :_: the_DT shares_NNS acquired_VBN by_IN GlaxoSmithKline_NNP in_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP were_VBD similarly_RB accounted_VBN for_IN at_IN the_DT nominal_JJ value_NN of_IN the_DT shares_NNS issued_VBN ._.
In_IN the_DT consolidated_JJ Financial_NNP statements_NNS of_IN GlaxoSmithKline_NNP ,_, the_DT results_NNS and_CC net_JJ assets_NNS of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP were_VBD combined_VBN at_IN their_PRP$ book_NN amounts_NNS ,_, subject_JJ to_TO alignment_VB adjustments_NNS ._.
6_CD Segment_NN information_NN An_DT analysis_NN of_IN turnover_NN ,_, profit_NN before_IN taxation_NN ,_, total_JJ assets_NNS and_CC net_JJ assets_NNS by_IN business_NN and_CC geographical_JJ sector_NN ,_, tangible_JJ xed_JJ assets_NNS by_IN geographical_JJ sector_NN and_CC turnover_NN by_IN location_NN of_IN customer_NN are_VBP set_VBN out_RP below_IN ._.
The_DT business_NN sectors_NNS consist_VBP of_IN Pharmaceuticals_NNS prescription_NN pharmaceuticals_NNS and_CC vaccines_NNS and_CC Consumer_NN Healthcare_NNP oral_JJ care_NN ,_, OTC_NNP medicines_NNS and_CC nutritional_JJ healthcare_NN ._.
Assets_NNS by_IN business_NN sector_NN in_IN 2003_CD have_VBP been_VBN adjusted_VBN to_TO ensure_VB consistency_NN with_IN 2004_CD ._.
The_DT geographical_JJ sectors_NNS reect_VBP the_DT Groups_NNS most_RBS significant_JJ regional_JJ markets_NNS and_CC are_VBP consistent_JJ with_IN the_DT Groups_NNS regional_JJ market_NN management_NN reporting_VBG structure_NN ._.
Business_NNP sector_NN data_NN includes_VBZ an_DT allocation_NN of_IN corporate_JJ costs_NNS to_TO each_DT sector_NN ._.
There_EX are_VBP no_DT sales_NNS between_IN business_NN sectors_NNS ._.
The_DT Groups_NNS activities_NNS are_VBP organised_VBN on_IN a_DT global_JJ basis_NN ._.
The_DT geographical_JJ sector_NN gures_NNS are_VBP therefore_RB inuenced_VBN by_IN the_DT location_NN of_IN the_DT Groups_NNS operating_VBG resources_NNS ,_, in_IN particular_JJ manufacturing_NN and_CC research_NN ,_, and_CC by_IN variations_NNS over_IN time_NN in_IN intra-Group_JJ trading_NN and_CC funding_NN arrangements_NNS ._.
Where_WRB the_DT Group_NNP co-promotes_NNS a_DT product_NN and_CC the_DT third_JJ party_NN records_NNS the_DT sale_NN ,_, the_DT Group_NNP records_NNS its_PRP$ share_NN of_IN revenue_NN as_IN co-promotion_JJ income_NN within_IN turnover_NN ._.
The_DT nature_NN of_IN co-promotion_NN activities_NNS is_VBZ such_JJ that_IN the_DT Group_NNP records_NNS no_DT costs_NNS of_IN sales_NNS ._.
Pharmaceutical_NNP turnover_NN includes_VBZ co-promotion_JJ income_NN of_IN 65_CD million_CD 2003_CD 35_CD million_CD ,_, 2002_CD nil_NN ._.
2003 2002 2004_CD restated_VBN restated_VBN Turnover_NN by_IN business_NN sector_NN m_NN m_FW m_FW Pharmaceuticals_NNPS 17,146_CD 18,181_CD 17,995_CD Consumer_NN Healthcare_NNP 3,213_CD 3,260_CD 3,217_CD External_NNP turnover_NN 20,359_CD 21,441_CD 21,212_CD Statutory_JJ profit_NN before_IN tax_NN by_IN business_NN sector_NN Pharmaceuticals_NNS 5,428_CD 5,785_CD 5,085_CD Consumer_NN Healthcare_NNP 662 591 484_CD Operating_NN profit_NN 6,090_CD 6,376_CD 5,569_CD Share_NN of_IN profits_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 95_CD 93_CD 75_CD profit_NN on_IN disposal_NN of_IN interest_NN in_IN associate_JJ 138_CD Loss_NN profit_NN on_IN disposal_NN of_IN businesses_NNS 1_CD 5_CD 10_CD Product_NN divestments_VBZ 11_CD Net_JJ interest_NN payable_JJ 203 161 141_CD profit_NN before_IN taxation_NN 6,119_CD 6,313_CD 5,524_CD profit_NN before_IN taxation_NN 6,119_CD 6,313_CD 5,524_CD Taxation_NNP 1,701_CD 1,729_CD 1,464_CD Minority_NNP interests_NNS 114_CD 94_CD 110_CD Preference_NN share_NN dividends_NNS 2_CD 12_CD 20_CD Statutory_JJ earnings_NNS 4,302_CD 4,478_CD 3,930_CD Total_JJ assets_NNS by_IN business_NN sector_NN Pharmaceuticals_NNS 18,875_CD 17,384_CD Consumer_NN Healthcare_NNP 3,703_CD 3,816_CD Total_JJ assets_NNS 22,578_CD 21,200_CD Net_JJ assets_NNS by_IN business_NN sector_NN Pharmaceuticals_NNS 3,698_CD 3,316_CD Consumer_NN Healthcare_NNP 2,504_CD 2,488_CD Net_JJ assets_NNS 6,202_CD 5,804_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 101_CD 6_CD Segment_NN information_NN continued_VBD 2003 2002 2004_CD restated_VBN restated_VBN Turnover_NN by_IN location_NN of_IN subsidiary_NN undertaking_NN m_NN m_FW m_FW USA_NNP 9,524_CD 10,569_CD 11,096_CD Europe_NNP 11,431_CD 11,798_CD 10,423_CD International_NNP 7,847_CD 7,945_CD 6,824_CD Turnover_NN including_VBG inter-segment_JJ turnover_NN 28,802_CD 30,312_CD 28,343_CD USA_NNP 289 219 168_CD Europe_NNP 4,278_CD 4,690_CD 3,873_CD International_NNP 3,876_CD 3,962_CD 3,090_CD Inter-segment_NN turnover_NN 8,443_CD 8,871_CD 7,131_CD USA_NNP 9,235_CD 10,350_CD 10,928_CD Europe_NNP 7,153_CD 7,108_CD 6,550_CD International_NNP 3,971_CD 3,983_CD 3,734_CD External_NNP turnover_NN 20,359_CD 21,441_CD 21,212_CD Statutory_JJ profit_NN before_IN tax_NN by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 1,266_CD 1,983_CD 2,117_CD Europe_NNP 2,739_CD 3,045_CD 2,508_CD International_NNP 2,085_CD 1,348_CD 944_CD Operating_NN profit_NN 6,090_CD 6,376_CD 5,569_CD Share_NN of_IN profits_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 95_CD 93_CD 75_CD profit_NN on_IN disposal_NN of_IN interest_NN in_IN associate_JJ 138_CD profit_NN on_IN disposal_NN of_IN businesses_NNS 1_CD 5_CD 10_CD Product_NN divestments_VBZ 11_CD Net_JJ interest_NN payable_JJ 203 161 141_CD profit_NN before_IN taxation_NN 6,119_CD 6,313_CD 5,524_CD profit_NN before_IN taxation_NN 6,119_CD 6,313_CD 5,524_CD Taxation_NNP 1,701_CD 1,729_CD 1,464_CD Minority_NNP interests_NNS 114_CD 94_CD 110_CD Preference_NN share_NN dividends_NNS 2_CD 12_CD 20_CD Statutory_JJ earnings_NNS 4,302_CD 4,478_CD 3,930_CD Total_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 4,351_CD 4,385_CD Europe_NNP 11,374_CD 10,362_CD International_NNP 2,874_CD 2,998_CD Total_JJ operating_VBG assets_NNS 18,599_CD 17,745_CD Cash_NN at_IN bank_NN and_CC liquid_JJ investments_NNS 3,979_CD 3,455_CD Total_JJ assets_NNS 22,578_CD 21,200_CD Net_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN USA_NNP 233_CD 484_CD Europe_NNP 5,973_CD 4,922_CD International_NNP 1,980_CD 2,046_CD Net_NN operating_VBG assets_NNS 8,186_CD 7,452_CD Net_JJ debt_NN 1,984_CD 1,648_CD Net_JJ assets_NNS 6,202_CD 5,804_CD 102_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 6_CD Segment_NN information_NN continued_VBD 2004_CD 2003_CD Plant_NN ,_, Land_NNP and_CC equipment_NN Computer_NN Assets_NNS in_IN buildings_NNS and_CC vehicles_NNS software_NN construction_NN Total_JJ Total_JJ Tangible_JJ xed_JJ assets_NNS by_IN location_NN of_IN subsidiary_NN undertaking_NN m_NN m_FW m_FW m_FW m_FW m_FW USA_NNP 662_CD 399_CD 40_CD 157_CD 1,258_CD 1,295_CD Europe_NNP 1,591_CD 2,023_CD 159_CD 500_CD 4,273_CD 4,184_CD International_NNP 503_CD 357_CD 11 69 940 962_CD Total_JJ 2,756_CD 2,779_CD 210_CD 726_CD 6,471_CD 6,441_CD 2004 2003 2002_CD Turnover_NN by_IN location_NN of_IN customer_NN m_NN mm_NN USA_NNP 9,243_CD 10,333_CD 10,807_CD Europe_NNP 6,658_CD 6,611_CD 6,064_CD International_NNP 4,458_CD 4,497_CD 4,341_CD External_NNP turnover_NN 20,359_CD 21,441_CD 21,212_CD UK_NNP segment_NN Information_NN is_VBZ given_VBN separately_RB in_IN respect_NN of_IN the_DT UK_NNP ,_, which_WDT ,_, although_IN included_VBN in_IN the_DT Groups_NNS Europe_NNP market_NN region_NN ,_, is_VBZ considered_VBN the_DT Groups_NNS home_NN segment_NN for_IN the_DT purposes_NNS of_IN segmental_JJ reporting_NN ._.
2003 2002 2004_CD restated_VBN restated_VBN m_FW m_FW m_FW Turnover_NN by_IN location_NN of_IN customer_NN 1,461_CD 1,404_CD 1,366_CD Turnover_NN including_VBG inter-segment_JJ turnover_NN 4,467_CD 4,678_CD 4,945_CD Inter-segment_NN turnover_NN 2,709_CD 2,883_CD 3,230_CD Turnover_NN by_IN location_NN of_IN subsidiary_NN 1,758_CD 1,795_CD 1,715_CD Operating_NN profit_NN 1,403_CD 1,519_CD 1,294_CD Total_JJ assets_NNS 7,578_CD 7,145_CD Net_NN operating_VBG assets_NNS 2,635_CD 2,023_CD 7_CD Merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC divested_JJ businesses_NNS Manufacturing_NNP and_CC other_JJ restructuring_NN costs_NNS were_VBD incurred_VBN by_IN GlaxoSmithKline_NNP during_IN 2003_CD and_CC 2002_CD in_IN the_DT implementation_NN of_IN previously_RB announced_VBN plans_NNS for_IN the_DT restructuring_NN of_IN manufacturing_NN and_CC other_JJ activities_NNS ._.
Merger_NN integration_NN costs_NNS relate_VBP to_TO the_DT integration_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP into_IN a_DT unied_JJ GlaxoSmithKline_NNP business_NN ._.
These_DT costs_NNS include_VBP consultancy_NN fees_NNS in_IN respect_NN of_IN integration_NN planning_NN ,_, severance_NN costs_NNS ,_, asset_NN write-offs_NNS ,_, costs_NNS related_VBN to_TO the_DT early_JJ vesting_NN or_CC lapse_NN of_IN performance_NN conditions_NNS on_IN share_NN options_NNS and_CC share_NN incentive_NN awards_NNS and_CC costs_NNS of_IN the_DT program_NN to_TO encourage_VB staff_NN to_TO convert_VB Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP share_NN options_NNS into_IN GlaxoSmithKline_NNP share_NN options_NNS ._.
Integration_NN costs_NNS were_VBD incurred_VBN in_IN 2003_CD and_CC 2002_CD relating_VBG to_TO the_DT integration_NN of_IN the_DT Block_NNP Drug_NNP businesses_NNS ._.
These_DT costs_NNS include_VBP professional_JJ fees_NNS ,_, severance_NN costs_NNS and_CC asset_NN write-offs_NNS ._.
Product_NN divestment_NN income_NN arising_VBG in_IN 2002_CD related_VBN to_TO the_DT nalisation_NN of_IN the_DT disposals_NNS of_IN Famvir_NNP ,_, Kytril_NNP and_CC other_JJ products_NNS required_VBN in_IN 2000_CD in_IN order_NN to_TO obtain_VB regulatory_JJ approval_NN for_IN the_DT merger_NN ._.
The_DT disposal_NN of_IN businesses_NNS in_IN 2003_CD and_CC 2002_CD related_VBN to_TO the_DT nalisation_NN of_IN the_DT disposals_NNS of_IN Clinical_JJ Laboratories_NNPS and_CC Healthcare_NNP Services_NNPS in_IN 1999_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 103_CD 7_CD Merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC divested_JJ businesses_NNS continued_VBD Disposal_NNP of_IN Merger_NNP Restructuring_NNP Block_NNP Drug_NNP subsidiaries_NNS Total_JJ 2003_CD m_FW m_FW m_FW m_FW m_FW Manufacturing_NNP and_CC other_JJ restructuring_NN 83_CD 83_CD Merger_NN integration_NN costs_NNS 286_CD 286_CD Block_NNP Drug_NNP integration_NN costs_NNS 26_CD 26_CD Effect_NN on_IN operating_NN profit_NN 286_CD 83_CD 26_CD 395_CD profit_NN on_IN disposal_NN of_IN businesses_NNS 5_CD 5_CD Effect_NN on_IN profit_NN before_IN tax_NN 286_CD 83_CD 26_CD 5_CD 390_CD Effect_NN on_IN taxation_NN operating_NN items_NNS 98_CD Effect_NN on_IN taxation_NN non-operating_JJ items_NNS 11_CD Effect_NN on_IN taxation_NN 109_CD Effect_NN on_IN earnings_NNS 281_CD Disposal_NN of_IN Merger_NNP Restructuring_NNP Block_NNP Drug_NNP subsidiaries_NNS Total_JJ 2002_CD m_FW m_FW m_FW m_FW m_FW Manufacturing_NNP and_CC other_JJ restructuring_NN 121_CD 121_CD Merger_NN integration_NN costs_NNS 851_CD 851_CD Block_NNP Drug_NNP integration_NN costs_NNS 60_CD 60_CD Effect_NN on_IN operating_NN profit_NN 851_CD 121_CD 60_CD 1,032_CD Product_NNP divestments_VBZ 11_CD 11_CD profit_NN on_IN disposal_NN of_IN businesses_NNS 10_CD 10_CD Effect_NN on_IN profit_NN before_IN tax_NN 840_CD 121_CD 60_CD 10_CD 1,011_CD Effect_NN on_IN taxation_NN operating_NN items_NNS 266_CD Effect_NN on_IN taxation_NN non-operating_JJ items_NNS 33_CD Effect_NN on_IN taxation_NN 299_CD Effect_NN on_IN earnings_NNS 712_CD 8_CD Other_JJ operating_NN income_NN expense_NN 2004 2003 2002_CD m_FW m_FW m_FW Royalties_NNPS and_CC other_JJ income_NN 96_CD 75_CD 75_CD Other_JJ operating_NN expense_NN 296 436 209 200_CD 361_CD 134_CD Income_NN from_IN equity_NN investments_NNS and_CC other_JJ disposals_NNS 140_CD 228_CD 23 60 133 111_CD Royalties_NNS and_CC other_JJ income_NN is_VBZ principally_RB a_DT core_NN of_IN recurring_VBG income_NN in_IN the_DT form_NN of_IN royalties_NNS from_IN the_DT out-licensing_NN of_IN intellectual_JJ property_NN ._.
Other_JJ operating_NN expense_NN includes_VBZ litigation_NN costs_NNS and_CC provisions_NNS relating_VBG to_TO legal_JJ claims_NNS on_IN withdrawn_VBN products_NNS ,_, product_NN withdrawals_NNS ,_, anti-trust_JJ matters_NNS and_CC claims_NNS with_IN respect_NN to_TO sales_NNS ,_, marketing_NN and_CC reimbursement_NN ._.
Income_NN from_IN equity_NN investments_NNS and_CC other_JJ disposals_NNS includes_VBZ equity_NN investment_NN carrying_VBG value_NN adjustments_NNS arising_VBG from_IN stock_NN market_NN changes_NNS ,_, product_NN disposals_NNS and_CC equity_NN investment_NN sales_NNS ._.
104_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 9_CD Operating_NN profit_NN 2003 2002 2004_CD restated_VBN restated_VBN m_FW m_FW m_FW The_DT following_JJ items_NNS have_VBP been_VBN charged_VBN in_IN operating_NN profit_NN :_: Employee_NN costs_NNS Note_VBP 35_CD 4,704_CD 5,074_CD 4,922_CD Advertising_NN 599 615 688_CD Distribution_NN costs_NNS 271 284 281_CD Depreciation_NN of_IN tangible_JJ xed_JJ assets_NNS :_: Owned_JJ assets_NNS 780 771 760_CD Leased_JJ assets_NNS 5_CD 24_CD Amortisation_NNP of_IN goodwill_NN 12_CD 13_CD 12_CD Amortisation_NNP of_IN intangible_JJ xed_JJ assets_NNS 94_CD 74_CD 60_CD Exchange_NNP losses_NNS on_IN foreign_JJ currency_NN deposits_NNS loans_NNS 1_CD Operating_NN lease_NN rentals_NNS :_: Plant_NNP 56_CD 90_CD 50_CD Land_NNP and_CC buildings_NNS 63_CD 62_CD 61_CD Audit_NNP fees_NNS 7.2_CD 6.9_CD 6.1_CD Fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN :_: Auditors_NNS UK_NNP rm_VBD 2.6_CD 1.7_CD 5.2_CD Auditors_NNS overseas_RB rms_VBZ 4.7_CD 5.9_CD 9.6_CD Analysis_NN of_IN fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN :_: Further_JJ assurance_NN audit-related_JJ services_NNS 3.4_CD 2.6_CD 1.8_CD Tax_NNP services_NNS 3.0_CD 4.6_CD 4.9_CD Merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP 6.0_CD Other_JJ services_NNS 0.9_CD 0.4_CD 2.1_CD Included_VBN within_IN audit_NN fees_NNS above_IN is_VBZ a_DT fee_NN of_IN 10,000_CD 2003_CD 10,000_CD ,_, 2002_CD 10,000_CD relating_VBG to_TO the_DT company_NN audit_NN of_IN GlaxoSmithKline_NNP plc._NNP ._.
Included_VBN in_IN further_JJ assurance_NN services_NNS in_IN 2004_CD and_CC 2003_CD are_VBP amounts_NNS related_VBN to_TO the_DT Groups_NNS preparation_NN for_IN the_DT adoption_NN of_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS and_CC preparation_NN for_IN section_NN 404_CD of_IN the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD ._.
Tax_NNP services_NNS relates_VBZ to_TO fees_NNS paid_VBN for_IN corporate_JJ tax_NN compliance_NN ,_, tax_NN planning_NN and_CC advice_NN ._.
Other_JJ services_NNS include_VBP human_JJ resources_NNS advisory_JJ ,_, compliance_NN and_CC treasury_NN related_VBN services_NNS ._.
Included_VBN within_IN fees_NNS to_TO auditors_NNS for_IN other_JJ work_NN in_IN 2002_CD is_VBZ 6.0_CD million_CD paid_VBN to_TO the_DT auditors_NNS management_NN consulting_NN practice_NN ,_, which_WDT was_VBD sold_VBN by_IN them_PRP in_IN 2002_CD ._.
In_IN 2004_CD and_CC 2003_CD ,_, the_DT Group_NNP applied_VBD discounting_VBG to_TO certain_JJ long-term_JJ assets_NNS and_CC liabilities_NNS ,_, using_VBG risk-free_JJ rates_NNS of_IN return_NN ._.
10_CD Joint_NNP ventures_NNS and_CC associated_VBN undertakings_NNS 2004 2003 2002_CD m_FW m_FW m_FW Associated_NNP undertakings_NNS :_: Share_NN of_IN profits_NNS of_IN Quest_NNP Diagnostics_NNPS Inc._NNP 100_CD 102_CD 94_CD Share_NN of_IN losses_NNS of_IN other_JJ associated_VBN undertakings_NNS 1_CD 3_CD Amortisation_NNP of_IN goodwill_NN 5_CD 6_CD 6_CD 94_CD 93_CD 88_CD Share_NN of_IN profits_NNS losses_NNS of_IN joint_JJ ventures_NNS 1_CD 13_CD 95_CD 93_CD 75_CD Share_NN of_IN turnover_NN of_IN joint_JJ ventures_NNS 31_CD 31_CD 29_CD Sales_NNS to_TO joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 50_CD 51_CD 49_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 105_CD 11_CD Net_JJ interest_NN payable_JJ 2004 2003 2002_CD m_NN mm_NN Interest_NN payable_JJ On_IN bank_NN loans_NNS and_CC overdrafts_NNS 6_CD 6_CD 6_CD On_IN other_JJ loans_NNS 273 186 198_CD In_IN respect_NN of_IN finance_NN leases_NNS 2_CD 2_CD 2_CD Realised_JJ losses_NNS 1_CD Unwinding_NN of_IN discount_NN on_IN provisions_NNS 16 20 298 214_CD 206_CD Share_NN of_IN interest_NN payable_JJ of_IN associate_JJ 7_CD 8_CD 8_CD 305 222 214_CD Investment_NN income_NN Interest_NN income_NN 99_CD 58_CD 71_CD Realised_VBN gains_NNS 2_CD Unwinding_NN of_IN discount_NN on_IN assets_NNS 3_CD 3_CD 102 6173 203 161_CD 141_CD 12_CD Taxation_NNP 2003 2002 2004_CD restated_VBN restated_VBN Taxation_NNP charge_NN based_VBN on_IN profits_NNS for_IN the_DT period_NN m_NN m_FW m_FW UK_NNP corporation_NN tax_NN at_IN the_DT UK_NNP statutory_JJ rate_NN 429 673479_CD Less_RBR double_JJ taxation_NN relief_NN 156 290 117 273_CD 383_CD 362_CD Overseas_JJ taxation_NN 1,394_CD 1,578_CD 1,036_CD Deferred_JJ taxation_NN 6_CD 272_CD 32_CD 1,661_CD 1,689_CD 1,430_CD Share_NN of_IN taxation_NN charge_NN of_IN associates_NNS 40_CD 40_CD 34_CD 1,701_CD 1,729_CD 1,464_CD 2003 2002 2004_CD restated_VBN restated_VBN Reconciliation_NNP of_IN the_DT current_JJ taxation_NN rate_NN on_IN Group_NNP profits_NNS %_NN %_NN %_NN UK_NNP statutory_JJ rate_NN of_IN taxation_NN 30.0_CD 30.0_CD 30.0_CD Overseas_JJ taxes_NNS 1.2_CD 0.1_CD 0.1_CD Average_NNP Group_NNP tax_NN rate_NN 31.2_CD 30.1_CD 30.1_CD Effect_NN of_IN special_JJ tax_NN status_NN in_IN manufacturing_VBG locations_NNS 3.6_CD 3.9_CD 3.9_CD Share_NN option_NN deductions_NNS 0.2_CD 0.1_CD 0.2_CD Merger_NNP and_CC restructuring_VBG costs_NNS 0.1_CD 0.7_CD R&D_NNP credits_NNS 1.5_CD 1.1_CD 1.2_CD Other_JJ permanent_JJ differences_NNS 2.1_CD 1.1_CD 0.8_CD Capital_NN allowances_NNS in_IN excess_NN of_IN depreciation_NN 0.3_CD 0.3_CD 0.5_CD Intra-Group_NNP profit_NN 0.3_CD 0.1_CD 1.3_CD Reversing_VBG timing_NN differences_NNS on_IN tax_NN losses_NNS 1.6_CD Other_JJ timing_NN differences_NNS 0.7_CD 4.0_CD 2.2_CD Prior_RB year_NN items_NNS 1.0_CD 1.5_CD 2.4_CD Current_JJ tax_NN rate_NN on_IN ordinary_JJ activities_NNS 27.3_CD 31.1_CD 25.3_CD Capital_NN allowances_NNS in_IN excess_NN of_IN depreciation_NN 0.3_CD 0.3_CD 0.5_CD Intra-Group_NNP profit_NN 0.3_CD 0.1_CD 1.3_CD Reversing_VBG timing_NN differences_NNS on_IN tax_NN losses_NNS 1.6_CD Other_JJ timing_NN differences_NNS 0.7_CD 4.0_CD 2.2_CD Share_NN of_IN taxation_NN charge_NN of_IN associates_NNS 0.6_CD 0.6_CD 0.6_CD Prior_RB year_NN items_NNS 1.8_CD 0.6_CD 3.6_CD UITF_NNP 17_CD restatement_NN 0.1_CD Tax_NNP rate_NN on_IN ordinary_JJ activities_NNS 27.8_CD 27.4_CD 26.5_CD The_DT Group_NNP operates_VBZ in_IN countries_NNS where_WRB the_DT tax_NN rate_NN differs_VBZ from_IN the_DT UK_NNP tax_NN rate_NN ._.
The_DT average_JJ Group_NNP tax_NN rate_NN has_VBZ been_VBN determined_VBN by_IN aggregating_VBG the_DT local_JJ standard_JJ tax_NN rates_NNS and_CC weighting_NN these_DT in_IN proportion_NN to_TO accounting_VBG profits_NNS ._.
profits_NNS arising_VBG from_IN manufacturing_VBG operations_NNS in_IN Singapore_NNP ,_, Puerto_NNP Rico_NNP and_CC Ireland_NNP are_VBP taxed_VBN at_IN reduced_JJ rates_NNS ._.
The_DT effect_NN of_IN this_DT reduction_NN in_IN the_DT taxation_NN charge_NN increased_VBD earnings_NNS per_IN share_NN by_IN 3.8_CD p_NN in_IN 2004_CD ,_, 4.2_CD p_NN in_IN 2003_CD and_CC 3.7_CD p_NN in_IN 2002_CD ._.
106_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 12_CD Taxation_NNP continued_VBD The_DT integrated_VBN nature_NN of_IN the_DT Groups_NNS worldwide_JJ operations_NNS ,_, involving_VBG significant_JJ investment_NN in_IN research_NN and_CC strategic_JJ manufacture_NN at_IN a_DT limited_JJ number_NN of_IN locations_NNS ,_, with_IN consequential_JJ cross-border_JJ supply_NN routes_NNS into_IN numerous_JJ end-markets_NNS ,_, gives_VBZ rise_NN to_TO complexity_NN and_CC delay_NN in_IN negotiations_NNS with_IN revenue_NN authorities_NNS as_IN to_TO the_DT profits_NNS on_IN which_WDT individual_JJ Group_NNP companies_NNS are_VBP liable_JJ to_TO tax_NN ._.
Disagreements_NNS with_IN ,_, and_CC between_IN ,_, revenue_NN authorities_NNS as_IN to_TO intra-Group_JJ transactions_NNS ,_, in_IN particular_JJ the_DT price_NN at_IN which_WDT goods_NNS should_MD be_VB transferred_VBN between_IN Group_NNP companies_NNS in_IN different_JJ tax_NN jurisdictions_NNS ,_, can_MD produce_VB conicting_VBG claims_NNS from_IN revenue_NN authorities_NNS as_IN to_TO the_DT profits_NNS to_TO be_VB taxed_VBN in_IN individual_JJ territories_NNS ._.
Resolution_NN of_IN such_JJ issues_NNS is_VBZ a_DT continuing_VBG fact_NN of_IN life_NN for_IN GlaxoSmithKline_NNP ._.
The_DT Group_NNP has_VBZ open_JJ issues_NNS with_IN the_DT revenue_NN authorities_NNS in_IN the_DT USA_NNP ,_, UK_NNP ,_, Japan_NNP and_CC Canada_NNP ._.
By_IN far_RB the_DT largest_JJS relates_VBZ to_TO Glaxo_NNP heritage_NN products_NNS ,_, in_IN respect_NN of_IN which_WDT the_DT US_NNP Internal_NNP Revenue_NNP Service_NNP IRS_NNP and_CC UK_NNP Inland_NNP Revenue_NN have_VBP made_VBN competing_VBG and_CC contradictory_JJ claims_NNS ._.
GlaxoSmithKline_NNP has_VBZ attempted_VBN to_TO settle_VB the_DT US_NNP dispute_NN ,_, first_RB through_IN direct_JJ discussion_NN with_IN the_DT IRS_NNP and_CC subsequently_RB through_IN discussions_NNS between_IN the_DT US_NNP and_CC UK_NNP authorities_NNS under_IN the_DT terms_NNS of_IN the_DT double_JJ tax_NN convention_NN between_IN the_DT two_CD countries_NNS and_CC discussions_NNS were_VBD terminated_VBN in_IN July_NNP 2003_CD ._.
On_IN 6th_JJ January_NNP 2004_CD ,_, the_DT IRS_NNP issued_VBD a_DT Notice_NNP of_IN deficiency_NN for_IN the_DT years_NNS 1989-1996_CD claiming_VBG additional_JJ taxes_NNS of_IN $_$ 2.7_CD billion_CD ._.
On_IN 2nd_JJ April_NNP 2004_CD the_DT Group_NNP led_VBD a_DT petition_NN in_IN the_DT US_NNP Tax_NNP Court_NNP disputing_VBG the_DT IRS_NNP claim_NN and_CC seeking_VBG a_DT refund_NN of_IN $_$ 1_CD billion_CD in_IN taxes_NNS ._.
On_IN 25th_JJ January_NNP 2005_CD the_DT IRS_NNP issued_VBD a_DT further_JJ Notice_NNP of_IN deficiency_NN for_IN the_DT years_NNS 1997-2000_CD claiming_VBG additional_JJ taxes_NNS of_IN $_$ 1.9_CD billion_CD ._.
If_IN the_DT IRS_NNP claims_NNS for_IN the_DT years_NNS 1989-2000_CD were_VBD upheld_VBN ,_, the_DT Group_NNP would_MD additionally_RB be_VB liable_JJ for_IN interest_NN on_IN late_JJ payment_NN ,_, estimated_VBN to_TO amount_VB to_TO $_$ 3.0_CD billion_CD net_NN of_IN federal_JJ tax_NN relief_NN at_IN 31st_CD December_NNP 2004_CD ,_, giving_VBG a_DT total_NN of_IN $_$ 7.6_CD billion_CD for_IN the_DT years_NNS 1989-2000_CD ._.
The_DT Group_NNP expects_VBZ to_TO le_FW a_DT petition_NN against_IN the_DT tax_NN claims_NNS for_IN 1997-2000_CD in_IN April_NNP 2005_CD ,_, including_VBG a_DT further_JJ claim_NN for_IN refund_NN of_IN taxes_NNS ,_, and_CC will_MD ask_VB the_DT Tax_NNP Court_NNP to_TO consolidate_VB the_DT IRS_NNP claims_NNS for_IN all_PDT the_DT years_NNS 1989-2000_CD into_IN a_DT single_JJ trial_NN ._.
A_DT provisional_JJ trial_NN date_NN for_IN the_DT 1989-1996_CD claims_NNS has_VBZ been_VBN set_VBN for_IN October_NNP 2006_CD ._.
As_IN similar_JJ tax_NN issues_NNS remain_VBP open_JJ for_IN 2001_CD to_TO date_NN ,_, GlaxoSmithKline_NNP expects_VBZ to_TO receive_VB further_JJ substantial_JJ claims_NNS by_IN the_DT IRS_NNP for_IN these_DT years_NNS ._.
GlaxoSmithKline_NNP continues_VBZ to_TO believe_VB that_IN the_DT profits_NNS reported_VBN by_IN its_PRP$ US_NNP subsidiaries_NNS for_IN the_DT period_NN 1989_CD to_TO date_NN ,_, on_IN which_WDT it_PRP has_VBZ paid_VBN taxes_NNS in_IN the_DT USA_NNP ,_, are_VBP more_RBR than_IN sufficient_JJ to_TO reect_VB the_DT activities_NNS of_IN its_PRP$ US_NNP operations_NNS ._.
GlaxoSmithKline_NNP is_VBZ in_IN continuing_VBG discussions_NNS with_IN the_DT Inland_NNP Revenue_NN in_IN respect_NN of_IN UK_NNP transfer_NN pricing_NN disputes_NNS ._.
GlaxoSmithKline_NNP uses_VBZ the_DT best_JJS advice_NN in_IN determining_VBG its_PRP$ transfer_NN pricing_NN methodology_NN and_CC in_IN seeking_VBG to_TO manage_VB transfer_NN pricing_NN issues_NNS to_TO a_DT satisfactory_JJ conclusion_NN and_CC ,_, on_IN the_DT basis_NN of_IN external_JJ professional_JJ advice_NN ,_, continues_VBZ to_TO believe_VB that_IN it_PRP has_VBZ made_VBN adequate_JJ provision_NN for_IN the_DT liabilities_NNS likely_JJ to_TO arise_VB from_IN open_JJ assessments_NNS ._.
However_RB ,_, there_EX continues_VBZ to_TO be_VB a_DT wide_JJ difference_NN of_IN views_NNS between_IN the_DT Group_NNP ,_, the_DT IRS_NNP ,_, the_DT Inland_NNP Revenue_NN and_CC other_JJ relevant_JJ taxation_NN authorities_NNS where_WRB open_JJ issues_NNS exist_VBP ._.
The_DT ultimate_JJ liability_NN for_IN such_JJ matters_NNS may_MD vary_VB from_IN amounts_NNS provided_VBN and_CC is_VBZ dependent_JJ upon_IN the_DT outcome_NN of_IN litigation_NN proceedings_NNS and_CC negotiations_NNS with_IN the_DT relevant_JJ tax_NN authorities_NNS ._.
Except_IN as_IN shown_VBN in_IN this_DT Annual_JJ Report_NNP ,_, no_DT provision_NN has_VBZ been_VBN made_VBN for_IN taxation_NN which_WDT would_MD arise_VB on_IN the_DT distribution_NN of_IN profits_NNS retained_VBN by_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS ,_, on_IN the_DT grounds_NNS that_IN no_DT remittance_NN of_IN profit_NN retained_VBN at_IN 31st_CD December_NNP 2004_CD is_VBZ required_VBN in_IN such_JJ a_DT way_NN that_IN incremental_JJ tax_NN will_MD arise_VB ._.
At_IN 31st_CD December_NNP 2004_CD ,_, the_DT Group_NNP had_VBD income_NN tax_NN losses_NNS of_IN approximately_RB 385_CD million_CD 2003_CD 225_CD million_CD and_CC capital_NN losses_NNS estimated_VBN to_TO be_VB in_IN excess_NN of_IN 10_CD billion_CD 2003_CD in_IN excess_NN of_IN 10_CD billion_CD on_IN which_WDT the_DT related_JJ deferred_JJ tax_NN assets_NNS are_VBP not_RB recognized_VBN because_IN there_EX is_VBZ insufficient_JJ evidence_NN that_IN these_DT losses_NNS will_MD be_VB used_VBN ._.
Current_JJ Deferred_NNP Deferred_NNP tax_NN creditor_NN tax_NN debtor_NN tax_NN provision_NN Tax_NNP balances_NNS m_VBP m_FW m_FW At_IN 1st_CD January_NNP 2004_CD 1,458_CD 1,441_CD 618_CD Exchange_NNP adjustments_NNS 67_CD 52_CD Charge_NNP to_TO profit_VB and_CC loss_NN account_NN 1,667_CD 148_CD 142_CD Cash_NN paid_VBN 1,583_CD Other_JJ movements_NNS 123_CD 50_CD At_IN 31st_CD December_NNP 2004_CD 1,598_CD 1,537_CD 710 2003 2004_CD restated_VBN Deferred_JJ taxation_NN asset_NN liability_NN m_NN m_NN Accelerated_VBD capital_NN allowances_NNS 664_CD 689_CD Stock_NNP valuation_NN adjustment_NN 51_CD 52_CD Intra-Group_NNP profit_NN 594_CD 485_CD Product_NNP and_CC business_NN disposals_NNS 31_CD 59_CD Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS 38_CD 113_CD Tax_NNP losses_NNS 20_CD 94_CD Legal_NNP and_CC other_JJ disputes_NNS 157_CD 167_CD Merger_NN integration_NN and_CC manufacturing_NN restructuring_NN 89_CD 157_CD Other_JJ net_JJ timing_NN differences_NNS 675 607 827 823_CD Deferred_JJ taxation_NN provided_VBN on_IN stock_NN valuation_NN adjustments_NNS ,_, intra-Group_JJ profit_NN and_CC other_JJ timing_NN differences_NNS shown_VBN above_IN are_VBP current_JJ ._.
All_DT deferred_VBN taxation_NN movements_NNS arise_VBP from_IN the_DT origination_NN and_CC reversal_NN of_IN timing_NN differences_NNS ._.
Other_JJ net_JJ timing_NN differences_NNS include_VBP accrued_VBN expenses_NNS and_CC other_JJ provisions_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 107_CD 13_CD Earnings_NNS per_IN share_NN 2003 2002 2004_CD restated_VBN restated_VBN p_FW p_FW p_FW Basic_JJ earnings_NNS per_IN share_NN 75.0_CD 77.1_CD 66.5_CD Adjustment_NNP for_IN merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC disposal_NN of_IN subsidiaries_NNS :_: Merger_NN integration_NN and_CC transaction_NN costs_NNS 3.8_CD 10.8_CD Restructuring_NN costs_NNS 1.0_CD 1.5_CD Block_NNP Drug_NNP integration_NN costs_VBZ 0.3_CD 0.7_CD Disposal_NNP of_IN businesses_NNS 0.2_CD 0.9_CD Adjusted_VBN earnings_NNS per_IN share_NN 75.0_CD 82.0_CD 78.6_CD Diluted_VBN earnings_NNS per_IN share_NN 74.8_CD 76.9_CD 66.3_CD Basic_JJ and_CC adjusted_JJ earnings_NNS per_IN share_NN have_VBP been_VBN calculated_VBN by_IN dividing_VBG the_DT profit_NN attributable_JJ to_TO shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN during_IN the_DT period_NN ._.
The_DT numbers_NNS used_VBN in_IN calculating_VBG basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN are_VBP reconciled_VBN below_IN ._.
Adjusted_VBN earnings_NNS per_IN share_NN is_VBZ calculated_VBN using_VBG business_NN performance_NN earnings_NNS ._.
During_IN the_DT years_NNS 2000_CD to_TO 2003_CD ,_, business_NN performance_NN was_VBD the_DT primary_JJ performance_NN measure_NN used_VBN by_IN management_NN and_CC was_VBD presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposals_NNS of_IN businesses_NNS ,_, as_IN management_NN believed_VBD that_IN exclusion_NN of_IN these_DT items_NNS provided_VBD a_DT better_JJR comparison_NN of_IN business_NN performance_NN for_IN the_DT periods_NNS presented_VBN ._.
For_IN 2004_CD ,_, with_IN the_DT completion_NN of_IN these_DT programs_NNS ,_, the_DT Group_NNP is_VBZ reporting_VBG results_NNS on_IN a_DT statutory_JJ basis_NN only_RB ._.
This_DT information_NN ,_, which_WDT is_VBZ provided_VBN in_IN addition_NN to_TO the_DT statutory_JJ results_NNS prepared_VBN under_IN UK_NNP GAAP_NNP ,_, is_VBZ given_VBN to_TO assist_VB shareholders_NNS to_TO gain_VB a_DT clearer_JJR understanding_NN of_IN the_DT underlying_VBG performance_NN of_IN the_DT business_NN and_CC to_TO increase_VB comparability_NN for_IN the_DT periods_NNS presented_VBN ._.
Net_JJ profit_NN for_IN the_DT period_NN attributable_JJ to_TO shareholders_NNS m_VBP mm_NN Earnings_NNS basic_JJ and_CC diluted_JJ 4,302_CD 4,478_CD 3,930_CD Adjustments_NNS for_IN merger_NN items_NNS ,_, restructuring_VBG costs_NNS and_CC disposal_NN of_IN subsidiaries_NNS 281_CD 712_CD Adjusted_VBN earnings_NNS 4,302_CD 4,759_CD 4,642_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS in_IN issue_NN millions_NNS millions_NNS millions_NNS Basic_JJ and_CC adjusted_JJ 5,736_CD 5,806_CD 5,912_CD Dilution_NN for_IN share_NN options_NNS 12_CD 18_CD 22_CD Diluted_NNP 5,748_CD 5,824_CD 5,934_CD Shares_NNS held_VBN by_IN the_DT ESOP_NNP Trusts_NNPS are_VBP excluded_VBN ._.
The_DT trustees_NNS have_VBP waived_VBN their_PRP$ rights_NNS to_TO dividends_NNS on_IN the_DT shares_NNS held_VBN by_IN the_DT ESOP_NNP Trusts_NNPS ._.
14_CD Dividends_NNPS 2004 2003 2002_CD m_FW m_FW m_FW First_NNP interim_JJ 575 524 535_CD Second_JJ interim_JJ 573 522 530_CD Third_JJ interim_JJ 571 520 527_CD Fourth_JJ interim_JJ 683 808 754_CD 2,402_CD 2,374_CD 2,346_CD 2004 2003 2002_CD Dividends_NNS per_IN share_NN p_NN pp_NN First_NNP interim_JJ 10_CD 99_CD Second_JJ interim_JJ 10_CD 9_CD 9_CD Third_NNP interim_JJ 10_CD 99_CD Fourth_JJ interim_JJ 12_CD 14_CD 13_CD 42_CD 41_CD 40_CD 108_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 15_CD Goodwill_NNP Total_NNP m_VBD Cost_NN at_IN 1st_CD January_NNP 2004_CD 195_CD Exchange_NNP adjustments_NNS 13_CD Asset_NNP written_VBN off_RP 2_CD Cost_NN at_IN 31st_CD December_NNP 2004_CD 206_CD Amortisation_NNP at_IN 1st_CD January_NNP 2004_CD 52_CD Exchange_NNP adjustments_NNS 4_CD Provision_NNP for_IN the_DT year_NN 12_CD Asset_NNP written_VBN off_RP 1_CD Amortisation_NNP at_IN 31st_CD December_NNP 2004_CD 67_CD Net_JJ book_NN value_NN at_IN 1st_CD January_NNP 2004_CD 143_CD Net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2004_CD 139_CD Licences_NNPS ,_, 16_CD Other_JJ intangible_JJ assets_NNS patents_NNS ,_, etc._FW ._.
Brands_NNP Total_NNP m_FW m_FW m_FW Cost_NN at_IN 1st_CD January_NNP 2004_CD 838_CD 1,169_CD 2,007_CD Exchange_NNP adjustments_NNS 24_CD 25_CD 49_CD Additions_NNS 462_CD 462_CD Disposals_NNS 1_CD 1_CD 2_CD Assets_NNS written_VBN off_RP 19_CD 19_CD Cost_NN at_IN 31st_CD December_NNP 2004_CD 1,256_CD 1,143_CD 2,399_CD Amortisation_NNP at_IN 1st_CD January_NNP 2004 229 229_CD Exchange_NNP adjustments_NNS 7_CD 7_CD Provision_NNP for_IN the_DT year_NN 94_CD 94_CD Disposals_NNS 1_CD 1_CD Assets_NNS written_VBN off_RP 1_CD 1_CD Amortisation_NNP at_IN 31st_CD December_NNP 2004 314 314_CD Impairment_NN at_IN 1st_CD January_NNP 2004_CD 58_CD 23_CD 81_CD Exchange_NNP adjustments_NNS 1_CD 1_CD 2_CD Impairment_NN loss_NN 4_CD 4_CD Disposals_NNS 1_CD 1_CD Impairment_NN at_IN 31st_CD December_NNP 2004_CD 61_CD 21_CD 82_CD Total_JJ amortisation_NN and_CC impairment_NN at_IN 31st_CD December_NNP 2004_CD 375_CD 21_CD 396_CD Net_JJ book_NN value_NN at_IN 1st_CD January_NNP 2004_CD 551_CD 1,146_CD 1,697_CD Net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2004_CD 881_CD 1,122_CD 2,003_CD The_DT additions_NNS to_TO licences_NNS and_CC patents_NNS in_IN the_DT year_NN relate_VBP to_TO the_DT purchases_NNS of_IN Fraxiparine_NNP and_CC Arixtra_NNP product_NN rights_NNS from_IN Sano-Synthelabo_NNP ,_, the_DT OTC_NNP marketing_NN rights_NNS for_IN orlistat_NN from_IN Roche_NNP and_CC various_JJ other_JJ compound_NN rights_NNS see_VBP Note_NN 26_CD ._.
Brands_NNP largely_RB comprise_VBP a_DT portfolio_NN of_IN products_NNS acquired_VBN with_IN the_DT acquisition_NN of_IN Sterling_NNP Winthrop_NNP Inc._NNP in_IN 1994_CD ,_, such_JJ as_IN Panadol_NNP ,_, Solpadeine_NNP and_CC Hedex_NNP ,_, and_CC the_DT products_NNS acquired_VBN with_IN the_DT acquisition_NN of_IN The_DT Block_NNP Drug_NNP Company_NNP in_IN 2001_CD ,_, such_JJ as_IN Sensodyne_NNP ,_, Polident_NNP and_CC Poligrip_NNP ._.
Each_DT of_IN these_DT is_VBZ considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN given_VBN the_DT strength_NN and_CC durability_NN of_IN the_DT brand_NN and_CC the_DT level_NN of_IN marketing_NN support_NN ._.
Accordingly_RB ,_, they_PRP are_VBP not_RB amortised_VBN ._.
The_DT valuation_NN of_IN each_DT Sterling_NN brand_NN is_VBZ reviewed_VBN annually_RB using_VBG a_DT 10_CD year_NN cash_NN ow_NN forecast_NN as_IN this_DT was_VBD the_DT basis_NN for_IN the_DT original_JJ independent_JJ assessment_NN when_WRB they_PRP were_VBD acquired_VBN in_IN 1994_CD and_CC a_DT post-tax_JJ discount_NN rate_NN of_IN eight_CD per_IN cent_NN ._.
The_DT valuation_NN of_IN each_DT Block_NNP Drug_NNP brand_NN is_VBZ also_RB reviewed_VBN annually_RB using_VBG a_DT five_CD year_NN cash_NN ow_NN forecast_NN and_CC a_DT post-tax_JJ discount_NN rate_NN of_IN eight_CD per_IN cent_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 109_CD Plant_NNP ,_, Land_NNP and_CC equipment_NN Computer_NN Assets_NNS in_IN 17_CD Tangible_JJ xed_JJ assets_NNS buildings_NNS and_CC vehicles_NNS software_NN construction_NN Total_JJ m_NN m_FW m_FW m_FW m_FW Cost_NN at_IN 1st_CD January_NNP 2004_CD 3,999_CD 7,206_CD 431_CD 768_CD 12,404_CD Exchange_NNP adjustments_NNS 78_CD 91_CD 6_CD 3_CD 178_CD Additions_NNPS 91_CD 363_CD 8_CD 531_CD 993_CD Disposals_NNPS 61_CD 270_CD 13_CD 6_CD 350_CD Reclassications_NNPS 113 291 133 537_CD Cost_NN at_IN 31st_CD December_NNP 2004_CD 4,064_CD 7,499_CD 553_CD 753_CD 12,869_CD Depreciation_NN at_IN 1st_CD January_NNP 2004_CD 1,112_CD 4,276_CD 239_CD 5,627_CD Exchange_NNP adjustments_NNS 25_CD 63_CD 4_CD 92_CD Provision_NNP for_IN the_DT year_NN 122_CD 569_CD 94_CD 785_CD Disposals_NNPS 29_CD 215_CD 12_CD 256_CD Reclassications_NNPS 8_CD 6_CD 2_CD Depreciation_NN at_IN 31st_CD December_NNP 2004_CD 1,172_CD 4,573_CD 319_CD 6,064_CD Impairment_NN at_IN 1st_CD January_NNP 2004 129 157_CD 22_CD 28_CD 336_CD Exchange_NNP adjustments_NNS 42_CD 6_CD Impairment_NN loss_NN 17_CD 9_CD 2_CD 28_CD Disposals_NNS 617_CD 1_CD 24_CD Impairment_NN at_IN 31st_CD December_NNP 2004 136 147_CD 24_CD 27_CD 334_CD Total_JJ depreciation_NN and_CC impairment_NN at_IN 31st_CD December_NNP 2004_CD 1,308_CD 4,720_CD 343_CD 27_CD 6,398_CD Net_JJ book_NN value_NN at_IN 1st_CD January_NNP 2004_CD 2,758_CD 2,773_CD 170_CD 740_CD 6,441_CD Net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2004_CD 2,756_CD 2,779_CD 210_CD 726_CD 6,471_CD The_DT net_JJ book_NN value_NN at_IN 31st_CD December_NNP 2004_CD of_IN the_DT Groups_NNS land_NN and_CC buildings_NNS comprises_VBZ freehold_NN properties_NNS 2,557_CD million_CD at_IN 1st_CD January_NNP 2004_CD 2,532_CD million_CD ,_, properties_NNS with_IN leases_NNS of_IN 50_CD years_NNS or_CC more_JJR 143_CD million_CD at_IN 1st_CD January_NNP 2004_CD 182_CD million_CD and_CC properties_NNS with_IN leases_NNS of_IN less_JJR than_IN 50_CD years_NNS 56_CD million_CD at_IN 1st_CD January_NNP 2004_CD 44_CD million_CD ._.
Included_VBN in_IN plant_NN ,_, equipment_NN and_CC vehicles_NNS at_IN 31st_CD December_NNP 2004_CD are_VBP leased_VBN assets_NNS with_IN a_DT cost_NN of_IN 93_CD million_CD at_IN 1st_CD January_NNP 2004_CD 3_CD million_CD ,_, accumulated_VBN depreciation_NN of_IN 25_CD million_CD at_IN 1st_CD January_NNP 2004_CD 2_CD million_CD and_CC a_DT net_JJ book_NN value_NN of_IN 68_CD million_CD at_IN 1st_CD January_NNP 2004_CD 1_CD million_CD ._.
The_DT impairment_NN loss_NN principally_RB arises_VBZ from_IN decisions_NNS to_TO rationalise_VB facilities_NNS and_CC is_VBZ calculated_VBN based_VBN on_IN either_DT net_JJ realisable_JJ value_NN or_CC value_NN in_IN use_NN ,_, typically_RB using_VBG a_DT discount_NN rate_NN of_IN eight_CD per_IN cent_NN ._.
Joint_NNP Associated_NNP Equity_NNP 18_CD Fixed_JJ asset_NN investments_NNS ventures_NNS undertakings_NNS investments_NNS Total_JJ m_NN m_FW m_FW m_FW At_IN 1st_CD January_NNP 2004_CD 13_CD 183_CD 98_CD 294_CD Exchange_NNP adjustments_NNS 14_CD 5_CD 19_CD Additions_NNS 2_CD 84_CD 86_CD Impairment_NN 20_CD 20_CD Transfers_NNPS 1_CD 4_CD 5_CD Disposals_NNPS 31_CD 8_CD 39_CD Retained_VBN profit_NN for_IN the_DT year_NN 1_CD 41_CD 40_CD Goodwill_NNP amortisation_NN 5_CD 5_CD At_IN 31st_CD December_NNP 2004 12 175 145_CD 332_CD Investments_NNP in_IN joint_JJ ventures_NNS comprise_VBP 14_CD million_CD share_NN of_IN gross_JJ assets_NNS 2003_CD 15_CD million_CD and_CC 2_CD million_CD share_NN of_IN gross_JJ liabilities_NNS 2003_CD 2_CD million_CD ._.
The_DT principal_NN associated_VBN undertaking_NN is_VBZ Quest_NNP Diagnostics_NNPS Inc._NNP a_DT US_NNP clinical_JJ laboratory_NN business_NN listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
The_DT investment_NN has_VBZ a_DT book_NN value_NN at_IN 31st_CD December_NNP 2004_CD of_IN 153_CD million_CD 2003_CD 158_CD million_CD and_CC a_DT market_NN value_NN of_IN 908_CD million_CD 2003_CD 904_CD million_CD ._.
At_IN 31st_CD December_NNP 2004_CD ,_, the_DT Group_NNP owned_VBD 18.6_CD per_IN cent_NN of_IN Quest_NNP 2003_CD 21_CD per_IN cent_NN ._.
The_DT book_NN value_NN includes_VBZ goodwill_NN which_WDT is_VBZ being_VBG amortised_VBN over_IN 20_CD years_NNS :_: the_DT amortisation_NN charge_NN for_IN 2004_CD was_VBD 5_CD million_CD 2003_CD -_: 6_CD million_CD ._.
The_DT goodwill_NN at_IN 31st_CD December_NNP 2004_CD amounts_NNS to_TO 61_CD million_CD 2003_CD 85_CD million_CD ._.
Goodwill_NN of_IN 80_CD million_CD which_WDT relates_VBZ to_TO the_DT continuing_VBG Group_NNP interest_NN in_IN Clinical_NNP Laboratories_NNP assets_NNS attributed_VBD to_TO Quest_NNP ,_, remains_VBZ eliminated_VBN against_IN Group_NNP reserves_NNS ._.
Equity_NNP investments_NNS comprise_VBP listed_VBN investments_NNS of_IN 91_CD million_CD 2003_CD 7_CD million_CD and_CC unlisted_JJ investments_NNS of_IN 54_CD million_CD 2003_CD 91_CD million_CD ._.
The_DT market_NN value_NN of_IN listed_VBN investments_NNS at_IN 31st_CD December_NNP 2004_CD was_VBD 98_CD million_CD 2003_CD 9_CD million_CD ._.
110_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 19_CD Equity_NN investments_NNS Total_JJ m_NN At_IN 1st_CD January_NNP 2004_CD 164_CD Exchange_NNP adjustments_NNS 6_CD Additions_NNPS 19_CD Impairments_NNS 5_CD Transfers_NNPS 5_CD Disposals_NNPS 24_CD At_IN 31st_CD December_NNP 2004_CD 153_CD Equity_NN investments_NNS include_VBP listed_VBN investments_NNS of_IN 127_CD million_CD 2003_CD 111_CD million_CD ._.
The_DT market_NN value_NN of_IN listed_VBN investments_NNS was_VBD 172_CD million_CD 2003_CD 184_CD million_CD ._.
20_CD Stocks_NNS 2004_CD 2003_CD m_NN m_NN Raw_NNP materials_NNS and_CC consumables_NNS 629_CD 636_CD Work_NN in_IN progress_NN 644_CD 474_CD Finished_VBN goods_NNS 919_CD 999_CD 2,192_CD 2,109_CD 21_CD Debtors_NNS 2004_CD 2003_CD m_NN m_NN Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP debtors_NNS 3,786_CD 3,715_CD Other_JJ debtors_NNS 374_CD 532_CD Prepaid_JJ pension_NN contributions_NNS 733_CD 440_CD Other_JJ prepayments_NNS and_CC accrued_VBN income_NN 282_CD 247_CD Amounts_NNS due_JJ after_IN one_CD year_NN Other_JJ debtors_NNS 596_CD 512_CD Prepayments_NNS and_CC accrued_VBN income_NN 1_CD 10_CD Deferred_VBN taxation_NN Note_NN 12_CD 1,537_CD 1,441_CD 7,309_CD 6,897_CD Debtors_NNS include_VBP trading_NN balances_NNS of_IN 7_CD million_CD 2003_CD 1_CD million_CD due_JJ from_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ._.
Other_JJ debtors_NNS due_RB after_IN one_CD year_NN include_VBP insurance_NN recovery_NN receivables_NN which_WDT have_VBP been_VBN discounted_VBN using_VBG a_DT risk-free_JJ rate_NN of_IN return_NN ._.
22_CD Other_JJ creditors_NNS 2003_CD 2004_CD restated_VBN m_NN m_NN Amounts_NNS due_JJ within_IN one_CD year_NN Trade_NNP creditors_NNS 707_CD 686_CD Taxation_NNP Note_NN 12_CD 1,598_CD 1,458_CD Social_NNP security_NN 114_CD 108_CD Other_JJ creditors_NNS 351_CD 313_CD Accruals_NNPS and_CC deferred_VBN income_NN 3,110_CD 3,121_CD Dividends_NNS payable_JJ 1,260_CD 1,333_CD 7,140_CD 7,019_CD Amounts_NNS due_JJ after_IN one_CD year_NN Other_JJ creditors_NNS 178_CD 130_CD Accruals_NNPS and_CC deferred_VBN income_NN 66_CD 102_CD ._.
244_CD 232_CD Accruals_NNS include_VBP obligations_NNS for_IN wages_NNS and_CC salaries_NNS of_IN 639_CD million_CD 2003_CD 689_CD million_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 111_CD 23_CD Provisions_NNS for_IN Pensions_NNS and_CC other_JJ Legal_JJ liabilities_NNS and_CC charges_NNS post-retirement_JJ Manufacturing_NNP Merger_NNP and_CC other_JJ Deferred_NNP Other_JJ benets_NNS restructuring_VBG integration_NN disputes_NNS taxation_NN provisions_NNS Total_JJ m_NN m_FW m_FW m_FW m_FW m_FW m_FW At_IN 1st_CD January_NNP 2004_CD 807_CD 99_CD 305_CD 1,007_CD 618_CD 206_CD 3,042_CD Exchange_NNP adjustments_NNS 40_CD 2_CD 5_CD 59_CD 4_CD 110_CD Charge_NNP for_IN the_DT year_NN 145 25 660 142_CD 24_CD 946_CD Unwinding_NN of_IN discount_NN 4_CD 11_CD 1_CD 16_CD Applied_NNP 208_CD 25 80 545 122_CD 980_CD Reclassications_NNS and_CC other_JJ movements_NNS 81_CD 1_CD 50_CD 85_CD 115_CD At_IN 31st_CD December_NNP 2004_CD 785_CD 46_CD 224_CD 1,074_CD 710_CD 190_CD 3,029_CD During_IN 2004_CD ,_, the_DT Group_NNP made_VBD special_JJ cash_NN contributions_NNS totalling_VBG 256_CD million_CD 2003_CD 368_CD million_CD into_IN the_DT UK_NNP and_CC US_NNP pension_NN schemes_NNS ._.
The_DT contribution_NN relating_VBG to_TO the_DT US_NNP pension_NN scheme_NN is_VBZ included_VBN within_IN the_DT amounts_NNS applied_VBD to_TO the_DT provision_NN above_IN :_: the_DT contributions_NNS relating_VBG to_TO the_DT UK_NNP pension_NN scheme_NN have_VBP increased_VBN the_DT pension_NN prepayment_NN amount_NN shown_VBN under_IN debtors_NNS in_IN Note_NN 21_CD ._.
The_DT Group_NNP has_VBZ recognized_VBN costs_NNS in_IN previous_JJ years_NNS in_IN respect_NN of_IN plans_NNS for_IN manufacturing_VBG the_DT other_JJ restructuring_NN initiated_VBN in_IN 1998_CD ,_, 1999_CD and_CC in_IN 2001_CD following_VBG the_DT merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP and_CC the_DT acquisition_NN of_IN Block_NNP Drug_NNP ._.
These_DT plans_NNS are_VBP largely_RB completed_VBN ._.
Costs_NNS recognized_VBD as_IN a_DT provision_NN ,_, principally_RB in_IN respect_NN of_IN identied_JJ severances_NNS at_IN sites_NNS where_WRB it_PRP has_VBZ been_VBN announced_VBN that_IN manufacturing_VBG activities_NNS will_MD cease_VB ,_, are_VBP expected_VBN to_TO be_VB incurred_VBN mainly_RB in_IN 2005_CD and_CC 2006_CD ._.
Costs_NNS of_IN asset_NN write-downs_NNS have_VBP been_VBN recognized_VBN as_IN impairments_NNS of_IN xed_JJ assets_NNS ._.
The_DT Group_NNP has_VBZ recognized_VBN costs_NNS in_IN previous_JJ years_NNS in_IN respect_NN of_IN plans_NNS for_IN the_DT integration_NN of_IN the_DT Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP businesses_NNS ._.
Implementation_NN of_IN the_DT integration_NN following_VBG the_DT merger_NN is_VBZ substantially_RB complete_JJ ._.
Costs_NNS recognized_VBD as_IN a_DT provision_NN in_IN respect_NN of_IN identied_JJ severances_NNS are_VBP expected_VBN to_TO be_VB incurred_VBN in_IN 2005_CD and_CC in_IN respect_NN of_IN the_DT program_NN to_TO encourage_VB staff_NN to_TO convert_VB Glaxo_NNP Wellcome_NNP or_CC SmithKline_NNP Beecham_NNP share_NN options_NNS into_IN GlaxoSmithKline_NNP share_NN options_NNS when_WRB employees_NNS exercise_VBP these_DT options_NNS up_IN to_TO 2010_CD ._.
This_DT latter_JJ provision_NN was_VBD discounted_VBN by_IN 21_CD million_CD in_IN 2004_CD 2003_CD 28_CD million_CD using_VBG risk-free_JJ rates_NNS of_IN return_NN ._.
GlaxoSmithKline_NNP is_VBZ involved_VBN in_IN a_DT number_NN of_IN legal_JJ and_CC other_JJ disputes_NNS ,_, including_VBG notication_NN of_IN possible_JJ claims_NNS ._.
Provisions_NNS for_IN legal_JJ and_CC other_JJ disputes_NNS include_VBP amounts_NNS relating_VBG to_TO US_NNP anti-trust_NN ,_, product_NN liability_NN ,_, contract_NN terminations_NNS ,_, self-insurance_NN ,_, environmental_JJ clean-up_JJ and_CC property_NN rental_NN ._.
The_DT companys_NNS Directors_NNS ,_, having_VBG taken_VBN legal_JJ advice_NN ,_, have_VBP established_VBN provisions_NNS after_IN taking_VBG into_IN account_NN insurance_NN and_CC other_JJ agreements_NNS and_CC having_VBG regard_NN to_TO the_DT relevant_JJ facts_NNS and_CC circumstances_NNS of_IN each_DT matter_NN and_CC in_IN accordance_NN with_IN accounting_NN requirements_NNS ._.
These_DT provisions_NNS were_VBD discounted_VBN by_IN 11_CD million_CD in_IN 2004_CD 2003_CD 25_CD million_CD using_VBG risk-free_JJ rates_NNS of_IN return_NN ._.
GlaxoSmithKline_NNP has_VBZ undertaken_VBN a_DT review_NN of_IN its_PRP$ product_NN liability_NN claims_NNS and_CC assessed_VBN that_IN a_DT number_NN of_IN products_NNS now_RB have_VBP a_DT history_NN of_IN claims_NNS made_VBN and_CC settlements_NNS which_WDT makes_VBZ it_PRP possible_JJ to_TO use_VB an_DT IBNR_NNP incurred_VBN but_CC not_RB reported_VBD actuarial_JJ technique_NN to_TO determine_VB a_DT reasonable_JJ estimate_NN of_IN the_DT Groups_NNS exposure_NN for_IN unasserted_JJ claims_NNS in_IN relation_NN to_TO those_DT products_NNS ._.
Apart_RB from_IN the_DT IBNR_NNP provision_NN ,_, no_DT provisions_NNS have_VBP been_VBN made_VBN for_IN unasserted_JJ claims_NNS ._.
The_DT ultimate_JJ liability_NN for_IN such_JJ matters_NNS may_MD vary_VB from_IN the_DT amounts_NNS provided_VBN and_CC is_VBZ dependent_JJ upon_IN the_DT outcome_NN of_IN litigation_NN proceedings_NNS ,_, investigations_NNS and_CC possible_JJ settlement_NN negotiations_NNS ._.
It_PRP is_VBZ in_IN the_DT nature_NN of_IN the_DT Groups_NNS business_NN that_IN a_DT number_NN of_IN these_DT matters_NNS ,_, including_VBG those_DT provided_VBN using_VBG the_DT IBNR_NNP actuarial_JJ technique_NN ,_, may_MD be_VB the_DT subject_NN of_IN negotiation_NN and_CC litigation_NN over_IN several_JJ years_NNS ._.
The_DT largest_JJS individual_JJ amounts_NNS provided_VBN are_VBP expected_VBN to_TO be_VB settled_VBN within_IN three_CD years_NNS ._.
For_IN a_DT discussion_NN of_IN legal_JJ issues_NNS ,_, refer_VBP to_TO Note_VB 30_CD ,_, Legal_NNP proceedings_NNS ._.
24_CD Contingent_JJ liabilities_NNS At_IN 31st_CD December_NNP 2004_CD contingent_JJ liabilities_NNS ,_, comprising_VBG guarantees_NNS ,_, discounted_VBD bills_NNS and_CC other_JJ items_NNS arising_VBG in_IN the_DT normal_JJ course_NN of_IN business_NN ,_, amounted_VBD to_TO 207_CD million_CD 2003_CD 236_CD million_CD ._.
For_IN a_DT discussion_NN of_IN tax_NN issues_NNS ,_, refer_VBP to_TO Note_VB 12_CD ,_, Taxation_NNP and_CC of_IN legal_JJ issues_NNS ,_, refer_VBP to_TO Note_VB 30_CD ,_, Legal_NNP proceedings_NNS ._.
112_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 25_CD Net_JJ debt_NN 2004_CD 2003_CD m_NN m_NN Liquid_NN investments_NNS 2,818_CD 2,493_CD Cash_NN at_IN bank_NN 1,161_CD 962_CD 3,979_CD 3,455_CD Loans_NNPS and_CC overdrafts_NNS due_JJ within_IN one_CD year_NN :_: 7.375_CD per_IN cent_NN US$_$ US_PRP Medium_NNP Term_NNP Note_VB 2005_CD 52_CD 8.75_CD per_IN cent_NN sterling_NN Euro_NNP Bond_NNP 2005_CD 500_CD Floating_VBG rate_NN US$_$ European_JJ Medium_NNP Term_NNP Notes_NNP 277_CD 2.0_CD per_IN cent_NN CHF_NNP Bond_NNP 2004_CD 106_CD Commercial_JJ paper_NN 830_CD 836_CD Bank_NNP loans_NNS and_CC overdrafts_NNS 163_CD 230_CD Other_JJ loans_NNS 2_CD 2_CD Obligations_NNS under_IN finance_NN leases_NNS 35_CD 1_CD 1,582_CD 1,452_CD Loans_NNS due_JJ after_IN one_CD year_NN :_: 7.375_CD per_IN cent_NN US$_$ Medium_NNP Term_NNP Note_VB 2005_CD 56_CD 8.75_CD per_IN cent_NN sterling_NN Euro_NNP Bond_NNP 2005_CD 499_CD 6.125_CD per_IN cent_NN US$_$ Notes_NNS 2006 260 279_CD 2.375_CD per_IN cent_NN US$_$ US_PRP Medium_NNP Term_NNP Note_VB 2007_CD 260_CD 3.375_CD per_IN cent_NN euro_NN European_JJ Medium_NNP Term_NNP Note_VB 2008 705 699_CD 4.875_CD per_IN cent_NN sterling_NN European_JJ Medium_NNP Term_NNP Note_VB 2008 498 498_CD 3.25_CD per_IN cent_NN euro_NN European_JJ Medium_NNP Term_NNP Note_VB 2009 348 357_CD 4.375_CD per_IN cent_NN US$_$ US_PRP Medium_NNP Term_NNP Note_VB 2014_CD 772_CD 5.25_CD per_IN cent_NN sterling_NN European_JJ Medium_NNP Term_NNP Note_VB 2033 975 974_CD 5.375_CD per_IN cent_NN US$_$ US_PRP Medium_NNP Term_NNP Note_VB 2034_CD 258_CD Loan_NNP Stock_NNP 12_CD 13_CD Bank_NNP loans_NNS 4_CD 4_CD Other_JJ loans_NNS and_CC private_JJ nancing_NN 231_CD 260_CD Obligations_NNS under_IN finance_NN leases_NNS 58_CD 12_CD 4,381_CD 3,651_CD Net_JJ debt_NN 1,984_CD 1,648_CD At_IN the_DT balance_NN sheet_NN date_NN the_DT Groups_NNS liquid_JJ investments_NNS had_VBD an_DT aggregate_JJ market_NN value_NN of_IN 2,820_CD million_CD 2003_CD 2,509_CD million_CD ._.
Liquid_NN investments_NNS include_VBP redeemable_JJ preference_NN shares_NNS ,_, which_WDT are_VBP fully_RB collateralised_VBN with_IN highly_RB rated_VBN bonds_NNS ,_, of_IN 1_CD billion_CD 2003_CD 1_CD billion_CD ._.
Loans_NNS and_CC overdrafts_NNS due_JJ within_IN one_CD year_NN Commercial_JJ paper_NN comprises_VBZ a_DT US$_$ 10_CD billion_CD program_NN ,_, of_IN which_WDT $_$ 1,593_CD million_CD 830_CD million_CD was_VBD in_IN issue_NN at_IN 31st_CD December_NNP 2004_CD 2003_CD $_$ 1,497_CD million_CD 836_CD million_CD ,_, backed_VBD up_RP by_IN committed_JJ facilities_NNS of_IN 364_CD days_NNS duration_NN of_IN $_$ 900_CD million_CD 469_CD million_CD 2003_CD $_$ 1,404_CD million_CD 784_CD million_CD renewable_JJ annually_RB ,_, and_CC liquid_JJ investments_NNS as_IN shown_VBN in_IN the_DT table_NN above_IN ._.
The_DT weighted_JJ average_JJ interest_NN rate_NN on_IN commercial_JJ paper_NN borrowings_NNS at_IN 31st_CD December_NNP 2004_CD was_VBD 2.35_CD per_IN cent_NN 2003_CD 1.1_CD per_IN cent_NN ._.
The_DT weighted_JJ average_JJ interest_NN rate_NN on_IN bank_NN loans_NNS and_CC overdrafts_NNS due_JJ within_IN one_CD year_NN at_IN 31st_CD December_NNP 2004_CD was_VBD 3.0_CD per_IN cent_NN ._.
Loans_NNS due_JJ after_IN one_CD year_NN In_IN 2004_CD ,_, three_CD bonds_NNS were_VBD issued_VBN under_IN the_DT US_NNP Medium_NNP Term_NNP Note_NN program_NN :_: a_DT US$_$ 500_CD million_CD ,_, 2.375_CD per_IN cent_NN coupon_NN bond_NN ,_, a_DT US$_$ 1.5_CD billion_CD ,_, 4.375_CD per_IN cent_NN coupon_NN bond_NN and_CC a_DT US$_$ 500_CD million_CD ,_, 5.375_CD per_IN cent_NN coupon_NN bond_NN ._.
Loans_NNS due_JJ after_IN one_CD year_NN are_VBP repayable_JJ over_IN various_JJ periods_NNS as_IN follows_VBZ :_: 2004_CD 2003_CD m_NN m_NN Between_IN one_CD and_CC two_CD years_NNS 289_CD 562_CD Between_IN two_CD and_CC three_CD years_NNS 279_CD 281_CD Between_IN three_CD and_CC four_CD years_NNS 1,210_CD 2_CD Between_IN four_CD and_CC five_CD years_NNS 352_CD 1,199_CD After_IN five_CD years_NNS 2,251_CD 1,607_CD 4,381_CD 3,651_CD The_DT loans_NNS repayable_JJ after_IN five_CD years_NNS carry_VBP interest_NN at_IN effective_JJ rates_NNS between_IN 4.4_CD per_IN cent_NN and_CC 5.4_CD per_IN cent_NN ._.
The_DT repayment_NN dates_NNS range_VBP from_IN 2010_CD to_TO 2034_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 113_CD 25_CD Net_JJ debt_NN continued_VBD Secured_JJ loans_NNS Loans_NNS amounting_VBG to_TO 11_CD million_CD 2003_CD 13_CD million_CD are_VBP secured_VBN by_IN charges_NNS on_IN xed_VBN and_CC current_JJ assets_NNS ._.
2004_CD 2003_CD Finance_NNP lease_NN obligations_NNS m_VBP m_FW Rental_JJ payments_NNS due_JJ within_IN one_CD year_NN 36_CD 1_CD Rental_JJ payments_NNS due_JJ between_IN one_CD and_CC two_CD years_NNS 28_CD 2_CD Rental_JJ payments_NNS due_JJ between_IN two_CD and_CC three_CD years_NNS 17_CD 1_CD Rental_JJ payments_NNS due_JJ between_IN three_CD and_CC four_CD years_NNS 5_CD 1_CD Rental_JJ payments_NNS due_JJ between_IN four_CD and_CC five_CD years_NNS 3_CD 2_CD Rental_JJ payments_NNS due_JJ after_IN five_CD years_NNS 7_CD 6_CD Total_JJ future_JJ rental_JJ payments_NNS 96_CD 13_CD Future_NNP finance_NN charges_NNS 3_CD Total_JJ finance_NN lease_NN obligations_NNS 93_CD 13_CD Financial_NNP instruments_NNS Further_JJ information_NN is_VBZ given_VBN in_IN Note_NN 34_CD ._.
26_CD Commitments_NNS 2004_CD 2003_CD Capital_NNP commitments_NNS m_VBP m_FW Contracted_VBN for_IN but_CC not_RB provided_VBN in_IN the_DT financial_JJ statements_NNS :_: Intangible_JJ xed_JJ assets_NNS 1,256_CD 1,412_CD Tangible_JJ xed_JJ assets_NNS 235_CD 171_CD 1,491_CD 1,583_CD A_DT number_NN of_IN commitments_NNS were_VBD made_VBN in_IN 2004_CD under_IN licensing_NN and_CC other_JJ agreements_NNS ,_, principally_RB with_IN Theravance_NNP Inc._NNP ._.
Exelixis_NNP Inc._NNP ._.
Tanabe_NNP Seiyaku_NNP Co._NNP ._.
Ltd._NNP and_CC Human_NNP Genome_NNP Sciences_NNPS ,_, Inc._NNP ._.
The_DT Group_NNP also_RB has_VBZ other_JJ commitments_NNS of_IN 85_CD million_CD 2003_CD 144_CD million_CD relating_VBG to_TO revenue_NN payments_NNS to_TO be_VB made_VBN under_IN licences_NNS and_CC other_JJ alliances_NNS ,_, principally_RB to_TO Exelixis_NNP Inc._NNP 2004_CD 2003_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS for_IN the_DT next_JJ year_NN m_FW m_FW Operating_NN leases_NNS on_IN land_NN and_CC buildings_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 4_CD 6_CD Between_IN one_CD and_CC five_CD years_NNS 16_CD 19_CD After_IN five_CD years_NNS 30_CD 35_CD 50_CD 60_CD Operating_NN leases_NNS on_IN plant_NN ,_, equipment_NN and_CC vehicles_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 10_CD 8_CD Between_IN one_CD and_CC five_CD years_NNS 23_CD 50_CD After_IN five_CD years_NNS 2_CD 33_CD 60_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS in_IN future_JJ years_NNS 2005_CD 83_CD 94_CD 2006_CD 73_CD 78_CD 2007_CD 54_CD 54_CD 2008_CD 42_CD 43_CD 2009_CD 36_CD 36_CD 2010_CD and_CC thereafter_RB 119 122 407 427_CD 114_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS Share_NN premium_NN Ordinary_NNP Shares_NNP of_IN 25p_JJ each_DT 27_CD Share_NN capital_NN and_CC share_NN premium_NN account_NN account_NN Number_NNP m_FW m_FW Share_NN capital_NN authorised_VBN At_IN 31st_CD December_NNP 2002_CD 10,000,000,000_CD 2,500_CD At_IN 31st_CD December_NNP 2003_CD 10,000,000,000_CD 2,500_CD At_IN 31st_CD December_NNP 2004_CD 10,000,000,000_CD 2,500_CD Share_NN capital_NN issued_VBN and_CC fully_RB paid_VBN At_IN 1st_CD January_NNP 2002_CD 6,172,965,989_CD 1,543_CD 170_CD Share_NN capital_NN issued_VBN under_IN share_NN option_NN schemes_NNS 7,049,394_CD 2_CD 54_CD Share_NN capital_NN purchased_VBN and_CC canceled_VBN 155,749,038_CD 39_CD At_IN 31st_CD December_NNP 2002_CD 6,024,266,345_CD 1,506_CD 224_CD Share_NN capital_NN issued_VBN under_IN share_NN option_NN schemes_NNS 6,041,283_CD 1_CD 40_CD Share_NN capital_NN purchased_VBN and_CC canceled_VBN 80,844,000_CD 20_CD At_IN 31st_CD December_NNP 2003_CD 5,949,463,628_CD 1,487_CD 264_CD Share_NN capital_NN issued_VBN under_IN share_NN option_NN schemes_NNS 6,300,203_CD 2_CD 40_CD Share_NN capital_NN purchased_VBN and_CC canceled_VBN 18,075,000_CD 5_CD At_IN 31st_CD December_NNP 2004_CD 5,937,688,831_CD 1,484_CD 304_CD 31st_CD December_NNP 31st_CD December_NNP 31st_CD December_NNP 2004 2003 2002_CD Number_NNP 000_CD of_IN shares_NNS issuable_JJ under_IN outstanding_JJ options_NNS Note_VBP 36_CD 276,954_CD 259,990_CD 217,953_CD Number_NNP 000_CD of_IN unissued_JJ shares_NNS not_RB under_IN option_NN 3,785,358_CD 3,790,546_CD 3,757,781_CD At_IN 31st_CD December_NNP 2004_CD ,_, of_IN the_DT issued_VBN share_NN capital_NN ,_, 174,527,097_CD shares_NNS were_VBD held_VBN in_IN the_DT ESOP_NNP Trust_NNP ,_, 69,948,000_CD shares_NNS were_VBD held_VBN in_IN Treasury_NNP and_CC 5,693,213,734_CD shares_NNS were_VBD in_IN free_JJ issue_NN ._.
In_IN October_NNP 2002_CD ,_, GlaxoSmithKline_NNP commenced_VBD a_DT new_JJ 4_CD billion_CD share_NN buy-back_JJ program_NN ._.
This_DT followed_VBD the_DT completion_NN of_IN the_DT 4_CD billion_CD buy-back_NN program_NN announced_VBN in_IN 2001_CD ._.
A_DT total_NN of_IN 2.2_CD billion_CD has_VBZ been_VBN spent_VBN on_IN the_DT new_JJ share_NN buy-back_NN program_NN ,_, of_IN which_WDT 1_CD billion_CD was_VBD spent_VBN in_IN 2004_CD ._.
The_DT exact_JJ amount_NN and_CC timing_NN of_IN future_JJ purchases_NNS ,_, and_CC whether_IN some_DT repurchased_VBN shares_NNS will_MD be_VB held_VBN as_IN Treasury_NNP shares_NNS or_CC be_VB canceled_VBN ,_, will_MD be_VB determined_VBN by_IN the_DT company_NN and_CC is_VBZ dependent_JJ on_IN market_NN conditions_NNS and_CC other_JJ factors_NNS ._.
No_DT shares_NNS were_VBD purchased_VBN in_IN the_DT period_NN 1st_CD January_NNP 2005_CD to_TO 10th_JJ February_NNP 2005_CD ._.
In_IN the_DT period_NN 11th_JJ February_NNP 2005_CD to_TO 25th_JJ February_NNP 2005_CD a_DT further_JJ 5.55_CD million_CD shares_NNS have_VBP been_VBN purchased_VBN at_IN a_DT cost_NN of_IN 70_CD million_CD ._.
All_DT purchases_NNS were_VBD through_IN the_DT publicly_RB announced_VBN buy-back_JJ program_NN ._.
The_DT table_NN below_IN sets_NNS out_IN the_DT monthly_JJ purchases_NNS under_IN the_DT current_JJ share_NN buy-back_NN program_NN :_: Average_JJ share_NN price_NN excluding_VBG Number_NNP of_IN shares_NNS commisson_NN and_CC stamp_VB duty_NN Month_NNP 000_CD January_NNP 2004_CD Nil_NNP February_NNP 2004_CD 4,950_CD 11.09_CD March_NNP 2004_CD 20,545_CD 10.81_CD April_NNP 2004_CD 1,010_CD 11.85_CD May_NNP 2004_CD 7,832_CD 11.73_CD June_NNP 2004_CD 10,156_CD 11.43_CD July_NNP 2004_CD 1,800_CD 11.06_CD August_NNP 2004_CD 11,850_CD 10.88_CD September_NNP 2004_CD 8,485_CD 11.72_CD October_NNP 2004_CD Nil_NNP November_NNP 2004_CD 10,305_CD 11.60_CD December_NNP 2004_CD 11,090_CD 11.64_CD Total_JJ 88,023_CD 11.29_CD For_IN details_NNS of_IN substantial_JJ shareholdings_NNS refer_VBP to_TO Substantial_NNP shareholdings_NNS on_IN page_NN 177_CD ._.
28_CD Non-equity_JJ minority_NN interests_NNS At_IN 1st_CD January_NNP 2004_CD SmithKline_NNP Beecham_NNP Holdings_NNP Corporation_NNP SBH_NNP Corp_NNP ,_, a_DT subsidiary_NN incorporated_VBN in_IN Delaware_NNP ,_, USA_NNP ,_, had_VBD in_IN issue_NN $_$ 500_CD million_CD of_IN Flexible_NNP Auction_NNP Market_NNP Preferred_NNP Stock_NNP Flex_NNP AMPS_NNP ,_, comprising_VBG 5,000_CD shares_NNS of_IN $_$ 100,000_CD each_DT ,_, issued_VBN in_IN six_CD series_NN ._.
SBH_NNP Corp_NNP also_RB had_VBD in_IN issue_NN $_$ 400_CD million_CD of_IN Auction_NNP Rate_NNP Preference_NNP Stock_NNP ARPS_NNP ,_, comprising_VBG 4,000_CD shares_NNS of_IN $_$ 100,000_CD each_DT issued_VBN in_IN five_CD series_NN ._.
The_DT ARPS_NNP and_CC the_DT Flex_NNP AMPS_NNP together_RB constituted_VBD the_DT preference_NN shares_NNS ,_, which_WDT represented_VBD the_DT non-equity_JJ minority_NN interests_NNS ._.
These_DT were_VBD redeemed_VBN in_IN March_NNP and_CC April_NNP 2004_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 115_CD Other_JJ profit_NN and_CC 29_CD Reserves_NNS reserves_NNS loss_NN account_NN Total_JJ restated_VBN restated_VBN restated_VBN m_FW m_FW m_FW At_IN 31st_CD December_NNP 2001_CD as_IN previously_RB reported_VBN 1,866_CD 3,811_CD 5,677_CD Prior_RB year_NN adjustment_NN implementation_NN of_IN UITF_NNP 17_CD revised_VBN and_CC UITF_NNP 38_CD 2,970_CD 63_CD 2,907_CD At_IN 31st_CD December_NNP 2001_CD as_IN restated_VBN 1,104_CD 3,874_CD 2,770_CD Exchange_NNP movements_NNS 82_CD 82_CD UK_NNP tax_NN on_IN exchange_NN movements_NNS 65_CD 65_CD Ordinary_NNP shares_NNS purchased_VBD and_CC canceled_VBD 39_CD 2,220_CD 2,181_CD Investment_NN in_IN ESOP_NNP shares_NNS 144_CD 67_CD 77_CD profit_NN attributable_JJ to_TO shareholders_NNS 3,930_CD 3,930_CD Dividends_NNS 2,346_CD 2,346_CD Unrealised_JJ profit_NN on_IN disposal_NN of_IN intellectual_JJ property_NN 7_CD 7_CD At_IN 31st_CD December_NNP 2002_CD 921_CD 3,031_CD 2,110_CD Exchange_NNP movements_NNS 113_CD 113_CD Tax_NNP on_IN exchange_NN movements_NNS and_CC unrealised_JJ profits_NNS 92_CD 92_CD Ordinary_NNP shares_NNS purchased_VBD and_CC canceled_VBD 20 980 960_CD Investment_NN in_IN ESOP_NNP shares_NNS 97_CD 64_CD 33_CD profit_NN attributable_JJ to_TO shareholders_NNS 4,478_CD 4,478_CD Dividends_NNS 2,374_CD 2,374_CD Unrealised_JJ profit_NN on_IN disposal_NN of_IN intellectual_JJ property_NN 7_CD 7_CD Revaluation_NN of_IN goodwill_NN due_JJ to_TO exchange_VB 7_CD 7_CD At_IN 31st_CD December_NNP 2003_CD 804_CD 4,112_CD 3,308_CD Goodwill_NNP written_VBN back_RB 20_CD 20_CD Exchange_NNP movements_NNS 54_CD 54_CD Tax_NNP on_IN exchange_NN movements_NNS and_CC unrealised_JJ profits_NNS 73_CD 73_CD Ordinary_NNP shares_NNS purchased_VBD and_CC canceled_VBD 5_CD 201_CD 196_CD Ordinary_JJ shares_NNS purchased_VBN and_CC held_VBN as_IN Treasury_NNP shares_NNS 799_CD 799_CD Investment_NN in_IN ESOP_NNP shares_NNS 155_CD 129_CD 26_CD profit_NN attributable_JJ to_TO shareholders_NNS 4,302_CD 4,302_CD Dividends_NNS 2,402_CD 2,402_CD Unrealised_JJ loss_NN on_IN disposal_NN of_IN intellectual_JJ property_NN 1_CD 1_CD Revaluation_NN of_IN goodwill_NN due_JJ to_TO exchange_VB 6_CD 6_CD At_IN 31st_CD December_NNP 2004_CD 644_CD 4,781_CD 4,137_CD Goodwill_NNP arising_VBG on_IN acquisitions_NNS before_IN 1st_CD January_NNP 1998_CD which_WDT has_VBZ been_VBN written_VBN off_RP against_IN profit_NN and_CC loss_NN account_NN reserves_NNS amounts_VBZ to_TO 6,180_CD million_CD ,_, including_VBG goodwill_NN of_IN 4,840_CD million_CD previously_RB held_VBN as_IN a_DT goodwill_NN reserve_NN which_WDT was_VBD offset_VBN against_IN profit_NN and_CC loss_NN account_NN reserves_NNS in_IN 2000_CD ._.
The_DT goodwill_NN written_VBN back_RB in_IN 2004_CD relates_VBZ to_TO the_DT disposal_NN of_IN part_NN of_IN the_DT Groups_NNS holding_VBG in_IN Quest_NNP Diagnostics_NNPS Inc._NNP and_CC the_DT disposal_NN of_IN the_DT Groups_NNS holding_VBG in_IN GlaxoSmithKline_NNP Pharmaceuticals_NNP Chongqing_NNP Limited_NNP ._.
Goodwill_NNP denominated_VBD in_IN local_JJ currencies_NNS which_WDT is_VBZ subject_JJ to_TO revaluation_NN amounted_VBD to_TO 294_CD million_CD at_IN 31st_CD December_NNP 2004_CD ._.
Goodwill_NN on_IN acquisitions_NNS after_IN 1st_CD January_NNP 1998_CD has_VBZ been_VBN capitalized_VBN ,_, in_IN accordance_NN with_IN the_DT accounting_NN policy_NN set_VBN out_RP in_IN Note_NN 2_CD ._.
Exchange_NNP movements_NNS taken_VBN to_TO reserves_NNS in_IN 2004_CD include_VBP losses_NNS of_IN 86_CD million_CD 2003_CD losses_NNS 27_CD million_CD ,_, 2002_CD losses_NNS 1,179_CD million_CD on_IN foreign_JJ currency_NN loans_NNS less_RBR deposits_NNS ,_, gains_NNS of_IN 38_CD million_CD 2003_CD gains_NNS 133_CD million_CD ,_, 2002_CD gains_NNS 1,097_CD million_CD on_IN the_DT retranslation_NN of_IN net_JJ assets_NNS and_CC 6_CD million_CD 2003_CD 7_CD million_CD ,_, 2002_CD nil_NN on_IN goodwill_NN eliminated_VBN against_IN reserves_NNS ._.
The_DT tax_NN on_IN exchange_NN movements_NNS and_CC unrealised_JJ profits_NNS in_IN 2004_CD of_IN 73_CD million_CD 2003_CD 92_CD million_CD ,_, 2002_CD 65_CD million_CD relates_VBZ to_TO the_DT taxable_JJ element_NN of_IN the_DT foreign_JJ currency_NN loans_NNS less_RBR deposits_NNS and_CC unrealised_JJ profits_NNS taken_VBN to_TO reserves_NNS ._.
Exchange_NNP adjustments_NNS debited_VBD to_TO reserves_NNS cumulatively_RB amount_VB to_TO 1,291_CD million_CD 2003_CD 1,243_CD million_CD ,_, 2002_CD 1,356_CD million_CD ._.
Other_JJ reserves_NNS include_VBP the_DT merger_NN reserve_NN created_VBN on_IN the_DT merger_NN of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP amounting_VBG to_TO 1,561_CD million_CD at_IN 31st_CD December_NNP 2004_CD 2003_CD 1,561_CD million_CD :_: 2002_CD 1,561_CD million_CD ._.
Other_JJ reserves_NNS also_RB include_VBP the_DT capital_NN redemption_NN reserve_NN created_VBN as_IN a_DT result_NN of_IN the_DT share_NN buy-back_JJ program_NN amounting_NN to_TO 81_CD million_CD at_IN 31st_CD December_NNP 2004_CD 2003_CD 76_CD million_CD ,_, 2002_CD 56_CD million_CD ._.
Following_VBG the_DT implementation_NN of_IN UITF_NNP 38_CD ,_, investments_NNS in_IN own_JJ shares_NNS held_VBN by_IN the_DT ESOP_NNP Trusts_NNPS amounting_VBG to_TO 2,574_CD million_CD at_IN 31st_CD December_NNP 2004_CD 2003_CD 2,729_CD million_CD ,_, 2002_CD 2,826_CD million_CD are_VBP now_RB shown_VBN as_IN a_DT deduction_NN from_IN other_JJ reserves_NNS ._.
Total_JJ reserves_NNS amounted_VBD to_TO 4,137_CD million_CD at_IN 31st_CD December_NNP 2004_CD 2003_CD 3,308_CD million_CD ,_, 2002_CD 2,110_CD million_CD ,_, of_IN which_WDT 8,303_CD million_CD 2003_CD 8,981_CD million_CD :_: 2002_CD 10,879_CD million_CD relates_VBZ to_TO the_DT company_NN and_CC 97_CD million_CD 2003_CD 86_CD million_CD ,_, 2002_CD 76_CD million_CD relates_VBZ to_TO joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS ._.
The_DT profit_NN of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN was_VBD 2,719_CD million_CD 2003_CD 1,436_CD million_CD ,_, 2002_CD 10,598_CD million_CD ,_, which_WDT after_IN dividends_NNS of_IN 2,402_CD million_CD 2003_CD 2,374_CD million_CD ,_, 2002_CD 2,352_CD million_CD ,_, gave_VBD a_DT retained_VBN profit_NN of_IN 317_CD million_CD 2003_CD loss_NN 938_CD million_CD ,_, 2002_CD profit_NN 8,246_CD million_CD ._.
After_IN the_DT cost_NN of_IN shares_NNS purchased_VBN and_CC canceled_VBN of_IN 201_CD million_CD 2003_CD 980_CD million_CD ,_, 2002_CD 2,220_CD million_CD ,_, shares_NNS purchased_VBD and_CC held_VBD as_IN Treasury_NNP shares_NNS of_IN 799_CD million_CD 2003_CD nil_NN ,_, 2002_CD nil_NN and_CC an_DT unrealised_JJ profit_NN on_IN capital_NN reduction_NN by_IN subsidiary_NN of_IN nil_NN 2003_CD nil_NN ,_, 2002_CD 4,096_CD million_CD ,_, the_DT profit_NN and_CC loss_NN account_NN reserve_NN at_IN 31st_CD December_NNP 2004_CD stood_VBD at_IN 8,222_CD million_CD 2003_CD 8,905_CD million_CD ,_, 2002_CD 10,823_CD million_CD ,_, of_IN which_WDT 4,096_CD million_CD is_VBZ unrealised_JJ 2003_CD 4,096_CD million_CD ,_, 2002_CD 4,096_CD million_CD ._.
116_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 30_CD Legal_JJ proceedings_NNS In_IN July_NNP 1998_CD ,_, GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Apotex_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Northern_NNP District_NNP of_IN Illinois_NNP for_IN The_NNP Group_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ and_CC administrative_JJ infringement_NN of_IN the_DT Groups_NNS patent_NN for_IN paroxetine_JJ hydrochloride_NN proceedings_NNS ,_, principally_RB product_NN liability_NN ,_, intellectual_JJ property_NN ,_, tax_NN ,_, hemihydrate_NN ._.
Apotex_NNP had_VBD led_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP anti-trust_JJ and_CC governmental_JJ investigations_NNS and_CC related_JJ private_JJ Application_NN ANDA_NNP with_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP litigation_NN ._.
The_DT Group_NNP makes_VBZ provision_NN for_IN these_DT proceedings_NNS on_IN a_DT FDA_NNP seeking_VBG approval_NN to_TO introduce_VB a_DT generic_JJ form_NN of_IN Paxil_NNP ._.
regular_JJ basis_NN as_IN summarised_VBN in_IN Notes_NNP 2_CD and_CC 23_CD ._.
The_DT Group_NNP may_MD Following_VBG a_DT trial_NN in_IN February_NNP 2003_CD the_DT judge_NN ruled_VBD make_VB additional_JJ significant_JJ provisions_NNS for_IN such_JJ legal_JJ proceedings_NNS ,_, GlaxoSmithKlines_NNP patent_NN valid_JJ but_CC not_RB infringed_VBN by_IN Apotexs_NNP as_IN required_VBN in_IN the_DT event_NN of_IN further_JJ developments_NNS in_IN these_DT matters_NNS ,_, product_NN ._.
On_IN the_DT Groups_NNS appeal_NN of_IN the_DT ruling_NN of_IN non-infringement_JJ ,_, consistent_JJ with_IN generally_RB accepted_VBN accounting_NN principles_NNS ._.
Litigation_NN ,_, the_DT US_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP CAFC_NNP ,_, which_WDT particularly_RB in_IN the_DT USA_NNP ,_, is_VBZ inherently_RB unpredictable_JJ and_CC excessive_JJ hears_VBZ all_DT appeals_NNS from_IN US_NNP District_NNP Courts_NNPS on_IN patent_NN matters_NNS ,_, ruled_VBD awards_NNS that_WDT may_MD not_RB be_VB justied_VBN by_IN the_DT evidence_NN may_MD occur_VB ._.
The_DT that_IN the_DT Groups_NNS patent_NN was_VBD infringed_VBN but_CC invalid_JJ based_VBN upon_IN Group_NNP could_MD in_IN the_DT future_NN incur_VBP judgments_NNS or_CC enter_VBP into_IN public_JJ use_NN in_IN clinical_JJ trials_NNS prior_RB to_TO the_DT ling_NN date_NN settlements_NNS of_IN claims_NNS that_WDT could_MD result_VB in_IN payments_NNS that_WDT exceed_VBP in_IN the_DT USA_NNP ._.
The_DT Group_NNP led_VBD a_DT petition_NN to_TO the_DT CAFC_NNP for_IN rehearing_NN its_PRP$ current_JJ provisions_NNS by_IN an_DT amount_NN that_WDT would_MD have_VB a_DT material_NN of_IN its_PRP$ appeal_NN by_IN the_DT full_JJ court_NN but_CC as_IN of_IN the_DT date_NN of_IN this_DT report_NN adverse_JJ effect_NN on_IN the_DT Groups_NNS financial_JJ condition_NN and_CC results_NNS no_DT decision_NN on_IN that_DT petition_NN has_VBZ yet_RB been_VBN announced_VBN ._.
In_IN June_NNP 1999_CD ,_, GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Geneva_NNP Intellectual_NNP property_NN claims_NNS include_VBP challenges_NNS to_TO the_DT validity_NN of_IN the_DT Pharmaceuticals_NNS ,_, a_DT subsidiary_NN of_IN Novartis_NNP Pharmaceuticals_NNP ,_, in_IN the_DT Groups_NNS patents_NNS on_IN various_JJ products_NNS or_CC processes_NNS and_CC assertions_NNS of_IN US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP for_IN non-infringement_NN of_IN those_DT patents_NNS ._.
A_DT loss_NN in_IN any_DT of_IN these_DT cases_NNS infringement_NN of_IN the_DT Groups_NNS patents_NNS for_IN paroxetine_JJ hydrochloride_NN could_MD result_VB in_IN loss_NN of_IN patent_NN protection_NN for_IN the_DT product_NN at_IN issue_NN ._.
following_VBG notice_NN of_IN Genevas_NNP ANDA_NNP ling_NN ._.
That_DT case_NN has_VBZ been_VBN The_DT consequence_NN of_IN any_DT such_JJ loss_NN could_MD be_VB a_DT significant_JJ decrease_NN consolidated_VBN with_IN similar_JJ infringement_NN actions_NNS against_IN other_JJ in_IN sales_NNS of_IN that_DT product_NN and_CC could_MD materially_RB affect_VB future_JJ results_NNS generic_JJ companies_NNS that_WDT subsequently_RB led_VBD ANDAs_NNP ._.
Additional_JJ of_IN operations_NNS for_IN the_DT Group_NNP ._.
infringement_NN actions_NNS have_VBP been_VBN brought_VBN based_VBN on_IN patents_NNS issued_VBN Legal_JJ expenses_NNS incurred_VBN ,_, relating_VBG to_TO the_DT defense_NN of_IN the_DT Groups_NNS subsequent_JJ to_TO the_DT original_JJ ling_NN against_IN Apotex_NNP in_IN the_DT Northern_NNP intellectual_JJ property_NN ,_, and_CC litigation_NN costs_NNS and_CC provisions_NNS related_VBN to_TO District_NNP of_IN Illinois_NNP ._.
The_DT Group_NNP also_RB led_VBD an_DT action_NN against_IN Apotex_NNP product_NN liability_NN claims_NNS on_IN existing_VBG products_NNS ,_, are_VBP charged_VBN to_TO selling_VBG ,_, relating_VBG to_TO those_DT new_JJ patents_NNS in_IN the_DT Eastern_NNP District_NNP of_IN general_JJ and_CC administration_NN costs_NNS ._.
Litigation_NN costs_NNS and_CC provisions_NNS Pennsylvania_NNP ._.
In_IN December_NNP 2002_CD the_DT judge_NN granted_VBN in_IN part_NN and_CC relating_VBG to_TO legal_JJ claims_NNS on_IN withdrawn_VBN products_NNS ,_, anti-trust_JJ and_CC denied_VBD in_IN part_NN summary_NN judgement_NN motions_NNS led_VBN by_IN Apotex_NNP with_IN pricing_NN matters_NNS are_VBP charged_VBN to_TO other_JJ operating_NN income_NN expense_NN ._.
the_DT result_NN that_IN issues_NNS of_IN validity_NN and_CC infringement_NN of_IN three_CD of_IN the_DT Provisions_NNS are_VBP made_VBN ,_, after_IN taking_VBG appropriate_JJ legal_JJ advice_NN ,_, when_WRB four_CD new_JJ patents_NNS remain_VBP for_IN trial_NN ._.
The_DT Group_NNP has_VBZ petitioned_VBN the_DT a_DT reasonable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT likely_JJ outcome_NN of_IN the_DT District_NNP Court_NNP to_TO permit_VB an_DT interim_JJ appeal_NN to_TO the_DT CAFC_NNP of_IN summary_NN dispute_NN ._.
In_IN 2004_CD the_DT Group_NNP established_VBD an_DT actuarially_RB determined_VBN rulings_NNS that_WDT one_CD of_IN the_DT four_CD new_JJ patents_NNS and_CC certain_JJ claims_NNS of_IN provision_NN for_IN product_NN liability_NN claims_NNS incurred_VBN but_CC not_RB yet_RB reported_VBN the_DT other_JJ three_CD are_VBP invalid_JJ ._.
In_IN June_NNP 2003_CD the_DT Group_NNP requested_VBD the_DT as_RB described_VBN in_IN Note_NN 23_CD ._.
At_IN 31st_CD December_NNP 2004_CD the_DT Groups_NNS FDA_NNP to_TO remove_VB three_CD patents_NNS related_VBN to_TO Paxil_NNP from_IN the_DT register_NN of_IN aggregate_JJ provision_NN for_IN legal_JJ and_CC other_JJ disputes_NNS not_RB including_VBG tax_NN pharmaceutical_JJ patents_NNS maintained_VBN by_IN the_DT FDA_NNP the_DT Orange_NNP Book_NNP ._.
matters_NNS described_VBN under_IN Taxation_NNP in_IN Note_NN 12_CD was_VBD just_RB over_IN The_DT delisting_NN did_VBD not_RB affect_VB the_DT validity_NN of_IN these_DT patents_NNS or_CC the_DT 1_CD billion_CD ._.
The_DT ultimate_JJ liability_NN for_IN legal_JJ claims_NNS may_MD vary_VB from_IN the_DT related_JJ patent_NN litigation_NN ._.
Following_VBG FDA_NNP approval_NN of_IN its_PRP$ ANDA_NNP ,_, amounts_VBZ provided_VBN and_CC is_VBZ dependent_JJ upon_IN the_DT outcome_NN of_IN litigation_NN Apotex_NNP subsequently_RB launched_VBD a_DT generic_JJ version_NN of_IN Paxil_NNP proceedings_NNS ,_, investigations_NNS and_CC possible_JJ settlement_NN negotiations_NNS ._.
The_DT most_RBS significant_JJ of_IN those_DT matters_NNS are_VBP described_VBN below_IN ._.
The_DT Group_NNP continues_VBZ to_TO pursue_VB patent_NN infringement_NN claims_NNS in_IN litigation_NN in_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP against_IN Apotex_NNP ,_, Intellectual_NNP property_NN Geneva_NNP ,_, Alphapharm_NNP ,_, Andrx_NNP ,_, Teva_NNP Pharmaceuticals_NNP and_CC Zenith_NNP ,_, USA_NNP and_CC bulk_JJ suppliers_NNS BASF_NNP and_CC Sumika_NNP Fine_NNP Chemicals_NNPS ._.
Apotex_NNP ,_, Alphapharm_NNP ,_, BASF_NNP and_CC Sumika_NNP have_VBP led_VBN counterclaims_NNS in_IN these_DT Paxil_NNP actions_NNS alleging_VBG that_IN the_DT Group_NNP has_VBZ violated_VBN anti-trust_JJ or_CC unfair_JJ In_IN the_DT USA_NNP a_DT number_NN of_IN distributors_NNS of_IN generic_JJ drugs_NNS led_VBD competition_NN laws_NNS ._.
In_IN February_NNP 2003_CD the_DT CAFC_NNP heard_VBD Apotexs_NNP applications_NNS with_IN the_DT FDA_NNP to_TO market_VB generic_JJ versions_NNS of_IN appeal_NN from_IN a_DT decision_NN by_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP Paxil_NNP Seroxat_NNP paroxetine_JJ hydrochloride_NN prior_RB to_TO the_DT expiration_NN of_IN Columbia_NNP denying_VBG Apotexs_NNP request_NN that_IN the_DT FDA_NNP be_VB required_VBN in_IN 2006_CD of_IN the_DT Groups_NNS patent_NN on_IN paroxetine_JJ hydrochloride_NN to_TO delist_VB certain_JJ of_IN the_DT Groups_NNS patents_NNS for_IN Paxil_NNP from_IN the_DT Orange_NNP hemihydrate_NN ._.
Apotex_NNP launched_VBD its_PRP$ generic_JJ version_NN of_IN Paxil_NNP in_IN Book_NNP ._.
In_IN October_NNP 2003_CD the_DT CAFC_NNP afrmed_VBD the_DT district_NN court_NN September_NNP 2003_CD ._.
Other_JJ distributors_NNS sought_VBD to_TO bring_VB to_TO market_NN decision_NN and_CC dismissed_VBD the_DT case_NN ._.
Certain_JJ but_CC not_RB all_DT of_IN the_DT claims_NNS anhydrate_VBP or_CC other_JJ versions_NNS of_IN paroxetine_JJ hydrochloride_NN and_CC in_IN and_CC counterclaims_NNS with_IN respect_NN to_TO Geneva_NNP ,_, Alphapharm_NNP ,_, BASF_NNP one_CD case_NN paroxetine_JJ mesylate_NN ._.
In_IN response_NN the_DT Group_NNP led_VBD actions_NNS and_CC Sumika_NNP have_VBP now_RB been_VBN settled_VBN ._.
against_IN all_PDT those_DT distributors_NNS for_IN infringement_NN of_IN various_JJ of_IN the_DT Groups_NNS patents_NNS on_IN the_DT basis_NN that_IN the_DT generic_JJ anhydrate_NN and_CC In_IN March_NNP 2000_CD ,_, GlaxoSmithKline_NNP led_VBD an_DT action_NN against_IN Pentech_NNP other_JJ versions_NNS infringe_VBP because_IN they_PRP contain_VBP and_CC or_CC convert_VB to_TO Pharmaceuticals_NNS in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Northern_NNP District_NNP the_DT hemihydrate_JJ form_NN and_CC or_CC infringe_VB other_JJ Group_NNP patents_NNS ._.
of_IN Illinois_NNP for_IN infringement_NN of_IN the_DT Groups_NNS patents_NNS for_IN paroxetine_JJ hydrochloride_NN ._.
Pentech_NNP led_VBD an_DT ANDA_NNP for_IN a_DT capsule_NN version_NN of_IN Paxil_NNP ,_, asserting_VBG that_IN its_PRP$ compound_NN and_CC presentation_NN do_VBP not_RB infringe_VB the_DT Groups_NNS patents_NNS or_CC that_IN the_DT patents_NNS are_VBP invalid_JJ ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 117_CD 30_CD Legal_NNP proceedings_NNS continued_VBD In_IN June_NNP 2003_CD ,_, the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN the_DT Faulding_NNP In_IN April_NNP 2003_CD ,_, the_DT Group_NNP reached_VBD a_DT settlement_NN with_IN Pentech_NNP and_CC Pharmaceutical_NNP Company_NNP alleging_VBG infringement_NN of_IN the_DT two_CD method_NN Par_NNP Pharmaceuticals_NNP to_TO which_WDT Pentech_NNP had_VBD granted_VBN rights_NNS under_IN of_IN use_NN patents_NNS for_IN ondansetron_NN ._.
Faulding_NNP did_VBD not_RB challenge_VB the_DT Pentechs_NNP ANDA_NNP for_IN paroxetine_JJ hydrochloride_NN capsules_NNS ._.
That_DT case_NN ,_, as_IN of_IN the_DT date_NN of_IN this_DT report_NN ,_, has_VBZ The_DT settlement_NN allowed_VBD Par_NN to_TO distribute_VB in_IN Puerto_NNP Rico_NNP been_VBN stayed_VBN pending_VBG decisions_NNS in_IN the_DT Teva_NNP ,_, Reddy_NNP and_CC Kali_NNP cases_NNS ._.
substitutable_JJ generic_JJ paroxetine_JJ hydrochloride_NN immediate_JJ release_NN In_IN August_NNP 2004_CD ,_, the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP tablets_NNS supplied_VBD and_CC licensed_VBD from_IN the_DT Group_NNP for_IN a_DT royalty_NN payable_JJ District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Pliva_NNP alleging_VBG to_TO the_DT Group_NNP ._.
Par_NN became_VBD entitled_VBN to_TO distribute_VB the_DT same_JJ product_NN infringement_NN of_IN the_DT Groups_NNS patent_NN for_IN a_DT reduced_VBN crystal_NN size_NN of_IN in_IN the_DT US_NNP market_NN once_RB Apotexs_NNP generic_JJ version_NN of_IN Paxil_NNP became_VBD ondansetron_NN ,_, which_WDT expires_VBZ in_IN March_NNP 2012_CD taking_VBG into_IN account_NN available_JJ there_EX in_IN September_NNP 2003_CD ._.
In_IN the_DT settlement_NN Par_NN and_CC the_DT extension_NN for_IN paediatric_JJ exclusivity_NN ._.
Pliva_NNP did_VBD not_RB challenge_VB the_DT Pentech_NNP acknowledge_VBP that_IN the_DT GlaxoSmithKline_NNP patent_NN covering_VBG compound_NN patent_NN or_CC the_DT emesis_NN use_NN patents_NNS ._.
The_DT case_NN is_VBZ in_IN its_PRP$ the_DT hemihydrate_JJ form_NN of_IN paroxetine_JJ hydrochloride_NN is_VBZ valid_JJ and_CC preliminary_JJ stages_NNS ._.
enforceable_JJ and_CC would_MD be_VB infringed_VBN by_IN Pentechs_NNP proposed_VBD capsule_JJ product_NN ._.
The_DT Bureau_NNP of_IN Competition_NN of_IN the_DT US_NNP Federal_NNP Trade_NNP In_IN January_NNP 2005_CD ,_, the_DT Group_NNP commenced_VBD two_CD additional_JJ actions_NNS ,_, Commission_NNP reviewed_VBD the_DT settlement_NN ._.
The_DT review_NN was_VBD voluntary_JJ both_DT in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP ,_, for_IN and_CC was_VBD conducted_VBN at_IN the_DT request_NN of_IN the_DT Group_NNP ,_, Par_NNP and_CC Pentech_NNP ._.
the_DT same_JJ reduced_VBN crystal_NN size_NN patent_NN against_IN Kali_NNP and_CC Apotex_NNP ._.
In_IN Pentechs_NNP former_JJ supplier_NN Asahi_NNP Glass_NNP Co._NNP led_VBD claims_NNS alleging_VBG that_IN contrast_NN to_TO its_PRP$ previous_JJ ANDA_NNP for_IN orally_RB disintegrating_VBG tablets_NNS ,_, the_DT settlement_NN violated_VBD the_DT anti-trust_JJ laws_NNS ._.
Those_DT claims_NNS have_VBP been_VBN Kali_NNP did_VBD not_RB challenge_VB the_DT emesis_NN use_NN patents_NNS in_IN its_PRP$ recent_JJ ANDA_NNP dismissed_VBN by_IN the_DT court_NN ._.
Similar_JJ claims_NNS brought_VBN by_IN Apotex_NNP and_CC for_IN oral_JJ tablets_NNS nor_CC did_VBD it_PRP challenge_VB the_DT compound_NN patent_NN ._.
Apotex_NNP Sumika_NNP are_VBP pending_VBG in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP did_VBD not_RB challenge_VB either_DT compound_NN or_CC emesis_NN use_NN patents_NNS in_IN District_NNP of_IN Pennsylvania_NNP ._.
Zofran_NNP Lamictal_NNP In_IN August_NNP 2001_CD the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP In_IN August_NNP 2002_CD ,_, the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Reddy-Cheminor_NNP and_CC Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Teva_NNP Pharmaceuticals_NNP Dr_NNP Reddys_NNP Laboratories_NNPS ._.
Dr_NNP Reddy_NNP had_VBD certied_VBN invalidity_NN of_IN three_CD USA_NNP ,_, Inc._NNP alleging_VBG infringement_NN of_IN the_DT Groups_NNS compound_VBP patent_NN patents_NNS for_IN ondansetron_NN ,_, the_DT active_JJ ingredient_NN in_IN Zofran_NNP tablets_NNS ,_, for_IN lamotrigine_NN ,_, the_DT active_JJ ingredient_NN in_IN Lamictal_JJ oral_JJ tablets_NNS ._.
That_DT including_VBG the_DT compound_NN patent_NN that_WDT expires_VBZ in_IN July_NNP 2005_CD and_CC two_CD patent_NN affords_NNS protection_NN through_IN January_NNP 2009_CD after_IN giving_VBG effect_NN method_NN of_IN use_NN patents_NNS ,_, the_DT later_JJ of_IN which_WDT expires_VBZ in_IN December_NNP to_TO an_DT expected_VBN grant_NN of_IN paediatric_JJ exclusivity_NN by_IN FDA_NNP ._.
The_DT 2006_CD ,_, in_IN both_DT instances_NNS taking_VBG into_IN account_NN the_DT extension_NN for_IN defendant_NN had_VBD led_VBN an_DT ANDA_NNP with_IN the_DT FDA_NNP with_IN a_DT certication_NN of_IN paediatric_JJ exclusivity_NN ._.
In_IN July_NNP 2003_CD the_DT Group_NNP led_VBD an_DT action_NN against_IN invalidity_NN of_IN the_DT Groups_NNS patent_NN ._.
The_DT Hatch-Waxman_NNP stay_VB on_IN the_DT Dr_NNP Reddys_NNPS Laboratories_NNPS in_IN the_DT same_JJ district_NN court_NN for_IN infringement_NN FDA_NNP approval_NN of_IN that_DT ANDA_NNP has_VBZ expired_VBN ._.
The_DT trial_NN in_IN the_DT Teva_NNP case_NN of_IN the_DT Groups_NNS patents_NNS related_VBN to_TO the_DT orally_RB disintegrating_VBG tablet_NN concluded_VBD in_IN January_NNP 2005_CD ._.
Following_VBG the_DT trial_NN the_DT parties_NNS reached_VBD presentation_NN of_IN Zofran_NNP ._.
In_IN October_NNP 2003_CD the_DT Group_NNP led_VBD an_DT action_NN a_DT settlement_NN agreement_NN subject_NN to_TO government_NN review_NN ,_, pursuant_JJ against_IN West-ward_JJ Pharmaceuticals_NNS ,_, Inc._NNP in_IN the_DT same_JJ district_NN court_NN to_TO which_WDT the_DT Group_NNP has_VBZ granted_VBN Teva_NNP an_DT exclusive_JJ royalty-bearing_NN for_IN infringement_NN of_IN the_DT Groups_NNS patents_NNS related_VBN to_TO an_DT injectable_JJ licence_NN to_TO distribute_VB in_IN the_DT USA_NNP a_DT generic_JJ version_NN of_IN lamotrigine_NN presentation_NN of_IN Zofran_NNP ._.
Both_DT the_DT Dr_NNP Reddy_NNP disintegrating_VBG tablet_NN chewable_JJ tablets_NNS on_IN a_DT date_NN not_RB later_RB than_IN June_NNP 2005_CD and_CC the_DT case_NN and_CC the_DT West-ward_JJ case_NN were_VBD consolidated_VBN with_IN the_DT earlier_JJR exclusive_JJ right_NN to_TO manufacture_VB and_CC sell_VB Tevas_NNP own_JJ generic_JJ version_NN Dr_NNP Reddy_NNP case_NN ._.
Prior_RB to_TO trial_NN both_DT Reddy-Cheminor_NNP and_CC West-ward_JJ of_IN lamotrigine_NN tablets_NNS in_IN the_DT USA_NNP with_IN an_DT expected_VBN launch_NN date_NN in_IN withdrew_VBD their_PRP$ challenges_NNS to_TO the_DT compound_NN patent_NN ._.
The_DT trial_NN 2008_CD ._.
over_IN infringement_NN of_IN the_DT Groups_NNS method_NN of_IN use_NN and_CC process_NN Imitrex_NNP patents_NNS was_VBD completed_VBN in_IN June_NNP 2004_CD but_CC as_IN of_IN the_DT date_NN of_IN this_DT In_IN December_NNP 2003_CD ,_, the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP report_NN closing_NN arguments_NNS have_VBP not_RB been_VBN held_VBN and_CC no_DT decision_NN District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN has_VBZ been_VBN announced_VBN ._.
Dr_NNP Reddys_NNP Laboratories_NNPS ,_, alleging_VBG infringement_NN of_IN one_CD of_IN two_CD In_IN March_NNP 2002_CD ,_, the_DT Group_NNP led_VBD a_DT similar_JJ action_NN against_IN Teva_NNP primary_JJ compound_NN patents_NNS for_IN sumatriptan_NN ,_, the_DT active_JJ ingredient_NN Pharmaceuticals_NNS USA_NNP Inc._NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN in_IN Imitrex_NNP ._.
The_DT patent_NN at_IN issue_NN affords_NNS protection_NN through_IN February_NNP Delaware_NNP alleging_VBG infringement_NN of_IN the_DT two_CD method_NN of_IN use_NN patents_NNS 2009_CD after_IN giving_VBG effect_NN to_TO a_DT grant_NN of_IN paediatric_JJ exclusivity_NN by_IN the_DT for_IN ondansetron_NN ._.
Teva_NNP had_VBD certied_VBN invalidity_NN or_CC non-infringement_JJ FDA_NNP ._.
The_DT defendant_NN has_VBZ led_VBN an_DT ANDA_NNP with_IN the_DT FDA_NNP with_IN a_DT of_IN the_DT two_CD method_NN of_IN use_NN patents_NNS ._.
Teva_NNP did_VBD not_RB challenge_VB the_DT certication_NN of_IN invalidity_NN of_IN that_DT compound_NN patent_NN but_CC did_VBD not_RB compound_JJ patent_NN ._.
The_DT trial_NN judge_NN ruled_VBD in_IN the_DT Groups_NNS favor_VBP ,_, certify_VBP invalidity_NN or_CC non-infringement_NN of_IN the_DT second_JJ compound_NN upholding_VBG the_DT validity_NN of_IN the_DT method_NN of_IN use_NN patents_NNS ._.
Teva_NNP appealed_VBD patent_NN that_IN expires_VBZ in_IN June_NNP 2007_CD after_IN giving_VBG effect_NN to_TO paediatric_VB that_DT decision_NN to_TO the_DT CAFC_NNP and_CC oral_JJ argument_NN is_VBZ expected_VBN in_IN the_DT exclusivity_NN ._.
The_DT case_NN is_VBZ in_IN its_PRP$ early_JJ stages_NNS ._.
Six_CD other_JJ generic_JJ third_JJ quarter_NN of_IN 2005_CD ._.
In_IN September_NNP 2003_CD ,_, November_NNP 2003_CD and_CC companies_NNS have_VBP led_VBN ANDAs_NNS for_IN Imitrex_NNP but_CC of_IN those_DT only_JJ Cobalt_NNP January_NNP 2004_CD the_DT Group_NNP led_VBD actions_NNS against_IN Teva_NNP in_IN the_DT same_JJ Pharmaceuticals_NNP has_VBZ certied_VBN invalidity_NN of_IN the_DT same_JJ compound_NN court_NN for_IN infringement_NN of_IN the_DT Groups_NNS patents_NNS related_VBN to_TO the_DT patent_NN at_IN issue_NN in_IN the_DT Dr._NNP Reddys_NNP case_NN ._.
The_DT Group_NNP has_VBZ commenced_VBN injectable_JJ and_CC orally_RB disintegrating_VBG tablet_JJ presentations_NNS of_IN Zofran_NNP ._.
an_DT infringement_NN action_NN against_IN Cobalt_NNP which_WDT has_VBZ recently_RB been_VBN These_DT cases_NNS were_VBD consolidated_VBN into_IN the_DT case_NN now_RB on_IN appeal_NN ._.
transferred_VBN to_TO the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
In_IN February_NNP 2005_CD ,_, the_DT Group_NNP commenced_VBD an_DT action_NN An_DT earlier_JJR ondansetron_NN case_NN ,_, involving_VBG orally_RB disintegrating_VBG Zofran_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP against_IN tablets_NNS ,_, was_VBD commenced_VBN by_IN the_DT Group_NNP in_IN January_NNP 2003_CD against_IN Spectrum_NNP Pharmaceuticals_NNP ,_, alleging_VBG infringement_NN of_IN the_DT same_JJ Kali_NNP Laboratories_NNPS in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP compound_NN patent_NN at_IN issue_NN in_IN the_DT Dr._NNP Reddys_NNP case_NN ._.
Both_DT Kali_NNP and_CC the_DT Group_NNP have_VBP subsequently_RB led_VBN motions_NNS its_PRP$ certication_NN of_IN invalidity_NN or_CC non-infringement_NN of_IN that_IN patent_NN as_IN for_IN summary_NN judgement_NN ._.
part_NN of_IN an_DT ANDA_NNP ling_NN for_IN approval_NN for_IN sumatriptan_NN injection_NN ._.
118_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 30_CD Legal_JJ proceedings_NNS continued_VBD Advair_NNP In_IN September_NNP 2004_CD ,_, the_DT Group_NNP applied_VBD to_TO the_DT US_NNP Patent_NNP and_CC Valtrex_NNP Trademark_NNP Ofce_NNP USPTO_NNP for_IN re-issue_NN of_IN its_PRP$ combination_NN patent_NN In_IN May_NNP 2003_CD ,_, the_DT Group_NNP commenced_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP for_IN Advair_NNP ,_, an_DT inhaled_JJ combination_NN of_IN salmeterol_NN and_CC uticasone_NN Court_NN for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Ranbaxy_NNP Laboratories_NNPS ,_, propionate_NN ,_, which_WDT expires_VBZ in_IN September_NNP 2010_CD ._.
This_DT followed_VBD alleging_VBG infringement_NN of_IN the_DT Groups_NNS compound_VBP patent_NN for_IN an_DT internal_JJ review_NN which_WDT concluded_VBD that_IN the_DT language_NN in_IN the_DT valaciclovir_NN ,_, the_DT active_JJ ingredient_NN in_IN Valtrex_NNP ._.
That_DT patent_NN expires_VBZ patent_NN may_MD not_RB accurately_RB describe_VB all_DT of_IN the_DT circumstances_NNS of_IN in_IN 2009_CD ._.
The_DT defendant_NN has_VBZ led_VBN an_DT ANDA_NNP with_IN the_DT FDA_NNP with_IN a_DT the_DT invention_NN and_CC may_MD not_RB claim_VB the_DT invention_NN as_IN precisely_RB as_IN it_PRP certication_NN of_IN invalidity_NN of_IN the_DT Groups_NNS compound_VBP patent_NN and_CC could_MD ._.
The_DT objective_NN of_IN seeking_VBG re-issuance_NN is_VBZ to_TO strengthen_VB the_DT non-infringement_NN of_IN two_CD other_JJ patents_NNS expiring_VBG in_IN 2016_CD that_WDT are_VBP protection_NN afforded_VBN by_IN the_DT patent_NN ._.
It_PRP is_VBZ expected_VBN that_IN the_DT listed_VBN in_IN the_DT Orange_NNP Book_NNP ._.
FDA_NNP approval_NN of_IN that_DT ANDA_NNP is_VBZ stayed_VBN administrative_JJ process_NN with_IN the_DT USPTO_NNP will_MD take_VB one_CD to_TO two_CD years_NNS ._.
until_IN the_DT earlier_JJR of_IN October_NNP 2005_CD or_CC resolution_NN of_IN the_DT patent_NN While_IN the_DT application_NN for_IN re-issue_NN is_VBZ pending_VBG ,_, the_DT patent_NN remains_VBZ infringement_NN litigation_NN ._.
Discovery_NNP is_VBZ underway_NN in_IN the_DT case_NN ._.
in_IN force_NN and_CC is_VBZ listed_VBN in_IN the_DT Orange_NNP Book_NNP ._.
Avandia_NNP and_CC Avandamet_NNP The_NNP Group_NNP holds_VBZ other_JJ patents_NNS relating_VBG to_TO Advair_NNP which_WDT are_VBP not_RB In_IN August_NNP 2003_CD ,_, the_DT Group_NNP led_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP Court_NNP affected_VBN by_IN the_DT re-issue_JJ application_NN ,_, including_VBG the_DT compound_NN for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Teva_NNP Pharmaceuticals_NNP USA_NNP Inc._NNP patent_NN related_VBN to_TO the_DT active_JJ ingredient_NN salmeterol_NN which_WDT affords_VBZ for_IN infringement_NN of_IN the_DT Groups_NNS patent_NN relating_VBG to_TO the_DT maleate_NN salt_NN protection_NN through_IN August_NNP 2008_CD after_IN giving_VBG effect_NN to_TO an_DT expected_VBN form_NN of_IN rosiglitazone_NN ,_, the_DT active_JJ ingredient_NN in_IN Avandia_NNP ,_, which_WDT grant_NN of_IN paediatric_JJ exclusivity_NN by_IN the_DT FDA_NNP ,_, various_JJ patents_NNS relating_VBG expires_VBZ in_IN 2015_CD ._.
In_IN September_NNP 2003_CD the_DT Group_NNP led_VBD a_DT comparable_JJ to_TO the_DT Diskus_NNP device_NN which_WDT expire_VBP over_IN a_DT period_NN from_IN 2011_CD to_TO 2016_CD action_NN in_IN the_DT same_JJ court_NN against_IN Dr_NNP Reddys_NNP Laboratories_NNPS ,_, alleging_VBG and_CC patents_NNS relating_VBG to_TO the_DT HFA_NNP formulation_NN and_CC related_JJ technology_NN infringement_NN of_IN the_DT same_JJ patent_NN for_IN the_DT maleate_NN salt_NN form_NN ._.
Both_DT which_WDT expire_VBP over_IN a_DT period_NN from_IN 2015_CD to_TO 2021_CD ._.
Dr_NNP Reddys_NNP Laboratories_NNPS and_CC Teva_NNP led_VBD ANDAs_NNS with_IN the_DT FDA_NNP with_IN certications_NNS of_IN invalidity_NN of_IN the_DT Groups_NNS maleate_VBP salt_NN patent_NN ._.
FDA_NNP Levitra_NNP approval_NN of_IN those_DT ANDAs_NNP is_VBZ stayed_VBN until_IN the_DT earlier_JJR of_IN November_NNP In_IN October_NNP 2002_CD ,_, Pzer_NNP Inc._NNP led_VBD an_DT action_NN against_IN Bayer_NNP AG_NNP and_CC 2006_CD or_CC resolution_NN of_IN the_DT respective_JJ patent_NN infringement_NN actions_NNS ._.
GlaxoSmithKline_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP ,_, alleging_VBG that_IN the_DT manufacture_NN and_CC sale_NN of_IN Levitra_NNP Teva_NNP subsequently_RB led_VBD an_DT additional_JJ certication_NN challenging_VBG the_DT vardenal_NN would_MD infringe_VB a_DT patent_NN newly_RB issued_VBN to_TO Pzer_NNP and_CC validity_NN of_IN the_DT Groups_NNS basic_JJ compound_NN patent_NN for_IN rosiglitazone_NN ,_, asking_VBG that_IN Bayer_NNP and_CC GlaxoSmithKline_NNP be_VB permanently_RB enjoined_VBN ._.
and_CC in_IN January_NNP 2004_CD the_DT Group_NNP commenced_VBD an_DT action_NN against_IN In_IN September_NNP 2003_CD the_DT US_NNP Patent_NNP and_CC Trademark_NNP Ofce_NNP initiated_VBD Teva_NNP in_IN the_DT same_JJ court_NN for_IN infringement_NN of_IN that_IN patent_NN ._.
The_DT basic_JJ a_DT re-examination_NN of_IN the_DT Pzer_NNP patent_NN based_VBN on_IN questions_NNS of_IN compound_NN patent_NN currently_RB expires_VBZ in_IN 2008_CD ,_, although_IN expiry_NN is_VBZ patentability_NN in_IN light_NN of_IN prior_JJ art_NN ._.
The_DT Pzer_NNP action_NN ,_, including_VBG an_DT expected_VBN to_TO be_VB extended_VBN to_TO 2012_CD after_IN the_DT US_NNP Patent_NNP and_CC additional_JJ suit_NN led_VBD in_IN the_DT same_JJ court_NN following_VBG the_DT launch_NN of_IN Trademark_NNP Ofce_NNP has_VBZ granted_VBN patent_NN term_NN restoration_NN ._.
Levitra_NNP in_IN the_DT USA_NNP ,_, was_VBD predicated_VBN on_IN the_DT validity_NN of_IN that_IN patent_NN In_IN January_NNP 2005_CD ,_, the_DT Group_NNP led_VBD an_DT action_NN in_IN the_DT US_NNP District_NNP Court_NNP and_CC was_VBD stayed_VBN pending_VBG the_DT outcome_NN of_IN the_DT re-examination_NN ._.
In_IN for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Teva_NNP for_IN infringement_NN of_IN the_DT December_NNP 2004_CD the_DT parties_NNS entered_VBD into_IN an_DT agreement_NN to_TO settle_VB same_JJ two_CD patents_NNS ._.
Teva_NNP had_VBD led_VBN an_DT ANDA_NNP with_IN the_DT FDA_NNP for_IN a_DT patent_NN infringement_NN and_CC validity_NN proceedings_NNS on_IN a_DT worldwide_JJ generic_JJ version_NN of_IN Avandamet_NNP with_IN certications_NNS of_IN invalidity_NN and_CC basis_NN ,_, including_VBG the_DT US_NNP action_NN ._.
FDA_NNP approval_NN of_IN that_DT ANDA_NNP is_VBZ Cervarix_NNP stayed_VBD until_IN the_DT earlier_JJR of_IN June_NNP 2007_CD or_CC resolution_NN of_IN the_DT patent_NN In_IN February_NNP 2005_CD ,_, Merck_NNP &_CC Co._NNP and_CC the_DT Group_NNP announced_VBD a_DT cross_NN infringement_NN action_NN but_CC since_IN Avandamet_NNP is_VBZ protected_VBN by_IN the_DT same_JJ licence_NN and_CC settlement_NN agreement_NN for_IN certain_JJ patent_NN rights_NNS related_VBN patents_NNS as_IN Avandia_NNP ,_, should_MD the_DT Avandia_NNP patents_NNS at_IN issue_NN be_VB found_VBN to_TO human_JJ papillomavirus_NN HPV_NNP vaccine_NN ._.
The_DT Group_NNP will_MD receive_VB invalid_JJ during_IN the_DT litigation_NN with_IN Teva_NNP or_CC Dr._NNP Reddys_NNP ,_, that_IN ruling_VBG an_DT upfront_JJ payment_NN and_CC royalties_NNS from_IN Merck_NNP based_VBN upon_IN sales_NNS would_MD be_VB dipositive_JJ for_IN Avandamet_NNP as_RB well_RB ._.
of_IN an_DT HPV_NNP vaccine_NN upon_IN development_NN and_CC launch_NN ._.
The_DT agreement_NN Wellbutrin_NNP XL_NNP resolves_VBZ competing_VBG intellectual_JJ property_NN claims_NNS related_VBN to_TO the_DT In_NNP December_NNP 2004_CD ,_, Biovail_NNP commenced_VBD actions_NNS in_IN the_DT US_NNP District_NNP Merck_NNP and_CC GlaxoSmithKline_NNP HPV_NNP vaccines_NNS ,_, respectively_RB ._.
Court_NNP for_IN the_DT Central_NNP District_NNP of_IN California_NNP against_IN Anchen_NNP Pharmaceuticals_NNP and_CC in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP UK_NNP and_CC Europe_NNP District_NNP of_IN Florida_NNP against_IN Abrika_NNP Pharmaceuticals_NNP ,_, in_IN each_DT case_NN Seroxat_NNP alleging_VBG infringement_NN of_IN Biovail_NNP formulation_NN patents_NNS for_IN Wellbutrin_NNP Following_VBG settlement_NN in_IN August_NNP 2004_CD of_IN most_JJS of_IN the_DT Groups_NNS XL_NNP ._.
Each_DT of_IN Anchen_NNP and_CC Abrika_NNP patent_NN litigation_NN with_IN Synthon_NNP BV_NNP ,_, Synthon_NNP is_VBZ free_JJ to_TO market_VB its_PRP$ had_VBD led_VBN an_DT ANDA_NNP with_IN the_DT FDA_NNP with_IN a_DT certication_NN of_IN invalidity_NN paroxetine_JJ mesylate_JJ product_NN in_IN many_JJ markets_NNS globally_RB where_WRB it_PRP or_CC non-infringement_NN of_IN the_DT Biovail_NNP patents_NNS ._.
FDA_NNP approval_NN of_IN each_DT has_VBZ obtained_VBN marketing_NN authorisations_NNS ._.
Paroxetine_JJ mesylate_NN is_VBZ a_DT of_IN those_DT ANDAs_NNP is_VBZ stayed_VBN until_IN the_DT earlier_JJR of_IN May_NNP 2007_CD or_CC different_JJ salt_NN form_NN of_IN paroxetine_NN than_IN that_DT used_VBN in_IN the_DT marketed_VBN resolution_NN of_IN the_DT applicable_JJ patent_NN infringement_NN action_NN ._.
The_DT form_NN of_IN Seroxat_NNP Paxil_NNP ._.
In_IN certain_JJ markets_NNS patent_NN litigation_NN with_IN Group_NNP is_VBZ a_DT party_NN to_TO the_DT action_NN as_IN a_DT licensee_NN under_IN those_DT patents_NNS Synthon_NNP is_VBZ ongoing_JJ and_CC Synthon_NNP is_VBZ asserting_VBG counterclaims_NNS for_IN and_CC owner_NN of_IN the_DT New_NNP Drug_NNP Application_NNP for_IN Wellbutrin_NNP XL_NNP ._.
Both_DT unfair_JJ competition_NN against_IN the_DT Group_NNP ._.
cases_NNS are_VBP in_IN their_PRP$ early_JJ stages_NNS ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 119_CD 30_CD Legal_NNP proceedings_NNS continued_VBD Phenylpropanolamine_NNP Following_VBG a_DT report_NN from_IN the_DT Yale_NNP Haemorrhagic_NNP Stroke_NNP Project_NNP Another_DT generic_JJ version_NN of_IN Seroxat_NNP Paxils_NNP active_JJ ingredient_NN is_VBZ that_IN found_VBD a_DT suggestion_NN of_IN an_DT association_NN between_IN first_JJ use_NN of_IN paroxetine_JJ hydrochloride_NN anhydrate_NN ._.
Generic_JJ products_NNS containing_VBG phenylpropanolamine_NN PPA_NNP decongestant_JJ and_CC hemorrhagic_JJ the_DT anhydrate_NN are_VBP now_RB on_IN the_DT market_NN in_IN most_JJS European_JJ countries_NNS ._.
stroke_NN ,_, the_DT Group_NNP and_CC most_RBS other_JJ manufacturers_NNS have_VBP voluntarily_RB Whilst_NNP some_DT of_IN these_DT products_NNS are_VBP the_DT subject_NN of_IN continuing_VBG withdrawn_VBN consumer_NN healthcare_NN products_NNS in_IN which_WDT PPA_NNP was_VBD an_DT litigation_NN ,_, most_JJS actions_NNS have_VBP now_RB been_VBN settled_VBN and_CC it_PRP is_VBZ expected_VBN active_JJ ingredient_NN ._.
Since_IN the_DT PPA_NNP product_NN withdrawal_NN the_DT Group_NNP that_IN more_RBR will_MD be_VB settled_VBN in_IN the_DT future_NN ._.
In_IN the_DT UK_NNP ,_, litigation_NN of_IN has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN numerous_JJ personal_JJ injury_NN and_CC several_JJ years_NNS standing_VBG between_IN the_DT Group_NNP and_CC Apotex_NNP culminated_VBD class_NN action_NN lawsuits_NNS led_VBD in_IN state_NN and_CC federal_JJ courts_NNS alleging_VBG in_IN an_DT Appeal_NNP Court_NNP decision_NN that_IN the_DT Groups_NNS anhydrate_JJ process_NN personal_JJ injury_NN or_CC increased_VBN risk_NN of_IN injury_NN from_IN use_NN of_IN products_NNS patent_NN was_VBD valid_JJ but_CC not_RB infringed_VBN ._.
That_DT decision_NN is_VBZ not_RB subject_JJ to_TO containing_VBG PPA_NNP and_CC unfair_JJ and_CC deceptive_JJ business_NN practices_NNS ._.
As_IN a_DT result_NN of_IN the_DT litigation_NN ,_, Apotex_NNP was_VBD enjoined_VBN Plaintiffs_NNS seek_VBP remedies_NNS including_VBG compensatory_JJ and_CC punitive_JJ from_IN launching_VBG its_PRP$ product_NN for_IN about_IN one_CD year_NN but_CC it_PRP is_VBZ now_RB on_IN damages_NNS and_CC refunds_NNS ._.
The_DT federal_JJ cases_NNS have_VBP been_VBN consolidated_VBN the_DT market_NN ._.
A_DT damages_NNS enquiry_VBP relating_VBG to_TO the_DT injunction_NN will_MD in_IN a_DT multidistrict_JJ litigation_NN proceeding_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN take_VB place_NN in_IN due_JJ course_NN ._.
The_DT judge_NN responsible_JJ for_IN those_DT proceedings_NNS has_VBZ denied_VBN class_NN certication_NN and_CC struck_VBD all_DT class_NN Product_NNP liability_NN allegations_NNS in_IN the_DT federal_JJ personal_JJ injury_NN and_CC consumer_NN refund_NN Paxil_NNP class_NN actions_NNS ._.
A_DT limited_JJ number_NN of_IN cases_NNS in_IN which_WDT the_DT Group_NNP or_CC The_NNP Group_NNP has_VBZ received_VBN lawsuits_NNS and_CC claims_NNS led_VBD on_IN behalf_NN other_JJ manufacturers_NNS are_VBP defendants_NNS are_VBP now_RB reaching_VBG trial_NN in_IN of_IN patients_NNS alleging_VBG that_IN they_PRP have_VBP suffered_VBN symptoms_NNS on_IN state_NN courts_NNS ._.
Class_NN certication_NN has_VBZ been_VBN denied_VBN in_IN California_NNP discontinuing_VBG treatment_NN with_IN Paxil_NNP paroxetine_NN ._.
Separately_RB ,_, the_DT state_NN court_NN and_CC a_DT Pennsylvania_NNP state_NN court_NN putative_JJ class_NN action_NN Group_NNP has_VBZ received_VBN lawsuits_NNS and_CC claims_NNS that_IN patients_NNS who_WP had_VBD has_VBZ been_VBN dismissed_VBN ,_, leaving_VBG no_DT putative_JJ class_NN actions_NNS pending_VBG commenced_VBD Paxil_NNP treatment_NN committed_VBN or_CC attempted_VBN to_TO commit_VB against_IN the_DT Group_NNP in_IN this_DT litigation_NN ._.
suicide_NN and_CC or_CC acts_NNS of_IN violence_NN ._.
There_EX are_VBP also_RB private_JJ consumer_NN lawsuits_NNS alleging_VBG that_IN the_DT Group_NNP concealed_VBD and_CC misrepresented_VBD Baycol_NNP data_NNS from_IN paediatric_JJ clinical_JJ trials_NNS of_IN Paxil_NNP ._.
In_IN August_NNP 2001_CD ,_, Bayer_NNP AG_NNP withdrew_VBD Baycol_NNP cerivastatin_NN sodium_NN worldwide_NN in_IN light_NN of_IN reports_NNS of_IN adverse_JJ events_NNS ,_, including_VBG deaths_NNS ,_, The_DT Group_NNP has_VBZ received_VBN lawsuits_NNS led_VBD in_IN state_NN and_CC federal_JJ courts_NNS involving_VBG rhabdomyolosis_NN ._.
GlaxoSmithKline_NNP had_VBD participated_VBN in_IN in_IN the_DT USA_NNP and_CC Canada_NNP on_IN behalf_NN of_IN thousands_NNS of_IN plaintiffs_NNS ,_, the_DT marketing_NN of_IN Baycol_NNP in_IN the_DT USA_NNP pursuant_JJ to_TO a_DT co-promotion_NN including_VBG 14_CD purported_JJ class_NN actions_NNS ,_, alleging_VBG that_IN paroxetine_JJ agreement_NN with_IN Bayer_NNP which_WDT was_VBD the_DT licence_NN holder_NN and_CC the_DT active_JJ ingredient_NN in_IN Paxil_NNP is_VBZ addictive_JJ and_CC causes_VBZ dependency_NN manufacturer_NN of_IN the_DT product_NN ._.
Plaintiffs_NNS seek_VBP remedies_NNS including_VBG compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ damages_NNS and_CC the_DT cost_NN of_IN Following_VBG the_DT withdrawal_NN ,_, Bayer_NNP and_CC GlaxoSmithKline_NNP have_VBP been_VBN a_DT fund_NN for_IN medical_JJ monitoring_NN ._.
In_IN 2003_CD a_DT federal_JJ judge_NN in_IN the_DT US_NNP named_VBD as_IN defendants_NNS in_IN thousands_NNS of_IN lawsuits_NNS led_VBN in_IN state_NN and_CC District_NNP Court_NNP for_IN the_DT Central_NNP District_NNP of_IN California_NNP denied_VBD class_NN federal_JJ courts_NNS in_IN the_DT USA_NNP on_IN behalf_NN of_IN both_DT individuals_NNS and_CC action_NN certications_NNS for_IN a_DT nationwide_JJ class_NN and_CC a_DT California_NNP putative_NN classes_NNS of_IN former_JJ Baycol_NNP users_NNS ._.
A_DT number_NN of_IN the_DT suits_NNS statewide_JJ class_NN as_IN to_TO cases_NNS led_VBN in_IN federal_JJ court_NN in_IN that_DT district_NN ._.
allege_VB that_IN the_DT plaintiffs_NNS have_VBP suffered_VBN personal_JJ injuries_NNS ,_, including_VBG Subsequently_NNP ,_, on_IN petition_NN from_IN plaintiffs_NNS counsel_NN all_DT federal_JJ court_NN rhabdomyolosis_NN ,_, from_IN the_DT use_NN of_IN Baycol_NNP ._.
Others_NNS claim_VBP that_IN persons_NNS cases_NNS have_VBP been_VBN transferred_VBN to_TO that_DT District_NNP Court_NNP for_IN consolidation_NN who_WP took_VBD Baycol_NNP ,_, although_IN not_RB injured_VBN ,_, may_MD be_VB at_IN risk_NN of_IN future_NN in_IN Multidistrict_NNP Litigation_NNP MDL_NNP ._.
The_DT first_JJ five_CD cases_NNS are_VBP scheduled_VBN injury_NN or_CC may_MD have_VB suffered_VBN economic_JJ damages_NNS from_IN purchasing_VBG to_TO start_VB trial_NN in_IN the_DT MDL_NNP court_NN in_IN May_NNP 2005_CD ._.
There_EX has_VBZ been_VBN no_DT and_CC using_VBG Baycol_NNP ._.
Plaintiffs_NNS seek_VBP remedies_NNS including_VBG compensatory_JJ ,_, determination_NN as_IN to_TO whether_IN any_DT of_IN the_DT other_JJ lawsuits_NNS pending_VBG punitive_JJ and_CC statutory_JJ damages_NNS and_CC creation_NN of_IN funds_NNS for_IN medical_JJ in_IN the_DT MDL_NNP or_CC in_IN state_NN courts_NNS will_MD be_VB permitted_VBN to_TO proceed_VB as_IN monitoring_NN ._.
GlaxoSmithKline_NNP and_CC Bayer_NNP Corporation_NNP ,_, the_DT principal_JJ class_NN actions_NNS ._.
US_NNP subsidiary_NN of_IN Bayer_NNP AG_NNP ,_, have_VBP signed_VBN an_DT allocation_NN agreement_NN under_IN which_WDT Bayer_NNP Corporation_NNP has_VBZ agreed_VBN to_TO pay_VB 95_CD per_IN cent_NN The_DT Group_NNP has_VBZ received_VBN a_DT number_NN of_IN claims_NNS and_CC lawsuits_NNS alleging_VBG of_IN all_DT settlements_NNS and_CC compensatory_JJ damages_NNS judgements_NNS with_IN that_DT treatment_NN with_IN Paxil_NNP has_VBZ caused_VBN homicidal_JJ or_CC suicidal_JJ each_DT party_NN retaining_VBG responsibility_NN for_IN its_PRP$ own_JJ attorneys_NNS fees_NNS and_CC behavior_NN exhibited_VBN by_IN users_NNS of_IN the_DT product_NN ._.
None_NN of_IN these_DT are_VBP any_DT punitive_JJ damages_NNS ._.
The_DT federal_JJ cases_NNS have_VBP been_VBN consolidated_JJ or_CC purport_VB to_TO be_VB class_NN actions_NNS ._.
In_IN October_NNP 2004_CD the_DT FDA_NNP in_IN a_DT multidistrict_JJ litigation_NN proceeding_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN announced_VBN that_IN it_PRP would_MD require_VB a_DT black_JJ box_NN warning_VBG about_IN the_DT District_NNP of_IN Minnesota_NNP ._.
Numerous_JJ cases_NNS are_VBP scheduled_VBN for_IN trial_NN suicidality_NN and_CC other_JJ strengthened_JJ warnings_NNS for_IN selective_JJ serotonin_NN in_IN state_NN and_CC federal_JJ courts_NNS during_IN 2005_CD ._.
To_TO date_NN ,_, a_DT statewide_JJ reuptake_NN inhibitor_NN SSRI_NNP products_NNS ,_, including_VBG Paxil_NNP ,_, as_IN a_DT class_NN ._.
medical_JJ monitoring_NN class_NN action_NN against_IN Bayer_NNP and_CC GlaxoSmithKline_NNP Avandia_NNP has_VBZ been_VBN certied_VBN in_IN Pennsylvania_NNP ,_, and_CC another_DT class_NN action_NN ,_, in_IN The_DT Group_NNP has_VBZ received_VBN lawsuits_NNS and_CC claims_NNS led_VBN in_IN state_NN and_CC which_WDT GlaxoSmithKline_NNP was_VBD not_RB named_VBN as_IN a_DT defendant_NN ,_, has_VBZ been_VBN federal_JJ courts_NNS in_IN the_DT USA_NNP on_IN behalf_NN of_IN numerous_JJ patients_NNS alleging_VBG certied_VBN in_IN Oklahoma_NNP ._.
A_DT substantial_JJ number_NN of_IN claims_NNS for_IN death_NN that_IN rosiglitazone_NN the_DT active_JJ ingredient_NN in_IN Avandia_NNP has_VBZ caused_VBN or_CC serious_JJ injury_NN have_VBP been_VBN settled_VBN ._.
congestive_JJ heart_NN failure_NN or_CC liver_NN damage_NN ._.
None_NN of_IN the_DT cases_NNS purports_VBZ to_TO be_VB a_DT class_NN action_NN ._.
Most_JJS of_IN the_DT cases_NNS are_VBP in_IN their_PRP$ early_JJ stages_NNS although_IN certain_JJ state_NN court_NN trials_NNS are_VBP scheduled_VBN to_TO take_VB place_NN in_IN 2005_CD ._.
120_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 30_CD Legal_JJ proceedings_NNS continued_VBD In_IN particular_JJ the_DT government_NN has_VBZ inquired_VBN about_IN alleged_JJ promotion_NN of_IN these_DT drugs_NNS for_IN off-label_JJ uses_NNS as_RB well_RB as_IN Group_NNP sponsored_VBD Fen-Phen_NNP continuing_VBG medical_JJ education_NN programs_NNS ,_, other_JJ speaker_NN events_NNS ,_, In_IN 1997_CD ,_, the_DT FDA_NNP became_VBD aware_JJ of_IN reports_NNS of_IN cardiac_JJ valvular_JJ special_JJ issue_NN boards_NNS ,_, advisory_JJ boards_NNS ,_, speaker_NN training_NN programs_NNS ,_, problems_NNS in_IN individuals_NNS for_IN whom_WP fenuramine_VBP or_CC dexfenuramine_VBP clinical_JJ studies_NNS ,_, and_CC related_JJ grants_NNS ,_, fees_NNS ,_, travel_NN and_CC entertainment_NN ._.
alone_RB or_CC in_IN combination_NN with_IN phentermine_NN was_VBD prescribed_VBN as_IN part_NN Although_IN the_DT original_JJ subpoena_NN issued_VBN from_IN the_DT US_NNP Attorneys_NNP of_IN a_DT regimen_NN of_IN weight_NN reduction_NN and_CC requested_VBD the_DT voluntary_JJ ofce_NN in_IN Colorado_NNP ,_, the_DT scope_NN of_IN the_DT inquiry_NN is_VBZ nationwide_JJ ._.
The_DT withdrawal_NN of_IN fenuramine_NN and_CC dexfenuramine_NN from_IN the_DT market_NN ._.
Group_NNP is_VBZ co-operating_VBG with_IN the_DT investigation_NN which_WDT is_VBZ in_IN its_PRP$ early_JJ The_DT reports_NNS of_IN cardiac_JJ valvular_JJ problems_NNS and_CC the_DT subsequent_JJ stages_NNS ._.
The_DT Group_NNP had_VBD earlier_RBR responded_VBD to_TO an_DT October_NNP 2002_CD letter_NN withdrawal_NN of_IN those_DT products_NNS from_IN the_DT market_NN spawned_VBD numerous_JJ from_IN the_DT FDAs_NNP Division_NNP of_IN Drug_NNP Marketing_NNP ,_, Advertising_NNP and_CC product_NN liability_NN lawsuits_NNS led_VBD against_IN the_DT manufacturers_NNS and_CC Communication_NNP requesting_VBG information_NN on_IN the_DT Groups_NNS alleged_VBD distributors_NNS of_IN fenuramine_NN ,_, dexfenuramine_NN and_CC phentermine_NN ._.
promotion_NN of_IN Wellbutrin_NNP SR_NNP for_IN off-label_JJ use_NN ._.
As_IN one_CD of_IN a_DT number_NN of_IN manufacturers_NNS of_IN phentermine_NN ,_, the_DT Group_NNP is_VBZ a_DT defendant_NN in_IN thousands_NNS of_IN lawsuits_NNS in_IN various_JJ state_NN and_CC federal_JJ Average_JJ wholesale_JJ price_NN district_NN courts_NNS in_IN the_DT USA_NNP ._.
Most_JJS of_IN the_DT lawsuits_NNS seek_VBP relief_NN including_VBG GlaxoSmithKline_NNP has_VBZ responded_VBN to_TO subpoenas_NNS from_IN the_DT Ofce_NNP some_DT combination_NN of_IN compensatory_JJ and_CC punitive_JJ damages_NNS ,_, of_IN the_DT Inspector_NNP General_NNP of_IN the_DT US_NNP Department_NNP of_IN Health_NNP and_CC medical_JJ monitoring_NN and_CC refunds_NNS for_IN purchases_NNS of_IN drugs_NNS ._.
In_IN 1997_CD Human_NNP Services_NNPS ,_, the_DT US_NNP Department_NNP of_IN Justice_NNP and_CC the_DT states_NNS of_IN the_DT Judicial_NNP Panel_NN on_IN Multidistrict_NNP Litigation_NNP issued_VBD an_DT order_NN Texas_NNP and_CC California_NNP in_IN connection_NN with_IN allegations_NNS that_WDT consolidating_VBG and_CC transferring_VBG all_DT federal_JJ actions_NNS to_TO the_DT District_NNP pharmaceutical_JJ companies_NNS ,_, including_VBG GlaxoSmithKline_NNP ,_, have_VBP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP ._.
That_DT court_NN approved_VBD violated_VBN federal_JJ fraud_NN and_CC abuse_NN laws_NNS such_JJ as_IN the_DT Federal_NNP False_NNP a_DT global_JJ settlement_NN proposed_VBN by_IN defendant_NN Wyeth_NNP ,_, which_WDT sold_VBD Claims_NNP Act_NNP and_CC ,_, with_IN respect_NN to_TO Texas_NNP and_CC California_NNP ,_, comparable_JJ fenuramine_NN and_CC dexfenuramine_NN ._.
The_DT settlement_NN ,_, subsequently_RB state_NN laws_NNS as_IN a_DT result_NN of_IN the_DT way_NN average_JJ wholesale_JJ price_NN AWP_NNP confirmed_VBD by_IN the_DT Third_NNP Circuit_NNP Court_NNP of_IN Appeals_NNPS ,_, does_VBZ not_RB include_VB was_VBD determined_VBN and_CC reported_VBN for_IN certain_JJ drugs_NNS and_CC the_DT way_NN the_DT any_DT of_IN the_DT phentermine_NN defendants_NNS ,_, including_VBG the_DT Group_NNP ._.
Medicare_NNP and_CC Medicaid_NNP programs_NNS reimburse_VBP for_IN those_DT drugs_NNS ._.
Individual_JJ plaintiffs_NNS may_MD elect_VB to_TO opt_VB out_IN of_IN the_DT class_NN settlement_NN Subsequently_RB ,_, several_JJ states_NNS through_IN their_PRP$ respective_JJ attorneys_NNS and_CC pursue_VB their_PRP$ claims_NNS individually_RB and_CC tens_NNS of_IN thousands_NNS of_IN general_JJ and_CC several_JJ counties_NNS in_IN New_NNP York_NNP state_NN led_VBD civil_JJ lawsuits_NNS plaintiffs_NNS have_VBP elected_VBN to_TO do_VB so_RB ._.
Wyeth_NNP continues_VBZ to_TO settle_VB in_IN state_NN and_CC federal_JJ court_NN against_IN GlaxoSmithKline_NNP and_CC several_JJ individual_JJ state_NN court_NN cases_NNS before_IN trial_NN and_CC the_DT Group_NNP continues_VBZ other_JJ drug_NN companies_NNS ._.
The_DT actions_NNS claim_VBP ,_, on_IN behalf_NN of_IN the_DT states_NNS to_TO be_VB dismissed_VBN from_IN lawsuits_NNS as_IN they_PRP are_VBP settled_VBN by_IN Wyeth_NNP ._.
as_IN payers_NNS and_CC on_IN behalf_NN of_IN in-state_JJ patients_NNS as_IN consumers_NNS ,_, Thimerosal_NNP damages_NNS and_CC restitution_NN due_JJ to_TO AWP_NNP based_VBN price_NN reporting_VBG for_IN an_DT GlaxoSmithKline_NNP ,_, along_IN with_IN a_DT number_NN of_IN other_JJ pharmaceutical_JJ undefined_JJ set_NN of_IN pharmaceutical_JJ products_NNS covered_VBN by_IN the_DT states_NNS companies_NNS ,_, has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN numerous_JJ individual_JJ Medicaid_NNP programs_NNS ._.
In_IN addition_NN ,_, private_JJ payer_NN class_NN action_NN personal_JJ injury_NN lawsuits_NNS in_IN state_NN and_CC federal_JJ district_NN courts_NNS in_IN lawsuits_NNS have_VBP been_VBN led_VBN against_IN GlaxoSmithKline_NNP in_IN several_JJ the_DT USA_NNP alleging_VBG that_IN thimerosal_JJ ,_, a_DT preservative_JJ used_VBN in_IN the_DT federal_JJ district_NN and_CC state_NN courts_NNS ._.
All_PDT the_DT federal_JJ cases_NNS have_VBP been_VBN manufacture_NN of_IN vaccines_NNS ,_, causes_VBZ neurodevelopmental_JJ disorders_NNS consolidated_VBN in_IN a_DT multidistrict_JJ litigation_NN proceeding_NN in_IN the_DT US_NNP and_CC other_JJ injuries_NNS ,_, including_VBG autism_NN ._.
Three_CD of_IN the_DT cases_NNS are_VBP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP ._.
The_DT Group_NNP is_VBZ purported_JJ class_NN actions_NNS :_: there_EX has_VBZ been_VBN no_DT determination_NN as_IN to_TO one_CD of_IN five_CD companies_NNS designated_VBN for_IN fast_JJ track_NN discovery_NN in_IN whether_IN any_DT of_IN those_DT cases_NNS will_MD be_VB permitted_VBN to_TO proceed_VB as_IN a_DT that_DT proceeding_NN ._.
A_DT hearing_NN on_IN the_DT private-payer_JJ plaintiffs_NNS motion_NN class_NN action_NN ._.
A_DT number_NN of_IN purported_JJ class_NN actions_NNS in_IN other_JJ for_IN class_NN certication_NN took_VBD place_NN in_IN February_NNP 2005_CD but_CC the_DT judge_NN jurisdictions_NNS have_VBP been_VBN withdrawn_VBN or_CC dismissed_VBN ._.
Plaintiffs_NNS seek_VBP has_VBZ not_RB yet_RB ruled_VBN on_IN that_DT motion_NN ._.
All_DT of_IN the_DT civil_JJ suits_NNS led_VBN in_IN state_NN remedies_NNS including_VBG compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ court_NN by_IN state_NN attorneys_NNS general_JJ and_CC a_DT private_JJ payer_NN class_NN action_NN damages_NNS and_CC the_DT cost_NN of_IN a_DT fund_NN for_IN medical_JJ monitoring_NN and_CC case_NN remanded_VBD to_TO state_NN court_NN are_VBP in_IN their_PRP$ early_JJ stages_NNS ._.
Although_IN many_JJ of_IN the_DT lawsuits_NNS are_VBP in_IN their_PRP$ early_JJ stages_NNS ,_, Nominal_JJ pricing_NN a_DT number_NN of_IN cases_NNS are_VBP scheduled_VBN for_IN trial_NN in_IN 2005_CD ._.
The_DT Group_NNP has_VBZ been_VBN advised_VBN by_IN the_DT US_NNP Department_NNP of_IN Justice_NNP Lotronex_NNP that_IN they_PRP are_VBP investigating_VBG certain_JJ of_IN the_DT Groups_NNS nominal_JJ pricing_NN Following_VBG the_DT voluntary_JJ withdrawal_NN of_IN Lotronex_NNP in_IN the_DT USA_NNP in_IN arrangements_NNS to_TO determine_VB whether_IN those_DT arrangements_NNS qualify_VBP November_NNP 2000_CD a_DT number_NN of_IN lawsuits_NNS have_VBP been_VBN led_VBN against_IN under_IN the_DT nominal_JJ price_NN exception_NN to_TO best_JJS price_NN reporting_VBG the_DT Group_NNP in_IN state_NN and_CC federal_JJ district_NN courts_NNS ,_, including_VBG individual_JJ requirements_NNS under_IN the_DT Medicaid_NNP Drug_NNP Rebate_NNP Programme_NNP or_CC personal_JJ injury_NN actions_NNS and_CC purported_JJ class_NN actions_NNS asserting_VBG violate_VBP civil_JJ statutes_NNS or_CC laws_NNS ._.
The_DT Group_NNP is_VBZ cooperating_VBG in_IN that_DT product_NN liability_NN and_CC consumer_NN fraud_NN claims_NNS ._.
Plaintiffs_NNS seek_VBP remedies_NNS investigation_NN which_WDT is_VBZ being_VBG conducted_VBN by_IN the_DT same_JJ government_NN including_VBG compensatory_JJ ,_, punitive_JJ and_CC statutory_JJ damages_NNS ._.
The_DT class_NN attorneys_NNS involved_VBN in_IN the_DT AWP_NNP investigation_NN and_CC has_VBZ provided_VBN previously_RB certied_VBN in_IN West_NNP Virginia_NNP has_VBZ been_VBN decertied_VBN and_CC the_DT documents_NNS and_CC information_NN regarding_VBG nominal_JJ pricing_NN action_NN has_VBZ been_VBN dismissed_VBN ._.
A_DT large_JJ number_NN of_IN claims_NNS brought_VBD arrangements_NNS for_IN a_DT number_NN of_IN the_DT Groups_NNS products_NNS ._.
following_VBG the_DT withdrawal_NN have_VBP now_RB been_VBN settled_VBN ._.
Paxil_NNP Seroxat_NNP Following_VBG announcement_NN of_IN the_DT New_NNP York_NNP State_NNP Attorney_NNP Generals_NNP Government_NNP investigations_NNS ofce_VBP over_IN the_DT states_NNS lawsuit_NN ,_, subsequently_RB settled_VBN in_IN August_NNP 2004_CD ,_, Marketing_NNP and_CC promotion_NN alleging_VBG failure_NN to_TO disclose_VB data_NNS on_IN the_DT use_NN of_IN Paxil_NNP in_IN children_NNS In_IN February_NNP 2004_CD ,_, GlaxoSmithKline_NNP received_VBD a_DT subpoena_NN from_IN and_CC adolescents_NNS ,_, similar_JJ cases_NNS ,_, some_DT of_IN which_WDT purport_VBP to_TO be_VB the_DT US_NNP Attorneys_NNP ofce_NN in_IN Colorado_NNP regarding_VBG the_DT Groups_NNS sales_NNS class_NN actions_NNS ,_, have_VBP been_VBN led_VBN in_IN state_NN and_CC federal_JJ courts_NNS by_IN and_CC promotional_JJ practices_NNS relating_VBG to_TO nine_CD of_IN its_PRP$ largest_JJS selling_NN private_JJ plaintiffs_NNS ._.
All_PDT those_DT cases_NNS are_VBP in_IN their_PRP$ early_JJ stages_NNS ._.
products_NNS for_IN the_DT period_NN from_IN January_NNP 1997_CD to_TO the_DT present_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 121_CD 30_CD Legal_NNP proceedings_NNS continued_VBD Relafen_NNP In_IN August_NNP 2001_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN In_IN the_DT UK_NNP an_DT investigation_NN remains_VBZ pending_VBG by_IN the_DT UK_NNP Medicines_NNP Massachusetts_NNP ruled_VBD the_DT Groups_NNS patent_NN for_IN nabumetone_NN Relafen_NNP and_CC Healthcare_NNP products_NNS Regulatory_NNP Agency_NNP MHRA_NNP to_TO determine_VB invalid_JJ for_IN anticipatory_JJ art_NN and_CC unenforceable_JJ on_IN the_DT grounds_NNS of_IN whether_IN the_DT Group_NNP has_VBZ complied_VBN with_IN its_PRP$ pharmacovigilance_NN inequitable_JJ conduct_NN ._.
In_IN August_NNP 2002_CD the_DT CAFC_NNP issued_VBD a_DT decision_NN obligations_NNS in_IN reporting_NN of_IN data_NNS from_IN clinical_JJ trials_NNS for_IN Seroxat_NNP Paxil_NNP afrming_VBG the_DT District_NNP Courts_NNPS judgement_NN of_IN invalidity_NN but_CC declining_VBG in_IN children_NNS and_CC adolescents_NNS ._.
to_TO rule_VB on_IN the_DT judgement_NN of_IN inequitable_JJ conduct_NN ._.
Cidra_NNP ,_, Puerto_NNP Rico_NNP manufacturing_VBG site_NN Following_VBG the_DT District_NNP Court_NNP decision_NN ,_, anti-trust_JJ claims_NNS alleging_VBG In_IN October_NNP 2003_CD ,_, the_DT FDA_NNP inspected_VBD the_DT Groups_NNS manufacturing_VBG competitive_JJ injury_NN and_CC overcharges_NNS were_VBD led_VBN by_IN Teva_NNP and_CC Eon_NNP facility_NN in_IN Cidra_NNP ,_, Puerto_NNP Rico_NNP ._.
The_DT Cidra_NNP site_NN is_VBZ engaged_VBN in_IN tableting_VBG Pharmaceuticals_NNS ,_, generic_JJ manufacturers_NNS of_IN nabumetone_NN ,_, by_IN and_CC packaging_NN for_IN a_DT range_NN of_IN GlaxoSmithKline_NNP products_NNS primarily_RB purported_JJ classes_NNS of_IN direct_JJ and_CC indirect_JJ purchasers_NNS and_CC payers_NNS for_IN the_DT US_NNP market_NN including_VBG Paxil_NNP ,_, Paxil_NNP CR_NNP ,_, Coreg_NNP ,_, Avandia_NNP and_CC by_IN individual_JJ retail_JJ chains_NNS ._.
Following_VBG that_DT inspection_NN the_DT FDA_NNP has_VBZ issued_VBN two_CD Forms_NNS 483_CD observations_NNS of_IN possible_JJ deficiencies_NNS in_IN The_DT plaintiffs_NNS claims_NNS are_VBP based_VBN on_IN allegations_NNS of_IN fraudulent_JJ manufacturing_NN practices_NNS to_TO the_DT Group_NNP ._.
The_DT FDA_NNP carried_VBD out_RP a_DT procurement_NN of_IN a_DT patent_NN ,_, wrongful_JJ listing_NN of_IN the_DT patent_NN in_IN the_DT further_JJ inspection_NN in_IN November_NNP 2004_CD and_CC subsequently_RB issued_VBN FDA_NNP Orange_NNP Book_NNP and_CC prosecution_NN of_IN sham_NN patent_NN infringement_NN two_CD further_JJ Forms_NNS 483_CD ._.
litigation_NN ._.
Those_DT cases_NNS ,_, which_WDT were_VBD originally_RB led_VBN in_IN the_DT US_NNP District_NNP Courts_NNPS for_IN the_DT District_NNP of_IN Massachusetts_NNP and_CC the_DT Eastern_NNP District_NNP of_IN The_DT FDA_NNP observations_NNS relate_VBP to_TO certain_JJ aspects_NNS of_IN production_NN Pennsylvania_NNP ,_, were_VBD all_DT transferred_VBN to_TO the_DT District_NNP of_IN Massachusetts_NNP ._.
controls_NNS ,_, process_NN validation_NN and_CC laboratory_NN investigations_NNS ._.
The_DT The_NNP Group_NNP has_VBZ settled_VBN the_DT cases_NNS led_VBN by_IN Teva_NNP ,_, Eon_NNP ,_, a_DT group_NN of_IN Group_NNP continues_VBZ to_TO cooperate_VB with_IN the_DT FDA_NNP in_IN responding_VBG to_TO major_JJ retail_JJ pharmacy_NN chains_NNS and_CC the_DT class_NN of_IN direct_JJ purchasers_NNS ._.
the_DT observations_NNS contained_VBN in_IN the_DT Forms_NNS 483_CD ,_, but_CC there_RB can_MD be_VB The_DT court_NN has_VBZ given_VBN preliminary_JJ approval_NN to_TO the_DT settlement_NN that_IN no_DT assurance_NN as_IN to_TO any_DT remedy_NN the_DT FDA_NNP may_MD ultimately_RB seek_VB ._.
the_DT Group_NNP has_VBZ reached_VBN with_IN a_DT class_NN of_IN indirect_JJ purchasers_NNS ._.
A_DT hearing_NN on_IN final_JJ approval_NN of_IN that_DT settlement_NN is_VBZ scheduled_VBN for_IN Anti-trust_JJ 4th_JJ May_NNP 2005_CD ._.
Additionally_RB ,_, a_DT settlement_NN agreement_NN has_VBZ been_VBN Paxil_NNP signed_VBD with_IN the_DT states_NNS regarding_VBG their_PRP$ global_JJ claim_NN for_IN alleged_JJ In_IN November_NNP 2000_CD ,_, the_DT US_NNP Federal_NNP Trade_NNP Commission_NNP FTC_NNP staff_NN overcharges_NNS in_IN connection_NN with_IN state_NN purchases_NNS of_IN the_DT drug_NN ._.
advised_VBD the_DT Group_NNP that_IN they_PRP were_VBD conducting_VBG a_DT non-public_JJ investigation_NN to_TO determine_VB whether_IN the_DT Group_NNP was_VBD violating_VBG Augmentin_NNP Section_NNP 5_CD of_IN the_DT Federal_NNP Trade_NNP Commission_NNP Act_NNP by_IN monopolizing_VBG In_IN 2002_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Virginia_NNP or_CC attempting_VBG to_TO monopolize_VB the_DT market_NN for_IN paroxetine_JJ found_VBN various_JJ patents_NNS covering_VBG Augmentin_NNP invalid_JJ ._.
That_DT holding_VBG hydrochloride_NN by_IN preventing_VBG generic_JJ competition_NN to_TO Paxil_NNP and_CC was_VBD subsequently_RB afrmed_VBN by_IN the_DT CAFC_NNP ._.
Following_VBG the_DT adverse_JJ requested_VBD the_DT Group_NNP to_TO submit_VB certain_JJ information_NN in_IN connection_NN trial_NN court_NN decision_NN ,_, purported_JJ anti-trust_JJ class_NN actions_NNS were_VBD led_VBN with_IN that_DT investigation_NN ._.
In_IN October_NNP 2003_CD the_DT FTC_NNP closed_VBD its_PRP$ on_IN behalf_NN of_IN classes_NNS of_IN direct_JJ and_CC indirect_JJ purchasers_NNS that_WDT were_VBD investigation_NN on_IN the_DT basis_NN of_IN its_PRP$ nding_NN that_IN no_DT further_JJ action_NN is_VBZ ultimately_RB consolidated_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP warranted_VBD ._.
Plaintiffs_NNS alleged_VBD that_IN the_DT Group_NNP knowingly_RB obtained_VBD invalid_JJ patents_NNS and_CC engaged_VBN in_IN other_JJ anticompetitive_JJ Following_VBG public_JJ reference_NN to_TO the_DT FTC_NNP investigation_NN regarding_VBG Paxil_NNP ,_, conduct_NN to_TO prevent_VB entry_NN of_IN generic_JJ products_NNS in_IN violation_NN of_IN the_DT purported_JJ class_NN actions_NNS were_VBD led_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT monopolization_NN section_NN of_IN the_DT US_NNP anti-trust_JJ laws_NNS ._.
The_DT court_NN has_VBZ Eastern_NNP District_NNP of_IN Pennsylvania_NNP on_IN behalf_NN of_IN indirect_JJ purchasers_NNS ,_, approved_VBD the_DT Groups_NNS settlement_NN of_IN those_DT class_NN action_NN claims_NNS ._.
In_IN including_VBG consumers_NNS and_CC third_JJ party_NN payers_NNS ,_, and_CC direct_JJ purchasers_NNS ._.
February_NNP 2005_CD the_DT Group_NNP reached_VBD an_DT agreement_NN in_IN principle_NN with_IN The_DT plaintiffs_NNS claimed_VBD that_IN the_DT Group_NNP monopolized_VBD a_DT market_NN for_IN Lek_NNP Pharmaceuticals_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Novartis_NNP ,_, to_TO Paxil_NNP by_IN bringing_VBG allegedly_RB sham_JJ patent_NN litigation_NN and_CC allegedly_RB resolve_VB the_DT anti-trust_JJ lawsuit_NN led_VBN by_IN Lek_NNP in_IN that_DT same_JJ District_NNP abusing_VBG the_DT regulatory_JJ procedures_NNS for_IN the_DT listing_NN of_IN patents_NNS in_IN the_DT Court_NNP which_WDT sought_VBD lost_VBN profits_NNS ,_, treble_JJ damages_NNS ,_, injunctive_JJ relief_NN FDA_NNP Orange_NNP Book_NNP ._.
The_DT court_NN has_VBZ granted_VBN final_JJ approval_NN to_TO and_CC attorneys_NNS fees_NNS ._.
settlement_NN with_IN the_DT direct_JJ purchaser_NN class_NN and_CC preliminary_JJ approval_NN to_TO settlement_NN with_IN the_DT purported_JJ class_NN of_IN indirect_JJ purchasers_NNS ._.
Canadian_JJ importation_NN The_DT hearing_NN date_NN for_IN final_JJ approval_NN for_IN the_DT indirect_JJ purchaser_NN class_NN The_DT Group_NNP has_VBZ been_VBN named_VBN in_IN seven_CD purported_JJ class_NN action_NN settlement_NN is_VBZ 9th_JJ March_NNP 2005_CD ._.
The_DT Group_NNP has_VBZ also_RB reached_VBN a_DT final_JJ lawsuits_NNS along_IN with_IN eight_CD other_JJ pharmaceutical_JJ companies_NNS ._.
settlement_NN with_IN a_DT group_NN of_IN chain_NN drugstores_NNS ._.
In_IN state_NN courts_NNS a_DT Following_VBG the_DT Groups_NNS actions_NNS in_IN 2003_CD to_TO reduce_VB illegal_JJ importation_NN purported_JJ consumer_NN fraud_NN class_NN action_NN in_IN California_NNP remains_VBZ at_IN of_IN prescription_NN drugs_NNS from_IN Canada_NNP ,_, the_DT lawsuits_NNS an_DT early_JJ stage_NN and_CC ,_, separately_RB ,_, both_DT a_DT state_NN court_NN class_NN action_NN in_IN allege_VBP that_IN the_DT companies_NNS entered_VBD an_DT unlawful_JJ conspiracy_NN to_TO California_NNP and_CC a_DT federal_JJ class_NN action_NN in_IN Florida_NNP ,_, each_DT of_IN which_WDT is_VBZ prevent_VB Canadian_JJ pharmacies_NNS from_IN selling_VBG their_PRP$ products_NNS to_TO a_DT purported_JJ indirect_JJ purchaser_NN class_NN action_NN ,_, have_VBP been_VBN stayed_VBN US_NNP customers_NNS ._.
pending_VBG disposition_NN of_IN the_DT federal_JJ court_NN settlement_NN ._.
A_DT separate_JJ The_DT Group_NNP has_VBZ also_RB been_VBN named_VBN as_IN a_DT defendant_NN ,_, along_IN with_IN action_NN by_IN the_DT City_NNP of_IN New_NNP York_NNP for_IN alleged_JJ overcharges_NNS is_VBZ also_RB in_IN thirteen_CD other_JJ drug_NN companies_NNS ,_, in_IN a_DT state_NN court_NN action_NN in_IN California_NNP ,_, its_PRP$ early_JJ stages_NNS ._.
in_IN which_WDT the_DT plaintiffs_NNS ,_, independent_JJ pharmacies_NNS ,_, allege_VBP that_IN the_DT Apotex_NNP ,_, Alphapharm_NNP ,_, BASF_NNP and_CC Sumika_NNP have_VBP led_VBN anti-trust_JJ and_CC defendants_NNS unlawfully_RB conspired_VBD to_TO keep_VB prices_NNS artificially_RB high_JJ unfair_JJ competition_NN counterclaims_NNS against_IN the_DT Group_NNP based_VBN on_IN in_IN the_DT USA_NNP to_TO the_DT detriment_NN of_IN the_DT plaintiffs_NNS ._.
In_IN relation_NN to_TO the_DT allegations_NNS similar_JJ to_TO those_DT made_VBN in_IN the_DT purported_JJ class_NN actions_NNS same_JJ matter_NN ,_, the_DT Minnesota_NNP State_NNP Attorney_NNP General_NNP has_VBZ led_VBN a_DT identied_VBN in_IN the_DT proceeding_NN paragraph_NN ._.
While_IN discovery_NN in_IN the_DT complaint_NN alleging_VBG that_IN the_DT Group_NNP has_VBZ violated_VBN state_NN anti-trust_NN Apotex_NNP matter_NN is_VBZ in_IN the_DT early_JJ stages_NNS ,_, the_DT three_CD other_JJ actions_NNS have_VBP and_CC commercial_JJ laws_NNS ._.
All_DT of_IN these_DT actions_NNS are_VBP in_IN their_PRP$ early_JJ stages_NNS ._.
122_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 30_CD Legal_JJ proceedings_NNS continued_VBD 31_CD Post_NNP balance_NN sheet_NN event_NN Wellbutrin_NNP SR_NNP On_IN 10th_JJ January_NNP 2005_CD ,_, GlaxoSmithKline_NNP announced_VBD it_PRP had_VBD In_IN December_NNP 2004_CD ,_, and_CC January_NNP and_CC February_NNP 2005_CD ,_, lawsuits_NNS ,_, agreed_VBD to_TO transfer_VB most_JJS of_IN its_PRP$ European_JJ and_CC International_JJ several_JJ of_IN which_WDT purported_JJ to_TO be_VB class_NN actions_NNS ,_, were_VBD led_VBN in_IN the_DT co-promotion_NN rights_NNS for_IN Levitra_NNP to_TO Bayer_NNP for_IN a_DT cash_NN consideration_NN US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP against_IN the_DT of_IN 148_CD million_CD and_CC a_DT reduction_NN in_IN the_DT Groups_NNS commitment_NN to_TO Group_NNP on_IN behalf_NN of_IN direct_JJ and_CC indirect_JJ purchasers_NNS of_IN Wellbutrin_NNP SR._NNP fund_NN future_NN research_NN and_CC development_NN on_IN the_DT product_NN ._.
The_DT complaints_NNS allege_VBP violations_NNS of_IN US_NNP anti-trust_JJ laws_NNS through_IN sham_NN GlaxoSmithKline_NNP retains_VBZ co-promotion_NN or_CC co-marketing_NN rights_NNS litigation_NN and_CC fraud_NN on_IN the_DT patent_NN ofce_NN by_IN the_DT Group_NNP in_IN obtaining_VBG to_TO Levitra_NNP in_IN the_DT USA_NNP and_CC more_JJR than_IN 20_CD other_JJ markets_NNS ._.
and_CC enforcing_VBG patents_NNS covering_VBG Wellbutrin_NNP SR._NNP ._.
The_DT complaints_NNS follow_VBP the_DT introduction_NN of_IN generic_JJ competition_NN to_TO Wellbutrin_NNP SR_NNP in_IN 32_CD Related_VBN party_NN transactions_NNS April_NNP 2004_CD after_IN district_NN and_CC appellate_JJ court_NN rulings_NNS that_IN a_DT generic_JJ GlaxoSmithKline_NNP held_VBD an_DT 18.6_CD per_IN cent_NN interest_NN in_IN Quest_NNP manufacturer_NN did_VBD not_RB infringe_VB the_DT Groups_NNS patents_NNS ._.
The_DT cases_NNS are_VBP Diagnostics_NNPS Inc._NNP at_IN 31st_CD December_NNP 2004_CD 2003_CD 21_CD per_IN cent_NN ._.
The_DT Group_NNP and_CC Quest_NNP Diagnostics_NNPS are_VBP parties_NNS to_TO a_DT long-term_JJ contractual_JJ relationship_NN under_IN which_WDT Quest_NNP Diagnostics_NNPS is_VBZ the_DT Environmental_JJ matters_NNS primary_JJ provider_NN of_IN clinical_JJ laboratory_NN testing_NN to_TO support_VB the_DT GlaxoSmithKline_NNP has_VBZ been_VBN notied_VBN of_IN its_PRP$ potential_JJ responsibility_NN Groups_NNS clinical_JJ trials_NNS testing_NN requirements_NNS worldwide_VBP ._.
During_IN relating_VBG to_TO past_JJ operations_NNS and_CC its_PRP$ past_JJ waste_NN disposal_NN practices_NNS 2004_CD ,_, Quest_NNP Diagnostics_NNPS provided_VBD services_NNS of_IN 35_CD million_CD at_IN certain_JJ sites_NNS ,_, primarily_RB in_IN the_DT USA_NNP ._.
Some_DT of_IN these_DT matters_NNS are_VBP 2003_CD 31_CD million_CD to_TO the_DT Group_NNP ._.
the_DT subject_NN of_IN litigation_NN ,_, including_VBG proceedings_NNS initiated_VBN by_IN the_DT US_NNP federal_JJ or_CC state_NN governments_NNS for_IN waste_NN disposal_NN site_NN In_IN 2004_CD ,_, both_CC the_DT Group_NNP and_CC Shionogi_NNP &_CC Co._NNP ._.
Ltd._NNP entered_VBD into_IN remediation_NN costs_NNS and_CC tort_NN actions_NNS brought_VBN by_IN private_JJ parties_NNS ._.
transactions_NNS with_IN their_PRP$ 50_CD 50_CD US_NNP joint_JJ venture_NN company_NN in_IN support_NN of_IN the_DT research_NN and_CC development_NN activities_NNS conducted_VBN by_IN that_DT GlaxoSmithKline_NNP has_VBZ been_VBN advised_VBN that_IN it_PRP may_MD be_VB a_DT responsible_JJ joint_JJ venture_NN company_NN ._.
During_IN 2004_CD ,_, GlaxoSmithKline_NNP provided_VBD party_NN at_IN approximately_RB 27_CD sites_NNS ,_, of_IN which_WDT 14_CD appear_VBP on_IN the_DT services_NNS to_TO the_DT joint_JJ venture_NN of_IN 1_CD million_CD 2003_CD 1_CD million_CD ._.
National_NNP Priority_NNP List_NN created_VBN by_IN the_DT Comprehensive_NNP Environmental_NNP At_IN 31st_CD December_NNP 2004_CD the_DT balance_NN due_JJ to_TO GlaxoSmithKline_NNP Response_NNP Compensation_NNP and_CC Liability_NNP Act_NNP Superfund_NNP ._.
from_IN the_DT joint_JJ venture_NN was_VBD 2_CD million_CD 2003_CD 3_CD million_CD ._.
These_DT proceedings_NNS seek_VBP to_TO require_VB the_DT operators_NNS of_IN hazardous_JJ Dr_NNP Shapiro_NNP ,_, a_DT Non-Executive_JJ Director_NNP of_IN GlaxoSmithKline_NNP plc_NN ,_, waste_NN facilities_NNS ,_, transporters_NNS of_IN waste_NN to_TO the_DT sites_NNS and_CC generators_NNS received_VBD fees_NNS of_IN $_$ 85,000_CD 2003_CD $_$ 85,000_CD of_IN which_WDT $_$ 30,000_CD of_IN hazardous_JJ waste_NN disposed_VBD of_IN at_IN the_DT sites_NNS to_TO clean_VB up_RP the_DT sites_NNS 2003_CD $_$ 30,000_CD was_VBD in_IN the_DT form_NN of_IN ADSs_NNS ,_, from_IN a_DT subsidiary_NN of_IN or_CC to_TO reimburse_VB the_DT government_NN for_IN cleanup_NN costs_NNS ._.
In_IN most_JJS the_DT company_NN ,_, for_IN the_DT membership_NN on_IN the_DT Groups_NNS scientific_JJ instances_NNS ,_, GlaxoSmithKline_NNP is_VBZ involved_VBN as_IN an_DT alleged_JJ generator_NN Advisory_NNP Board_NNP ._.
These_DT are_VBP included_VBN within_IN Annual_JJ remuneration_NN of_IN hazardous_JJ waste_NN although_IN there_EX are_VBP a_DT few_JJ sites_NNS where_WRB in_IN the_DT Remuneration_NNP Report_NNP on_IN pages_NNS 43_CD to_TO 58_CD ._.
GlaxoSmithKline_NNP is_VBZ involved_VBN as_IN a_DT current_JJ or_CC former_JJ operator_NN of_IN the_DT facility_NN ._.
Although_IN Superfund_NNP provides_VBZ that_IN the_DT defendants_NNS Dr_NNP Barzach_NNP ,_, a_DT former_JJ Non-Executive_NNP Director_NNP of_IN GlaxoSmithKline_NNP are_VBP jointly_RB and_CC severally_RB liable_JJ for_IN cleanup_NN costs_NNS ,_, these_DT proceedings_NNS plc_NN ,_, received_VBD fees_NNS of_IN 83,005_CD 2003_CD 72,268_CD from_IN a_DT subsidiary_NN are_VBP frequently_RB resolved_VBN on_IN the_DT basis_NN of_IN the_DT nature_NN and_CC quantity_NN of_IN of_IN the_DT company_NN for_IN healthcare_NN consultancy_NN provided_VBN ._.
These_DT are_VBP waste_NN disposed_VBD of_IN at_IN the_DT site_NN by_IN the_DT generator_NN ._.
GlaxoSmithKlines_NNS included_VBD within_IN Annual_JJ remuneration_NN in_IN the_DT Remuneration_NNP proportionate_NN liability_NN for_IN cleanup_NN costs_NNS has_VBZ been_VBN substantially_RB Report_NNP ._.
determined_VBN for_IN about_RB 20_CD of_IN the_DT sites_NNS referred_VBD to_TO above_IN ._.
GlaxoSmithKlines_NNS potential_JJ liability_NN varies_VBZ greatly_RB from_IN site_NN to_TO site_NN ._.
While_IN the_DT cost_NN of_IN investigation_NN ,_, study_NN and_CC remediation_NN at_IN such_JJ sites_NNS could_MD ,_, over_IN time_NN ,_, be_VB substantial_JJ ,_, GlaxoSmithKline_NNP routinely_RB accrues_VBZ amounts_NNS related_VBN to_TO its_PRP$ share_NN of_IN liability_NN for_IN such_JJ matters_NNS ._.
Tax_NNP matters_VBZ Pending_NNP tax_NN matters_NNS are_VBP described_VBN in_IN Note_NN 12_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 123_CD 33_CD Acquisitions_NNS and_CC disposals_NNS Details_NNS of_IN the_DT acquisition_NN and_CC disposal_NN of_IN subsidiary_NN and_CC associated_VBN undertakings_NNS ,_, joint_JJ ventures_NNS and_CC other_JJ businesses_NNS are_VBP given_VBN below_IN :_: 2004_CD Book_NNP Fair_NNP value_NN Net_JJ assets_NNS Goodwill_NNP Cost_NN of_IN values_NNS adjustments_NNS acquired_VBD capitalized_JJ acquisition_NN Acquisitions_NNS m_VBP m_FW m_FW m_FW m_FW Fraxiparine_NNP ,_, Fraxodi_NNP and_CC Arixtra_NNP 135 162 297 297_CD Fraxiparine_NNP ,_, Fraxodi_NNP and_CC Arixtra_NNP In_IN September_NNP 2004_CD ,_, for_IN a_DT cash_NN consideration_NN of_IN 297_CD million_CD the_DT Group_NNP acquired_VBD Fraxiparine_NNP ,_, Fraxodi_NNP and_CC Arixtra_NNP and_CC related_JJ assets_NNS including_VBG a_DT manufacturing_NN facility_NN ._.
Euclid_NNP SR_NNP Partners_NNPS ,_, LP_NNP During_IN the_DT year_NN an_DT additional_JJ 2_CD million_CD was_VBD invested_VBN in_IN Euclid_NNP SR_NNP Partners_NNPS ,_, LP_NNP ,_, an_DT associate_JJ company_NN in_IN which_WDT the_DT Group_NNP has_VBZ a_DT 38.7_CD per_IN cent_NN interest_NN ._.
Disposals_NNS Quest_NNP Diagnostics_NNPS Inc._NNP ._.
During_IN 2004_CD ,_, the_DT Group_NNP disposed_VBD of_IN 3.8_CD million_CD shares_NNS from_IN its_PRP$ investment_NN in_IN Quest_NNP Diagnostics_NNPS Inc._NNP for_IN cash_NN proceeds_NNS of_IN 188_CD million_CD ,_, reducing_VBG the_DT Groups_NNS shareholding_NN at_IN 31st_CD December_NNP 2004_CD to_TO 18.6_CD per_IN cent_NN ._.
After_IN recognizing_VBG a_DT charge_NN for_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS of_IN 17_CD million_CD a_DT profit_NN of_IN 139_CD million_CD was_VBD recognized_VBN ._.
GlaxoSmithKline_NNP Vehicle_NNP Finance_NNP Ltd_NNP During_IN 2004_CD ,_, the_DT Group_NNP disposed_VBD of_IN its_PRP$ employee_NN vehicle_NN nancing_VBG subsidiary_NN resulting_VBG in_IN a_DT loss_NN of_IN 3_CD million_CD ._.
GlaxoSmithKline_NNP Pharmaceuticals_NNP Chongqing_NNP Ltd_NNP During_IN 2004_CD ,_, the_DT Group_NNP disposed_VBD of_IN GlaxoSmithKline_NNP Pharmaceuticals_NNP Chongqing_NNP Ltd_NNP ,_, a_DT Group_NNP subsidiary_NN located_VBN in_IN China_NNP ,_, for_IN 7_CD million_CD ._.
A_DT profit_NN on_IN disposal_NN of_IN 1_CD million_CD was_VBD realized_VBN ,_, after_IN recognizing_VBG a_DT charge_NN for_IN goodwill_NN previously_RB written_VBN off_RP to_TO reserves_NNS of_IN 3_CD million_CD ._.
Beeyar_NNP Investments_NNP Pty_NNP Ltd_NNP In_IN July_NNP 2004_CD ,_, the_DT Group_NNP disposed_VBD of_IN Beeyar_NNP Investments_NNP Pty_NNP Ltd_NNP ,_, a_DT subsidiary_NN located_VBN in_IN South_NNP Africa_NNP ,_, for_IN cash_NN proceeds_NNS of_IN 1_CD million_CD ,_, realizing_VBG a_DT profit_NN of_IN 1_CD million_CD ._.
OptiLead_NNP S._NNP r._NNP l._VBD During_IN the_DT year_NN ,_, part_NN of_IN the_DT Groups_NNS holding_VBG in_IN an_DT associated_VBN undertaking_NN ,_, OptiLead_NNP S._NNP r._NNP l._NN was_VBD sold_VBN ,_, resulting_VBG in_IN a_DT loss_NN of_IN 1_CD million_CD ._.
Fraxiparine_NNP GSK_NNP GSK_NNP Fraxodi_NNP Quest_NNP Vehicle_NNP Pharmaceuticals_NNP Beeyar_NNP and_CC Arixtra_NNP Euclid_NNP SR_NNP Diagnostics_NNPS Finance_NNP Chongqing_NNP Investments_NNP Total_NNP Cash_NNP ows_VBZ m_FW m_FW m_FW m_FW m_FW m_FW m_FW Cash_NN consideration_NN paid_VBD 297_CD 2_CD 299_CD Net_JJ cash_NN proceeds_NNS from_IN disposals_NNS 188_CD 34_CD 7_CD 1_CD 230_CD 2003_CD Book_NNP Fair_NNP value_NN Net_JJ assets_NNS Goodwill_NNP Cost_NN of_IN values_NNS adjustments_NNS acquired_VBD capitalized_JJ acquisition_NN Acquisitions_NNS m_VBP m_FW m_FW m_FW m_FW Europharm_FW 1_CD 123_CD Europharm_NNP During_IN 2003_CD ,_, the_DT Group_NNP completed_VBD the_DT buyout_NN of_IN the_DT minority_NN interests_NNS in_IN Europharm_NNP Holdings_NNP SA_NNP ,_, a_DT Group_NNP subsidiary_NN located_VBN in_IN Romania_NNP ,_, for_IN 3_CD million_CD ,_, giving_VBG rise_NN to_TO goodwill_NN of_IN a_DT further_RBR 2_CD million_CD ,_, which_WDT has_VBZ been_VBN capitalized_VBN ._.
Iter_SYM -_: Sterilyo_NNP During_IN 2003_CD ,_, a_DT further_JJ payment_NN of_IN 9_CD million_CD was_VBD made_VBN pursuant_JJ to_TO the_DT 2002_CD acquisition_NN agreement_NN based_VBN on_IN the_DT financial_JJ performance_NN of_IN the_DT acquired_VBN company_NN ._.
This_DT amount_NN has_VBZ been_VBN included_VBN as_IN deferred_VBN compensation_NN in_IN 2002_CD ._.
124_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 33_CD Acquisitions_NNS and_CC disposals_NNS continued_VBD Disposals_NNP SB_NNP Clinical_NNP Laboratories_NNPS An_DT additional_JJ cash_NN refund_NN of_IN 3_CD million_CD was_VBD received_VBN during_IN 2003_CD in_IN respect_NN of_IN indemnified_JJ liabilities_NNS arising_VBG from_IN the_DT SB_NNP Clinical_NNP Laboratories_NNP disposal_NN which_WDT occurred_VBD in_IN 1999_CD ._.
This_DT refund_NN follows_VBZ the_DT successful_JJ outcome_NN of_IN a_DT case_NN in_IN the_DT US_NNP Court_NNP of_IN Appeal_NNP ._.
IterSB_NNP Clinical_NNP Sterilyo_NNP Europharm_NNP Laboratories_NNP Other_JJ Total_NNP Cash_NNP ows_VBZ m_FW m_FW m_FW m_FW m_FW Cash_NN consideration_NN paid_VBD 9_CD 3_CD 3_CD 15_CD Net_JJ cash_NN proceeds_NNS from_IN disposals_NNS 3_CD 3_CD 2002_CD Book_NNP Fair_NNP value_NN Net_JJ assets_NNS Goodwill_NNP Cost_NN of_IN values_NNS adjustments_NNS acquired_VBD capitalized_JJ acquisition_NN Acquisitions_NNS m_VBP m_FW m_FW m_FW m_FW Iter_NNP Sterilyo_NNP 7_CD 4_CD 3_CD 21_CD 18_CD Human_NNP Kft_NNP 10_CD 10_CD 1_CD 11_CD Other_JJ 11_CD 3_CD 4_CD 7_CD 23_CD 30_CD Iter_NNP Sterilyo_NNP During_IN 2002_CD ,_, the_DT Group_NNP acquired_VBD Iter-Sterilyo_NNP Group_NNP for_IN an_DT initial_JJ cash_NN consideration_NN of_IN 9_CD million_CD ._.
A_DT further_JJ payment_NN was_VBD paid_VBN during_IN 2003_CD ,_, of_IN 9_CD million_CD ,_, which_WDT was_VBD based_VBN on_IN the_DT financial_JJ performance_NN of_IN the_DT acquired_VBN company_NN during_IN 2002_CD ._.
The_DT net_JJ assets_NNS of_IN Iter-Sterilyo_NNP have_VBP been_VBN incorporated_VBN in_IN the_DT financial_JJ statements_NNS at_IN their_PRP$ provisional_JJ fair_JJ values_NNS ._.
No_DT adjustments_NNS were_VBD made_VBN to_TO these_DT values_NNS in_IN 2003_CD ._.
Human_JJ Kft_NNP During_IN 2002_CD ,_, the_DT Group_NNP acquired_VBD the_DT vaccine_NN related_VBN assets_NNS of_IN Human_JJ Kft_NNP ,_, a_DT manufacturing_NN business_NN located_VBN in_IN Hungary_NNP ,_, for_IN a_DT cash_NN consideration_NN of_IN 11_CD million_CD ._.
Disposals_NNS SB_NNP Clinical_NNP Laboratories_NNPS A_DT cash_NN refund_NN of_IN 6_CD million_CD was_VBD received_VBN during_IN 2002_CD in_IN respect_NN of_IN indemnified_JJ liabilities_NNS arising_VBG from_IN the_DT SB_NNP Clinical_NNP Laboratories_NNP disposal_NN which_WDT occurred_VBD in_IN 1999_CD ._.
The_DT refund_NN follows_VBZ the_DT successful_JJ outcome_NN of_IN a_DT case_NN in_IN the_DT US_NNP Court_NNP of_IN Appeal_NNP ._.
SB_NNP Clinical_NNP Iter_NNP -_: Human_JJ Laboratories_NNPS Sterilyo_NNP Kft_NNP Other_JJ Total_NNP Cash_NNP ows_VBZ m_FW m_FW m_FW m_FW m_FW Cash_NN consideration_NN paid_VBD 9_CD 11_CD 6_CD 26_CD Net_JJ cash_NN proceeds_NNS from_IN disposals_NNS 6_CD 6_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 125_CD 34_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS The_DT Group_NNP applies_VBZ Board-approved_JJ limits_NNS to_TO the_DT amount_NN of_IN credit_NN exposure_NN to_TO any_DT one_CD counterparty_NN and_CC employs_VBZ strict_JJ minimum_NN Policies_NNS credit_NN worthiness_NN criteria_NNS as_IN to_TO the_DT choice_NN of_IN counterparty_NN ._.
Discussion_NN of_IN the_DT Groups_NNS objectives_NNS and_CC policies_NNS for_IN the_DT management_NN of_IN financial_JJ instruments_NNS and_CC associated_VBN risks_NNS is_VBZ Fair_NNP value_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS included_VBN under_IN Treasury_NNP Policies_NNS in_IN the_DT Operating_NN and_CC financial_JJ The_DT table_NN on_IN page_NN 126_CD presents_VBZ the_DT carrying_VBG amounts_NNS under_IN review_NN and_CC prospects_NNS on_IN pages_NNS 74_CD to_TO 75_CD ._.
UK_NNP GAAP_NNP and_CC the_DT fair_JJ values_NNS of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC liabilities_NNS at_IN 31st_CD December_NNP 2004_CD and_CC 31st_CD December_NNP 2003_CD ._.
Investments_NNP Debtors_NNPS and_CC creditors_NNS due_JJ within_IN one_CD year_NN have_VBP been_VBN excluded_VBN ._.
The_DT Group_NNP holds_VBZ a_DT number_NN of_IN equity_NN investments_NNS ,_, frequently_RB in_IN entities_NNS where_WRB the_DT Group_NNP has_VBZ entered_VBN into_IN research_NN collaborations_NNS ._.
The_DT fair_JJ values_NNS of_IN the_DT financial_JJ assets_NNS and_CC liabilities_NNS are_VBP included_VBN The_DT Group_NNP seeks_VBZ to_TO realize_VB the_DT value_NN in_IN these_DT investments_NNS ,_, which_WDT at_IN the_DT amount_NN at_IN which_WDT the_DT instrument_NN could_MD be_VB exchanged_VBN in_IN a_DT in_IN part_NN the_DT research_NN collaboration_NN helps_VBZ to_TO create_VB ,_, and_CC therefore_RB current_JJ transaction_NN between_IN willing_JJ parties_NNS ,_, other_JJ than_IN in_IN a_DT forced_JJ certain_JJ of_IN these_DT investments_NNS are_VBP regarded_VBN as_IN available_JJ for_IN sale_NN and_CC or_CC liquidation_NN sale_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD are_VBP accounted_VBN for_IN as_IN current_JJ asset_NN investments_NNS ._.
For_IN the_DT purposes_NNS used_VBN to_TO estimate_VB the_DT fair_JJ values_NNS :_: of_IN US_NNP GAAP_NNP all_PDT the_DT current_JJ asset_NN investments_NNS are_VBP classied_VBN as_IN Equity_NNP investments_NNS market_NN value_NN based_VBN on_IN quoted_VBN market_NN available_JJ for_IN sale_NN ._.
prices_NNS in_IN the_DT case_NN of_IN listed_VBN investments_NNS :_: market_NN value_NN by_IN In_IN 2002_CD ,_, GlaxoSmithKline_NNP hedged_VBD part_NN of_IN the_DT equity_NN value_NN of_IN its_PRP$ reference_NN to_TO quoted_VBN prices_NNS for_IN similar_JJ companies_NNS or_CC recent_JJ holdings_NNS in_IN its_PRP$ largest_JJS equity_NN investment_NN ,_, Quest_NNP Diagnostics_NNPS Inc._NNP nancing_VBG information_NN in_IN the_DT case_NN of_IN material_NN unlisted_JJ through_IN a_DT series_NN of_IN variable_JJ sale_NN forward_RB contracts_NNS ._.
These_DT contracts_NNS investments_NNS the_DT equity_NN collar_NN are_VBP structured_VBN in_IN five_CD series_NN ,_, each_DT over_IN one_CD Cash_NN at_IN bank_NN approximates_VBZ to_TO the_DT carrying_VBG amount_NN million_CD Quest_NNP shares_NNS ,_, and_CC mature_VBP between_IN 2006_CD and_CC 2008_CD ._.
Liquid_NN investments_NNS based_VBN on_IN quoted_VBN market_NN prices_NNS for_IN similar_JJ companies_NNS or_CC recent_JJ nancing_NN information_NN in_IN the_DT case_NN of_IN The_DT Group_NNP has_VBZ liquid_JJ investments_NNS ,_, representing_VBG funds_NNS surplus_NN to_TO marketable_JJ securities_NNS :_: approximates_VBZ to_TO the_DT carrying_VBG amount_NN immediate_JJ operating_NN requirements_NNS ,_, which_WDT are_VBP accounted_VBN for_IN as_RB in_IN the_DT case_NN of_IN time_NN deposits_NNS because_IN of_IN their_PRP$ short_JJ maturity_NN current_JJ asset_NN investments_NNS ._.
For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP the_DT Short-term_JJ loans_NNS and_CC overdrafts_NNS approximates_VBZ to_TO the_DT carrying_VBG investments_NNS are_VBP classied_VBN as_IN available_JJ for_IN sale_NN ._.
The_DT proceeds_NNS from_IN amount_NN because_IN of_IN the_DT short_JJ maturity_NN of_IN these_DT instruments_NNS sale_NN of_IN investments_NNS classied_VBD as_IN available_JJ for_IN sale_NN under_IN US_NNP GAAP_NNP Medium-term_JJ loans_NNS market_NN value_NN based_VBN on_IN quoted_VBN market_NN were_VBD 15,048_CD million_CD in_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2004_CD ._.
prices_NNS in_IN the_DT case_NN of_IN the_DT Eurobonds_NNS and_CC other_JJ xed_JJ rate_NN The_DT proceeds_NNS include_VBP the_DT roll-over_NN of_IN liquid_JJ funds_NNS on_IN short-term_JJ borrowings_NNS :_: approximates_VBZ to_TO the_DT carrying_VBG amount_NN in_IN the_DT case_NN deposit_NN ._.
Under_IN US_NNP GAAP_NNP the_DT gross_JJ gains_NNS and_CC losses_NNS reected_VBD in_IN of_IN oating_NN rate_NN bank_NN loans_NNS and_CC other_JJ loans_NNS the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN in_IN respect_NN of_IN investments_NNS Forward_RB exchange_NN contracts_NNS based_VBN on_IN market_NN prices_NNS and_CC classied_VBD as_IN available_JJ for_IN sale_NN were_VBD 34_CD million_CD and_CC 2_CD million_CD ,_, exchange_NN rates_NNS at_IN the_DT balance_NN sheet_NN date_NN respectively_RB ._.
Currency_NNP swaps_NNS based_VBN on_IN market_NN valuations_NNS at_IN the_DT balance_NN sheet_NN date_NN Foreign_JJ exchange_NN risk_NN management_NN Equity_NN collar_NN fair_JJ value_NN is_VBZ determined_VBN based_VBN on_IN an_DT option_NN The_DT Group_NNP has_VBZ entered_VBN into_IN forward_RB foreign_JJ exchange_NN contracts_NNS pricing_VBG model_NN in_IN order_NN to_TO swap_VB liquid_JJ assets_NNS and_CC borrowings_NNS into_IN the_DT currencies_NNS Interest_NN rate_NN instruments_NNS fair_JJ value_NN is_VBZ determined_VBN using_VBG the_DT net_NN required_VBN for_IN Group_NNP purposes_NNS ._.
At_IN 31st_CD December_NNP 2004_CD the_DT Group_NNP present_JJ value_NN of_IN discounted_JJ cash_NN ows_NNS had_VBD outstanding_JJ contracts_NNS to_TO sell_VB or_CC purchase_VB foreign_JJ currency_NN Debtors_NNS and_CC creditors_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN having_VBG a_DT total_JJ notional_JJ principal_NN amount_NN of_IN 11,137_CD million_CD Provisions_NNS approximates_VBZ to_TO the_DT carrying_VBG amount_NN 2003_CD 8,544_CD million_CD ._.
The_DT majority_NN of_IN contracts_NNS are_VBP for_IN periods_NNS Auction_NNP rate_NN preference_NN stock_NN approximates_VBZ to_TO the_DT carrying_NN of_IN 12_CD months_NNS or_CC less_JJR ._.
amount_NN in_IN the_DT case_NN of_IN oating_NN rate_NN instruments_NNS At_IN the_DT end_NN of_IN 2004_CD ,_, the_DT Group_NNP had_VBD a_DT number_NN of_IN currency_NN swaps_NNS Flexible_JJ auction_NN market_NN preferred_VBN stock_NN based_VBN on_IN market_NN in_IN place_NN in_IN respect_NN of_IN medium-term_JJ debt_NN instruments_NNS ._.
Borrowings_NNS valuations_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
denominated_VBN in_IN ,_, or_CC swapped_VBD into_IN ,_, foreign_JJ currencies_NNS which_WDT match_VBP investments_NNS in_IN overseas_JJ Group_NNP assets_NNS are_VBP treated_VBN as_IN a_DT hedge_NN Fair_NN value_NN of_IN investments_NNS in_IN own_JJ shares_NNS against_IN the_DT relevant_JJ net_JJ assets_NNS and_CC exchange_NN gains_NNS or_CC losses_NNS are_VBP The_DT Group_NNP had_VBD at_IN 31st_CD December_NNP 2004_CD investments_NNS in_IN own_JJ recorded_VBN in_IN reserves_NNS ._.
shares_NNS of_IN 2,574_CD million_CD 2003_CD 2,729_CD million_CD with_IN a_DT fair_JJ value_NN of_IN 2,123_CD million_CD 2003_CD 2,276_CD million_CD based_VBN on_IN quoted_VBN Interest_NN rate_NN risk_NN management_NN market_NN price_NN ._.
The_DT shares_NNS represent_VBP purchases_NNS by_IN the_DT ESOP_NNP Trusts_NNPS To_TO manage_VB the_DT xed_VBN oating_NN interest_NN rate_NN prole_NN of_IN debt_NN ,_, the_DT to_TO satisfy_VB future_JJ exercises_NNS of_IN options_NNS and_CC awards_NNS under_IN employee_NN Group_NNP had_VBD several_JJ interest_NN rate_NN swaps_NNS outstanding_JJ with_IN incentive_NN schemes_NNS ._.
They_PRP are_VBP excluded_VBN from_IN financial_JJ instrument_NN commercial_JJ banks_NNS at_IN 31st_CD December_NNP 2004_CD ._.
disclosure_NN ._.
Concentrations_NNS of_IN credit_NN risk_NN and_CC credit_NN exposures_NNS of_IN financial_JJ instruments_NNS The_DT Group_NNP does_VBZ not_RB believe_VB it_PRP is_VBZ exposed_VBN to_TO major_JJ concentrations_NNS of_IN credit_NN risk_NN on_IN its_PRP$ financial_JJ instruments_NNS ._.
The_DT Group_NNP is_VBZ exposed_VBN to_TO credit-related_JJ losses_NNS in_IN the_DT event_NN of_IN non-performance_JJ by_IN counterparties_NNS to_TO financial_JJ instruments_NNS ,_, but_CC does_VBZ not_RB expect_VB any_DT counterparties_NNS to_TO fail_VB to_TO meet_VB their_PRP$ obligations_NNS ._.
126_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 34_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS continued_VBD Classication_NNP and_CC fair_JJ values_NNS of_IN financial_JJ assets_NNS and_CC liabilities_NNS The_DT following_JJ table_NN sets_VBZ out_RP the_DT classication_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS and_CC provides_VBZ a_DT reconciliation_NN to_TO Group_NNP net_JJ debt_NN in_IN Note_NN 25_CD ._.
Short-term_JJ debtors_NNS and_CC creditors_NNS have_VBP been_VBN excluded_VBN from_IN financial_JJ assets_NNS and_CC liabilities_NNS ._.
Provisions_NNS have_VBP been_VBN included_VBN where_WRB there_EX is_VBZ a_DT contractual_JJ obligation_NN to_TO settle_VB in_IN cash_NN ._.
2004_CD 2003_CD Carrying_VBG Fair_NNP Carrying_VBG Fair_NNP amount_NN value_NN amount_NN value_NN mm_NN mm_NN Net_JJ debt_NN Liquid_NN investments_NNS 2,818_CD 2,820_CD 2,493_CD 2,509_CD Cash_NN at_IN bank_NN 1,161_CD 1,161_CD 962_CD 962_CD Current_JJ asset_NN financial_JJ instruments_NNS 3,979_CD 3,981_CD 3,455_CD 3,471_CD Sterling_NN notes_NNS and_CC bonds_NNS 1,475_CD 1,533_CD 1,474_CD 1,552_CD 1,475_CD 1,533_CD 1,474_CD 1,552_CD US_NNP dollar_NN notes_NNS ,_, bonds_NNS and_CC private_JJ nancing_NN 1,828_CD 1,817_CD 866_CD 893_CD Notes_NNS and_CC bonds_NNS swapped_VBD into_IN US_NNP dollars_NNS 498 497 498 499_CD Currency_NN swaps_NNS 92_CD 59_CD Interest_NN rate_NN swaps_NNS 28_CD 2_CD 2,326_CD 2,250_CD 1,364_CD 1,335_CD Notes_NNS and_CC bonds_NNS swapped_VBD into_IN Yen_NNP 348 338 463 457_CD Currency_NNP swaps_NNS 10_CD 3_CD 348 328 463 454_CD Euro_NNP notes_NNS and_CC bonds_NNS 705 717 699 700_CD Interest_NN rate_NN swap_NN 12_CD 4_CD 705 705 699 704_CD Other_JJ medium-term_JJ borrowings_NNS 79_CD 79_CD 34_CD 34_CD Other_JJ short-term_JJ loans_NNS and_CC overdrafts_NNS 1,030_CD 1,030_CD 1,069_CD 1,069_CD Total_JJ borrowings_NNS 5,963_CD 5,925_CD 5,103_CD 5,148_CD Total_JJ net_JJ debt_NN 1,984_CD 1,944_CD 1,648_CD 1,677_CD Fixed_VBN asset_NN equity_NN investments_NNS 145_CD 151_CD 98_CD 100_CD Current_JJ asset_NN equity_NN investments_NNS 153 199 164 237_CD Other_JJ debtors_NNS due_JJ after_IN 1_CD year_NN 597 499 522 522_CD Other_JJ creditors_NNS due_JJ after_IN 1_CD year_NN 244 244 232 232_CD Provisions_NNS 256 256 245 245_CD Other_JJ foreign_JJ exchange_NN derivatives_NNS 67_CD 79_CD 52_CD 71_CD Non-hedging_JJ derivatives_NNS 59_CD 36_CD Auction_NN rate_NN preference_NN stock_NN 224_CD 224_CD Flexible_JJ auction_NN market_NN preferred_VBN stock_NN 279_CD 279_CD Total_JJ non-equity_JJ minority_NN interests_NNS 503_CD 503_CD Total_JJ financial_JJ assets_NNS and_CC liabilities_NNS 1,656_CD 1,733_CD 1,792_CD 1,691_CD Total_JJ financial_JJ assets_NNS 4,874_CD 4,830_CD 4,291_CD 4,437_CD Total_JJ financial_JJ liabilities_NNS 6,530_CD 6,563_CD 6,083_CD 6,128_CD Where_WRB appropriate_JJ ,_, currency_NN and_CC interest_NN rate_NN swaps_NNS have_VBP been_VBN presented_VBN alongside_IN the_DT underlying_VBG principal_NN instrument_NN ._.
The_DT carrying_VBG amounts_NNS of_IN these_DT instruments_NNS have_VBP been_VBN adjusted_VBN for_IN the_DT effect_NN of_IN the_DT currency_NN and_CC interest_NN rate_NN swaps_NNS acting_VBG as_IN hedges_NNS ._.
The_DT difference_NN between_IN the_DT carrying_VBG amount_NN and_CC the_DT fair_JJ value_NN of_IN equity_NN xed_VBD and_CC current_JJ assets_NNS and_CC liquid_JJ investments_NNS represents_VBZ gross_JJ unrealised_JJ gains_NNS of_IN 52_CD million_CD and_CC 2_CD million_CD ,_, respectively_RB ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 127_CD 34_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS continued_VBD Currency_NNP and_CC interest_NN rate_NN risk_NN prole_NN of_IN financial_JJ liabilities_NNS Financial_JJ liabilities_NNS ,_, after_IN taking_VBG account_NN of_IN currency_NN and_CC interest_NN rate_NN swaps_NNS ,_, are_VBP analyzed_VBN below_IN ._.
Total_JJ financial_JJ liabilities_NNS comprise_VBP total_JJ borrowings_NNS of_IN 5,963_CD million_CD 2003_CD 5,103_CD million_CD ,_, other_JJ creditors_NNS due_RB after_IN one_CD year_NN of_IN 244_CD million_CD 2003_CD 232_CD million_CD ,_, provisions_NNS of_IN 256_CD million_CD 2003_CD 245_CD million_CD and_CC non-equity_JJ minority_NN interest_NN preference_NN shares_NNS of_IN nil_NN 2003_CD 503_CD million_CD but_CC exclude_VB creditors_NNS due_JJ within_IN one_CD year_NN and_CC foreign_JJ exchange_NN derivatives_NNS of_IN 67_CD million_CD 2003_CD nil_NN ._.
The_DT benchmark_JJ rate_NN for_IN determining_VBG interest_NN payments_NNS for_IN all_DT oating_NN rate_NN financial_JJ liabilities_NNS in_IN the_DT tables_NNS below_IN is_VBZ LIBOR_NNP ._.
Fixed_JJ rate_NN Floating_VBG rate_NN Non-interest_JJ bearing_NN Weighted_NNP Weighted_NNP average_JJ average_JJ Weighted_JJ interest_NN years_NNS for_IN average_JJ At_IN 31st_CD December_NNP 2004_CD rate_NN which_WDT rate_NN years_NNS to_TO Total_JJ Currency_NN m_CD %_NN is_VBZ xed_VBN m_FW m_FW maturity_NN m_NN US_NNP dollars_NNS 571_CD 5.9_CD 13.8_CD 1,764_CD 411_CD 8.9_CD 2,746_CD Sterling_NNP 1,489_CD 6.4_CD 19.3_CD 842_CD 123_CD 2.1_CD 2,454_CD Euro_NNP 747_CD 44_CD 5.3_CD 791_CD Japanese_JJ Yen_NNP 348_CD 0.4_CD 4.6_CD 348_CD Other_JJ currencies_NNS 89_CD 35_CD 6.1_CD 124_CD 2,408_CD 5.4_CD 15.9_CD 3,442_CD 613_CD 4.6_CD 6,463_CD Fixed_VBN rate_NN Floating_VBG rate_NN Non-interest_JJ bearing_NN Weighted_NNP Weighted_NNP average_JJ average_JJ Weighted_JJ interest_NN years_NNS for_IN average_JJ At_IN 31st_CD December_NNP 2003_CD rate_NN which_WDT rate_NN years_NNS to_TO Total_JJ Currency_NN m_CD %_NN is_VBZ xed_VBN m_FW m_FW maturity_NN m_NN US_NNP dollars_NNS 279_CD 6.1_CD 2.1_CD 1,676_CD 311_CD 10.5_CD 2,266_CD Sterling_NNP 1,478_CD 6.4_CD 20.4_CD 852_CD 100_CD 4.1_CD 2,430_CD Euro_NNP 3_CD 750_CD 34_CD 5.6_CD 787_CD Japanese_JJ Yen_NNP 463_CD 0.5_CD 4.3_CD 52_CD 515_CD Other_JJ currencies_NNS 14_CD 39_CD 32_CD 4.8_CD 85_CD 2,237_CD 5.1_CD 14.7_CD 3,369_CD 477_CD 8.4_CD 6,083_CD Currency_NN and_CC interest_NN rate_NN risk_NN prole_NN of_IN financial_JJ assets_NNS Total_JJ financial_JJ assets_NNS comprise_VBP xed_JJ asset_NN equity_NN investments_NNS of_IN 145_CD million_CD 2003_CD 98_CD million_CD ,_, current_JJ asset_NN equity_NN investments_NNS of_IN 153_CD million_CD 2003_CD 164_CD million_CD ,_, liquid_JJ investments_NNS of_IN 2,818_CD million_CD 2003_CD 2,493_CD million_CD ,_, cash_NN at_IN bank_NN of_IN 1,161_CD million_CD 2003_CD 962_CD million_CD and_CC debtors_NNS due_RB after_IN one_CD year_NN of_IN 597_CD million_CD 2003_CD 522_CD million_CD ,_, but_CC exclude_VBP foreign_JJ exchange_NN derivatives_NNS of_IN nil_NN 2003_CD 52_CD million_CD ._.
The_DT benchmark_JJ rate_NN for_IN determining_VBG interest_NN receipts_NNS for_IN all_DT oating_NN rate_NN assets_NNS in_IN the_DT tables_NNS below_IN is_VBZ LIBOR_NNP ._.
Fixed_JJ rate_NN Floating_VBG rate_NN Non-interest_JJ bearing_NN Weighted_NNP Weighted_NNP Fixed_VBN average_JJ average_JJ years_NNS At_IN 31st_CD December_NNP 2004_CD rate_NN interest_NN rate_NN for_IN which_WDT Total_JJ Currency_NN m_CD %_NN rate_NN is_VBZ xed_VBN m_FW m_FW m_FW US_PRP dollars_NNS 164_CD 6.2_CD 11.9_CD 1,429_CD 757_CD 2,350_CD Sterling_NNP 1,088_CD 89_CD 1,177_CD Euro_NNP 629_CD 57_CD 686_CD Japanese_JJ Yen_NN 1_CD 28_CD 29_CD Other_JJ currencies_NNS 155_CD 3.0_CD 0.2_CD 353 124 632 319_CD 4.7_CD 6.2_CD 3,500_CD 1,055_CD 4,874_CD Fixed_VBN rate_NN Floating_VBG rate_NN Non-interest_JJ bearing_NN Weighted_NNP Weighted_NNP Fixed_VBN average_JJ average_JJ years_NNS At_IN 31st_CD December_NNP 2003_CD rate_NN interest_NN rate_NN for_IN which_WDT Total_JJ Currency_NN m_CD %_NN rate_NN is_VBZ xed_VBN m_FW m_FW m_FW US_PRP dollars_NNS 300_CD 6.6_CD 5_CD 1,248_CD 479_CD 2,027_CD Sterling_NNP 20_CD 7.8_CD 2.6_CD 1,209_CD 60_CD 1,289_CD Euro_NNP 1_CD 3.0_CD 0.6_CD 328_CD 77_CD 406_CD Japanese_JJ Yen_NN 1_CD 33_CD 34_CD Other_JJ currencies_NNS 103_CD 2.7_CD 0.1_CD 293 87 483 424_CD 5.0_CD 3.6_CD 3,079_CD 736_CD 4,239_CD 128_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 34_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS continued_VBD Currency_NNP exposure_NN of_IN net_JJ monetary_JJ assets_NNS liabilities_NNS The_DT Groups_NNS currency_NN exposures_NNS that_WDT give_VBP rise_VB to_TO net_JJ currency_NN gains_NNS and_CC losses_NNS that_WDT are_VBP recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN arise_VB principally_RB in_IN companies_NNS with_IN sterling_NN functional_JJ currency_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN overseas_JJ functional_JJ currency_NN and_CC borrowings_NNS designated_VBN as_IN a_DT hedge_NN against_IN overseas_JJ net_JJ assets_NNS are_VBP excluded_VBN from_IN the_DT table_NN below_IN ._.
At_IN 31st_CD December_NNP 2004_CD Functional_JJ currency_NN of_IN Group_NNP operation_NN Net_JJ monetary_JJ assets_NNS liabilities_NNS Sterling_NNP US$_$ Euro_NNP Yen_NNP Other_JJ Total_NNP held_VBD in_IN non-functional_JJ currency_NN m_NN m_FW m_FW m_FW m_FW m_FW Sterling_NN 5_CD 53 130 178_CD US_NNP dollars_NNS 234_CD 18_CD 1_CD 23_CD 228_CD Euro_NNP 97_CD 15_CD 46_CD 158_CD Japanese_JJ Yen_NNP 29_CD 1_CD 1_CD 31_CD Other_JJ 39_CD 8_CD 4_CD 27_CD 205_CD 18_CD 38_CD 1_CD 198_CD 50_CD At_IN 31st_CD December_NNP 2003_CD Functional_JJ currency_NN of_IN Group_NNP operation_NN Net_JJ monetary_JJ assets_NNS liabilities_NNS Sterling_NNP US$_$ Euro_NNP Yen_NNP Other_JJ Total_NNP held_VBD in_IN non-functional_JJ currency_NN m_NN m_FW m_FW m_FW m_FW m_FW Sterling_NN 157 30 242 369_CD US_NNP dollars_NNS 41_CD 12_CD 45_CD 98_CD Euro_NNP 55_CD 111_CD 6_CD 62_CD Japanese_JJ Yen_NN 7_CD 1_CD 6_CD Other_JJ 145_CD 55 12 212 152_CD 212 30 293 323_CD Finance_NNP Total_NNP Total_NNP Debt_NNP leases_VBZ Other_JJ 2004_CD 2003_CD Maturity_NN of_IN financial_JJ liabilities_NNS m_VBP m_FW m_FW m_FW m_FW Within_IN one_CD year_NN or_CC on_IN demand_NN 1,547_CD 35_CD 53_CD 1,635_CD 2,032_CD Between_IN one_CD and_CC two_CD years_NNS 262_CD 27 88 377 630_CD Between_IN two_CD and_CC five_CD years_NNS 1,817_CD 24_CD 132_CD 1,973_CD 1,597_CD After_IN five_CD years_NNS 2,244_CD 7_CD 227_CD 2,478_CD 1,824_CD 5,870_CD 93_CD 500_CD 6,463_CD 6,083_CD 2004_CD Gains_NNS Losses_NNS Net_JJ Hedges_NNP m_FW m_FW m_FW Unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT beginning_NN of_IN the_DT year_NN 171_CD 60_CD 111_CD Unrecognised_JJ gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS and_CC recognized_VBN in_IN the_DT year_NN 27_CD 27_CD Unrecognised_JJ gains_NNS and_CC losses_NNS arising_VBG in_IN the_DT year_NN 8_CD 77_CD 69_CD Total_JJ unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT end_NN of_IN the_DT year_NN 152_CD 137_CD 15_CD Expected_VBN to_TO be_VB recognized_VBN within_IN one_CD year_NN 9_CD 9_CD Expected_VBN to_TO be_VB recognized_VBN after_IN one_CD year_NN 152_CD 128_CD 24_CD Total_JJ unrecognised_JJ gains_NNS and_CC losses_NNS at_IN the_DT end_NN of_IN the_DT year_NN 152_CD 137_CD 15_CD The_DT unrecognised_JJ gains_NNS and_CC losses_NNS above_IN represent_VBP the_DT difference_NN between_IN the_DT carrying_VBG amount_NN and_CC the_DT fair_JJ value_NN of_IN the_DT currency_NN swaps_NNS ,_, interest_NN rate_NN swaps_NNS ,_, equity_NN collar_NN and_CC other_JJ foreign_JJ exchange_NN derivatives_NNS ._.
Committed_VBN facilities_NNS The_DT Group_NNP has_VBZ committed_VBN facilities_NNS to_TO back_VB up_RP the_DT commercial_JJ paper_NN program_NN of_IN $_$ 900_CD million_CD 469_CD million_CD 2003_CD $_$ 1,404_CD million_CD 784_CD million_CD of_IN 364_CD days_NNS duration_NN ,_, renewable_JJ annually_RB ._.
At_IN 31st_CD December_NNP 2004_CD ,_, undrawn_JJ committed_JJ facilities_NNS totalled_VBD $_$ 900_CD million_CD 469_CD million_CD 2003_CD $_$ 1,404_CD million_CD 784_CD million_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 129_CD 35_CD Employee_NN costs_NNS 2003 2002 2004_CD restated_VBN restated_VBN m_NN mm_NN Wages_NNS and_CC salaries_NNS 3,864_CD 3,999_CD 3,876_CD Social_NNP security_NN costs_NNS 430 444 385_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS 295 386 257_CD Cost_NN of_IN share-based_JJ incentive_NN plans_NNS 24_CD 20_CD 117_CD Severance_NN costs_NNS arising_VBG from_IN integration_NN and_CC restructuring_NN activities_NNS 80 222 228_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS arising_VBG from_IN integration_NN and_CC restructuring_NN activities_NNS 6_CD 43_CD 59_CD 4,699_CD 5,074_CD 4,922_CD The_DT Group_NNP provides_VBZ benets_NNS to_TO employees_NNS ,_, commensurate_JJ with_IN local_JJ practice_NN in_IN individual_JJ countries_NNS ,_, including_VBG ,_, in_IN some_DT markets_NNS ,_, healthcare_NN insurance_NN ,_, subsidised_VBN car_NN schemes_NNS and_CC personal_JJ life_NN assurance_NN ._.
Information_NN on_IN Directors_NNS remuneration_NN is_VBZ given_VBN in_IN the_DT Remuneration_NNP Report_NNP on_IN pages_NNS 43_CD to_TO 58_CD ._.
2004 2003 2002_CD The_DT average_JJ number_NN of_IN persons_NNS employed_VBN by_IN the_DT Group_NNP including_VBG Directors_NNS during_IN the_DT year_NN Number_NNP Number_NNP Number_NNP Manufacturing_NNP 31,427_CD 34,265_CD 36,548_CD Selling_NNP ,_, general_JJ and_CC administration_NN 53,513_CD 54,128_CD 54,810_CD Research_NNP and_CC development_NN 14,897_CD 14,773_CD 14,808_CD 99,837_CD 103,166_CD 106,166_CD The_DT average_JJ number_NN of_IN Group_NNP employees_NNS excludes_VBZ temporary_JJ and_CC contract_NN staff_NN ._.
The_DT numbers_NNS of_IN Group_NNP employees_NNS at_IN the_DT end_NN of_IN each_DT financial_JJ year_NN are_VBP given_VBN in_IN the_DT Financial_NNP record_NN page_NN 162_CD ._.
2004 2003 2002_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS m_VBP m_FW m_FW UK_NNP pension_NN schemes_NNS 96_CD 113_CD 18_CD US_NNP pension_NN schemes_NNS 28_CD 75_CD 86_CD Other_JJ overseas_JJ pensions_NNS schemes_NNS 69_CD 74_CD 52_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 84_CD 100_CD 61_CD Post-employment_NN costs_NNS 18_CD 24 40 295 386_CD 257_CD Analysed_VBN as_IN :_: Funded_VBN dened_VBN benefit_NN hybrid_NN schemes_NNS 148_CD 213_CD 92_CD Unfunded_JJ dened_VBN benefit_NN schemes_NNS 22_CD 24_CD 34_CD Dened_VBN contribution_NN schemes_NNS 23_CD 25_CD 30_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 84_CD 100_CD 61_CD Post-employment_NN costs_NNS 18_CD 24 40 295 386_CD 257_CD Pension_NN and_CC other_JJ post-retirement_JJ costs_NNS arising_VBG from_IN integration_NN and_CC restructuring_NN 6_CD 43_CD 59_CD Pensions_NNP Group_NNP undertakings_NNS operate_VBP pension_NN arrangements_NNS which_WDT cover_VBP the_DT Groups_NNS material_NN obligations_NNS to_TO provide_VB pensions_NNS to_TO retired_JJ employees_NNS ._.
These_DT arrangements_NNS have_VBP been_VBN developed_VBN in_IN accordance_NN with_IN local_JJ practices_NNS in_IN the_DT countries_NNS concerned_VBN ._.
Pension_NNP benets_NNS can_MD be_VB provided_VBN by_IN state_NN schemes_NNS :_: by_IN dened_VBN contribution_NN schemes_NNS ,_, whereby_WRB retirement_NN benets_NNS are_VBP determined_VBN by_IN the_DT value_NN of_IN funds_NNS arising_VBG from_IN contributions_NNS paid_VBN in_IN respect_NN of_IN each_DT employee_NN ,_, or_CC by_IN dened_JJ benefit_NN schemes_NNS ,_, whereby_WRB retirement_NN benets_NNS are_VBP based_VBN on_IN employee_NN pensionable_JJ remuneration_NN and_CC length_NN of_IN service_NN ._.
Some_DT dened_VBD benefit_NN schemes_NNS now_RB also_RB include_VBP dened_VBN contribution_NN sections_NNS and_CC are_VBP described_VBN as_IN hybrid_JJ schemes_NNS in_IN the_DT table_NN ._.
In_IN the_DT majority_NN of_IN cases_NNS the_DT contributions_NNS to_TO dened_JJ benefit_NN schemes_NNS are_VBP determined_VBN in_IN accordance_NN with_IN the_DT advice_NN of_IN independent_JJ ,_, professionally_RB qualied_VBD actuaries_NNS ._.
Formal_JJ ,_, independent_JJ ,_, actuarial_JJ valuations_NNS of_IN the_DT Groups_NNS main_JJ plans_NNS are_VBP undertaken_VBN regularly_RB ,_, normally_RB at_IN least_JJS every_DT three_CD years_NNS ._.
The_DT assets_NNS of_IN funded_JJ schemes_NNS are_VBP generally_RB held_VBN in_IN separately_RB administered_VBN trusts_NNS or_CC are_VBP insured_VBN ._.
Assets_NNS are_VBP invested_VBN in_IN different_JJ classes_NNS in_IN order_NN to_TO maintain_VB a_DT balance_NN between_IN risk_NN and_CC return_NN ._.
Investments_NNP are_VBP diversied_VBN to_TO limit_VB the_DT financial_JJ effect_NN of_IN the_DT failure_NN of_IN any_DT individual_JJ investment_NN ._.
130_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 35_CD Employee_NN costs_NNS continued_VBD Pension_NN costs_NNS of_IN dened_VBN benefit_NN schemes_NNS for_IN accounting_NN purposes_NNS have_VBP been_VBN assessed_VBN in_IN accordance_NN with_IN independent_JJ actuarial_JJ advice_NN ,_, generally_RB using_VBG the_DT projected_VBN unit_NN method_NN and_CC by_IN spreading_VBG surpluses_NNS or_CC deficits_NNS over_IN the_DT average_NN expected_VBN remaining_VBG service_NN lives_NNS of_IN the_DT respective_JJ memberships_NNS ._.
In_IN certain_JJ countries_NNS pension_NN benets_NNS are_VBP provided_VBN on_IN an_DT unfunded_JJ basis_NN ,_, some_DT administered_VBN by_IN trustee_NN companies_NNS ._.
Where_WRB assets_NNS are_VBP not_RB held_VBN with_IN the_DT specic_JJ purpose_NN of_IN matching_VBG the_DT liabilities_NNS of_IN unfunded_JJ schemes_NNS ,_, a_DT provision_NN is_VBZ included_VBN within_IN provisions_NNS for_IN pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS ._.
Liabilities_NNS are_VBP generally_RB assessed_VBN annually_RB in_IN accordance_NN with_IN the_DT advice_NN of_IN independent_JJ actuaries_NNS ._.
The_DT market_NN value_NN of_IN the_DT assets_NNS of_IN the_DT Groups_NNS funded_VBN dened_VBD benefit_NN pension_NN funds_NNS at_IN the_DT dates_NNS of_IN the_DT latest_JJS actuarial_JJ valuations_NNS ,_, some_DT of_IN which_WDT date_NN back_RB to_TO 2001_CD ,_, was_VBD 5.1_CD billion_CD and_CC the_DT actuarial_JJ value_NN of_IN assets_NNS was_VBD sufficient_JJ to_TO cover_VB approximately_RB 97_CD per_IN cent_NN of_IN the_DT benets_NNS that_WDT had_VBD accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN future_JJ salary_NN and_CC pension_NN increases_NNS ._.
The_DT UK_NNP dened_VBD benefit_NN pension_NN schemes_NNS account_VBP for_IN approximately_RB 60_CD per_IN cent_NN of_IN the_DT Groups_NNS plans_NNS in_IN asset_NN valuation_NN and_CC projected_VBD benefit_NN terms_NNS and_CC the_DT US_NNP dened_VBD benefit_NN pension_NN schemes_NNS account_VBP for_IN approximately_RB 30_CD per_IN cent_NN of_IN the_DT Groups_NNS plans_NNS in_IN asset_NN valuation_NN and_CC projected_VBD benefit_NN terms_NNS ._.
During_IN 2004_CD ,_, the_DT Group_NNP made_VBD special_JJ funding_NN contributions_NNS to_TO the_DT UK_NNP and_CC US_NNP pension_NN schemes_NNS totalling_VBG 256_CD million_CD ._.
The_DT Group_NNP has_VBZ agreed_VBN with_IN the_DT trustees_NNS of_IN certain_JJ of_IN the_DT pension_NN schemes_NNS to_TO make_VB additional_JJ contributions_NNS dependent_JJ on_IN the_DT funding_NN status_NN of_IN those_DT schemes_NNS ._.
In_IN 2005_CD ,_, following_VBG the_DT move_NN to_TO IFRS_NNP ,_, pension_NN costs_NNS for_IN the_DT Group_NNP are_VBP expected_VBN to_TO be_VB approximately_RB 35_CD million_CD higher_JJR than_IN they_PRP were_VBD in_IN 2004_CD ._.
UK_NNP In_IN the_DT UK_NNP the_DT dened_VBN benefit_NN pension_NN schemes_NNS operated_VBD for_IN the_DT benefit_NN of_IN former_JJ Glaxo_NNP Wellcome_NNP employees_NNS and_CC former_JJ SmithKline_NNP Beecham_NNP employees_NNS remain_VBP separate_JJ ._.
These_DT schemes_NNS were_VBD closed_VBN to_TO new_JJ entrants_NNS in_IN 2001_CD and_CC subsequent_JJ UK_NNP employees_NNS are_VBP entitled_VBN to_TO join_VB a_DT dened_VBN contribution_NN scheme_NN ._.
The_DT relevant_JJ assumptions_NNS used_VBN in_IN calculating_VBG the_DT pension_NN costs_NNS of_IN all_DT of_IN the_DT UK_NNP dened_VBD benefit_NN schemes_NNS for_IN accounting_NN purposes_NNS are_VBP as_IN follows_VBZ :_: 2004_CD 2003_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN of_IN future_JJ earnings_NNS 3.75_CD 3.75_CD Discount_NNP rate_NN 7.75_CD 7.75_CD Expected_VBN long-term_JJ rate_NN of_IN return_NN on_IN investments_NNS 7.75_CD 7.75_CD Expected_VBN pension_NN increases_NNS 2.25_CD 2.25_CD The_DT regular_JJ cost_NN for_IN the_DT Glaxo_NNP Wellcome_NNP pension_NN arrangements_NNS in_IN 2004_CD was_VBD 57_CD million_CD ,_, which_WDT reduced_VBD to_TO an_DT accounting_NN cost_NN of_IN 47_CD million_CD ,_, after_IN allowance_NN was_VBD made_VBN for_IN spreading_VBG the_DT surplus_NN disclosed_VBD as_IN a_DT level_NN percentage_NN of_IN salary_NN over_IN the_DT expected_JJ future_NN working_VBG lifetime_NN of_IN the_DT existing_VBG members_NNS some_DT 9_CD years_NNS ._.
The_DT most_RBS recent_JJ triennial_JJ actuarial_JJ valuations_NNS for_IN funding_VBG purposes_NNS were_VBD carried_VBN out_RP as_IN at_IN 31st_CD December_NNP 2002_CD ._.
At_IN that_DT date_NN the_DT assets_NNS of_IN the_DT schemes_NNS represented_VBD 92_CD per_IN cent_NN of_IN the_DT actuarial_JJ value_NN of_IN all_DT benets_NNS accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN future_JJ salary_NN and_CC pension_NN increases_NNS ._.
The_DT market_NN value_NN of_IN the_DT assets_NNS held_VBN by_IN the_DT schemes_NNS at_IN 31st_CD December_NNP 2002_CD was_VBD 2,103_CD million_CD ._.
The_DT regular_JJ cost_NN for_IN the_DT SmithKline_NNP Beecham_NNP schemes_NNS in_IN 2004_CD was_VBD 15_CD million_CD ,_, which_WDT increased_VBD to_TO an_DT accounting_NN cost_NN of_IN 49_CD million_CD after_IN allowance_NN was_VBD made_VBN for_IN the_DT spreading_VBG of_IN the_DT deficit_NN over_IN the_DT expected_JJ future_NN working_VBG lifetime_NN of_IN current_JJ employees_NNS in_IN the_DT scheme_NN some_DT 10_CD years_NNS ._.
The_DT latest_JJS valuation_NN was_VBD carried_VBN out_RP at_IN 31st_CD December_NNP 2002_CD and_CC at_IN that_DT date_NN the_DT scheme_NN assets_NNS represented_VBD 56_CD per_IN cent_NN of_IN the_DT actuarial_JJ value_NN of_IN the_DT accrued_JJ service_NN liabilities_NNS based_VBN on_IN the_DT 2003_CD assumptions_NNS ._.
The_DT market_NN value_NN of_IN assets_NNS held_VBN by_IN the_DT scheme_NN at_IN 31st_CD December_NNP 2002_CD was_VBD 856_CD million_CD ._.
USA_NNP In_IN the_DT USA_NNP the_DT former_JJ Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP dened_VBD benefit_NN and_CC hybrid_JJ schemes_NNS were_VBD merged_VBN during_IN 2001_CD ._.
The_DT relevant_JJ assumptions_NNS used_VBN in_IN calculating_VBG the_DT pension_NN costs_NNS for_IN accounting_NN purposes_NNS are_VBP as_IN follows_VBZ :_: 2004_CD 2003_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN of_IN future_JJ earnings_NNS 5.50_CD 5.50_CD Discount_NNP rate_NN 7.75_CD 8.50_CD Expected_VBN long-term_JJ rate_NN of_IN return_NN on_IN investments_NNS 7.75_CD 8.50_CD Cash_NN balance_NN credit_NN conversion_NN rate_NN 5.25_CD 5.75_CD The_DT regular_JJ cost_NN for_IN the_DT main_JJ US_NNP schemes_NNS in_IN 2004_CD was_VBD 51_CD million_CD ,_, which_WDT decreased_VBD to_TO an_DT accounting_NN cost_NN of_IN 28_CD million_CD after_IN allowance_NN was_VBD made_VBN for_IN the_DT spreading_VBG of_IN the_DT surplus_NN over_IN the_DT expected_JJ future_NN working_VBG lifetime_NN of_IN current_JJ employees_NNS in_IN the_DT schemes_NNS ._.
The_DT latest_JJS valuation_NN was_VBD carried_VBN out_RP at_IN 1st_CD January_NNP 2004_CD and_CC at_IN that_DT date_NN the_DT actuarial_JJ value_NN of_IN scheme_NN assets_NNS represented_VBD 110_CD per_IN cent_NN of_IN the_DT actuarial_JJ value_NN of_IN the_DT accrued_JJ service_NN liabilities_NNS ._.
The_DT market_NN value_NN of_IN assets_NNS held_VBN by_IN the_DT scheme_NN at_IN 1st_CD January_NNP 2004_CD was_VBD 1,593_CD million_CD ._.
Post-retirement_NN healthcare_NN The_DT Group_NNP operates_VBZ a_DT number_NN of_IN post-retirement_JJ healthcare_NN schemes_NNS ,_, the_DT principal_NN one_CD of_IN which_WDT is_VBZ in_IN the_DT USA_NNP ._.
The_DT cost_NN of_IN the_DT US_NNP scheme_NN has_VBZ been_VBN assessed_VBN using_VBG the_DT same_JJ assumptions_NNS as_IN for_IN the_DT US_NNP pension_NN scheme_NN ,_, together_RB with_IN the_DT assumption_NN for_IN future_JJ medical_JJ ination_NN of_IN 10_CD per_IN cent_NN reducing_VBG by_IN one_CD per_IN cent_NN per_IN year_NN to_TO five_CD per_IN cent_NN ._.
The_DT total_JJ provision_NN for_IN post-retirement_JJ benets_NNS at_IN 31st_CD December_NNP 2004_CD amounted_VBD to_TO 594_CD million_CD 2003_CD 569_CD million_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 131_CD 35_CD Employee_NN costs_NNS continued_VBD FRS_NNP 17_CD disclosures_NNS The_DT Group_NNP continues_VBZ to_TO account_VB for_IN pension_NN arrangements_NNS in_IN accordance_NN with_IN SSAP_NNP 24_CD Accounting_NNP for_IN Pension_NNP Costs_NNS ._.
Under_IN the_DT transitional_JJ provisions_NNS of_IN FRS_NNP 17_CD Retirement_NNP Benets_NNPS certain_JJ disclosures_NNS are_VBP required_VBN on_IN the_DT basis_NN of_IN the_DT valuation_NN methodology_NN adopted_VBN by_IN FRS_NNP 17_CD ._.
For_IN dened_VBN benefit_NN schemes_NNS the_DT fair_JJ values_NNS of_IN pension_NN scheme_NN assets_NNS at_IN 31st_CD December_NNP 2004_CD are_VBP compared_VBN with_IN the_DT future_JJ pension_NN liabilities_NNS calculated_VBN under_IN the_DT projected_VBN unit_NN method_NN applying_VBG the_DT following_VBG assumptions_NNS :_: UK_NNP USA_NNP Rest_VBP of_IN World_NNP 2004 2003 2002 2004_CD 2003 2002 2004 2003_CD 2002_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN increase_NN of_IN future_JJ earnings_NNS 4.00_CD 4.00_CD 3.75_CD 5.00_CD 5.50_CD 5.50_CD 3.25_CD 3.00_CD 3.00_CD Discount_NNP rate_NN 5.25_CD 5.25_CD 5.75_CD 5.75_CD 6.25_CD 6.75_CD 4.25_CD 4.75_CD 4.75_CD Expected_VBN pension_NN increases_NNS 2.50_CD 2.50_CD 2.25_CD n_VBD a_DT n_NN a_DT n_NN a_DT 2.00_CD 2.00_CD 1.50_CD Cash_NN balance_NN credit_NN conversion_NN rate_NN n_VBD a_DT n_NN a_DT n_NN a_DT 4.75_CD 5.25_CD 5.75_CD 1.75_CD 1.50_CD n_NN a_DT Ination_NNP rate_NN 2.50_CD 2.50_CD 2.25_CD 2.50_CD 2.50_CD 2.25_CD 1.75_CD 1.50_CD 1.50_CD The_DT expected_VBN long-term_JJ rates_NNS of_IN return_NN on_IN the_DT assets_NNS determined_VBD based_VBN on_IN actuarial_JJ advice_NN and_CC the_DT fair_JJ values_NNS of_IN the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT UK_NNP and_CC US_NNP dened_VBD benefit_NN schemes_NNS ,_, together_RB with_IN aggregated_JJ data_NNS for_IN other_JJ dened_VBN benefit_NN schemes_NNS in_IN the_DT Group_NNP are_VBP as_IN follows_VBZ :_: UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Average_JJ At_IN 31st_CD December_NNP 2004_CD Expected_VBN rate_NN Fair_NN Expected_VBN rate_NN Fair_NN expected_VBN rate_NN Fair_NN Fair_NN of_IN return_NN value_NN of_IN return_NN value_NN of_IN return_NN value_NN value_NN %_NN m_CD %_NN m_CD %_NN m_NN m_NN Equities_NNS 8.25_CD 2,716_CD 8.50_CD 1,229_CD 7.50_CD 205_CD 4,150_CD Property_NN 6.50_CD 58_CD 6.25_CD 7_CD 65_CD Bonds_NNS 4.50_CD 1,404_CD 5.75_CD 307_CD 3.75_CD 270_CD 1,981_CD Other_JJ assets_NNS 4.00_CD 44_CD 2.50_CD 50_CD 2.25_CD 62_CD 156_CD Fair_NNP value_NN of_IN assets_NNS 4,164_CD 1,644_CD 544_CD 6,352_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 5,326_CD 1,750_CD 760_CD 7,836_CD 1,162_CD 106_CD 216_CD 1,484_CD Value_NN of_IN schemes_NNS in_IN surplus_NN 18_CD 7_CD 25_CD Deferred_JJ tax_NN liability_NN 7_CD 2_CD 9_CD 11_CD 5_CD 16_CD Value_NN of_IN schemes_NNS in_IN deficit_NN 1,162_CD 124_CD 223_CD 1,509_CD Deferred_JJ tax_NN asset_NN 349_CD 46 78 473 813_CD 78_CD 145_CD 1,036_CD Group_NNP total_JJ 1,020_CD UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Average_JJ At_IN 31st_CD December_NNP 2003_CD Expected_VBN rate_NN Fair_NN Expected_VBN rate_NN Fair_NN expected_VBN rate_NN Fair_NN Fair_NN of_IN return_NN value_NN of_IN return_NN value_NN of_IN return_NN value_NN value_NN %_NN m_CD %_NN m_CD %_NN m_NN m_NN Equities_NNS 8.25_CD 2,927_CD 8.50_CD 1,201_CD 7.75_CD 174_CD 4,302_CD Property_NN 6.50_CD 52_CD 6.50_CD 6_CD 58_CD Bonds_NNS 4.50_CD 574_CD 5.75_CD 314_CD 4.00_CD 226_CD 1,114_CD Other_JJ assets_NNS 4.00_CD 185_CD 1.00_CD 26_CD 2.00_CD 18_CD 229_CD Fair_NNP value_NN of_IN assets_NNS 3,686_CD 1,593_CD 424_CD 5,703_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 5,181_CD 1,743_CD 674_CD 7,598_CD 1,495_CD 150_CD 250_CD 1,895_CD Value_NN of_IN schemes_NNS in_IN surplus_NN 7_CD 7_CD Deferred_JJ tax_NN liability_NN 2_CD 2_CD 5_CD 5_CD Value_NN of_IN schemes_NNS in_IN deficit_NN 1,495_CD 150_CD 257_CD 1,902_CD Deferred_JJ tax_NN asset_NN 449_CD 53_CD 95_CD 597_CD 1,046_CD 97_CD 162_CD 1,305_CD Group_NNP total_JJ 1,300_CD 132_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 35_CD Employee_NN costs_NNS continued_VBD UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Average_JJ At_IN 31st_CD December_NNP 2002_CD Expected_VBN rate_NN Fair_NN Expected_VBN rate_NN Fair_NN expected_VBN rate_NN Fair_NN Fair_NN of_IN return_NN value_NN of_IN return_NN value_NN of_IN return_NN value_NN value_NN %_NN m_CD %_NN m_CD %_NN m_NN m_NN Equities_NNS 8.25_CD 2,523_CD 9.25_CD 804_CD 6.75_CD 172_CD 3,499_CD Property_NN 7.00_CD 53_CD 7.00_CD 5_CD 58_CD Bonds_NNS 4.50_CD 299_CD 6.25_CD 265_CD 4.50_CD 145_CD 709_CD Other_JJ assets_NNS 4.00_CD 137_CD 1.50_CD 240_CD 1.75_CD 9_CD 386_CD Fair_NNP value_NN of_IN assets_NNS 2,959_CD 1,362_CD 331_CD 4,652_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 4,153_CD 1,782_CD 578_CD 6,513_CD 1,194_CD 420_CD 247_CD 1,861_CD Value_NN of_IN schemes_NNS in_IN surplus_NN 11_CD 11_CD Deferred_JJ tax_NN liability_NN 3_CD 3_CD 88_CD Value_NN of_IN schemes_NNS in_IN deficit_NN 1,194_CD 420_CD 258_CD 1,872_CD Deferred_JJ tax_NN asset_NN 358_CD 147 97 602 836_CD 273_CD 161_CD 1,270_CD Group_NNP total_JJ 1,262_CD The_DT UK_NNP dened_VBD benefit_NN schemes_NNS also_RB have_VBP dened_VBN contribution_NN sections_NNS with_IN account_NN balances_NNS totalling_VBG 404_CD million_CD at_IN 31st_CD December_NNP 2004 2003 327_CD million_CD ,_, 2002_CD 281_CD million_CD ._.
The_DT dened_VBN benefit_NN sections_NNS of_IN the_DT UK_NNP schemes_NNS have_VBP been_VBN closed_VBN to_TO new_JJ members_NNS and_CC ,_, under_IN the_DT projected_VBN unit_NN method_NN of_IN valuing_VBG the_DT pension_NN scheme_NN liabilities_NNS ,_, the_DT current_JJ service_NN cost_NN will_MD increase_VB as_IN a_DT percentage_NN of_IN payroll_NN as_IN the_DT members_NNS of_IN the_DT schemes_NNS approach_VBP retirement_NN ._.
The_DT deficits_NNS under_IN FRS_NNP 17_CD reect_NN the_DT different_JJ basis_NN for_IN valuing_VBG liabilities_NNS compared_VBN with_IN SSAP_NNP 24_CD ._.
The_DT liability_NN under_IN FRS_NNP 17_CD for_IN the_DT US_NNP post-retirement_NN healthcare_NN scheme_NN has_VBZ been_VBN assessed_VBN using_VBG the_DT same_JJ assumptions_NNS as_IN for_IN the_DT US_NNP pension_NN scheme_NN ,_, together_RB with_IN the_DT assumption_NN for_IN future_JJ medical_JJ ination_NN of_IN 9_CD per_IN cent_NN ,_, reducing_VBG by_IN one_CD per_IN cent_NN per_IN year_NN to_TO five_CD per_IN cent_NN ._.
On_IN this_DT basis_NN the_DT liability_NN for_IN the_DT US_NNP scheme_NN has_VBZ been_VBN assessed_VBN at_IN 895_CD million_CD 2003_CD 908_CD million_CD :_: 2002_CD 766_CD million_CD ,_, which_WDT reduced_VBD to_TO 564_CD million_CD 2003_CD 590_CD million_CD :_: 2002_CD 475_CD million_CD after_IN taking_VBG account_NN of_IN deferred_JJ tax_NN ._.
If_IN the_DT dened_VBN benefit_NN pension_NN and_CC post-retirement_NN benefit_NN schemes_NNS had_VBD been_VBN accounted_VBN for_IN under_IN FRS_NNP 17_CD ,_, the_DT following_JJ amounts_NNS would_MD have_VB been_VBN recorded_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN and_CC statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT three_CD years_NNS ended_VBN 31st_CD December_NNP 2004_CD ._.
Post-retirement_NN Pensions_NNS benets_VBZ 2004_CD UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW Amounts_NNPS charged_VBD to_TO operating_VBG profit_NN Current_JJ service_NN cost_NN 117_CD 58_CD 42_CD 217_CD 37_CD Past_JJ service_NN cost_NN 3_CD 2_CD 5_CD Curtailments_NNP settlements_NNS 5_CD 5_CD 125_CD 58_CD 44_CD 227_CD 37_CD Amounts_NNS credited_VBD charged_VBN to_TO net_JJ interest_NN Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 274_CD 118_CD 20_CD 412_CD Interest_NN on_IN scheme_NN liabilities_NNS 269_CD 104_CD 27_CD 400_CD 55_CD 5_CD 14_CD 7_CD 12_CD 55_CD Amounts_NNS recorded_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN scheme_NN assets_NNS 106_CD 82_CD 1_CD 189_CD Experience_NN gains_NNS losses_NNS arising_VBG on_IN scheme_NN liabilities_NNS 11_CD 6_CD 43_CD 48_CD 47_CD Changes_NNS in_IN assumptions_NNS relating_VBG to_TO present_JJ value_NN of_IN scheme_NN liabilities_NNS 62_CD 31_CD 93_CD 82_CD 117_CD 14_CD 13_CD 144_CD 35_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 133_CD 35_CD Employee_NN costs_NNS continued_VBD Post-retirement_JJ Pensions_NNS benets_VBZ 2003_CD UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW Amounts_NNPS charged_VBD to_TO operating_VBG profit_NN Current_JJ service_NN cost_NN 108_CD 67_CD 44_CD 219_CD 29_CD Past_JJ service_NN cost_NN 7_CD 16_CD 23_CD 3_CD Curtailments_NNP settlements_NNS 78_CD 15_CD 93_CD 186_CD 75_CD 28_CD 289_CD 26_CD Amounts_NNS credited_VBD charged_VBN to_TO net_JJ interest_NN Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 231_CD 111_CD 17_CD 359_CD Interest_NN on_IN scheme_NN liabilities_NNS 246_CD 119_CD 25_CD 390_CD 64_CD 15_CD 8_CD 8_CD 31_CD 64_CD Amounts_NNS recorded_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN scheme_NN assets_NNS 368_CD 230_CD 10_CD 608_CD Experience_NN losses_NNS gains_NNS arising_VBG on_IN scheme_NN liabilities_NNS 193_CD 5_CD 28 216 123_CD Changes_NNS in_IN assumptions_NNS relating_VBG to_TO present_JJ value_NN of_IN scheme_NN liabilities_NNS 616_CD 61_CD 32_CD 709 67 441 174_CD 50 317 190_CD Post-retirement_NN Pensions_NNS benets_VBZ 2002_CD UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW Amounts_NNPS charged_VBD to_TO operating_VBG profit_NN Current_JJ service_NN cost_NN 118_CD 74_CD 32_CD 224_CD 24_CD Past_JJ service_NN cost_NN 28_CD 34_CD 62_CD Curtailments_NNP settlements_NNS 1_CD 1_CD 146_CD 108_CD 33_CD 287_CD 24_CD Amounts_NNS credited_VBD charged_VBN to_TO net_JJ interest_NN Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 293_CD 129_CD 14_CD 436_CD Interest_NN on_IN scheme_NN liabilities_NNS 235_CD 129_CD 22_CD 386_CD 53_CD 58_CD 8_CD 50_CD 53_CD Amounts_NNS recorded_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN scheme_NN assets_NNS 1,024_CD 293_CD 56_CD 1,373_CD Experience_NN gains_NNS losses_NNS arising_VBG on_IN scheme_NN liabilities_NNS 34_CD 3_CD 2_CD 33_CD 95_CD Changes_NNS in_IN assumptions_NNS relating_VBG to_TO present_JJ value_NN of_IN scheme_NN liabilities_NNS 15_CD 57_CD 10_CD 62_CD 124_CD 1,005_CD 353_CD 44_CD 1,402_CD 29_CD 134_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 35_CD Employee_NN costs_NNS continued_VBD Post-retirement_JJ Pensions_NNS benets_VBZ Movements_NNP in_IN deficits_NNS UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW deficits_NNS in_IN schemes_NNS at_IN 1st_CD January_NNP 2002 255 245 214_CD 714_CD 854_CD Exchange_NNP adjustments_NNS 37_CD 9_CD 28_CD 85_CD Charged_VBN to_TO operating_VBG profit_NN 146_CD 108_CD 33_CD 287_CD 24_CD Employer_NN contributions_NNS 154_CD 249_CD 61_CD 464_CD 41_CD Other_JJ finance_NN income_NN expense_NN 58_CD 8_CD 50_CD 53_CD Actuarial_JJ losses_NNS recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 1,005_CD 353_CD 44_CD 1,402_CD 29_CD deficits_NNS in_IN schemes_NNS at_IN 31st_CD December_NNP 2002_CD 1,194_CD 420_CD 247_CD 1,861_CD 834_CD Exchange_NNP adjustments_NNS 20_CD 15_CD 5_CD 96_CD Charged_VBN to_TO operating_VBG profit_NN 186_CD 75_CD 28_CD 289_CD 26_CD Employer_NN contributions_NNS 341_CD 159_CD 98_CD 598_CD 41_CD Other_JJ finance_NN income_NN expense_NN 15_CD 8_CD 8_CD 31_CD 64_CD Actuarial_JJ losses_NNS gains_NNS recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 441_CD 174 50 317 190_CD deficits_NNS in_IN schemes_NNS at_IN 31st_CD December_NNP 2003_CD 1,495_CD 150_CD 250_CD 1,895_CD 977_CD Exchange_NNP adjustments_NNS 9_CD 4_CD 13_CD 59_CD Charged_VBN to_TO operating_VBG profit_NN 125_CD 58_CD 44_CD 227_CD 37_CD Employer_NN contributions_NNS 336_CD 65_CD 68_CD 469_CD 40_CD Other_JJ finance_NN income_NN expense_NN 5_CD 14_CD 7_CD 12_CD 55_CD Actuarial_JJ losses_NNS gains_NNS recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 117_CD 14_CD 13_CD 144_CD 35_CD deficits_NNS in_IN schemes_NNS at_IN 31st_CD December_NNP 2004_CD 1,162_CD 106_CD 216_CD 1,484_CD 1,005_CD Post-retirement_NN Pensions_NNS benets_VBZ History_NN of_IN experience_NN gains_NNS and_CC losses_NNS UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW 2004_CD Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS m_VBP 106_CD 82_CD 1_CD 189_CD Percentage_NN of_IN scheme_NN assets_NNS at_IN 31st_CD December_NNP 2004_CD 3_CD %_NN 5_CD %_NN 3_CD %_NN Experience_NN gains_NNS losses_NNS of_IN scheme_NN liabilities_NNS m_VBP 11_CD 6_CD 43_CD 48_CD 47_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2004_CD 6_CD %_NN 1_CD %_NN 5_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS m_VBP 117_CD 14_CD 13_CD 144_CD 35_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2004_CD 2_CD %_NN 1_CD %_NN 2_CD %_NN 2_CD %_NN 3_CD %_NN Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 135_CD 35_CD Employee_NN costs_NNS continued_VBD Post-retirement_JJ Pensions_NNS benets_VBZ History_NN of_IN experience_NN gains_NNS and_CC losses_NNS UK_NNP USA_NNP Rest_VBP of_IN World_NNP Group_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW 2003_CD Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS m_VBP 368_CD 230_CD 10_CD 608_CD Percentage_NN of_IN scheme_NN assets_NNS at_IN 31st_CD December_NNP 2003_CD 10_CD %_NN 14_CD %_NN 2_CD %_NN 11_CD %_NN Experience_NN losses_NNS gains_NNS of_IN scheme_NN liabilities_NNS m_VBP 193_CD 5_CD 28 216 123_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2003_CD 4_CD %_NN 4_CD %_NN 3_CD %_NN 13_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS m_VBP 441_CD 174 50 317 190_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2003_CD 9_CD %_NN 10_CD %_NN 7_CD %_NN 4_CD %_NN 19_CD %_NN 2002_CD Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS m_VBP 1,024_CD 293_CD 56_CD 1,373_CD Percentage_NN of_IN scheme_NN assets_NNS at_IN 31st_CD December_NNP 2002_CD 35_CD %_NN 22_CD %_NN 17_CD %_NN 30_CD %_NN Experience_NN gains_NNS losses_NNS of_IN scheme_NN liabilities_NNS m_VBP 34_CD 3_CD 2_CD 33_CD 95_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2002_CD 1_CD %_NN 1_CD %_NN 11_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS m_VBP 1,005_CD 353_CD 44_CD 1,402_CD 29_CD Percentage_NN of_IN present_JJ value_NN of_IN scheme_NN liabilities_NNS at_IN 31st_CD December_NNP 2002_CD 24_CD %_NN 20_CD %_NN 8_CD %_NN 22_CD %_NN 3_CD %_NN If_IN the_DT FRS_NNP 17_CD valuation_NN basis_NN had_VBD been_VBN applied_VBN in_IN the_DT financial_JJ statements_NNS instead_RB of_IN the_DT SSAP_NNP 24_CD valuation_NN basis_NN ,_, the_DT effect_NN on_IN the_DT profit_NN and_CC loss_NN account_NN reserve_NN after_IN taking_VBG account_NN of_IN deferred_JJ tax_NN would_MD have_VB been_VBN as_IN follows_VBZ :_: 2003_CD 2004_CD restated_VBN m_FW m_FW m_FW m_FW profit_NN and_CC loss_NN account_NN reserve_NN per_IN balance_NN sheet_NN 4,781_CD 4,112_CD Pension_NN liability_NN under_IN FRS_NNP 17_CD 1,020_CD 1,300_CD Net_JJ pension_NN asset_NN under_IN SSAP_NNP 24_CD per_IN balance_NN sheet_NN 387_CD 152_CD 1,407_CD 1,452_CD Post-retirement_NN healthcare_NN schemes_NNS under_IN FRS_NNP 17 640 638_CD Net_JJ post-retirement_JJ healthcare_NN schemes_NNS provision_NN per_IN balance_NN sheet_NN 379 372 261 266_CD profit_NN and_CC loss_NN account_NN reserve_NN including_VBG FRS_NNP 17_CD pension_NN and_CC post-retirement_JJ healthcare_NN liability_NN 3,113_CD 2,394_CD 136_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 36_CD Employee_NN share_NN schemes_NNS The_DT Group_NNP operates_VBZ share_NN option_NN schemes_NNS ,_, whereby_WRB options_NNS are_VBP granted_VBN to_TO employees_NNS to_TO acquire_VB shares_NNS or_CC ADSs_NNS in_IN GlaxoSmithKline_NNP plc_NN at_IN the_DT grant_NN price_NN ,_, and_CC share_NN award_NN schemes_NNS ,_, whereby_WRB awards_NNS are_VBP granted_VBN to_TO employees_NNS to_TO acquire_VB shares_NNS or_CC ADSs_NNS in_IN GlaxoSmithKline_NNP plc_NN at_IN no_DT cost_NN ,_, subject_JJ to_TO the_DT achievement_NN of_IN performance_NN targets_NNS ._.
In_IN 2004_CD ,_, the_DT Group_NNP introduced_VBD a_DT new_JJ share_NN award_NN scheme_NN ,_, the_DT Restricted_NNP Share_NNP Plan_NNP ,_, whereby_WRB awards_NNS are_VBP granted_VBN to_TO employees_NNS to_TO acquire_VB shares_NNS or_CC ADSs_NNS in_IN GlaxoSmithKline_NNP plc_NN at_IN no_DT cost_NN after_IN a_DT three_CD year_NN period_NN ._.
The_DT granting_VBG of_IN restricted_JJ share_NN awards_NNS has_VBZ replaced_VBN the_DT granting_VBG of_IN options_NNS to_TO certain_JJ employees_NNS as_IN the_DT cost_NN of_IN the_DT scheme_NN more_RBR readily_RB equates_VBZ to_TO the_DT potential_JJ gain_NN to_TO be_VB made_VBN by_IN the_DT employee_NN ._.
The_DT Group_NNP operates_VBZ share_NN option_NN schemes_NNS and_CC savings-related_JJ share_NN option_NN schemes_NNS ._.
Grants_NNPS under_IN share_NN option_NN schemes_NNS are_VBP normally_RB exercisable_JJ between_IN three_CD and_CC ten_CD years_NNS from_IN the_DT date_NN of_IN grant_NN ._.
Grants_NNPS under_IN savings-related_JJ share_NN option_NN schemes_NNS are_VBP normally_RB exercisable_JJ after_IN three_CD years_NNS saving_VBG ._.
Options_NNS under_IN the_DT share_NN option_NN schemes_NNS are_VBP normally_RB granted_VBN at_IN the_DT market_NN price_NN ruling_NN at_IN the_DT date_NN of_IN grant_NN ._.
In_IN accordance_NN with_IN UK_NNP practice_NN ,_, the_DT majority_NN of_IN options_NNS under_IN the_DT savings-related_JJ share_NN option_NN schemes_NNS are_VBP granted_VBN at_IN a_DT price_NN 20_CD per_IN cent_NN below_IN the_DT market_NN price_NN ruling_NN at_IN the_DT date_NN of_IN grant_NN ._.
In_IN accordance_NN with_IN the_DT exemption_NN granted_VBN in_IN UITF_NNP 17_CD revised_VBN no_DT charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN is_VBZ made_VBN in_IN relation_NN to_TO these_DT savings-related_JJ share_NN option_NN schemes_NNS ._.
Share_NN option_NN Share_NN option_NN Savings-related_JJ Options_NNS outstanding_JJ schemes_NNS shares_NNS schemes_NNS ADSs_NNS share_NN option_NN schemes_NNS Weighted_NNP Weighted_NNP Weighted_NNP Number_NNP exercise_NN Number_NNP exercise_NN Number_NNP exercise_NN 000_CD price_NN 000_CD price_NN 000_CD price_NN At_IN 31st_CD December_NNP 2001_CD 179,936_CD 15.67_CD 73,825_CD $_$ 50.31_CD 8,200_CD 14.13_CD Options_NNS granted_VBN 33,454_CD 11.91_CD 22,991_CD $_$ 37.57_CD 9,793_CD 9.16_CD Options_NNS exercised_VBN 8,857_CD 10.55_CD 1,504_CD $_$ 21.75_CD 398_CD 14.04_CD Options_NNS canceled_VBN 7,061_CD 17.53_CD 4,435_CD $_$ 54.69_CD 4,607_CD 14.41_CD At_IN 31st_CD December_NNP 2002_CD 197,472_CD 15.20_CD 90,877_CD $_$ 47.34_CD 12,988_CD 10.29_CD Options_NNS granted_VBN 32,750_CD 12.84_CD 23,630_CD $_$ 43.34_CD 1,416_CD 10.20_CD Options_NNS exercised_VBN 4,728_CD 4.75_CD 1,828_CD $_$ 22.22_CD 112_CD 10.23_CD Options_NNS canceled_VBN 19,789_CD 7.45_CD 6,150_CD $_$ 32.73_CD 3,709_CD 12.23_CD At_IN 31st_CD December_NNP 2003_CD 205,705_CD 14.89_CD 106,529_CD $_$ 46.58_CD 10,583_CD 9.59_CD Options_NNS granted_VBN 9,837_CD 11.23_CD 9,222_CD $_$ 42.99_CD 1,580_CD 9.52_CD Options_NNS exercised_VBN 5,764_CD 6.54_CD 1,845_CD $_$ 25.65_CD 232_CD 9.18_CD Options_NNS canceled_VBN 11,997_CD 15.33_CD 3,427_CD $_$ 48.28_CD 1,790_CD 10.46_CD At_IN 31st_CD December_NNP 2004_CD 197,781_CD 14.92_CD 110,479_CD $_$ 46.57_CD 10,141_CD 9.44_CD Range_NNP of_IN exercise_NN prices_NNS 3.98_CD 19.77_CD $_$ 12.83_CD $_$ 61.35_CD 9.16_CD 14.12_CD In_IN order_NN to_TO encourage_VB employees_NNS to_TO convert_VB options_NNS ,_, excluding_VBG savings-related_JJ share_NN options_NNS ,_, held_VBN over_IN Glaxo_NNP Wellcome_NNP or_CC SmithKline_NNP Beecham_NNP shares_NNS or_CC ADSs_NNS ,_, into_IN those_DT over_IN GlaxoSmithKline_NNP shares_NNS or_CC ADSs_NNS ,_, a_DT program_NN was_VBD established_VBN to_TO give_VB an_DT additional_JJ cash_NN benefit_NN of_IN 10_CD per_IN cent_NN of_IN the_DT exercise_NN price_NN of_IN the_DT original_JJ option_NN provided_VBD that_IN the_DT employee_NN did_VBD not_RB voluntarily_RB leave_VB the_DT Group_NNP for_IN two_CD years_NNS from_IN the_DT date_NN of_IN the_DT merger_NN and_CC did_VBD not_RB exercise_VB the_DT option_NN before_IN the_DT earlier_JJR of_IN six_CD months_NNS from_IN the_DT expiry_NN date_NN of_IN the_DT original_JJ option_NN and_CC two_CD years_NNS from_IN the_DT date_NN of_IN the_DT merger_NN ._.
The_DT cash_NN benefit_NN will_MD also_RB be_VB paid_VBN if_IN the_DT options_NNS expire_VBP unexercised_JJ if_IN the_DT market_NN price_NN is_VBZ below_IN the_DT exercise_NN price_NN on_IN the_DT date_NN of_IN expiry_NN ._.
There_EX has_VBZ been_VBN no_DT change_NN in_IN the_DT effective_JJ exercise_NN price_NN of_IN any_DT outstanding_JJ options_NNS during_IN the_DT year_NN ._.
No_DT further_RBR options_NNS were_VBD granted_VBN between_IN 31st_CD December_NNP 2004_CD and_CC 25th_JJ February_NNP 2005_CD ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 137_CD 36_CD Employee_NN share_NN schemes_NNS continued_VBD Share_NN option_NN Share_NN option_NN Savings-related_JJ Options_NNS exercisable_JJ schemes_NNS shares_NNS schemes_NNS ADSs_NNS share_NN option_NN schemes_NNS Weighted_NNP Weighted_NNP Weighted_NNP Number_NNP exercise_NN Number_NNP exercise_NN Number_NNP exercise_NN 000_CD price_NN 000_CD price_NN 000_CD price_NN At_IN 31st_CD December_NNP 2002_CD 72,611_CD 14.33_CD 27,129_CD $_$ 48.89_CD 2,227_CD 13.27_CD At_IN 31st_CD December_NNP 2003_CD 79,693_CD 14.56_CD 22,364_CD $_$ 49.82_CD 192_CD 16.48_CD At_IN 31st_CD December_NNP 2004_CD 126,917_CD 16.49_CD 57,421_CD $_$ 51.75_CD 270_CD 14.12_CD GlaxoSmithKline_NNP share_NN award_NN schemes_NNS Performance_NNP Share_NNP Plan_NNP The_NNP Group_NNP operates_VBZ a_DT Performance_NNP Share_NNP Plan_NNP whereby_WRB awards_NNS are_VBP granted_VBN to_TO Directors_NNS and_CC senior_JJ executives_NNS at_IN no_DT cost_NN ._.
The_DT percentage_NN of_IN each_DT award_NN that_WDT vests_NNS is_VBZ based_VBN upon_IN the_DT performance_NN of_IN the_DT Group_NNP over_IN a_DT three_CD year_NN measurement_NN period_NN ._.
The_DT performance_NN conditions_NNS consist_VBP of_IN two_CD parts_NNS ,_, each_DT of_IN which_WDT applies_VBZ to_TO 50_CD per_IN cent_NN of_IN the_DT award_NN ._.
For_IN awards_NNS granted_VBN in_IN 2002_CD and_CC 2003_CD ,_, the_DT first_JJ part_NN of_IN the_DT condition_NN compares_VBZ GlaxoSmithKlines_NNP Total_NNP Shareholder_NN Return_NN TSR_NNP over_IN the_DT period_NN with_IN the_DT TSR_NNP of_IN companies_NNS in_IN the_DT UK_NNP FTSE_NNP 100_CD Index_NNP over_IN the_DT same_JJ period_NN ._.
For_IN awards_NNS granted_VBN in_IN 2004_CD the_DT first_JJ part_NN of_IN the_DT condition_NN compares_VBZ GlaxoSmithKlines_NNP TSR_NNP over_IN the_DT period_NN with_IN TSR_NNP of_IN 13_CD pharmaceutical_JJ companies_NNS in_IN the_DT comparator_NN group_NN over_IN the_DT same_JJ period_NN ._.
The_DT second_JJ part_NN of_IN the_DT performance_NN condition_NN compares_VBZ GlaxoSmithKlines_NNP earnings_NNS per_IN share_NN growth_NN to_TO the_DT increase_NN in_IN the_DT UK_NNP Retail_NNP Prices_NNS Index_NN over_IN the_DT three_CD year_NN performance_NN period_NN ._.
Awards_RB granted_VBN to_TO Directors_NNS and_CC members_NNS of_IN the_DT CET_NNP from_IN 15th_JJ December_NNP 2003_CD are_VBP subject_JJ to_TO a_DT single_JJ performance_NN condition_NN which_WDT compares_VBZ GlaxoSmithKlines_NNP TSR_NNP over_IN the_DT period_NN with_IN the_DT TSR_NNP of_IN companies_NNS in_IN the_DT comparator_NN group_NN over_IN the_DT same_JJ period_NN ._.
Other_JJ awards_NNS Shares_NNP ADSs_NNP Number_NNP of_IN shares_NNS and_CC ADSs_NNS issuable_JJ Number_NNP 000_CD Number_NNP 000_CD At_IN 31st_CD December_NNP 2001_CD 3,181_CD 1,760_CD Awards_NNPS granted_VBD 863_CD 477_CD Awards_NNPS exercised_VBN 728_CD 197_CD Awards_NNPS canceled_VBD 152_CD 97_CD At_IN 31st_CD December_NNP 2002_CD 3,164_CD 1,943_CD Awards_NNPS granted_VBD 1,070_CD 832_CD Awards_NNPS exercised_VBN 625_CD 189_CD Awards_NNPS canceled_VBD 109_CD 107_CD At_IN 31st_CD December_NNP 2003_CD 3,500_CD 2,479_CD Awards_NNPS granted_VBD 1,778_CD 1,339_CD Awards_NNS exercised_VBN 409_CD 187_CD Awards_NNPS canceled_VBD 520_CD 276_CD At_IN 31st_CD December_NNP 2004_CD 4,349_CD 3,355_CD Restricted_NNP Share_NNP Plan_NNP The_NNP Group_NNP operates_VBZ a_DT Restricted_NNP Share_NNP Plan_NNP whereby_WRB awards_NNS are_VBP granted_VBN to_TO employees_NNS at_IN no_DT cost_NN ._.
The_DT award_NN vests_NNS after_IN three_CD years_NNS with_IN no_DT performance_NN criteria_NNS attached_VBN ._.
Shares_NNP ADSs_NNP Number_NNP of_IN shares_NNS and_CC ADSs_NNS issuable_JJ Number_NNP 000_CD Number_NNP 000_CD At_IN 31st_CD December_NNP 2003_CD Awards_NNPS granted_VBD 4,419_CD 3,562_CD At_IN 31st_CD December_NNP 2004_CD 4,419_CD 3,562_CD 138_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 36_CD Employee_NN share_NN schemes_NNS continued_VBD Employee_NNP Share_NNP Ownership_NNP Plan_NNP Trusts_NNP The_NNP Group_NNP sponsors_VBZ Employee_NNP Share_NNP Ownership_NNP Plan_NNP ESOP_NNP Trusts_NNPS to_TO acquire_VB and_CC hold_VB shares_NNS in_IN GlaxoSmithKline_NNP plc_NN to_TO satisfy_VB awards_NNS made_VBN under_IN employee_NN incentive_NN plans_NNS and_CC options_NNS granted_VBN under_IN employee_NN share_NN option_NN schemes_NNS ._.
The_DT trustees_NNS of_IN the_DT ESOP_NNP Trusts_NNPS purchase_NN shares_NNS on_IN the_DT open_JJ market_NN with_IN finance_NN provided_VBN by_IN the_DT Group_NNP by_IN way_NN of_IN loans_NNS or_CC contributions_NNS ._.
The_DT expected_VBN cost_NN of_IN the_DT obligations_NNS to_TO deliver_VB shares_NNS under_IN the_DT schemes_NNS are_VBP normally_RB spread_VBN over_IN the_DT periods_NNS of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT awards_NNS and_CC options_NNS are_VBP granted_VBN ._.
An_DT accelerated_JJ charge_NN was_VBD made_VBN in_IN 2000_CD in_IN respect_NN of_IN the_DT outstanding_JJ cost_NN of_IN providing_VBG shares_NNS for_IN awards_NNS and_CC options_NNS which_WDT became_VBD exercisable_JJ solely_RB as_IN a_DT result_NN of_IN the_DT merger_NN ._.
Shares_NNP held_VBD for_IN share_NN award_NN schemes_NNS 2003_CD 2004_CD restated_VBN Number_NNP of_IN shares_NNS 000_CD 22,992_CD 7,748_CD m_NN m_NN Nominal_JJ value_NN 6_CD 2_CD Carrying_VBG value_NN 213_CD 84_CD Market_NN value_NN 281_CD 99_CD Shares_NNS held_VBN for_IN share_NN option_NN schemes_NNS 2004_CD 2003_CD Number_NN of_IN shares_NNS 000_CD 151,535_CD 170,066_CD m_NN m_NN Nominal_JJ value_NN 38_CD 43_CD Carrying_VBG value_NN 2,361_CD 2,645_CD Market_NN value_NN 1,852_CD 2,177_CD Results_NNS in_IN 2003_CD have_VBP been_VBN restated_VBN following_VBG the_DT implementation_NN of_IN UITF17_NNP revised_VBD ._.
UITF17_CD revised_VBN requires_VBZ that_IN the_DT minimum_JJ expense_NN should_MD be_VB the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN award_NN and_CC the_DT amount_NN that_IN an_DT employee_NN may_MD be_VB required_VBN to_TO pay_VB for_IN the_DT shares_NNS i._VBP e._VB the_DT intrinsic_JJ value_NN of_IN the_DT award_NN ._.
The_DT Trusts_NNS also_RB acquire_VB and_CC hold_VB shares_NNS to_TO meet_VB notional_JJ dividends_NNS re-invested_VBD on_IN deferred_VBN awards_NNS under_IN the_DT SmithKline_NNP Beecham_NNP Mid-Term_NNP Incentive_NNP Plan_NNP ._.
The_DT trustees_NNS have_VBP waived_VBN their_PRP$ rights_NNS to_TO dividends_NNS on_IN the_DT shares_NNS held_VBN by_IN the_DT Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS ._.
Option_NN pricing_NN For_IN the_DT purposes_NNS of_IN valuing_VBG options_NNS to_TO arrive_VB at_IN the_DT stock-based_JJ compensation_NN adjustment_NN in_IN the_DT Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS in_IN Note_NN 37_CD ,_, the_DT Black-Scholes_NNP option_NN pricing_NN model_NN has_VBZ been_VBN used_VBN ._.
The_DT assumptions_NNS used_VBN in_IN the_DT model_NN for_IN 2004_CD and_CC 2003_CD are_VBP as_IN follows_VBZ :_: 2004_CD 2003_CD Risk-free_JJ interest_NN rate_NN 3.3_CD %_NN 4.6_CD %_NN 4.2_CD %_NN 4.9_CD %_NN Dividend_NN yield_NN 3.1_CD %_NN 2.9_CD %_NN Volatility_NN 26_CD %_NN 29_CD %_NN 34_CD %_NN Expected_VBN lives_NNS of_IN options_NNS granted_VBN under_IN :_: Share_NN option_NN schemes_NNS 5_CD years_NNS 5_CD years_NNS Savings-related_JJ share_NN option_NN schemes_NNS 3_CD years_NNS 3_CD years_NNS Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 139_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS Additionally_RB ,_, the_DT Group_NNP reassesses_VBZ the_DT useful_JJ lives_NNS of_IN existing_VBG recognized_VBN intangible_JJ assets_NNS ._.
Intangible_JJ assets_NNS deemed_VBD to_TO have_VB The_DT analyses_NNS and_CC reconciliations_NNS presented_VBN in_IN this_DT Note_NN represent_VBP indefinite_JJ lives_NNS are_VBP no_RB longer_RB amortised_VBN ,_, instead_RB they_PRP are_VBP tested_VBN the_DT financial_JJ information_NN prepared_VBN on_IN the_DT basis_NN of_IN US_NNP Generally_RB annually_RB for_IN potential_JJ impairment_NN ._.
Separable_JJ intangible_JJ assets_NNS Accepted_JJ Accounting_NN Principles_NNPS US_NNP GAAP_NNP rather_RB than_IN UK_NNP GAAP_NNP ._.
with_IN nite_JJ lives_NNS continue_VBP to_TO be_VB amortised_VBN over_IN their_PRP$ useful_JJ lives_NNS ._.
Summary_NN of_IN material_NN differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP The_NNP Group_NNP adopted_VBD SFAS_NNP 142_CD as_IN of_IN 1st_CD January_NNP 2002_CD ._.
The_DT Acquisition_NNP of_IN SmithKline_NNP Beecham_NNP implementation_NN of_IN SFAS_NNP 142_CD resulted_VBD in_IN no_DT impairment_NN of_IN the_DT The_DT combination_NN of_IN Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP Groups_NNS goodwill_NN and_CC an_DT initial_JJ impairment_NN of_IN 173_CD million_CD plc_NN was_VBD accounted_VBN for_IN as_IN a_DT merger_NN pooling_VBG of_IN interests_NNS in_IN 127_CD million_CD net_NN of_IN tax_NN on_IN indefinite-lived_JJ assets_NNS ._.
This_DT is_VBZ shown_VBN accordance_NN with_IN UK_NNP GAAP_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, this_DT business_NN as_IN a_DT cumulative_JJ effect_NN of_IN an_DT accounting_NN change_NN ._.
combination_NN did_VBD not_RB qualify_VB for_IN pooling_VBG of_IN interests_NNS accounting_VBG Under_IN UK_NNP GAAP_NNP ,_, costs_VBZ to_TO be_VB incurred_VBN in_IN integrating_VBG and_CC and_CC Glaxo_NNP Wellcome_NNP was_VBD determined_VBN to_TO be_VB the_DT accounting_NN restructuring_VBG the_DT Wellcome_NNP ,_, SmithKline_NNP Beecham_NNP and_CC Block_NNP Drug_NNP acquirer_NN in_IN a_DT purchase_NN business_NN combination_NN ._.
businesses_NNS following_VBG the_DT acquisitions_NNS in_IN 1995_CD ,_, 2000_CD and_CC 2001_CD Accordingly_RB the_DT net_JJ assets_NNS of_IN SmithKline_NNP Beecham_NNP were_VBD fair_JJ valued_VBN respectively_RB were_VBD charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN post_NN as_IN at_IN the_DT date_NN of_IN acquisition_NN ._.
As_IN a_DT result_NN of_IN the_DT fair_JJ value_NN exercise_NN ,_, acquisition_NN ._.
Under_IN US_NNP GAAP_NNP ,_, certain_JJ of_IN such_JJ costs_NNS were_VBD considered_VBN increases_NNS in_IN the_DT values_NNS of_IN SmithKline_NNP Beechams_NNP inventory_NN ,_, tangible_JJ in_IN the_DT allocation_NN of_IN purchase_NN consideration_NN thereby_RB affecting_VBG xed_JJ assets_NNS ,_, investments_NNS and_CC pension_NN obligations_NNS were_VBD recognized_VBN the_DT goodwill_NN arising_VBG on_IN acquisition_NN ._.
and_CC fair_JJ market_NN values_NNS attributed_VBD to_TO its_PRP$ intangible_JJ assets_NNS ,_, mainly_RB Under_IN UK_NNP GAAP_NNP ,_, certain_JJ intangible_JJ assets_NNS related_VBN to_TO specic_JJ product_NN rights_NNS inclusive_NN of_IN patents_NNS and_CC trade_NN marks_NNS and_CC in-process_JJ compounds_NNS or_CC products_NNS which_WDT are_VBP purchased_VBN from_IN a_DT third_JJ party_NN research_NN and_CC development_NN ,_, together_RB with_IN appropriate_JJ deferred_VBN and_CC are_VBP developed_VBN for_IN commercial_JJ applications_NNS are_VBP capitalized_VBN ._.
The_DT difference_NN between_IN the_DT cost_NN of_IN acquisition_NN Under_IN US_NNP GAAP_NNP ,_, payments_NNS made_VBD for_IN these_DT compounds_NNS or_CC products_NNS and_CC the_DT fair_JJ value_NN of_IN the_DT assets_NNS and_CC liabilities_NNS of_IN SmithKline_NNP which_WDT are_VBP still_RB in_IN development_NN and_CC have_VBP not_RB yet_RB received_VBN regulatory_JJ Beecham_NNP has_VBZ been_VBN recorded_VBN as_IN goodwill_NN ._.
approval_NN are_VBP charged_VBN directly_RB to_TO the_DT profit_NN and_CC loss_NN account_NN Capitalised_VBN interest_NN until_IN such_JJ time_NN that_IN they_PRP receive_VBP regulatory_JJ approval_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP does_VBZ not_RB capitalize_VB interest_NN ._.
US_NNP GAAP_NNP requires_VBZ interest_NN incurred_VBN as_IN part_NN of_IN the_DT cost_NN of_IN constructing_VBG xed_VBD Restructuring_NN costs_NNS assets_NNS to_TO be_VB capitalized_VBN and_CC amortised_VBN over_IN the_DT life_NN of_IN the_DT asset_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, restructuring_VBG costs_NNS incurred_VBN following_VBG acquisitions_NNS were_VBD charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN post_NN acquisition_NN ._.
Computer_NNP software_NN For_IN US_NNP GAAP_NNP purposes_NNS ,_, certain_JJ of_IN these_DT costs_NNS were_VBD recognized_VBN Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP capitalises_VBZ costs_NNS incurred_VBN in_IN acquiring_VBG as_IN liabilities_NNS upon_IN acquisition_NN in_IN the_DT opening_NN balance_NN sheet_NN ._.
and_CC developing_VBG computer_NN software_NN for_IN internal_JJ use_NN where_WRB the_DT software_NN supports_VBZ a_DT significant_JJ business_NN system_NN and_CC the_DT Other_JJ restructuring_NN costs_NNS are_VBP recorded_VBN as_IN a_DT provision_NN under_IN UK_NNP expenditure_NN leads_VBZ to_TO the_DT creation_NN of_IN a_DT durable_JJ asset_NN ._.
For_IN US_NNP GAAP_NNP when_WRB a_DT restructuring_NN plan_NN has_VBZ been_VBN announced_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP applies_VBZ SOP_NNP 98-1_CD ,_, Accounting_NNP for_IN the_DT Costs_NNS of_IN GAAP_NNP ,_, a_DT provision_NN may_MD only_RB be_VB recognized_VBN when_WRB further_JJ criteria_NNS Computer_NNP Software_NNP Developed_VBD or_CC Obtained_VBN for_IN Internal_NNP Use_NNP ,_, are_VBP met_VBN or_CC the_DT liability_NN is_VBZ incurred_VBN ._.
Accordingly_RB ,_, adjustments_NNS have_VBP which_WDT restricts_VBZ the_DT categories_NNS of_IN costs_NNS which_WDT can_MD be_VB capitalized_VBN ._.
been_VBN made_VBN to_TO eliminate_VB the_DT UK_NNP GAAP_NNP provisions_NNS for_IN restructuring_VBG costs_NNS that_WDT do_VBP not_RB meet_VB US_NNP GAAP_NNP requirements_NNS ._.
Goodwill_NNP and_CC intangible_JJ xed_JJ assets_NNS Under_IN UK_NNP GAAP_NNP ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS before_IN 1998_CD Marketable_JJ securities_NNS accounted_VBD for_IN under_IN the_DT purchase_NN method_NN has_VBZ been_VBN eliminated_VBN Marketable_JJ securities_NNS consist_VBP primarily_RB of_IN equity_NN securities_NNS and_CC against_IN shareholders_NNS funds_NNS ._.
Additionally_RB ,_, UK_NNP GAAP_NNP requires_VBZ that_IN certain_JJ other_JJ liquid_JJ investments_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, these_DT securities_NNS on_IN subsequent_JJ disposal_NN or_CC closure_NN of_IN a_DT business_NN ,_, any_DT goodwill_NN are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Under_IN previously_RB taken_VBN directly_RB to_TO shareholders_NNS funds_NNS is_VBZ then_RB charged_VBN US_NNP GAAP_NNP these_DT securities_NNS are_VBP considered_VBN available_JJ for_IN sale_NN under_IN against_IN income_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS SFAS_NNP 115_CD Accounting_NN for_IN certain_JJ investments_NNS in_IN debt_NN and_CC equity_NN from_IN 1998_CD is_VBZ capitalized_VBN and_CC amortised_VBN over_IN a_DT period_NN not_RB exceeding_VBG securities_NNS and_CC are_VBP carried_VBN at_IN fair_JJ value_NN ,_, with_IN the_DT unrealised_JJ gains_NNS 20_CD years_NNS ._.
Intangible_JJ assets_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN and_CC losses_NNS ,_, net_NN of_IN tax_NN ,_, recorded_VBN as_IN a_DT separate_JJ component_NN of_IN useful_JJ economic_JJ life_NN except_IN in_IN the_DT case_NN of_IN certain_JJ acquired_VBN brands_NNS shareholders_NNS equity_NN ._.
where_WRB the_DT end_NN of_IN the_DT useful_JJ economic_JJ life_NN of_IN the_DT brand_NN can_MD not_RB be_VB foreseen_VBN ._.
Equity_NNP securities_NNS are_VBP reviewed_VBN at_IN least_JJS annually_RB for_IN other_JJ than_IN temporary_JJ impairment_NN ._.
The_DT factors_NNS considered_VBN are_VBP :_: Under_IN US_NNP GAAP_NNP ,_, goodwill_NN arising_VBG on_IN acquisitions_NNS prior_RB to_TO 30th_JJ June_NNP 2001_CD was_VBD capitalized_VBN and_CC amortised_VBN over_IN a_DT period_NN not_RB the_DT investees_NNS current_JJ financial_JJ performance_NN and_CC future_JJ exceeding_VBG 40_CD years_NNS ._.
All_DT intangible_JJ assets_NNS ,_, including_VBG brands_NNS ,_, were_VBD prospects_NNS amortised_VBN over_IN a_DT nite_JJ life_NN ._.
In_IN July_NNP 2001_CD ,_, the_DT Financial_NNP Accounting_NNP the_DT general_JJ market_NN condition_NN of_IN the_DT geographic_JJ or_CC Standards_NNP Board_NNP FASB_NNP issued_VBD Statement_NNP of_IN Financial_NNP Accounting_NNP industry_NN area_NN in_IN which_WDT the_DT investee_NN operates_VBZ Standard_NNP SFAS_NNP 142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ._.
the_DT duration_NN and_CC extent_NN to_TO which_WDT the_DT market_NN value_NN SFAS_NNP 142_CD requires_VBZ that_IN goodwill_NN no_RB longer_RB be_VB amortised_VBN over_IN its_PRP$ if_IN available_JJ has_VBZ been_VBN below_IN cost_NN ._.
The_DT Group_NNP must_MD instead_RB identify_VB and_CC value_VB Gross_NNP unrealised_JJ gains_NNS and_CC losses_NNS on_IN marketable_JJ securities_NNS were_VBD its_PRP$ reporting_VBG units_NNS for_IN the_DT purpose_NN of_IN assessing_VBG ,_, at_IN least_JJS annually_RB ,_, 60_CD million_CD and_CC 3_CD million_CD respectively_RB at_IN 31st_CD December_NNP 2004_CD potential_JJ impairment_NN of_IN goodwill_NN allocated_VBN to_TO each_DT reporting_VBG unit_NN ._.
68_CD million_CD and_CC 5_CD million_CD respectively_RB at_IN 31st_CD December_NNP 2003_CD ._.
140_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD These_DT changes_NNS have_VBP been_VBN accounted_VBN for_IN as_IN prior_JJ year_NN adjustments_NNS under_IN UK_NNP GAAP_NNP and_CC the_DT reconciliations_NNS of_IN profit_NN attributable_JJ to_TO Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS shareholders_NNS and_CC Equity_NN shareholders_NNS funds_NNS from_IN UK_NNP GAAP_NNP to_TO The_DT key_JJ differences_NNS between_IN UK_NNP SSAP_NNP 24_CD and_CC US_NNP GAAP_NNP US_NNP GAAP_NNP have_VBP been_VBN restated_VBN accordingly_RB to_TO reconcile_VB from_IN the_DT in_IN relation_NN to_TO dened_VBN benefit_NN pension_NN plans_NNS are_VBP :_: restated_VBN UK_NNP GAAP_NNP gures_VBZ ._.
under_IN UK_NNP GAAP_NNP ,_, the_DT effect_NN of_IN variations_NNS in_IN cost_NN can_MD be_VB A_DT reconciling_VBG difference_NN between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP remains_VBZ accumulated_VBN at_IN successive_JJ valuations_NNS and_CC amortised_VBN on_IN an_DT in_IN respect_NN of_IN the_DT charge_NN recognized_VBN against_IN profit_NN ._.
Under_IN US_NNP GAAP_NNP ,_, aggregate_JJ basis_NN ._.
Under_IN US_NNP GAAP_NNP the_DT amortisation_NN of_IN the_DT shares_NNS purchased_VBN by_IN the_DT ESOP_NNP Trusts_NNPS are_VBP accounted_VBN for_IN within_IN transition_NN asset_NN and_CC the_DT costs_NNS of_IN past_JJ service_NN benefit_NN shareholders_NNS equity_NN with_IN gains_NNS and_CC losses_NNS on_IN issuance_NN of_IN shares_NNS to_TO improvements_NNS are_VBP separately_RB tracked_VBN :_: experience_NN gains_NNS losses_NNS employees_NNS being_VBG recorded_VBN as_IN adjustments_NNS to_TO shareholders_NNS equity_NN ._.
are_VBP dealt_VBN with_IN on_IN an_DT aggregate_JJ basis_NN but_CC amortised_VBD only_RB if_IN outside_IN a_DT 10_CD per_IN cent_NN corridor_NN Guarantor_NNP obligations_NNS The_DT Group_NNP adopted_VBD the_DT FASBs_NNP Financial_NNP Interpretation_NNP No._NN ._.
45_CD UK_NNP GAAP_NNP allows_VBZ measurements_NNS of_IN plan_NN assets_NNS and_CC liabilities_NNS FIN_NNP 45_CD ,_, Guarantors_NNP Accounting_NNP and_CC Disclosure_NNP Requirements_NNP to_TO be_VB based_VBN on_IN the_DT result_NN of_IN the_DT latest_JJS actuarial_JJ valuation_NN ._.
for_IN Guarantees_NNP ,_, Including_VBG Indirect_NNP Guarantees_NNP of_IN Indebtedness_NNP US_NNP GAAP_NNP requires_VBZ measurement_NN of_IN plan_NN assets_NNS and_CC liabilities_NNS of_IN Others_NNS with_IN effect_NN from_IN 1st_CD January_NNP 2003_CD ._.
to_TO be_VB made_VBN at_IN the_DT date_NN of_IN the_DT Financial_NNP statements_NNS or_CC up_RB to_TO three_CD months_NNS prior_RB to_TO that_DT date_NN This_DT requires_VBZ that_IN the_DT Group_NNP recognize_VB and_CC measure_VB ,_, at_IN fair_JJ value_NN ,_, the_DT pension_NN adjustment_NN also_RB includes_VBZ the_DT impact_NN of_IN changes_NNS on_IN a_DT prospective_JJ basis_NN ,_, certain_JJ guarantees_NNS issued_VBN or_CC modied_VBN after_IN in_IN minimum_JJ pension_NN liabilities_NNS included_VBD within_IN accumulated_VBN 31st_CD December_NNP 2002_CD ._.
Under_IN UK_NNP GAAP_NNP ,_, such_JJ guarantor_NN obligations_NNS other_JJ comprehensive_JJ income_NN ._.
are_VBP recognized_VBN when_WRB further_JJ additional_JJ criteria_NNS are_VBP met_VBN or_CC the_DT liability_NN is_VBZ incurred_VBN ._.
During_IN 2002_CD ,_, the_DT Group_NNP decided_VBD to_TO align_VB the_DT measurement_NN date_NN for_IN all_DT of_IN its_PRP$ pension_NN and_CC post-retirement_NN benefit_NN plans_VBZ to_TO Derivative_JJ instruments_NNS 31st_VBP December_NNP as_IN certain_JJ of_IN the_DT Groups_NNS plans_NNS had_VBD a_DT measurement_NN SFAS_NNP 133_CD ,_, Accounting_NNP for_IN Derivative_NNP Instruments_NNP and_CC Hedging_NNP date_NN for_IN assets_NNS and_CC liabilities_NNS of_IN 30th_JJ September_NNP ._.
Activities_NNS ,_, as_IN amended_VBN by_IN SFAS_NNP 137_CD and_CC SFAS_NNP 138_CD and_CC as_IN The_DT impact_NN ,_, reected_VBD as_IN a_DT cumulative_JJ effect_NN of_IN an_DT accounting_NN interpreted_VBN by_IN the_DT Derivatives_NNS Implementation_NNP Group_NNP ,_, was_VBD adopted_VBN change_NN ,_, was_VBD a_DT 37_CD million_CD credit_NN ,_, net_NN of_IN tax_NN ,_, to_TO income_NN ._.
by_IN the_DT Group_NNP with_IN effect_NN from_IN 1st_CD January_NNP 2001_CD ._.
SFAS_NNP 133_CD establishes_VBZ accounting_NN and_CC reporting_NN standards_NNS for_IN derivative_JJ Stock-based_JJ compensation_NN instruments_NNS ,_, including_VBG certain_JJ derivative_JJ instruments_NNS embedded_VBD Under_IN UK_NNP GAAP_NNP ,_, share_NN options_NNS are_VBP accounted_VBN for_IN as_IN equity_NN when_WRB in_IN other_JJ contracts_NNS collectively_RB ,_, referred_VBD to_TO as_IN derivatives_NNS and_CC for_IN exercised_VBN ,_, valued_VBN at_IN the_DT issuance_NN price_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP hedging_NN activities_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, some_DT derivative_JJ instruments_NNS applies_VBZ SFAS_NNP 123_CD ,_, Accounting_NNP for_IN stock-based_JJ compensation_NN ,_, and_CC used_VBN for_IN hedging_VBG are_VBP not_RB recognized_VBN on_IN the_DT balance_NN sheet_NN and_CC related_JJ accounting_NN interpretations_NNS in_IN accounting_NN for_IN its_PRP$ option_NN plans_VBZ the_DT matching_VBG principle_NN is_VBZ used_VBN to_TO match_VB the_DT gain_NN or_CC loss_NN under_IN which_WDT require_VBP options_NNS to_TO be_VB fair_JJ valued_VBN at_IN their_PRP$ grant_NN date_NN and_CC these_DT hedging_VBG contracts_NNS to_TO the_DT foreign_JJ currency_NN transaction_NN or_CC included_VBN in_IN profit_NN and_CC loss_NN over_IN the_DT vesting_JJ period_NN of_IN the_DT options_NNS ._.
profits_NNS to_TO which_WDT they_PRP relate_VBP ._.
SFAS_NNP 133_CD requires_VBZ that_IN an_DT entity_NN recognize_VB all_DT derivatives_NNS as_IN either_DT assets_NNS or_CC liabilities_NNS in_IN the_DT The_NNP Group_NNP is_VBZ entitled_VBN to_TO receive_VB a_DT tax_NN deduction_NN for_IN the_DT amount_NN consolidated_JJ balance_NN sheet_NN and_CC measure_VB those_DT instruments_NNS at_IN treated_VBN as_IN compensation_NN under_IN US_NNP tax_NN rules_NNS for_IN employee_NN fair_JJ value_NN ._.
Changes_NNS in_IN fair_JJ value_NN over_IN the_DT period_NN are_VBP recorded_VBN in_IN stock_NN options_NNS which_WDT have_VBP been_VBN exercised_VBN by_IN US_NNP employees_NNS during_IN current_JJ earnings_NNS unless_IN hedge_JJ accounting_NN is_VBZ obtained_VBN ._.
Under_IN UK_NNP GAAP_NNP ,_, this_DT is_VBZ treated_VBN as_IN a_DT reduction_NN of_IN tax_NN does_VBZ not_RB designate_VB any_DT of_IN its_PRP$ derivatives_NNS as_IN qualifying_VBG hedge_JJ expense_NN whereas_IN ,_, under_IN US_NNP GAAP_NNP ,_, a_DT portion_NN of_IN this_DT amount_NN instruments_NNS under_IN SFAS_NNP 133_CD ._.
SFAS_NNP 133_CD prescribes_VBZ requirements_NNS is_VBZ credited_VBN to_TO equity_NN ._.
for_IN designation_NN and_CC documentation_NN of_IN hedging_VBG relationships_NNS and_CC ongoing_JJ assessments_NNS of_IN effectiveness_NN in_IN order_NN to_TO qualify_VB for_IN hedge_NN Employee_NNP Share_NNP Ownership_NNP Plan_NNP Trusts_NNPS accounting_NN ._.
Prior_RB to_TO 2004_CD ,_, under_IN UK_NNP GAAP_NNP shares_NNS of_IN the_DT Groups_NNS stock_NN held_VBN by_IN The_DT Group_NNP also_RB evaluates_VBZ contracts_NNS for_IN embedded_VBN derivatives_NNS ,_, the_DT ESOP_NNP Trusts_NNPS were_VBD recorded_VBN at_IN cost_NN ,_, less_JJR a_DT provision_NN representing_VBG and_CC considers_VBZ whether_IN any_DT embedded_VBN derivatives_NNS have_VBP to_TO be_VB the_DT difference_NN between_IN the_DT cost_NN and_CC the_DT option_NN exercise_NN price_NN ,_, and_CC bifurcated_VBN ,_, or_CC separated_VBD ,_, from_IN the_DT host_NN contracts_NNS in_IN accordance_NN accounted_VBD for_IN as_IN xed_JJ asset_NN investments_NNS ._.
Projected_JJ losses_NNS on_IN the_DT with_IN SFAS_NNP 133_CD requirements_NNS ._.
If_IN embedded_VBN derivatives_NNS exist_VBP and_CC exercise_VBP of_IN the_DT options_NNS covered_VBN by_IN the_DT shares_NNS were_VBD recorded_VBN are_VBP not_RB clearly_RB and_CC closely_RB related_VBN to_TO the_DT host_NN contract_NN ,_, they_PRP are_VBP through_IN the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT life_NN of_IN the_DT options_NNS ._.
In_IN accounted_VBN for_IN separately_RB from_IN the_DT host_NN contract_NN as_IN derivatives_NNS ._.
2004_CD ,_, UITF_NNP Abstract_NNP 38_CD ,_, Accounting_NNP for_IN ESOP_NNP Trusts_NNPS ,_, and_CC related_JJ amendments_NNS to_TO UITF_NNP Abstract_NNP 17_CD ,_, Employee_NNP share_NN schemes_NNS ,_, were_VBD Gains_NNS and_CC losses_NNS related_VBN to_TO the_DT fair_JJ value_NN adjustments_NNS of_IN all_DT implemented_VBN in_IN the_DT Groups_NNS UK_NNP GAAP_NNP financial_JJ statements_NNS ._.
UITF_NNP 38_CD derivative_JJ instruments_NNS are_VBP classied_VBN in_IN the_DT consolidated_JJ statement_NN changes_VBZ the_DT presentation_NN of_IN an_DT entitys_JJ own_JJ shares_NNS held_VBN in_IN an_DT ESOP_NNP of_IN income_NN and_CC cash_NN ows_NNS in_IN accordance_NN with_IN the_DT nature_NN of_IN Trust_NNP from_IN requiring_VBG them_PRP to_TO be_VB recognized_VBN as_IN assets_NNS to_TO requiring_VBG the_DT derivative_NN ._.
them_PRP to_TO be_VB deducted_VBN in_IN arriving_VBG at_IN shareholders_NNS funds_NNS ,_, as_IN under_IN The_DT fair_JJ value_NN and_CC book_NN value_NN of_IN derivative_JJ instruments_NNS in_IN respect_NN US_NNP GAAP_NNP ._.
UITF_NNP 17_CD revised_VBN requires_VBZ that_IN the_DT minimum_JJ expense_NN of_IN financial_JJ assets_NNS and_CC liabilities_NNS as_IN at_IN 31st_CD December_NNP 2004_CD is_VBZ should_MD be_VB the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN disclosed_VBN in_IN the_DT Classication_NNP and_CC fair_JJ value_NN of_IN financial_JJ assets_NNS the_DT date_NN of_IN award_NN and_CC the_DT amount_NN that_IN an_DT employee_NN may_MD be_VB and_CC liabilities_NNS table_NN in_IN Note_NN 34_CD ._.
required_VBN to_TO pay_VB for_IN the_DT shares_NNS i._VBP e._VB the_DT intrinsic_JJ value_NN of_IN the_DT award_NN ._.
Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 141_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Sales_NNS incentives_NNS In_IN accordance_NN with_IN UK_NNP GAAP_NNP ,_, certain_JJ amounts_NNS paid_VBN by_IN the_DT Group_NNP Valuation_NNP of_IN derivative_JJ instruments_NNS to_TO its_PRP$ customers_NNS are_VBP recorded_VBN as_IN promotional_JJ expense_NN included_VBD in_IN The_DT fair_JJ value_NN of_IN derivative_JJ instruments_NNS is_VBZ sensitive_JJ to_TO movements_NNS operating_VBG income_NN ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT items_NNS are_VBP recorded_VBN as_IN a_DT in_IN the_DT underlying_VBG market_NN rates_NNS and_CC variables_NNS ._.
The_DT Group_NNP monitors_VBZ reduction_NN in_IN revenue_NN ._.
While_IN these_DT items_NNS do_VBP not_RB result_VB in_IN a_DT net_NN the_DT fair_JJ value_NN of_IN derivative_JJ instruments_NNS on_IN at_IN least_JJS a_DT quarterly_JJ basis_NN ,_, impact_NN to_TO the_DT income_NN statement_NN under_IN US_NNP GAAP_NNP ,_, the_DT amount_NN that_WDT with_IN a_DT formal_JJ review_NN every_DT six_CD months_NNS ._.
Derivatives_NNS including_VBG would_MD be_VB classied_VBN as_IN a_DT reduction_NN in_IN revenue_NN in_IN 2004_CD would_MD interest_VB rate_NN swaps_NNS and_CC cross-currency_NN swaps_NNS are_VBP valued_VBN using_VBG be_VB 373_CD million_CD 2003_CD 324_CD million_CD ._.
standard_JJ valuation_NN models_NNS ,_, counterparty_NN valuations_NNS ,_, or_CC third_JJ party_NN valuations_NNS ._.
Standard_NNP valuation_NN models_NNS used_VBN by_IN the_DT Group_NNP consider_VB Variable_JJ interest_NN entities_NNS relevant_JJ discount_NN rates_NNS ,_, the_DT market_NN yield_NN curve_NN on_IN the_DT valuation_NN In_IN January_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD Interpretation_NNP No._NN ._.
46_CD FIN_NNP 46_CD ,_, date_NN ,_, forward_RB currency_NN exchange_NN rates_NNS and_CC counterparty_NN risk_NN ._.
All_DT Consolidation_NN of_IN Variable_JJ Interest_NN Entities_NNS ,_, and_CC in_IN December_NNP significant_JJ rates_NNS and_CC variables_NNS are_VBP obtained_VBN from_IN market_NN sources_NNS ._.
2003_CD issued_VBN FIN_NNP 46R_NNP ,_, a_DT revision_NN of_IN this_DT Interpretation_NN ._.
Under_IN the_DT All_NNP valuations_NNS are_VBP based_VBN on_IN the_DT remaining_VBG term_NN to_TO maturity_NN of_IN the_DT revised_VBN Interpretation_NNP ,_, certain_JJ entities_NNS ,_, known_VBN as_IN Variable_JJ Interest_NN instrument_NN ._.
Foreign_JJ exchange_NN contracts_NNS are_VBP valued_VBN using_VBG forward_RB Entities_NNPS VIEs_NNPS ,_, must_MD be_VB consolidated_VBN by_IN the_DT primary_JJ beneciary_JJ rates_NNS observed_VBD from_IN quoted_VBN prices_NNS in_IN the_DT relevant_JJ markets_NNS when_WRB of_IN the_DT entity_NN ._.
The_DT primary_JJ beneciary_NN is_VBZ generally_RB dened_VBN as_IN possible_JJ ._.
The_DT Group_NNP assumes_VBZ parties_NNS to_TO long-term_JJ contracts_NNS are_VBP having_VBG the_DT majority_NN of_IN the_DT risks_NNS and_CC rewards_NNS arising_VBG from_IN the_DT VIE_NNP ._.
economically_RB viable_JJ but_CC reserves_NNS the_DT right_NN to_TO exercise_VB early_JJ Additionally_RB ,_, for_IN VIEs_NNS in_IN which_WDT a_DT significant_JJ ,_, but_CC not_RB majority_NN ,_, termination_NN rights_NNS if_IN economically_RB beneficial_JJ when_WRB such_JJ rights_NNS variable_JJ interest_NN is_VBZ held_VBN ,_, certain_JJ disclosures_NNS are_VBP required_VBN ._.
The_DT Group_NNP has_VBZ completed_VBN a_DT review_NN of_IN potential_JJ VIEs_NNS and_CC ,_, as_IN a_DT Dividends_NNP consequence_NN ,_, has_VBZ consolidated_VBN Theravance_NNP Inc._NNP from_IN May_NNP 2004_CD Under_IN UK_NNP GAAP_NNP ,_, dividends_NNS proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT year_NN see_VBP Note_NN c_NN on_IN page_NN 145_CD ._.
No_DT other_JJ VIEs_NNS of_IN which_WDT the_DT Group_NNP is_VBZ in_IN respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN the_DT Board_NNP the_DT primary_JJ beneciary_JJ were_VBD identied_VBN ._.
of_IN Directors_NNS for_IN approval_NN by_IN the_DT shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, such_JJ dividends_NNS are_VBP not_RB provided_VBN for_IN until_IN declared_VBN by_IN the_DT Board_NNP Recent_JJ Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP of_IN Directors_NNS ._.
pronouncements_NNS In_IN May_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD FASB_NNP Staff_NNP Position_NNP FSP_NNP Consolidated_NNP summary_NN statement_NN of_IN cash_NN ows_VBZ FAS_NNP 106-2_CD ,_, Accounting_NNP and_CC Disclosure_NNP Requirements_NNP Related_NNP to_TO The_DT US_NNP GAAP_NNP cash_NN ow_NN statement_NN reports_NNS changes_NNS in_IN cash_NN and_CC the_DT Medicare_NNP Prescription_NNP Drug_NNP ,_, Improvement_NNP and_CC Modernization_NNP cash_NN equivalents_NNS ,_, which_WDT includes_VBZ short-term_JJ highly_RB liquid_JJ Act_NN of_IN 2003_CD ,_, superseding_VBG FSP_NNP 106-1_CD ._.
FSP_NNP 106-2_CD addresses_NNS the_DT investments_NNS with_IN original_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ._.
accounting_VBG implications_NNS of_IN the_DT Act_NNP for_IN an_DT entity_NN that_WDT sponsors_VBZ a_DT Only_RB three_CD categories_NNS of_IN cash_NN ows_NNS are_VBP reported_VBN :_: operating_VBG post-retirement_JJ health_NN care_NN plan_NN providing_VBG prescription_NN drug_NN activities_NNS including_VBG tax_NN and_CC interest_NN :_: investing_VBG activities_NNS benets_NNS ._.
The_DT Act_NNP introduces_VBZ in_IN the_DT USA_NNP a_DT prescription_NN drug_NN including_VBG capital_NN expenditure_NN ,_, acquisitions_NNS and_CC disposals_NNS together_RB benefit_VBP under_IN Medicare_NNP ,_, as_RB well_RB as_IN a_DT federal_JJ subsidy_NN to_TO sponsors_NNS with_IN cash_NN ows_NNS from_IN available_JJ for_IN sale_NN current_JJ asset_NN investments_NNS :_: of_IN certain_JJ post-retirement_JJ health_NN care_NN plans_NNS ._.
For_IN companies_NNS that_WDT and_CC nancing_VBG activities_NNS including_VBG dividends_NNS paid_VBN ._.
A_DT summary_NN elected_VBN for_IN deferral_JJ under_IN FSP_NNP 106-1_CD ,_, FSP_NNP 106-2_CD is_VBZ effective_JJ for_IN statement_NN of_IN cash_NN ows_NNS is_VBZ presented_VBN on_IN page_NN 143_CD ._.
reporting_VBG periods_NNS commencing_VBG after_IN 15th_JJ June_NNP 2004_CD ._.
The_DT estimated_VBN amount_NN of_IN the_DT federal_JJ subsidy_NN is_VBZ treated_VBN as_IN a_DT prior_JJ Cash_NN and_CC cash_NN equivalents_NNS service_NN gain_NN and_CC credited_VBD to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT Under_IN UK_NNP GAAP_NNP ,_, the_DT cash_NN balance_NN includes_VBZ only_RB cash_NN at_IN bank_NN and_CC average_JJ service_NN lives_NNS of_IN the_DT employees_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, this_DT other_JJ cash_NN balances_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, cash_NN and_CC cash_NN equivalents_NNS change_VBP resulted_VBN in_IN a_DT decrease_NN of_IN 71_CD million_CD in_IN the_DT accumulated_VBN include_VBP cash_NN at_IN bank_NN and_CC certain_JJ liquid_JJ investments_NNS with_IN original_JJ benefit_NN obligation_NN and_CC a_DT reduction_NN of_IN 2_CD million_CD in_IN net_JJ periodic_JJ maturities_NNS of_IN three_CD months_NNS or_CC less_JJR ._.
post-retirement_JJ benefit_NN cost_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2004_CD ._.
Comprehensive_JJ income_NN statement_NN The_DT requirement_NN of_IN SFAS_NNP 130_CD ,_, Reporting_NNP comprehensive_JJ income_NN ,_, to_TO provide_VB a_DT comprehensive_JJ income_NN statement_NN is_VBZ met_VBN under_IN UK_NNP GAAP_NNP by_IN the_DT Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS pages_NNS 90_CD and_CC 91_CD ._.
Reclassications_NNS Certain_NNP prior_JJ year_NN balances_NNS have_VBP been_VBN reclassied_VBN for_IN comparative_JJ purposes_NNS ._.
Certain_JJ amounts_NNS previously_RB presented_VBN in_IN aggregate_NN in_IN the_DT reconciliation_NN of_IN profit_NN under_IN US_NNP GAAP_NNP to_TO UK_NNP GAAP_NNP have_VBP been_VBN presented_VBN separately_RB in_IN the_DT current_JJ year_NN presentation_NN to_TO provide_VB more_JJR information_NN related_VBN to_TO these_DT adjustments_NNS ._.
142_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO profit_VB and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
2003 2002 2004_CD restated_VBN restated_JJ profit_NN Notes_NNS m_VBP m_FW m_FW profit_NN attributable_JJ to_TO shareholders_NNS under_IN UK_NNP GAAP_NNP 4,302_CD 4,478_CD 3,930_CD Goodwill_NNP amortisation_NN reversal_NN including_VBG goodwill_NN in_IN associated_VBN undertakings_NNS a_DT 17_CD 1918_CD Amortisation_NNP and_CC impairment_NN of_IN intangible_JJ assets_NNS b_NN 1,426_CD 2,292_CD 4,089_CD Acquisition_NNP and_CC disposal_NN of_IN product_NN rights_NNS b_NN 210 105 181_CD Capitalised_VBN interest_NN 17_CD 23_CD 20_CD Tangible_JJ xed_JJ assets_NNS 2_CD 525_CD Disposal_NN of_IN interest_NN in_IN associate_JJ 81_CD Disposal_NN of_IN goodwill_NN in_IN subsidiaries_NNS 3_CD Product_NNP divestments_NNS 1_CD 77_CD Equity_NN investments_NNS 30_CD 31_CD 8_CD Recognition_NN of_IN cost_NN of_IN sales_NNS on_IN fair_JJ value_NN step-up_NN of_IN inventory_NN 13_CD Pensions_NNS and_CC post-retirement_JJ benets_NNS f_LS 162 122 138_CD Stock-based_JJ compensation_NN 296 372 320_CD Derivative_JJ instruments_NNS and_CC hedging_VBG 33_CD 41_CD 37_CD Fair_NNP value_NN of_IN put_NN option_NN granted_VBN to_TO minority_NN shareholders_NNS c_NN 17_CD Guarantor_NNP obligations_NNS 19_CD 21_CD Restructuring_NN 12_CD 98_CD 37_CD Tax_NNP benets_NNS on_IN exercise_NN of_IN US_NNP stock_NN options_NNS d_LS 10_CD 13_CD 13_CD Deferred_JJ taxation_NN d_SYM 661_CD 787_CD 1,178_CD Variable_JJ interest_NN entities_NNS c_NN 60_CD Net_JJ income_NN under_IN US_NNP GAAP_NNP before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 2,732_CD 2,420_CD 503_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 90_CD Net_JJ income_NN after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 2,732_CD 2,420_CD 413_CD Certain_NNP items_NNS for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD have_VBP been_VBN reclassied_VBN for_IN comparative_JJ purposes_NNS ._.
2004 2003 2002_CD Earnings_NNS per_IN share_NN under_IN US_NNP GAAP_NNP pence_NN pence_NN pence_NN Basic_JJ net_JJ income_NN per_IN share_NN before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 47.6_CD 41.7_CD 8.5_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS per_IN share_NN under_IN US_NNP GAAP_NNP 1.5_CD Basic_JJ net_JJ income_NN per_IN share_NN after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 47.6_CD 41.7_CD 7.0_CD Diluted_NNP net_JJ income_NN per_IN share_NN before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 47.5_CD 41.6_CD 8.5_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS per_IN share_NN under_IN US_NNP GAAP_NNP 1.5_CD Diluted_NNP net_JJ income_NN per_IN share_NN after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 47.5_CD 41.6_CD 7.0_CD 2004 2003 2002_CD Earnings_NNS per_IN ADS_NNPS under_IN US_NNP GAAP_NNP $_$ $_$ $_$ Basic_JJ net_JJ income_NN per_IN ADS_NNPS before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 1.74_CD 1.37_CD 0.26_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS per_IN ADS_NNPS under_IN US_NNP GAAP_NNP 0.05_CD Basic_JJ net_JJ income_NN per_IN ADS_NNPS after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 1.74_CD 1.37_CD 0.21_CD Diluted_NNP net_JJ income_NN per_IN ADS_NNPS before_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 1.74_CD 1.36_CD 0.26_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS per_IN ADS_NNPS under_IN US_NNP GAAP_NNP 0.05_CD Diluted_NNP net_JJ income_NN per_IN ADS_NNPS after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS under_IN US_NNP GAAP_NNP 1.74_CD 1.36_CD 0.21_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 143_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2003_CD 2004_CD restated_VBN Equity_NNP shareholders_NNS funds_NNS Notes_NNS m_VBP m_NN Equity_NN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 5,925_CD 5,059_CD US_NNP GAAP_NNP adjustments_NNS :_: Goodwill_NNP a_DT 17,982_CD 17,986_CD Product_NNP rights_NNS b_NN 13,994_CD 15,652_CD Pension_NN intangible_JJ asset_NN b_NN 102_CD 128_CD Tangible_JJ xed_JJ assets_NNS 43_CD 45_CD Capitalised_VBN interest_NN 180_CD 198_CD Marketable_JJ securities_NNS 49_CD 84_CD Other_JJ investments_NNS 554_CD 832_CD Fair_NNP value_NN step-up_NN of_IN inventory_NN 1_CD Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS f_LS 1,287_CD 1,702_CD Restructuring_NN costs_NNS 80_CD 92_CD Derivative_JJ instruments_NNS and_CC hedging_VBG 15_CD 26_CD Fair_NNP value_NN of_IN put_NN option_NN granted_VBN to_TO minority_NN shareholders_NNS c_NN 17_CD Guarantor_NNP obligations_NNS 2_CD 21_CD Dividends_NNPS 683_CD 808_CD Deferred_JJ taxation_NN e_SYM 4,204_CD 5,071_CD Variable_JJ interest_NN entities_NNS c_NN 60_CD Shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP 34,042_CD 34,116_CD 2004 2003 2002_CD Consolidated_NNP statement_NN of_IN cash_NN ows_NNS under_IN US_NNP GAAP_NNP m_NN mm_NN Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS 4,618_CD 4,895_CD 5,345_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 988_CD 904_CD 1,051_CD Net_JJ cash_NN used_VBN in_IN nancing_VBG activities_NNS 3,038_CD 3,051_CD 4,002_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 592 940 292_CD Exchange_NNP rate_NN movements_NNS 93_CD 36_CD 42_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN year_NN 1,986_CD 1,082_CD 832_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN year_NN 2,485_CD 1,986_CD 1,082_CD Notes_NNS to_TO the_DT profit_NN and_CC Equity_NN shareholders_NNS funds_NNS reconciliations_VBZ a_DT Goodwill_NNP The_NNP following_VBG tables_NNS set_VBN out_RP the_DT UK_NNP to_TO US_NNP GAAP_NNP adjustments_NNS required_VBN to_TO the_DT UK_NNP GAAP_NNP statement_NN of_IN profit_NN and_CC loss_NN and_CC balance_NN sheet_NN in_IN respect_NN of_IN goodwill_NN including_VBG goodwill_NN in_IN respect_NN of_IN associated_VBN undertakings_NNS :_: 2004 2003 2002_CD Income_NNP statement_NN m_NN m_FW m_FW Amortisation_NNP under_IN UK_NNP GAAP_NNP 17_CD 19_CD 18_CD Amortisation_NNP under_IN US_NNP GAAP_NNP UK_NNP to_TO US_NNP GAAP_NNP adjustment_NN for_IN amortisation_NN including_VBG goodwill_NN in_IN respect_NN of_IN associated_VBN undertakings_NNS 17_CD 19 18 2004 2003_CD Balance_NN sheet_NN m_NN m_NN Goodwill_NNP under_IN UK_NNP GAAP_NNP 139_CD 143_CD Goodwill_NNP under_IN US_NNP GAAP_NNP 18,121_CD 18,129_CD UK_NNP to_TO US_NNP GAAP_NNP adjustments_NNS 17,982_CD 17,986_CD Of_IN the_DT 18,121_CD million_CD 2003_CD -_: 18,129_CD million_CD US_NNP GAAP_NNP goodwill_NN balance_NN at_IN 31st_CD December_NNP 2004_CD ,_, 15,875_CD million_CD 2003_CD -_: 15,875_CD million_CD is_VBZ in_IN respect_NN of_IN the_DT goodwill_NN arising_VBG on_IN the_DT acquisition_NN of_IN SmithKline_NNP Beecham_NNP by_IN Glaxo_NNP Wellcome_NNP in_IN 2000_CD ._.
144_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD The_DT following_JJ tables_NNS present_VBP the_DT changes_NNS in_IN goodwill_NN allocated_VBN to_TO the_DT Groups_NNS reportable_JJ segments_NNS :_: Consumer_NNP Pharmaceuticals_NNP Healthcare_NNP Total_NNP m_FW m_FW m_FW At_IN 31st_CD December_NNP 2002_CD 15,679_CD 2,481_CD 18,160_CD Additions_NNPS 2_CD 2_CD Exchange_NNP adjustments_NNS 13_CD 20_CD 33_CD At_IN 31st_CD December_NNP 2003_CD 15,668_CD 2,461_CD 18,129_CD Asset_NNP written_VBN off_RP 1_CD 1_CD Exchange_NNP adjustments_NNS 5_CD 12_CD 7_CD At_IN 31st_CD December_NNP 2004_CD 15,672_CD 2,449_CD 18,121_CD b_NN Intangible_JJ assets_NNS The_DT following_JJ tables_NNS set_VBN out_RP the_DT UK_NNP to_TO US_NNP GAAP_NNP adjustments_NNS required_VBN to_TO the_DT UK_NNP GAAP_NNP statement_NN of_IN profit_NN and_CC loss_NN and_CC balance_NN sheet_NN in_IN respect_NN of_IN intangible_JJ assets_NNS :_: 2004 2003 2002_CD Income_NNP statement_NN m_NN m_FW m_FW Amortisation_NNP charge_NN under_IN UK_NNP GAAP_NNP 94_CD 74_CD 60_CD Amortisation_NNP charge_NN under_IN US_NNP GAAP_NNP 1,516_CD 1,641_CD 1,787_CD UK_NNP to_TO US_NNP GAAP_NNP adjustment_NN for_IN amortisation_NN 1,422_CD 1,567_CD 1,727_CD Impairment_NN charge_NN under_IN UK_NNP GAAP_NNP 22_CD 41_CD 46_CD Impairment_NN charge_NN under_IN US_NNP GAAP_NNP 26_CD 766_CD 2,581_CD UK_NNP to_TO US_NNP GAAP_NNP adjustment_NN for_IN impairments_NNS 4_CD 725_CD 2,535_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN principle_NN 173_CD UK_NNP to_TO US_NNP GAAP_NNP adjustment_NN for_IN impairments_NNS for_IN the_DT period_NN 4_CD 725_CD 2,362_CD Following_VBG the_DT initial_JJ implementation_NN of_IN SFAS_NNP 142_CD in_IN 2002_CD ,_, the_DT carrying_VBG value_NN of_IN the_DT brands_NNS determined_VBD to_TO have_VB indefinite_JJ lives_NNS were_VBD reviewed_VBN and_CC an_DT impairment_NN of_IN 173_CD million_CD 127_CD million_CD net_NN of_IN tax_NN was_VBD recognized_VBN ._.
This_DT was_VBD recorded_VBN as_IN a_DT cumulative_JJ effect_NN of_IN a_DT change_NN in_IN accounting_NN principle_NN ._.
In_IN addition_NN to_TO the_DT above_JJ adjustments_NNS for_IN amortisation_NN and_CC impairments_NNS ,_, further_JJ UK_NNP to_TO US_NNP GAAP_NNP adjustments_NNS arose_VBD during_IN the_DT year_NN of_IN 173_CD million_CD 2003_CD -_: 105_CD million_CD :_: 2002_CD -_: 181_CD million_CD in_IN respect_NN of_IN the_DT acquisition_NN of_IN licences_NNS ,_, patents_NNS etc._FW ._.
which_WDT are_VBP capitalized_VBN under_IN UK_NNP GAAP_NNP but_CC charged_VBD directly_RB to_TO research_NN and_CC development_NN expense_NN under_IN US_NNP GAAP_NNP ,_, and_CC 37_CD million_CD 2003_CD and_CC 2002_CD nil_NN in_IN respect_NN of_IN disposals_NNS of_IN product_NN rights_NNS which_WDT have_VBP a_DT higher_JJR carrying_VBG value_NN under_IN US_NNP GAAP_NNP than_IN under_IN UK_NNP GAAP_NNP ._.
2004_CD 2003_CD Balance_NN sheet_NN m_NN m_NN Intangible_JJ assets_NNS under_IN UK_NNP GAAP_NNP 2,003_CD 1,697_CD Intangible_JJ assets_NNS under_IN US_NNP GAAP_NNP 16,099_CD 17,477_CD UK_NNP to_TO US_NNP GAAP_NNP adjustments_NNS 14,096_CD 15,780_CD Less_RBR pensions_NNS intangible_JJ asset_NN 102_CD 128_CD Net_JJ UK_NNP to_TO US_NNP GAAP_NNP product_NN rights_NNS adjustments_NNS 13,994_CD 15,652_CD Intangible_JJ assets_NNS under_IN US_NNP GAAP_NNP are_VBP analyzed_VBN as_IN follows_VBZ :_: 2004_CD 2003_CD m_NN m_NN Acquired_VBN products_NNS 10,589_CD 12,054_CD Licences_NNPS ,_, patents_NNS etc._FW ._.
371_CD 126_CD Brands_NNP 5,037_CD 5,169_CD Pensions_NNS 102_CD 128_CD Intangible_JJ assets_NNS under_IN US_NNP GAAP_NNP 16,099_CD 17,477_CD The_DT following_VBG tables_NNS present_JJ details_NNS of_IN the_DT Groups_NNS intangible_JJ assets_NNS ,_, differentiating_VBG between_IN those_DT subject_JJ to_TO amortisation_NN and_CC those_DT which_WDT are_VBP not_RB subject_JJ to_TO amortisation_NN :_: 2004_CD 2003_CD m_NN m_NN Intangible_JJ assets_NNS subject_JJ to_TO amortisation_NN 11,922_CD 13,234_CD Intangible_JJ assets_NNS not_RB subject_JJ to_TO amortisation_NN 4,177_CD 4,243_CD Intangible_JJ assets_NNS under_IN US_NNP GAAP_NNP 16,099_CD 17,477_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 145_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD The_DT following_JJ intangible_JJ assets_NNS are_VBP subject_JJ to_TO amortisation_NN :_: 2004_CD 2003_CD Product_NNP Product_NNP rights_NNS rights_NNS m_NN m_NN Cost_NN 21,555_CD 21,329_CD Accumulated_VBN amortisation_NN 6,872_CD 5,360_CD Impairment_NN 2,761_CD 2,735_CD Net_JJ 11,922_CD 13,234_CD The_DT carrying_NN values_NNS of_IN certain_JJ product_NN rights_NNS were_VBD reviewed_VBN and_CC an_DT impairment_NN of_IN 26_CD million_CD has_VBZ been_VBN recorded_VBN ._.
In_IN 2003_CD ,_, impairments_NNS of_IN 658_CD million_CD were_VBD recorded_VBN ,_, of_IN which_WDT 633_CD million_CD related_VBN to_TO Paxil_NNP which_WDT was_VBD impaired_VBN following_VBG the_DT launch_NN in_IN the_DT USA_NNP of_IN a_DT generic_JJ Paxil_NNP product_NN ._.
Fair_NNP values_NNS are_VBP determined_VBN using_VBG a_DT discounted_JJ cash_NN ow_NN model_NN ._.
As_IN discussed_VBN in_IN Note_NN 30_CD Legal_NNP proceedings_NNS ,_, a_DT number_NN of_IN distributors_NNS of_IN generic_JJ drugs_NNS have_VBP led_VBN applications_NNS to_TO market_NN generic_JJ versions_NNS of_IN a_DT number_NN of_IN the_DT Groups_NNS products_NNS prior_RB to_TO the_DT expiration_NN of_IN the_DT Groups_NNS patents_NNS ._.
If_IN generic_JJ versions_NNS of_IN products_NNS are_VBP launched_VBN in_IN future_NN periods_NNS at_IN earlier_JJR dates_NNS than_IN the_DT Group_NNP currently_RB expects_VBZ ,_, impairments_NNS of_IN the_DT carrying_VBG value_NN of_IN the_DT products_NNS may_MD arise_VB ._.
The_DT estimated_JJ future_JJ amortisation_NN expense_NN for_IN the_DT next_JJ five_CD years_NNS for_IN intangible_JJ assets_NNS subject_JJ to_TO amortisation_NN as_IN of_IN 31st_CD December_NNP 2004_CD is_VBZ as_IN follows_VBZ :_: Year_NN m_NN 2005_CD 1,528_CD 2006_CD 1,487_CD 2007_CD 1,473_CD 2008_CD 1,472_CD 2009_CD 756_CD Total_JJ 6,716_CD Intangible_JJ assets_NNS which_WDT are_VBP not_RB subject_JJ to_TO amortisation_NN include_VBP a_DT pension_NN asset_NN of_IN 102_CD million_CD at_IN 31st_CD December_NNP 2004_CD 128_CD million_CD at_IN 31st_CD December_NNP 2003_CD and_CC certain_JJ product_NN rights_NNS ._.
The_DT intangible_JJ assets_NNS relating_VBG to_TO product_NN rights_NNS are_VBP analyzed_VBN as_IN follows_VBZ :_: 2004_CD 2003_CD m_NN m_NN Cost_NN 4,652_CD 4,693_CD Impairment_NN 577_CD 578_CD Net_JJ 4,075_CD 4,115_CD An_DT impairment_NN charge_NN of_IN nil_NN was_VBD recognized_VBN during_IN 2004 2003 108_CD million_CD ._.
c_NN Theravance_NNP In_IN May_NNP 2004_CD ,_, the_DT Group_NNP formed_VBD a_DT strategic_JJ alliance_NN with_IN Theravance_NNP Inc._NNP to_TO develop_VB and_CC commercialise_VB novel_JJ medicines_NNS across_IN a_DT variety_NN of_IN important_JJ therapeutic_JJ areas_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT alliance_NN ,_, Theravance_NNP received_VBD $_$ 129_CD million_CD ,_, a_DT significant_JJ part_NN of_IN which_WDT related_VBN to_TO the_DT Groups_NNS purchase_NN of_IN Theravance_NNP shares_NNS ._.
The_DT Group_NNP has_VBZ a_DT call_NN option_NN in_IN 2007_CD to_TO further_JJ increase_NN its_PRP$ ownership_NN to_TO over_IN 50_CD per_IN cent_NN at_IN a_DT significant_JJ premium_NN to_TO the_DT price_NN paid_VBN in_IN the_DT 2004_CD transaction_NN ._.
Theravances_NNS shareholders_NNS have_VBP a_DT put_NN option_NN at_IN a_DT lower_JJR exercise_NN price_NN to_TO cause_VB GlaxoSmithKline_NNP to_TO acquire_VB up_RP to_TO half_DT of_IN their_PRP$ outstanding_JJ stock_NN in_IN 2007_CD ._.
Given_VBN the_DT maximum_JJ number_NN of_IN shares_NNS subject_JJ to_TO the_DT put_NN option_NN ,_, the_DT Groups_NNS obligation_NN is_VBZ capped_VBN at_IN $_$ 525_CD million_CD ._.
The_DT Group_NNP has_VBZ an_DT exclusive_JJ option_NN to_TO license_VB potential_JJ new_JJ medicines_NNS from_IN all_DT of_IN Theravances_NNS programs_NNS until_IN August_NNP 2007_CD ._.
Upon_IN exercising_VBG its_PRP$ option_NN over_IN a_DT Theravance_NNP program_NN ,_, the_DT Group_NNP will_MD be_VB responsible_JJ for_IN the_DT relevant_JJ development_NN ,_, manufacturing_NN and_CC commercialisation_NN activities_NNS ._.
Depending_VBG on_IN the_DT success_NN of_IN such_JJ programs_NNS ,_, Theravance_NNP will_MD receive_VB clinical_JJ ,_, regulatory_JJ and_CC commercial_JJ milestone_NN payments_NNS and_CC royalties_NNS on_IN the_DT subsequent_JJ sales_NNS of_IN medicines_NNS ._.
Based_VBN on_IN the_DT assessment_NN performed_VBN ,_, the_DT Group_NNP is_VBZ the_DT primary_JJ beneciary_NN of_IN Theravance_NNP ,_, as_IN dened_VBN by_IN FIN_NNP 46R_NNP ,_, and_CC as_IN a_DT result_NN Theravance_NNP has_VBZ been_VBN consolidated_VBN into_IN the_DT Groups_NNS US_NNP GAAP_NNP financial_JJ statements_NNS from_IN May_NNP 2004_CD ._.
The_DT net_JJ assets_NNS acquired_VBN were_VBD measured_VBN at_IN fair_JJ value_NN ._.
The_DT principal_JJ adjustment_NN to_TO the_DT carrying_VBG value_NN of_IN the_DT net_JJ assets_NNS in_IN Theravances_NNS balance_NN sheet_NN prior_RB to_TO the_DT acquisition_NN was_VBD recognition_NN of_IN in-process_JJ research_NN and_CC development_NN IPR&D_NNP at_IN a_DT valuation_NN of_IN 273_CD million_CD ._.
The_DT IPR&D_NNP was_VBD written-off_JJ immediately_RB after_IN the_DT acquisition_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP purchase_NN accounting_NN ._.
The_DT effect_NN of_IN consolidating_VBG Theravance_NNP has_VBZ been_VBN to_TO decrease_VB shareholders_NNS equity_NN and_CC net_JJ income_NN by_IN 60_CD million_CD ._.
Additionally_RB ,_, the_DT Group_NNP has_VBZ accounted_VBN for_IN the_DT Theravance_NNP put_VBD option_NN discussed_VBN above_IN in_IN accordance_NN with_IN SFAS_NNP 150_CD ,_, Accounting_NNP for_IN Certain_NNP Financial_NNP Instruments_NNPS with_IN Characteristics_NNPS of_IN both_DT Liabilities_NNPS and_CC Equity_NNP ,_, which_WDT requires_VBZ the_DT Group_NNP to_TO record_VB the_DT fair_JJ value_NN of_IN the_DT put_NN option_NN as_IN a_DT liability_NN ._.
The_DT fair_JJ value_NN of_IN the_DT Theravance_NNP put_VBD option_NN at_IN 31st_CD December_NNP 2004_CD is_VBZ 69_CD million_CD :_: as_RB at_IN the_DT initial_JJ consolidation_NN of_IN Theravance_NNP ,_, the_DT value_NN of_IN the_DT put_NN option_NN was_VBD 86_CD million_CD ._.
In_IN accordance_NN with_IN SFAS_NNP 133_CD ,_, Accounting_NNP for_IN Derivative_NNP Instruments_NNP and_CC Hedging_NNP Activities_NNPS the_DT call_NN option_NN is_VBZ not_RB recognized_VBN in_IN the_DT financial_JJ statements_NNS as_IN it_PRP is_VBZ not_RB readily_RB convertible_JJ into_IN cash_NN ._.
146_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD d_SYM Taxation_NNP 2003 2002 2004_CD restated_VBN restated_VBN Total_JJ tax_NN expense_NN m_NN m_FW m_FW UK_NNP GAAP_NNP :_: Current_JJ tax_NN expense_NN 1,707_CD 2,001_CD 1,432_CD Deferred_JJ tax_NN credit_NN expense_NN 6_CD 272_CD 32_CD Total_JJ tax_NN expense_NN 1,701_CD 1,729_CD 1,464_CD US_NNP GAAP_NNP :_: Current_JJ tax_NN expense_NN 1,717_CD 2,014_CD 1,445_CD Deferred_JJ tax_NN credit_NN 667_CD 1,059_CD 1,146_CD Total_JJ tax_NN expense_NN 1,050_CD 955_CD 299_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 34_CD Total_JJ tax_NN expense_NN 1,050_CD 955_CD 265_CD UK_NNP to_TO US_NNP GAAP_NNP adjustments_NNS :_: Current_JJ tax_NN expense_NN 10_CD 13_CD 13_CD Deferred_JJ tax_NN credit_NN 661_CD 787_CD 1,178_CD Total_JJ tax_NN expense_NN 651_CD 774_CD 1,165_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 34_CD Total_JJ tax_NN expense_NN 651_CD 774_CD 1,199_CD e_SYM Deferred_VBN taxation_NN under_IN US_NNP GAAP_NNP Classication_NNP of_IN GlaxoSmithKlines_NNP deferred_VBD taxation_NN liabilities_NNS and_CC assets_NNS under_IN US_NNP GAAP_NNP is_VBZ as_IN follows_VBZ :_: 2003_CD 2004_CD restated_VBN m_FW m_FW Liabilities_NNP Stock_NNP valuation_NN adjustment_NN 51_CD 52_CD Current_JJ deferred_VBN taxation_NN liabilities_NNS 51_CD 52_CD Accelerated_VBN capital_NN allowances_NNS 664_CD 689_CD Product_NN rights_NNS 4,454_CD 4,917_CD Other_JJ timing_NN differences_NNS 66_CD 229_CD Total_JJ deferred_VBN taxation_NN liabilities_NNS 5,103_CD 5,887_CD Assets_NNS Intra-Group_JJ profit_NN 594_CD 485_CD Other_JJ timing_NN differences_NNS 675_CD 607_CD Current_JJ deferred_VBN taxation_NN assets_NNS 1,269_CD 1,092_CD Asset_NNP disposal_NN 31_CD 59_CD Pensions_NNS and_CC other_JJ post-retirement_JJ benets_NNS 57_CD 86_CD Tax_NNP losses_NNS 20_CD 94_CD Manufacturing_NNP restructuring_NN 66_CD 132_CD Legal_NNP and_CC other_JJ disputes_NNS 157_CD 167_CD Other_JJ timing_NN differences_NNS 188_CD 127_CD Total_JJ deferred_VBN taxation_NN assets_NNS 1,726_CD 1,639_CD Net_JJ deferred_VBN taxation_NN under_IN US_NNP GAAP_NNP 3,377_CD 4,248_CD Net_JJ deferred_VBN taxation_NN under_IN UK_NNP GAAP_NNP 827_CD 823_CD UK_NNP to_TO US_NNP GAAP_NNP adjustment_NN 4,204_CD 5,071_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 147_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD f_SYM Pensions_NNPS and_CC post-retirement_NN costs_NNS under_IN US_NNP GAAP_NNP 2004 2003 2002_CD m_FW m_FW m_FW UK_NNP pension_NN schemes_NNS 225 278 103_CD US_NNP pension_NN schemes_NNS 54_CD 79_CD 67_CD Other_JJ overseas_JJ pension_NN schemes_NNS 77_CD 83_CD 51_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 96_CD 118_CD 78_CD Post-employment_NN costs_NNS 18_CD 24 40 470 582_CD 339_CD Analysed_VBN as_IN :_: Funded_VBN dened_VBN benefit_NN hybrid_NN schemes_NNS 298 389 149_CD Unfunded_JJ dened_VBN benefit_NN schemes_NNS 37_CD 26_CD 48_CD Dened_VBN contribution_NN schemes_NNS 21_CD 25_CD 24_CD Unfunded_JJ post-retirement_NN healthcare_NN schemes_NNS 96_CD 118_CD 78_CD Post-employment_NN costs_NNS 18_CD 24 40 470 582_CD 339_CD The_DT disclosures_NNS below_IN include_VBP the_DT additional_JJ information_NN required_VBN by_IN SFAS_NNP 132R_NNP ._.
The_DT pension_NN costs_NNS of_IN the_DT UK_NNP ,_, US_NNP and_CC major_JJ overseas_JJ dened_VBN benefit_NN pension_NN plans_NNS have_VBP been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN US_NNP GAAP_NNP ._.
Pension_NN costs_NNS in_IN 2004_CD of_IN 5_CD million_CD 2003_CD 9_CD million_CD :_: 2002_CD 12_CD million_CD ,_, in_IN respect_NN of_IN minor_JJ retirement_NN plans_NNS ,_, which_WDT have_VBP not_RB been_VBN recalculated_VBN in_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP 87_CD ,_, have_VBP been_VBN excluded_VBN ._.
2004 2003 2002_CD Net_JJ periodic_JJ pension_NN cost_NN for_IN the_DT major_JJ retirement_NN plans_NNS m_VBP m_FW m_FW Service_NNP cost_NN 213 211 219_CD Interest_NN cost_NN 400 392 388_CD Expected_VBN return_NN on_IN plan_NN assets_NNS 431 408 470_CD Amortisation_NNP of_IN prior_JJ service_NN cost_NN 14_CD 17_CD 20_CD Amortisation_NNP of_IN transition_NN obligation_NN 2_CD 3_CD 6_CD Amortisation_NNP of_IN net_JJ actuarial_JJ loss_NN 115_CD 79_CD 3_CD Net_JJ periodic_JJ pension_NN cost_NN under_IN US_NNP GAAP_NNP 313 294 154_CD Termination_NN benets_NNS and_CC curtailment_NN costs_NNS 13_CD 112_CD 56_CD Adjustment_NNP for_IN change_NN in_IN accounting_NN principle_NN 62_CD During_IN 2002_CD ,_, the_DT Group_NNP decided_VBD to_TO align_VB the_DT measurement_NN date_NN for_IN all_DT of_IN its_PRP$ pension_NN plans_NNS ._.
As_IN certain_JJ of_IN the_DT Groups_NNS pension_NN plans_NNS had_VBD a_DT measurement_NN date_NN for_IN pension_NN assets_NNS and_CC liabilities_NNS of_IN 30th_JJ September_NNP ,_, the_DT Group_NNP elected_VBD to_TO change_VB the_DT measurement_NN date_NN for_IN these_DT plans_NNS from_IN 30th_JJ September_NNP to_TO 31st_VB December_NNP ._.
2004 2003 2002_CD Major_JJ assumptions_NNS used_VBN in_IN computing_VBG pension_NN costs_NNS %_NN pa_CD %_NN pa_CD %_NN pa_NN Rates_NNS of_IN future_JJ pay_NN increases_VBZ 4.25_CD 4.25_CD 4.25_CD Discount_NNP rate_NN 5.25_CD 5.50_CD 6.00_CD Expected_VBN long-term_JJ rates_NNS of_IN return_NN on_IN plan_NN assets_NNS 7.00_CD 7.50_CD 7.75_CD In_IN aggregate_JJ ,_, average_JJ international_JJ plan_NN assumptions_NNS did_VBD not_RB vary_VB signicantly_RB from_IN US_NNP assumptions_NNS ._.
Estimated_JJ future_NN benefit_NN payments_NNS m_VBP 2005 297 2006 306_CD 2007 317 2008 330_CD 2009 346 20102014_CD 2,011_CD 148_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD 2004_CD 2003_CD Change_NNP in_IN benefit_NN obligation_NN m_NN m_NN benefit_NN obligation_NN at_IN beginning_NN of_IN year_NN 7,866_CD 6,760_CD Amendments_NNS 2_CD 20_CD Service_NNP cost_NN 213_CD 211_CD Interest_NN cost_NN 400_CD 392_CD Plan_NN participants_NNS contributions_NNS 15_CD 16_CD Actuarial_JJ loss_NN 137_CD 899_CD Benets_NNPS paid_VBD 345_CD 328_CD Termination_NN benets_NNS and_CC curtailment_NN costs_NNS 5_CD 92_CD Exchange_NNP 122_CD 156_CD benefit_NN obligation_NN at_IN end_NN of_IN year_NN 8,171_CD 7,866_CD benefit_NN obligation_NN at_IN end_NN of_IN year_NN for_IN pension_NN plans_NNS with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS 5,554_CD 6,960_CD The_DT accumulated_VBN benefit_NN obligation_NN at_IN 31st_CD December_NNP 2004_CD was_VBD 7,691_CD million_CD 31st_JJ December_NNP 2003_CD 7,391_CD million_CD ._.
2004_CD 2003_CD Change_NNP in_IN plan_NN assets_NNS m_VBP m_NN Fair_NN value_NN of_IN plan_NN assets_NNS at_IN beginning_NN of_IN year_NN 5,968_CD 4,855_CD Actual_JJ return_NN on_IN plan_NN assets_NNS 651_CD 979_CD Employer_NN contributions_NNS 465_CD 596_CD Plan_NN participants_NNS contributions_NNS 15_CD 16_CD Benets_NNPS paid_VBD 345_CD 328_CD Exchange_NNP 64_CD 150_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN 6,690_CD 5,968_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN for_IN pension_NN plans_NNS with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS 4,519_CD 5,525_CD Plan_NN assets_NNS consist_VBP primarily_RB of_IN investments_NNS in_IN UK_NNP and_CC overseas_JJ equities_NNS ,_, xed_VBN interest_NN securities_NNS ,_, securities_NNS linked_VBN to_TO the_DT UK_NNP Retail_NNP Prices_NNS Index_NNP and_CC property_NN ._.
At_IN 31st_CD December_NNP 2004_CD UK_NNP equities_NNS included_VBD 0.3_CD million_CD GlaxoSmithKline_NNP shares_NNS 2003_CD 0.5_CD million_CD shares_NNS with_IN a_DT market_NN value_NN of_IN 4_CD million_CD 2003_CD 7_CD million_CD ._.
Normal_JJ employer_NN contributions_NNS are_VBP expected_VBN to_TO be_VB approximately_RB 360_CD million_CD in_IN 2005_CD ._.
2004_CD 2003_CD Funded_VBN status_NN m_NN m_NN Funded_VBN status_NN 1,481_CD 1,898_CD Unrecognised_JJ net_JJ actuarial_JJ loss_NN 1,900_CD 2,123_CD Unrecognised_JJ prior_JJ service_NN cost_NN 75_CD 96_CD Unrecognised_JJ transition_NN obligation_NN 24_CD 26_CD Net_JJ amount_NN recognized_VBN 518 347 2004 2003_CD Amounts_NNS recognized_VBN in_IN the_DT statement_NN of_IN financial_JJ position_NN m_NN m_FW Prepaid_FW benefit_NN cost_NN 365_CD 18_CD Accrued_VBN pension_NN liability_NN 1,065_CD 1,471_CD Intangible_JJ asset_NN 102_CD 128_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 1,116_CD 1,672_CD Net_JJ amount_NN recognized_VBN 518_CD 347_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 149_CD 37_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS continued_VBD Post-retirement_JJ healthcare_NN under_IN US_NNP GAAP_NNP The_NNP post-retirement_JJ healthcare_NN costs_NNS of_IN the_DT UK_NNP ,_, US_NNP and_CC major_JJ overseas_JJ post-retirement_NN healthcare_NN schemes_NNS have_VBP been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN US_NNP GAAP_NNP ._.
Costs_NNS in_IN 2004_CD of_IN nil_NN 2003_CD 13_CD million_CD ,_, 2002_CD nil_NN ,_, which_WDT have_VBP not_RB been_VBN recalculated_VBN ,_, have_VBP been_VBN excluded_VBN ._.
2004 2003 2002_CD Net_JJ healthcare_NN cost_NN m_NN mm_NNP Service_NNP cost_NN 32_CD 29_CD 23_CD Interest_NN cost_NN 55_CD 64_CD 53_CD Amortisation_NNP of_IN prior_JJ service_NN cost_NN 1_CD 2_CD 1_CD Amortisation_NNP of_IN net_JJ actuarial_JJ loss_NN 11_CD 14_CD 3_CD Net_JJ healthcare_NN cost_NN 97_CD 105_CD 78_CD The_DT major_JJ assumptions_NNS used_VBN in_IN calculating_VBG the_DT net_JJ healthcare_NN cost_NN were_VBD :_: %_NN pa_CD %_NN pa_CD %_NN pa_NN Rate_NN of_IN future_JJ healthcare_NN ination_NN 9.0_CD to_TO 5.0_CD 10.0_CD to_TO 5.0_CD 11.0_CD to_TO 5.0_CD Discount_NNP rate_NN 5.75_CD 6.25_CD 6.75_CD The_DT rate_NN of_IN future_JJ healthcare_NN ination_NN reects_VBZ the_DT fact_NN that_IN the_DT benets_NNS of_IN certain_JJ groups_NNS of_IN participants_NNS are_VBP capped_VBN ._.
2004_CD 2003_CD Change_NNP in_IN benefit_NN obligation_NN m_NN m_NN benefit_NN obligation_NN at_IN beginning_NN of_IN year_NN 975_CD 830_CD Amendments_NNS 3_CD Service_NNP cost_NN 32_CD 29_CD Interest_NN cost_NN 55_CD 64_CD Plan_NN participants_NNS contributions_NNS 8_CD 8_CD Actuarial_JJ loss_NN 6_CD 192_CD Benets_NNPS paid_VBD 47_CD 49_CD Exchange_NNP 64_CD 96_CD benefit_NN obligation_NN at_IN end_NN of_IN year_NN 965_CD 975_CD Change_NNP in_IN plan_NN assets_NNS Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN beginning_NN of_IN year_NN Employer_NN and_CC plan_NN participants_NNS contributions_NNS 47_CD 49_CD Benets_NNPS paid_VBD 47_CD 49_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN Funded_VBN status_NN Funded_VBN status_NN 965_CD 975_CD Unrecognised_JJ net_JJ actuarial_JJ loss_NN 340_CD 371_CD Unrecognised_JJ prior_JJ service_NN cost_NN 14_CD 17_CD Accrued_VBN post-retirement_JJ healthcare_NN cost_NN 639_CD 621_CD 1_CD %_NN decrease_NN 1_CD %_NN increase_NN Impact_NN of_IN a_DT one_CD per_IN cent_NN variation_NN in_IN the_DT rate_NN of_IN future_JJ healthcare_NN ination_NN m_FW m_FW Effect_NN on_IN total_JJ service_NN and_CC interest_NN cost_NN 7_CD 8_CD Effect_NN on_IN provision_NN for_IN post-retirement_JJ benets_NNS 75_CD 82_CD 150_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 38_CD Principal_NN Group_NNP companies_NNS The_DT following_JJ represent_VBP the_DT principal_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS of_IN the_DT GlaxoSmithKline_NNP Group_NNP at_IN 31st_CD December_NNP 2004_CD ._.
Details_NNS are_VBP given_VBN of_IN the_DT principal_JJ country_NN of_IN operation_NN ,_, the_DT location_NN of_IN the_DT headquarters_NN ,_, the_DT business_NN segment_NN and_CC the_DT business_NN activities_NNS ._.
The_DT equity_NN share_NN capital_NN of_IN these_DT undertakings_NNS is_VBZ wholly_RB owned_VBN by_IN the_DT Group_NNP except_IN where_WRB its_PRP$ percentage_NN interest_NN is_VBZ shown_VBN otherwise_RB ._.
All_DT companies_NNS are_VBP incorporated_VBN in_IN their_PRP$ principal_JJ country_NN of_IN operation_NN except_IN where_WRB stated_VBN ._.
Europe_NNP Location_NNP Subsidiary_NNP undertaking_VBG Segment_NNP Activity_NNP %_NN England_NNP Brentford_NNP GlaxoSmithKline_NNP Holdings_NNP One_CD Limited_NNP Ph_NNP ,_, CH_NNP h_NNP Brentford_NNP GlaxoSmithKline_NNP Services_NNPS Unlimited_NNP Ph_NNP ,_, CH_NNP s_VBZ Brentford_NNP GlaxoSmithKline_NNP Finance_NNP plc_NN Ph_NNP ,_, CH_NNP f_LS Brentford_NNP GlaxosmithKline_NNP Capital_NNP plc_NN Ph_NNP f_SYM Brentford_NNP SmithKline_NNP Beecham_NNP p._FW l._FW c._FW Ph_FW ,_, CH_NNP d_LS e_SYM h_FW m_FW p_FW r_NN Brentford_NNP Wellcome_NNP Limited_NNP Ph_NNP ,_, CH_NNP h_NNP Greenford_NNP Glaxo_NNP Group_NNP Limited_NNP Ph_NNP h_VBP Greenford_NNP Glaxo_NNP Operations_NNP UK_NNP Limited_NNP Ph_NNP p_VBP Brentford_NNP Glaxo_NNP Wellcome_NNP International_NNP B._NNP V._NNP Footnote_NNP i_FW Ph_NNP ,_, CH_NNP h_NNP Brentford_NNP Glaxo_NNP Wellcome_NNP Investments_NNP B._NNP V._NNP Footnote_NNP i_FW Ph_NNP ,_, CH_NNP h_NNP Stockley_NNP Park_NNP Glaxo_NNP Wellcome_NNP UK_NNP Limited_NNP Ph_NNP h_VBP m_FW p_FW Brentford_NNP GlaxoSmithKline_NNP Export_NNP Limited_NNP Ph_NNP e_SYM Brentford_NNP GlaxoSmithKline_NNP Research_NNP &_CC Development_NNP Limited_NNP Ph_NNP d_SYM r_SYM Brentford_NNP GlaxoSmithKline_NNP UK_NNP Limited_NNP Ph_NNP m_FW p_FW Brentford_NNP SmithKline_NNP Beecham_NNP Investments_NNP Limited_NNP Ph_NNP ,_, CH_NNP f_LS Brentford_NNP SmithKline_NNP Beecham_NNP SWG_NNP Limited_NNP CH_NNP e_LS m_FW Brentford_NNP SmithKline_NNP Beecham_NNP Research_NNP Limited_NNP Ph_NNP m_NN Brentford_NNP Stafford-Miller_NNP Limited_NNP CH_NNP m_FW p_FW Greenford_NNP The_DT Wellcome_NNP Foundation_NNP Limited_NNP Ph_NNP p_VBP Brentford_NNP Setrst_NNP No._NN ._.
2_CD Limited_JJ Ph_NNP ,_, CH_NNP f_LS h_FW formerly_RB GlaxoSmithKline_NNP Luxembourg_NNP S._NNP A._NNP Footnote_NNP ii_FW Austria_NNP Vienna_NNP GlaxoSmithKline_NNP Pharma_NNP G._NNP m._FW b._FW H_NNP Ph_NNP m_NN Belgium_NNP Genval_NNP GlaxoSmithKline_NNP S._NNP A._NNP Ph_NNP m_NN Rixensart_NNP GlaxoSmithKline_NNP Biologicals_NNP S._NNP A._NNP Ph_NNP d_SYM e_SYM m_FW p_FW r_NN Rixensart_NNP GlaxoSmithKline_NNP Biologicals_NNP Manufacturing_NNP S._NNP A._NNP Phh_NNP Guernsey_NNP St._NNP Peter_NNP Port_NNP SmithKline_NNP Beecham_NNP Limited_NNP Ph_NNP ,_, CH_NNP i_FW Denmark_NNP Ballerup_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP A_NNP S_NNP CH_NNP m_FW Brndby_NNP GlaxoSmithKline_NNP Pharma_NNP A_NNP S_NNP Ph_NNP m_VBD Finland_NNP Espoo_NNP GlaxoSmithKline_NNP Oy_NNP Ph_NNP m_NN France_NNP Marly_NNP le_FW Roi_NNP Groupe_NNP GlaxoSmithKline_NNP S._NNP A._NNP S_NNP Ph_NNP h_VBP Marly_NNP le_FW Roi_NNP Laboratoire_NNP GlaxoSmithKline_NNP S._NNP A._NNP S_NNP Ph_NNP m_NN Marly_NNP le_FW Roi_NNP Glaxo_NNP Wellcome_NNP Production_NNP S._NNP A._NNP S_NNP Ph_NNP m_FW p_FW Marly_NNP le_FW Roi_NNP GlaxoSmithKline_NNP Sante_NNP Grand_NNP Public_NNP S._NNP A._NNP S._NNP CH_NNP m_NNP Germany_NNP Buehl_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP GmbH_NNP &_CC Co_NNP KG_NNP CH_NNP d_LS h_FW m_FW p_FW r_NN s_VBZ Buehl_NNP GlaxoSmithKline_NNP Healthcare_NNP GmbH_NNP CH_NNP h_NNP Greece_NNP Athens_NNP GlaxoSmithKline_NNP A._NNP E._NNP B._NNP E_NNP Ph_NNP ,_, CH_NNP h_FW m_FW Hungary_NNP Budapest_NNP GlaxoSmithKline_NNP Kft_NNP Ph_NNP ,_, CH_NNP e_LS m_FW Italy_NNP Verona_NNP GlaxoSmithKline_NNP S._NNP p._NNP A._NN Ph_NNP d_SYM h_FW m_FW r_NN Milan_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP S._NNP p_NNP A._NN CH_NNP h_FW m_FW Luxembourg_NNP Mamer_NNP GlaxoSmithKline_NNP International_NNP Luxembourg_NNP S._NNP A._NNP Ph_NNP ,_, CH_NNP f_LS h_VBP Notes_NNS to_TO the_DT financial_JJ statements_NNS GlaxoSmithKline_NNP 151_CD 38_CD Principal_NN Group_NNP companies_NNS continued_VBD Europe_NNP Location_NNP Subsidiary_NNP undertaking_VBG Segment_NNP Activity_NNP %_NN Netherlands_NNP Zeist_NNP GlaxoSmithKline_NNP B._NNP V._NNP Ph_NNP m_NN Zeist_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP B._NNP V._NNP CH_NNP m_FW Norway_NNP Oslo_NNP GlaxoSmithKline_NNP AS_NNP Ph_NNP m_NN Poland_NNP Poznan_NNP GlaxoSmithKline_NNP Pharmaceuticals_NNP S._NNP A._NNP Ph_NNP m_NN p_NN 97_CD Warsaw_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP Sp_NNP ._.
o._FW CH_FW m_FW e_SYM Portugal_NNP Lisbon_NNP Farmaceuticos_NNP Lda_NNP Ph_NNP m_NN Republic_NNP of_IN Dublin_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP Ireland_NNP Limited_NNP Footnote_NNP iii_FW CH_NNP m_FW Ireland_NNP Carrigaline_NNP SmithKline_NNP Beecham_NNP Cork_NNP Limited_NNP Footnote_NNP iii_FW Ph_NNP p_FW Carrigaline_NNP SmithKline_NNP Beecham_NNP Manufacturing_NNP Limited_NNP Footnote_NNP iii_FW Ph_NNP p_NN Spain_NNP Tres_NNP Cantos_NNP GlaxoSmithKline_NNP ,_, S._NNP A._NNP Ph_NNP m_NN Aranda_NNP fide_NNP Duero_NNP GlaxoSmithKline_NNP ,_, S._NNP A._NNP Ph_NNP p_NN Alcala_NNP fide_NNP Henares_NNPS SmithKline_NNP Beecham_NNP S._NNP A._NNP Ph_NNP p_VBP Sweden_NNP Mlndal_NNP GlaxoSmithKline_NNP AB_NNP Ph_NNP m_NN Switzerland_NNP Muenchenbuchsee_NNP GlaxoSmithKline_NNP Investments_NNP Switzerland_NNP GmbH_NNP Ph_NNP ,_, CH_NNP h_NNP Muenchenbuchsee_NNP GlaxoSmithKline_NNP AG_NNP Ph_NNP m_NN Zug_NNP Adechsa_NNP GmbH_NNP Ph_NNP e_SYM USA_NNP USA_NNP Philadelphia_NNP SmithKline_NNP Beecham_NNP Corporation_NNP Ph_NNP ,_, CH_NNP d_LS e_SYM h_FW m_FW p_FW r_NN s_VBZ Pittsburgh_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP ,_, L._NNP P._NNP CH_NNP m_FW p_FW 88_CD Pittsburgh_NNP Block_NNP Drug_NNP Company_NNP ,_, Inc_NNP CH_NNP h_VBP m_FW p_FW Wilmington_NNP GlaxoSmithKline_NNP Financial_NNP Inc_NNP Ph_NNP f_SYM Wilmington_NNP GlaxoSmithKline_NNP Holdings_NNPS Americas_NNPS Inc_NNP Ph_NNP ,_, CH_NNP h_NNP Americas_NNP Bermuda_NNP Hamilton_NNP GlaxoSmithKline_NNP Insurance_NNP Ltd_NNP Ph_NNP ,_, CH_NNP i_FW Canada_NNP Mississauga_NNP GlaxoSmithKline_NNP Inc_NNP Ph_NNP ,_, CH_NNP m_FW p_FW r_NN Asia_NNP Pacic_NNP Australia_NNP Boronia_NNP Glaxo_NNP Wellcome_NNP Australia_NNP Pty_NNP Ltd_NNP Ph_NNP ,_, CH_NNP d_LS e_SYM m_FW p_FW r_NN China_NNP Hong_NNP Kong_NNP GlaxoSmithKline_NNP Limited_NNP Ph_NNP ,_, CH_NNP m_NNP Tianjin_NNP Sino-American_NNP Tianjin_NNP Smith_NNP Kline_NNP &_CC French_NNP Laboratories_NNPS Ltd_NNP Ph_NNP d_SYM m_FW p_FW r_NN 55_CD India_NNP Mumbai_NNP GlaxoSmithKline_NNP Pharmaceuticals_NNP Limited_NNP Ph_NNP m_FW p_FW 59_CD Nabha_NNP GlaxoSmithKline_NNP Consumer_NNP Healthcare_NNP Limited_NNP Footnote_NNP iv_NN CH_NNP m_FW p_FW 40_CD Malaysia_NNP Petaling_NNP Jaya_NNP Selangor_NNP GlaxoSmithKline_NNP Pharmaceutical_NNP Sdn_NNP Bhd_NNP Ph_NNP m_NN Darul_NNP Ehsan_NNP New_NNP Zealand_NNP Auckland_NNP GlaxoSmithKline_NNP NZ_NNP Limited_NNP Ph_NNP ,_, CH_NNP m_NNP Pakistan_NNP Karachi_NNP GlaxoSmithKline_NNP Pakistan_NNP Limited_NNP Ph_NNP ,_, CH_NNP m_FW pe79_FW Philippines_NNPS Makati_NNP GlaxoSmithKline_NNP Philippines_NNPS Inc._NNP ._.
Ph_NNP ,_, CH_NNP m_NNP Singapore_NNP Singapore_NNP Glaxo_NNP Wellcome_NNP Manufacturing_NNP Pte_NNP Ltd_NNP Ph_NNP p_VBP Singapore_NNP GlaxoSmithKline_NNP Pte_NNP Ltd_NNP Ph_NNP m_NN South_NNP Korea_NNP Seoul_NNP GlaxoSmithKline_NNP Korea_NNP Ph_NNP m_FW p_FW Taiwan_NNP Taipei_NNP Glaxo_NNP Wellcome_NNP Taiwan_NNP Limited_NNP Ph_NNP m_NN p_NN 152_CD GlaxoSmithKline_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 38_CD Principal_NN Group_NNP companies_NNS continued_VBD Japan_NNP Location_NNP Subsidiary_NNP undertaking_VBG Segment_NNP Activity_NNP %_NN Japan_NNP Tokyo_NNP GlaxoSmithKline_NNP K._NNP K._NNP Ph_NNP ,_, CH_NNP d_LS m_FW p_FW r_NN 85_CD Latin_NNP America_NNP Argentina_NNP Buenos_NNP Aires_NNP GlaxoSmithKline_NNP Argentina_NNP S._NNP A._NNP Ph_NNP ,_, CH_NNP m_FW p_FW Brazil_NNP Rio_NNP fide_VBD Janeiro_NNP GlaxoSmithKline_NNP Brasil_NNP Ltda_NNP Ph_NNP ,_, CH_NNP m_FW p_FW Colombia_NNP Bogota_NNP GlaxoSmithKline_NNP Colombia_NNP S._NNP A._NNP Ph_NNP ,_, CH_NNP m_NNP Mexico_NNP Mexico_NNP City_NNP GlaxoSmithKline_NNP Mexico_NNP ,_, S._NNP A._NNP fide_NNP C._NNP V._NNP Ph_NNP ,_, CH_NNP e_LS m_FW p_FW s_PRP Puerto_NNP Rico_NNP Guaynabo_NNP GlaxoSmithKline_NNP Puerto_NNP Rico_NNP Inc._NNP ._.
Ph_NNP m_FW San_NNP Juan_NNP SB_NNP Pharmco_NNP Puerto_NNP Rico_NNP Inc._NNP ._.
Ph_NNP p_NN Venezuela_NNP Caracas_NNP GlaxoSmithKline_NNP Venezuela_NNP C._NNP A._NNP Ph_NNP ,_, CH_NNP m_NNP Middle_NNP East_NNP &_CC Africa_NNP Egypt_NNP Cairo_NNP GlaxoSmithKlineS_NNP ._.
A._NN E_NNP Ph_NNP m_FW p_FW 90_CD South_NNP Africa_NNP Bryanston_NNP GlaxoSmithKline_NNP South_NNP Africa_NNP Pty_NNP Ltd_NNP Ph_NNP ,_, CH_NNP m_FW p_FW Turkey_NNP Istanbul_NNP GlaxoSmithKline_NNP Ilaclari_NNP Sanayi_NNP five_CD Ticaret_NNP A._NNP S._NNP Ph_NNP m_NN p_NN USA_NNP Location_NNP Associated_NNP undertaking_VBG Business_NN %_NN USA_NNP Teterboro_NNP Quest_NNP Diagnostics_NNPS Incorporated_NNP Footnote_NNP v._CC Clinical_JJ testing_NN 19_CD Footnotes_NNP i_FW Incorporated_NNP in_IN the_DT Netherlands_NNP ii_FW Originally_RB incorporated_VBN in_IN Luxembourg_NNP ,_, now_RB registered_VBN in_IN Guernsey_NNP ._.
iii_FW Exempt_FW from_IN the_DT provisions_NNS of_IN Section_NN 7_CD of_IN the_DT Companies_NNS Amendment_NNP Act_NNP 1986_CD Ireland_NNP iv_NNP Consolidated_NNP as_IN a_DT subsidiary_NN undertaking_NN in_IN accordance_NN with_IN Section_NN 258_CD 4_CD a_DT of_IN the_DT Companies_NNS Act_NNP on_IN the_DT grounds_NNS of_IN dominant_JJ inuence_NN v_NN Equity_NN accounted_VBD on_IN the_DT grounds_NNS of_IN significant_JJ inuence_NN Directly_RB held_VBD wholly_RB owned_VBN subsidiary_NN of_IN GlaxoSmithKline_NNP plc_NNP Business_NNP segment_NN :_: Ph_NNP Pharmaceuticals_NNP ,_, CH_NNP Consumer_NNP Healthcare_NNP Business_NNP activity_NN :_: d_LS development_NN ,_, e_SYM exporting_VBG ,_, f_SYM finance_NN ,_, h_VBP holding_VBG company_NN ,_, i_FW insurance_NN ,_, m_NN marketing_NN ,_, p_NN production_NN ,_, r_NN research_NN ,_, s_VBZ service_NN Full_NNP details_NNS of_IN all_DT Group_NNP subsidiary_NN and_CC associated_VBN undertakings_NNS will_MD be_VB attached_VBN to_TO the_DT companys_NNS Annual_JJ Return_NN to_TO be_VB led_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
GlaxoSmithKline_NNP 153_CD Investor_NNP information_NN This_DT section_NN includes_VBZ the_DT financial_JJ record_NN presenting_VBG historical_JJ information_NN prepared_VBN under_IN UK_NNP GAAP_NNP ._.
In_IN addition_NN ,_, historical_JJ information_NN restated_VBN in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS is_VBZ presented_VBN ._.
This_DT section_NN also_RB discusses_VBZ shareholder_NN return_NN the_DT return_NN to_TO shareholders_NNS in_IN the_DT form_NN of_IN dividends_NNS and_CC share_NN price_NN movements_NNS and_CC provides_VBZ other_JJ information_NN for_IN shareholders_NNS ._.
Financial_NNP record_NN Information_NN prepared_VBN under_IN UK_NNP GAAP_NNP 154_CD Quarterly_JJ trend_NN 160_CD Five_CD year_NN record_NN Financial_NNP information_NN under_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP 163_CD Background_NN 164_CD IFRS_NNP accounting_NN policies_NNS 167_CD IFRS_NNS adjustments_NNS 169_CD IFRS_NNS pharmaceutical_JJ turnover_NN -_: total_JJ Group_NNP 170_CD IFRS_NNP Consolidated_NNP income_NN statement_NN 172_CD IFRS_NNP Consolidated_NNP balance_NN sheet_NN 172_CD IFRS_NNP Consolidated_NNP statement_NN of_IN recognized_VBN income_NN and_CC expense_NN 173_CD IFRS_NNP Consolidated_NNP cash_NN ow_NN statement_NN 174_CD Shareholder_NN return_NN 175_CD Shareholder_NN information_NN 176_CD Share_NN capital_NN 178_CD Taxation_NNP information_NN for_IN shareholders_NNS
